Showing
25 changed files
with
4068 additions
and
0 deletions
results/Dendogram_2clusters.png
0 → 100644

55 KB
results/Dendogram_3clusters.png
0 → 100644

55.2 KB
results/Dendogram_4clusters.png
0 → 100644

55.4 KB
results/Dendogram_ward.png
0 → 100644

27.8 KB
1 | +#Cluster: 1 | ||
2 | +1_s 1 | ||
3 | +3_s 3 | ||
4 | +5_s 5 | ||
5 | +6_s 6 | ||
6 | +7_s 7 | ||
7 | +8_s 8 | ||
8 | +10_s 10 | ||
9 | +12_s 12 | ||
10 | +13_s 13 | ||
11 | +14_s 14 | ||
12 | +16_s 16 | ||
13 | +17_s 17 | ||
14 | +18_s 18 | ||
15 | +20_s 20 | ||
16 | +22_s 22 | ||
17 | +23_s 23 | ||
18 | +24_s 24 | ||
19 | +25_s 25 | ||
20 | +28_s 28 | ||
21 | +29_s 29 | ||
22 | +31_s 31 | ||
23 | +33_s 33 | ||
24 | +34_s 34 | ||
25 | +37_s 37 | ||
26 | +38_s 38 | ||
27 | +42_s 42 | ||
28 | +43_s 43 | ||
29 | +44_s 44 | ||
30 | +47_s 47 | ||
31 | +48_s 48 | ||
32 | +49_s 49 | ||
33 | +54_s 54 | ||
34 | +55_s 55 | ||
35 | +58_s 58 | ||
36 | +59_s 59 | ||
37 | +64_s 64 | ||
38 | +65_s 65 | ||
39 | +66_s 66 | ||
40 | +67_s 67 | ||
41 | +69_s 69 | ||
42 | +70_s 70 | ||
43 | +71_s 71 | ||
44 | +72_s 72 | ||
45 | +74_s 74 | ||
46 | +75_s 75 | ||
47 | +79_s 79 | ||
48 | +80_s 80 | ||
49 | +81_s 81 | ||
50 | +82_s 82 | ||
51 | +83_s 83 | ||
52 | +84_s 84 | ||
53 | +86_s 86 | ||
54 | +87_s 87 | ||
55 | +88_s 88 | ||
56 | +89_s 89 | ||
57 | +90_s 90 | ||
58 | +91_s 91 | ||
59 | +92_s 92 | ||
60 | +93_s 93 | ||
61 | +94_s 94 | ||
62 | +98_s 98 | ||
63 | +100_s 100 | ||
64 | +101_s 101 | ||
65 | +102_s 102 | ||
66 | +104_s 104 | ||
67 | +106_s 106 | ||
68 | +109_s 109 | ||
69 | +110_s 110 | ||
70 | +112_s 112 | ||
71 | +115_s 115 | ||
72 | +117_s 117 | ||
73 | +118_s 118 | ||
74 | +120_s 120 | ||
75 | +123_s 123 | ||
76 | +124_s 124 | ||
77 | +127_s 126 | ||
78 | +128_s 127 | ||
79 | +130_s 129 | ||
80 | +132_s 131 | ||
81 | +136_s 135 | ||
82 | +137_s 136 | ||
83 | +138_s 137 | ||
84 | +141_s 140 | ||
85 | +142_s 141 | ||
86 | +144_s 143 | ||
87 | +146_s 145 | ||
88 | +147_s 146 | ||
89 | +148_s 147 | ||
90 | +149_s 148 | ||
91 | +150_s 149 | ||
92 | +156_s 155 | ||
93 | +159_s 158 | ||
94 | +161_s 160 | ||
95 | +162_s 161 | ||
96 | +163_s 162 | ||
97 | +164_s 163 | ||
98 | +165_s 164 | ||
99 | +166_s 165 | ||
100 | +169_s 168 | ||
101 | +171_s 169 | ||
102 | +174_s 172 | ||
103 | +177_s 175 | ||
104 | +179_s 177 | ||
105 | +182_s 180 | ||
106 | +184_s 182 | ||
107 | +186_s 184 | ||
108 | +188_s 186 | ||
109 | +189_s 187 | ||
110 | +190_s 188 | ||
111 | +192_s 190 | ||
112 | +195_s 193 | ||
113 | +196_s 194 | ||
114 | +197_s 195 | ||
115 | +198_s 196 | ||
116 | +199_s 197 | ||
117 | +203_s 201 | ||
118 | +204_s 202 | ||
119 | +205_s 203 | ||
120 | +208_s 206 | ||
121 | +210_s 208 | ||
122 | +214_s 212 | ||
123 | +215_s 213 | ||
124 | +216_s 214 | ||
125 | +217_s 215 | ||
126 | +219_s 217 | ||
127 | +220_s 218 | ||
128 | +221_s 219 | ||
129 | +222_s 220 | ||
130 | +223_s 221 | ||
131 | +225_s 223 | ||
132 | +226_s 224 | ||
133 | +227_s 225 | ||
134 | +229_s 227 | ||
135 | +230_s 228 | ||
136 | +233_s 231 | ||
137 | +234_s 232 | ||
138 | +236_s 234 | ||
139 | +237_s 235 | ||
140 | +238_s 236 | ||
141 | +239_s 237 | ||
142 | +240_s 238 | ||
143 | +241_s 239 | ||
144 | +242_s 240 | ||
145 | +243_s 241 | ||
146 | +244_s 242 | ||
147 | +245_s 243 | ||
148 | +246_s 244 | ||
149 | +247_s 245 | ||
150 | +248_s 246 | ||
151 | +250_s 248 | ||
152 | +251_s 249 | ||
153 | +253_s 250 | ||
154 | +254_s 251 | ||
155 | +255_s 252 | ||
156 | +256_s 253 | ||
157 | +260_s 257 | ||
158 | +262_s 259 | ||
159 | +264_s 261 | ||
160 | +265_s 262 | ||
161 | +268_s 265 | ||
162 | +269_s 266 | ||
163 | +272_s 269 | ||
164 | +273_s 270 | ||
165 | +275_s 272 | ||
166 | +278_s 275 | ||
167 | +279_s 276 | ||
168 | +280_s 277 | ||
169 | +281_s 278 | ||
170 | +284_s 281 | ||
171 | +286_s 283 | ||
172 | +287_s 284 | ||
173 | +289_s 286 | ||
174 | +290_s 287 | ||
175 | +291_s 288 | ||
176 | +293_s 289 | ||
177 | +295_s 291 | ||
178 | +297_s 293 | ||
179 | +298_s 294 | ||
180 | +299_s 295 | ||
181 | +300_s 296 | ||
182 | +301_s 297 | ||
183 | +302_s 298 | ||
184 | +303_s 299 | ||
185 | +305_s 301 | ||
186 | +307_s 303 | ||
187 | +308_s 304 | ||
188 | +310_s 306 | ||
189 | +313_s 309 | ||
190 | +314_s 310 | ||
191 | +315_s 311 | ||
192 | +316_s 312 | ||
193 | +317_s 313 | ||
194 | +318_s 314 | ||
195 | +320_s 316 | ||
196 | +322_s 318 | ||
197 | +325_s 321 | ||
198 | +326_s 322 | ||
199 | +328_s 324 | ||
200 | +330_s 326 | ||
201 | +332_s 328 | ||
202 | +333_s 329 | ||
203 | +335_s 331 | ||
204 | +336_s 332 | ||
205 | +340_s 336 | ||
206 | +343_s 339 | ||
207 | +345_s 341 | ||
208 | +347_s 343 | ||
209 | +348_s 344 | ||
210 | +349_s 345 | ||
211 | +350_s 346 | ||
212 | +352_s 348 | ||
213 | +353_s 349 | ||
214 | +354_s 350 | ||
215 | +355_s 351 | ||
216 | +356_s 352 | ||
217 | +357_s 353 | ||
218 | +360_s 356 | ||
219 | +361_s 357 | ||
220 | +362_s 358 | ||
221 | +363_s 359 | ||
222 | +364_s 360 | ||
223 | +365_s 361 | ||
224 | +366_s 362 | ||
225 | +367_s 363 | ||
226 | +368_s 364 | ||
227 | +371_s 367 | ||
228 | +372_s 368 | ||
229 | +374_s 370 | ||
230 | +375_s 371 | ||
231 | +376_s 372 | ||
232 | +377_s 373 | ||
233 | +378_s 374 | ||
234 | +379_s 375 | ||
235 | +380_s 376 | ||
236 | +383_s 379 | ||
237 | +384_s 380 | ||
238 | +387_s 383 | ||
239 | +388_s 384 | ||
240 | +390_s 386 | ||
241 | +391_s 387 | ||
242 | +392_s 388 | ||
243 | +398_s 394 | ||
244 | +399_s 395 | ||
245 | +401_s 397 | ||
246 | +402_s 398 | ||
247 | +403_s 399 | ||
248 | +407_s 403 | ||
249 | +408_s 404 | ||
250 | +409_s 405 | ||
251 | +411_s 407 | ||
252 | +413_s 409 | ||
253 | +414_s 410 | ||
254 | +415_s 411 | ||
255 | +416_s 412 | ||
256 | +418_s 414 | ||
257 | +419_s 415 | ||
258 | +420_s 416 | ||
259 | +421_s 417 | ||
260 | +424_s 420 | ||
261 | +428_s 424 | ||
262 | +429_s 425 | ||
263 | +431_s 427 | ||
264 | +433_s 429 | ||
265 | +437_s 433 | ||
266 | +438_s 434 | ||
267 | +440_s 436 | ||
268 | +442_s 438 | ||
269 | +443_s 439 | ||
270 | +444_s 440 | ||
271 | +445_s 441 | ||
272 | +446_s 442 | ||
273 | +447_s 443 | ||
274 | +448_s 444 | ||
275 | +450_s 446 | ||
276 | +451_s 447 | ||
277 | +452_s 448 | ||
278 | +453_s 449 | ||
279 | +#Cluster: 2 | ||
280 | +2_s 2 | ||
281 | +4_s 4 | ||
282 | +9_s 9 | ||
283 | +11_s 11 | ||
284 | +15_s 15 | ||
285 | +19_s 19 | ||
286 | +21_s 21 | ||
287 | +26_s 26 | ||
288 | +27_s 27 | ||
289 | +30_s 30 | ||
290 | +32_s 32 | ||
291 | +35_s 35 | ||
292 | +36_s 36 | ||
293 | +39_s 39 | ||
294 | +40_s 40 | ||
295 | +41_s 41 | ||
296 | +45_s 45 | ||
297 | +46_s 46 | ||
298 | +50_s 50 | ||
299 | +51_s 51 | ||
300 | +52_s 52 | ||
301 | +53_s 53 | ||
302 | +56_s 56 | ||
303 | +57_s 57 | ||
304 | +60_s 60 | ||
305 | +61_s 61 | ||
306 | +62_s 62 | ||
307 | +63_s 63 | ||
308 | +68_s 68 | ||
309 | +73_s 73 | ||
310 | +76_s 76 | ||
311 | +77_s 77 | ||
312 | +78_s 78 | ||
313 | +85_s 85 | ||
314 | +95_s 95 | ||
315 | +96_s 96 | ||
316 | +97_s 97 | ||
317 | +99_s 99 | ||
318 | +103_s 103 | ||
319 | +105_s 105 | ||
320 | +107_s 107 | ||
321 | +108_s 108 | ||
322 | +111_s 111 | ||
323 | +113_s 113 | ||
324 | +114_s 114 | ||
325 | +116_s 116 | ||
326 | +119_s 119 | ||
327 | +121_s 121 | ||
328 | +122_s 122 | ||
329 | +125_s 125 | ||
330 | +129_s 128 | ||
331 | +131_s 130 | ||
332 | +133_s 132 | ||
333 | +134_s 133 | ||
334 | +135_s 134 | ||
335 | +139_s 138 | ||
336 | +140_s 139 | ||
337 | +143_s 142 | ||
338 | +145_s 144 | ||
339 | +151_s 150 | ||
340 | +152_s 151 | ||
341 | +153_s 152 | ||
342 | +154_s 153 | ||
343 | +155_s 154 | ||
344 | +157_s 156 | ||
345 | +158_s 157 | ||
346 | +160_s 159 | ||
347 | +167_s 166 | ||
348 | +168_s 167 | ||
349 | +172_s 170 | ||
350 | +173_s 171 | ||
351 | +175_s 173 | ||
352 | +176_s 174 | ||
353 | +178_s 176 | ||
354 | +180_s 178 | ||
355 | +181_s 179 | ||
356 | +183_s 181 | ||
357 | +185_s 183 | ||
358 | +187_s 185 | ||
359 | +191_s 189 | ||
360 | +193_s 191 | ||
361 | +194_s 192 | ||
362 | +200_s 198 | ||
363 | +201_s 199 | ||
364 | +202_s 200 | ||
365 | +206_s 204 | ||
366 | +207_s 205 | ||
367 | +209_s 207 | ||
368 | +211_s 209 | ||
369 | +212_s 210 | ||
370 | +213_s 211 | ||
371 | +218_s 216 | ||
372 | +224_s 222 | ||
373 | +228_s 226 | ||
374 | +231_s 229 | ||
375 | +232_s 230 | ||
376 | +235_s 233 | ||
377 | +249_s 247 | ||
378 | +257_s 254 | ||
379 | +258_s 255 | ||
380 | +259_s 256 | ||
381 | +261_s 258 | ||
382 | +263_s 260 | ||
383 | +266_s 263 | ||
384 | +267_s 264 | ||
385 | +270_s 267 | ||
386 | +271_s 268 | ||
387 | +274_s 271 | ||
388 | +276_s 273 | ||
389 | +277_s 274 | ||
390 | +282_s 279 | ||
391 | +283_s 280 | ||
392 | +285_s 282 | ||
393 | +288_s 285 | ||
394 | +294_s 290 | ||
395 | +296_s 292 | ||
396 | +304_s 300 | ||
397 | +306_s 302 | ||
398 | +309_s 305 | ||
399 | +311_s 307 | ||
400 | +312_s 308 | ||
401 | +319_s 315 | ||
402 | +321_s 317 | ||
403 | +323_s 319 | ||
404 | +324_s 320 | ||
405 | +327_s 323 | ||
406 | +329_s 325 | ||
407 | +331_s 327 | ||
408 | +334_s 330 | ||
409 | +337_s 333 | ||
410 | +338_s 334 | ||
411 | +339_s 335 | ||
412 | +341_s 337 | ||
413 | +342_s 338 | ||
414 | +344_s 340 | ||
415 | +346_s 342 | ||
416 | +351_s 347 | ||
417 | +358_s 354 | ||
418 | +359_s 355 | ||
419 | +369_s 365 | ||
420 | +370_s 366 | ||
421 | +373_s 369 | ||
422 | +381_s 377 | ||
423 | +382_s 378 | ||
424 | +385_s 381 | ||
425 | +386_s 382 | ||
426 | +389_s 385 | ||
427 | +393_s 389 | ||
428 | +394_s 390 | ||
429 | +395_s 391 | ||
430 | +396_s 392 | ||
431 | +397_s 393 | ||
432 | +400_s 396 | ||
433 | +404_s 400 | ||
434 | +405_s 401 | ||
435 | +406_s 402 | ||
436 | +410_s 406 | ||
437 | +412_s 408 | ||
438 | +417_s 413 | ||
439 | +422_s 418 | ||
440 | +423_s 419 | ||
441 | +425_s 421 | ||
442 | +426_s 422 | ||
443 | +427_s 423 | ||
444 | +430_s 426 | ||
445 | +432_s 428 | ||
446 | +434_s 430 | ||
447 | +435_s 431 | ||
448 | +436_s 432 | ||
449 | +439_s 435 | ||
450 | +441_s 437 | ||
451 | +449_s 445 | ||
452 | +454_s 450 | ||
453 | +455_s 451 | ||
... | \ No newline at end of file | ... | \ No newline at end of file |
results/Partition_2/cluster1.txt
0 → 100644
1 | +Recent advances in molecular targets and treatment of idiopathic pulmonary fibrosis: focus on TGFbeta signaling and the myofibroblast | ||
2 | +Tissue inhibitor of metalloproteinase-3 is up-regulated by transforming growth factor-beta1 in vitro and expressed in fibroblastic foci in vivo in idiopathic pulmonary fibrosis | ||
3 | +Defective histone acetylation is responsible for the diminished expression of cyclooxygenase 2 in idiopathic pulmonary fibrosis | ||
4 | +EZH2 enhances the differentiation of fibroblasts into myofibroblasts in idiopathic pulmonary fibrosis | ||
5 | +y-Herpes virus-68, but not Pseudomonas aeruginosa or influenza A (H1N1), exacerbates established murine lung fibrosis | ||
6 | +Microarray identifies ADAM family members as key responders to TGF-beta1 in alveolar epithelial cells | ||
7 | +Anti-pulmonary fibrotic activity of salvianolic acid B was screened by a novel method based on the cyto-biophysical properties | ||
8 | +Targeting genes for treatment in idiopathic pulmonary fibrosis: challenges and opportunities, promises and pitfalls | ||
9 | +Th1/Th2 cytokine gene polymorphisms in patients with idiopathic pulmonary fibrosis | ||
10 | +VCAM-1 is a TGF-b1 inducible gene upregulated in idiopathic pulmonary fibrosis | ||
11 | +Integrated analyses identify the involvement of microRNA-26a in epithelial-mesenchymal transition during idiopathic pulmonary fibrosis | ||
12 | +Upregulation of alveolar levels of activin B, but not activin A, in lungs of west highland white terriers with idiopathic pulmonary fibrosis and diffuse alveolar damage | ||
13 | +Roles for insulin-like growth factor I and transforming growth factor-beta in fibrotic lung disease | ||
14 | +Combined inhibition of TGFb and PDGF signaling attenuates radiation-induced pulmonary fibrosis | ||
15 | +Glucagon like peptide-1 attenuates bleomycin-induced pulmonary fibrosis, involving the inactivation of NF-kB in mice | ||
16 | +Carbon monoxide-bound hemoglobin-vesicles for the treatment of bleomycin-induced pulmonary fibrosis | ||
17 | +Protease activated receptor-1 regulates macrophage-mediated cellular senescence: a risk for idiopathic pulmonary fibrosis | ||
18 | +Control of virus reactivation arrests pulmonary herpesvirus-induced fibrosis in IFN-gamma receptor-deficient mice | ||
19 | +Regulation of TGF-b storage and activation in the human idiopathic pulmonary fibrosis lung | ||
20 | +Interleukin-17 induces human alveolar epithelial to mesenchymal cell transition via the TGF-b1 mediated Smad2/3 and ERK1/2 activation | ||
21 | +Prognostic factors for idiopathic pulmonary fibrosis: clinical, physiologic, pathologic, and molecular aspects | ||
22 | +Progressive transforming growth factor beta1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor | ||
23 | +Toll-like receptor 4 activation attenuates profibrotic response in control lung fibroblasts but not in fibroblasts from patients with IPF | ||
24 | +Free radical generation induces epithelial-to-mesenchymal transition in lung epithelium via a TGF-b1-dependent mechanism | ||
25 | +Methylation-mediated BMPER expression in fibroblast activation in vitro and lung fibrosis in mice in vivo | ||
26 | +Upregulation of activin-B and follistatin in pulmonary fibrosis - a translational study using human biopsies and a specific inhibitor in mouse fibrosis models | ||
27 | +Resveratrol inhibits transforming growth factor-b-induced proliferation and differentiation of ex vivo human lung fibroblasts into myofibroblasts through ERK/Akt inhibition and PTEN restoration | ||
28 | +Effects of doxycycline on production of growth factors and matrix metalloproteinases in pulmonary fibrosis | ||
29 | +MS80, a novel sulfated oligosaccharide, inhibits pulmonary fibrosis by targeting TGF-beta1 both in vitro and in vivo | ||
30 | +Association of HLA and cytokine gene polymorphisms with idiopathic pulmonary fibrosis | ||
31 | +Oxidant-antioxidant imbalance as a potential contributor to the progression of human pulmonary fibrosis | ||
32 | +A translational preclinical model of interstitial pulmonary fibrosis and pulmonary hypertension: mechanistic pathways driving disease pathophysiology | ||
33 | +Epithelial cell alpha3beta1 integrin links beta-catenin and Smad signaling to promote myofibroblast formation and pulmonary fibrosis | ||
34 | +Pirfenidone for the treatment of idiopathic pulmonary fibrosis | ||
35 | +Interactions between b-catenin and transforming growth factor-b signaling pathways mediate epithelial-mesenchymal transition and are dependent on the transcriptional co-activator cAMP-response element-binding protein (CREB)-binding protein (CBP) | ||
36 | +Uncoupling of the profibrotic and hemostatic effects of thrombin in lung fibrosis | ||
37 | +Studies of hepatocyte growth factor in bronchoalveolar lavage fluid in chronic interstitial lung diseases | ||
38 | +Syndecan-2 exerts antifibrotic effects by promoting caveolin-1-mediated transforming growth factor-b receptor I internalization and inhibiting transforming growth factor-b1 signaling | ||
39 | +Compromised peroxisomes in idiopathic pulmonary fibrosis, a vicious cycle inducing a higher fibrotic response via TGF-b signaling | ||
40 | +Simvastatin attenuates TGF-b1-induced epithelial-mesenchymal transition in human alveolar epithelial cells | ||
41 | +Expression of 150-kDa oxygen-regulated protein (ORP150) stimulates bleomycin-induced pulmonary fibrosis and dysfunction in mice | ||
42 | +Kinase inhibitors fail to induce mesenchymal-epithelial transition in fibroblasts from fibrotic lung tissue | ||
43 | +The small heat-shock protein aB-crystallin is essential for the nuclear localization of Smad4: impact on pulmonary fibrosis | ||
44 | +Blockade of the Wnt/b-catenin pathway attenuates bleomycin-induced pulmonary fibrosis | ||
45 | +Epithelial stem cell exhaustion in the pathogenesis of idiopathic pulmonary fibrosis | ||
46 | +CUX1/Wnt signaling regulates epithelial mesenchymal transition in EBV infected epithelial cells | ||
47 | +Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis | ||
48 | +Idiopathic pulmonary fibrosis: an altered fibroblast proliferation linked to cancer biology | ||
49 | +Lower expression of platelet derived growth factor is associated with better overall survival rate of patients with idiopathic nonspecific interstitial pneumonia | ||
50 | +Elevated expression of NEU1 sialidase in idiopathic pulmonary fibrosis provokes pulmonary collagen deposition, lymphocytosis, and fibrosis | ||
51 | +TGF-beta 1, but not TGF-beta 2 or TGF-beta 3, is differentially present in epithelial cells of advanced pulmonary fibrosis: an immunohistochemical study | ||
52 | +Cthrc1 lowers pulmonary collagen associated with bleomycin-induced fibrosis and protects lung function | ||
53 | +Pigment epithelium-derived factor in idiopathic pulmonary fibrosis: a role in aberrant angiogenesis | ||
54 | +Cytoskeletal protein modulation in pulmonary alveolar myofibroblasts during idiopathic pulmonary fibrosis | ||
55 | +Increased expression of 5-hydroxytryptamine2A/B receptors in idiopathic pulmonary fibrosis: a rationale for therapeutic intervention | ||
56 | +Signaling pathways and their miRNA regulators involved in the etiopathology of idiopathic pulmonary fibrosis (IPF) and hypersensitivity pneumonitis (HP) | ||
57 | +Alveolar epithelial cells express mesenchymal proteins in patients with idiopathic pulmonary fibrosis | ||
58 | +TGF-b1 induces tissue factor expression in human lung fibroblasts in a PI3K/JNK/Akt-dependent and AP-1-dependent manner | ||
59 | +Inhibitory effects of amines from Citrus reticulata on bleomycin-induced pulmonary fibrosis in rats | ||
60 | +Focal adhesion kinase signaling determines the fate of lung epithelial cells in response to TGF-b | ||
61 | +Beyond TGFb - Novel ways to target airway and parenchymal fibrosis | ||
62 | +Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis | ||
63 | +The profibrotic cytokine transforming growth factor-b1 increases endothelial progenitor cell angiogenic properties | ||
64 | +Tannic acid attenuates TGF-b1-induced epithelial-to-mesenchymal transition by effectively intervening TGF-b signaling in lung epithelial cells | ||
65 | +Differential expression of alpha E beta 7 integrins on bronchoalveolar lavage T lymphocyte subsets: regulation by alpha 4 beta 1-integrin crosslinking and TGF-beta | ||
66 | +Elevated sL1-CAM levels in BALF and serum of IPF patients | ||
67 | +The potential application of strategic released apigenin from polymeric carrier in pulmonary fibrosis | ||
68 | +Immunomodulation by mesenchymal stem cells in treating human autoimmune disease-associated lung fibrosis | ||
69 | +Epithelial-to-mesenchymal transition and its role in EGFR-mutant lung adenocarcinoma and idiopathic pulmonary fibrosis | ||
70 | +Effects of thymosin b4 and its N-terminal fragment Ac-SDKP on TGF-b-treated human lung fibroblasts and in the mouse model of bleomycin-induced lung fibrosis | ||
71 | +Epithelial contribution to the pro-fibrotic stiff microenvironment and myofibroblast population in lung fibrosis | ||
72 | +The matricellular protein CCN1 enhances TGF-b1/SMAD3-dependent profibrotic signaling in fibroblasts and contributes to fibrogenic responses to lung injury | ||
73 | +MicroRNA-326 regulates profibrotic functions of transforming growth factor-b in pulmonary fibrosis | ||
74 | +Significance of elevated procollagen-III-peptide and transforming growth factor-beta levels of bronchoalveolar lavage fluids from idiopathic pulmonary fibrosis patients | ||
75 | +The latent form of TGFbeta(1) is induced by TNFalpha through an ERK specific pathway and is activated by asbestos-derived reactive oxygen species in vitro and in vivo | ||
76 | +Protective role of gambogic acid in experimental pulmonary fibrosis in vitro and in vivo | ||
77 | +An ex vivo model to induce early fibrosis-like changes in human precision-cut lung slices | ||
78 | +Differential effects of human neutrophil peptide-1 on growth factor and interleukin-8 production by human lung fibroblasts and epithelial cells | ||
79 | +Human placental mesenchymal stem cells of fetal origins-alleviated inflammation and fibrosis by attenuating MyD88 signaling in bleomycin-induced pulmonary fibrosis mice | ||
80 | +Fibroblasts from idiopathic pulmonary fibrosis and normal lungs differ in growth rate, apoptosis, and tissue inhibitor of metalloproteinases expression | ||
81 | +Phosphatase and tensin homolog deleted on chromosome 10 contributes to phenotype transformation of fibroblasts in idiopathic pulmonary fibrosis via multiple pathways | ||
82 | +Release of biologically active TGF-beta1 by alveolar epithelial cells results in pulmonary fibrosis | ||
83 | +Overproduction of collagen and diminished SOCS1 expression are causally linked in fibroblasts from idiopathic pulmonary fibrosis | ||
84 | +Thalidomide reduces IL-18, IL-8 and TNF-alpha release from alveolar macrophages in interstitial lung disease | ||
85 | +Pathogenesis pathways of idiopathic pulmonary fibrosis in bleomycin-induced lung injury model in mice | ||
86 | +VEGF ameliorates pulmonary hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in rats | ||
87 | +Genomewide RNA expression profiling in lung identifies distinct signatures in idiopathic pulmonary arterial hypertension and secondary pulmonary hypertension | ||
88 | +Transforming growth factor-b1 downregulates vascular endothelial growth factor-D expression in human lung fibroblasts via the Jun NH2-terminal kinase signaling pathway | ||
89 | +Corilagin attenuates aerosol bleomycin-induced experimental lung injury | ||
90 | +Bleomycin induces molecular changes directly relevant to idiopathic pulmonary fibrosis: a model for "active" disease | ||
91 | +Long-acting human serum albumin-thioredoxin fusion protein suppresses bleomycin-induced pulmonary fibrosis progression | ||
92 | +Angiotensin-TGF-beta 1 crosstalk in human idiopathic pulmonary fibrosis: autocrine mechanisms in myofibroblasts and macrophages | ||
93 | +miR-199a-5p Is upregulated during fibrogenic response to tissue injury and mediates TGFbeta-induced lung fibroblast activation by targeting caveolin-1 | ||
94 | +Increased expression of protease nexin-1 in fibroblasts during idiopathic pulmonary fibrosis regulates thrombin activity and fibronectin expression | ||
95 | +Plasma CCN2 (connective tissue growth factor; CTGF) is a potential biomarker in idiopathic pulmonary fibrosis (IPF) | ||
96 | +Cysteine-rich protein 1 is regulated by transforming growth factor-b1 and expressed in lung fibrosis | ||
97 | +Microencapsulation of lefty-secreting engineered cells for pulmonary fibrosis therapy in mice | ||
98 | +Accelerated epithelial cell senescence in IPF and the inhibitory role of SIRT6 in TGF-b-induced senescence of human bronchial epithelial cells | ||
99 | +Pleural mesothelial cell transformation into myofibroblasts and haptotactic migration in response to TGF-beta1 in vitro | ||
100 | +p63 - Key molecule in the early phase of epithelial abnormality in idiopathic pulmonary fibrosis | ||
101 | +Increased interleukin-1 receptor antagonist in idiopathic pulmonary fibrosis | ||
102 | +Molecular pathogenesis of interstitial pneumonitis with TNF-alpha transgenic mice | ||
103 | +Wilms' tumor 1 (Wt1) regulates pleural mesothelial cell plasticity and transition into myofibroblasts in idiopathic pulmonary fibrosis | ||
104 | +Epithelium-specific deletion of TGF-b receptor type II protects mice from bleomycin-induced pulmonary fibrosis | ||
105 | +Bleomycin in the setting of lung fibrosis induction: From biological mechanisms to counteractions | ||
106 | +Assessment of the effect of potential antifibrotic compounds on total and aVb6 integrin-mediated TGF-b activation | ||
107 | +The anti-fibrotic effect of inhibition of TGFb-ALK5 signalling in experimental pulmonary fibrosis in mice is attenuated in the presence of concurrent y-herpesvirus infection | ||
108 | +Plasminogen activator inhibitor 1, fibroblast apoptosis resistance, and aging-related susceptibility to lung fibrosis | ||
109 | +Antifibrotic properties of receptor for advanced glycation end products in idiopathic pulmonary fibrosis | ||
110 | +Genetic polymorphism in matrix metalloproteinase-9 and transforming growth factor-b1 and susceptibility to combined pulmonary fibrosis and emphysema in a Chinese population | ||
111 | +Berberine attenuates bleomycin induced pulmonary toxicity and fibrosis via suppressing NF-kB dependant TGF-b activation: a biphasic experimental study | ||
112 | +Transforming growth factor-b inhibits IQ motif containing guanosine triphosphatase activating protein 1 expression in lung fibroblasts via the nuclear factor-kB signaling pathway | ||
113 | +Role of CD248 as a potential severity marker in idiopathic pulmonary fibrosis | ||
114 | +Immunoglobulin A in serum: an old acquaintance as a new prognostic biomarker in idiopathic pulmonary fibrosis | ||
115 | +Defect of hepatocyte growth factor secretion by fibroblasts in idiopathic pulmonary fibrosis | ||
116 | +Possible involvement of pirfenidone metabolites in the antifibrotic action of a therapy for idiopathic pulmonary fibrosis | ||
117 | +Effect of pirfenidone on proliferation, TGF-b-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts | ||
118 | +Olodaterol shows anti-fibrotic efficacy in in vitro and in vivo models of pulmonary fibrosis | ||
119 | +[Quantifying plasma levels of transforming growth factor beta1 in idiopathic pulmonary fibrosis] | ||
120 | +BAX inhibitor-1-associated V-ATPase glycosylation enhances collagen degradation in pulmonary fibrosis | ||
121 | +Idiopathic pulmonary fibrosis: pathobiology of novel approaches to treatment | ||
122 | +Novel pharmacological approaches to manage interstitial lung fibrosis in the twenty-first century | ||
123 | +De-ubiquitinating enzyme, USP11, promotes transforming growth factor b-1 signaling through stabilization of transforming growth factor b receptor II | ||
124 | +SPARC suppresses apoptosis of idiopathic pulmonary fibrosis fibroblasts through constitutive activation of beta-catenin | ||
125 | +Aortic carboxypeptidase-like protein (ACLP) enhances lung myofibroblast differentiation through transforming growth factor b receptor-dependent and -independent pathways | ||
126 | +IL-4 polymorphisms, HRCT score and lung tissue markers in idiopathic pulmonary fibrosis | ||
127 | +TGF-beta1 induces human alveolar epithelial to mesenchymal cell transition (EMT) | ||
128 | +NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury | ||
129 | +TGF-beta 1 as an enhancer of Fas-mediated apoptosis of lung epithelial cells | ||
130 | +MicroRNA-29c regulates apoptosis sensitivity via modulation of the cell-surface death receptor, Fas, in lung fibroblasts | ||
131 | +Insulin-like growth factor binding proteins 3 and 5 are overexpressed in idiopathic pulmonary fibrosis and contribute to extracellular matrix deposition | ||
132 | +Bile acids induce activation of alveolar epithelial cells and lung fibroblasts through farnesoid X receptor-dependent and independent pathways | ||
133 | +Fibroblastic foci, covered with alveolar epithelia exhibiting epithelial-mesenchymal transition, destroy alveolar septa by disrupting blood flow in idiopathic pulmonary fibrosis | ||
134 | +Connective tissue growth factor expression and induction by transforming growth factor-beta is abrogated by simvastatin via a Rho signaling mechanism | ||
135 | +Regulation of human lung fibroblast C1q-receptors by transforming growth factor-beta and tumor necrosis factor-alpha | ||
136 | +Sorafenib ameliorates bleomycin-induced pulmonary fibrosis: potential roles in the inhibition of epithelial-mesenchymal transition and fibroblast activation | ||
137 | +Microarray profiling reveals suppressed interferon stimulated gene program in fibroblasts from scleroderma-associated interstitial lung disease | ||
138 | +Effects of antifibrotic agents on TGF-beta1, CTGF and IFN-gamma expression in patients with idiopathic pulmonary fibrosis | ||
139 | +NOX4/NADPH oxidase expression is increased in pulmonary fibroblasts from patients with idiopathic pulmonary fibrosis and mediates TGFbeta1-induced fibroblast differentiation into myofibroblasts | ||
140 | +[The expressions and meanings of BMP-7 and TGF-b in idiopathic pulmonary fibrosis and idiopathic nonspecific interstitial pneumonia] | ||
141 | +Increased deposition of chondroitin/dermatan sulfate glycosaminoglycan and upregulation of b1,3-glucuronosyltransferase I in pulmonary fibrosis | ||
142 | +Identification and validation of differentially expressed transcripts by RNA-sequencing of formalin-fixed, paraffin-embedded (FFPE) lung tissue from patients with Idiopathic Pulmonary Fibrosis | ||
143 | +Increased TGF-beta1 in the lungs of asbestos-exposed rats and mice: reduced expression in TNF-alpha receptor knockout mice | ||
144 | +Discovery and validation of extracellular/circulating microRNAs during idiopathic pulmonary fibrosis disease progression | ||
145 | +Idiopathic pulmonary fibrosis in relation to gene polymorphisms of transforming growth factor-b1 and plasminogen activator inhibitor 1 | ||
146 | +Comparative study of transforming growth factor-b signalling and regulatory molecules in human and canine idiopathic pulmonary fibrosis | ||
147 | +TGF-b1 T869C polymorphism may affect susceptibility to idiopathic pulmonary fibrosis and disease severity | ||
148 | +Inhibition of PI3K prevents the proliferation and differentiation of human lung fibroblasts into myofibroblasts: the role of class I P110 isoforms | ||
149 | +Medical treatment for pulmonary fibrosis: current trends, concepts, and prospects | ||
150 | +Contribution of the anaphylatoxin receptors, C3aR and C5aR, to the pathogenesis of pulmonary fibrosis | ||
151 | +Comparison between conventional and "clinical" assessment of experimental lung fibrosis | ||
152 | +Intratracheal bleomycin causes airway remodeling and airflow obstruction in mice | ||
153 | +Role of endoplasmic reticulum stress in age-related susceptibility to lung fibrosis | ||
154 | +Transforming growth factor b1 (TGFb1)-induced CD44V6-NOX4 signaling in pathogenesis of idiopathic pulmonary fibrosis | ||
155 | +Increased levels of prostaglandin E-major urinary metabolite (PGE-MUM) in chronic fibrosing interstitial pneumonia | ||
156 | +Pirfenidone inhibits TGF-b1-induced over-expression of collagen type I and heat shock protein 47 in A549 cells | ||
157 | +BAL cytokine profile in different interstitial lung diseases: a focus on systemic sclerosis | ||
158 | +Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis | ||
159 | +Effect of an immunotoxin to folate receptor beta on bleomycin-induced experimental pulmonary fibrosis | ||
160 | +Modulation of CD11c+ lung dendritic cells in respect to TGF-b in experimental pulmonary fibrosis | ||
161 | +Microsatellite instability in transforming growth factor-beta 1 type II receptor gene in alveolar lining epithelial cells of idiopathic pulmonary fibrosis | ||
162 | +Single-cell RNA sequencing identifies diverse roles of epithelial cells in idiopathic pulmonary fibrosis | ||
163 | +Expression of suppressor of cytokine signaling 1 in the peripheral blood of patients with idiopathic pulmonary fibrosis | ||
164 | +Prostaglandin F(2alpha) receptor signaling facilitates bleomycin-induced pulmonary fibrosis independently of transforming growth factor-beta | ||
165 | +Sphingosine-1-phosphate lyase is an endogenous suppressor of pulmonary fibrosis: role of S1P signalling and autophagy | ||
166 | +Roles of p38 MAPK and JNK in TGF-b1-induced human alveolar epithelial to mesenchymal transition | ||
167 | +The role of microRNA-155/liver X receptor pathway in experimental and idiopathic pulmonary fibrosis | ||
168 | +Sphingosine-1-phosphate is increased in patients with idiopathic pulmonary fibrosis and mediates epithelial to mesenchymal transition | ||
169 | +Nitric oxide attenuates epithelial-mesenchymal transition in alveolar epithelial cells | ||
170 | +Sirtuin 7 is decreased in pulmonary fibrosis and regulates the fibrotic phenotype of lung fibroblasts | ||
171 | +Evaluation of permeability alteration and epithelial-mesenchymal transition induced by transforming growth factor-b1 in A549, NCI-H441, and Calu-3 cells: Development of an in vitro model of respiratory epithelial cells in idiopathic pulmonary fibrosis | ||
172 | +Hydrogen peroxide is a diffusible paracrine signal for the induction of epithelial cell death by activated myofibroblasts | ||
173 | +TGF-b1 stimulates HDAC4 nucleus-to-cytoplasm translocation and NADPH oxidase 4-derived reactive oxygen species in normal human lung fibroblasts | ||
174 | +Effects of a leukotriene B4 receptor antagonist on bleomycin-induced pulmonary fibrosis | ||
175 | +Raised serum levels of IGFBP-1 and IGFBP-2 in idiopathic pulmonary fibrosis | ||
176 | +Inhibition of NF-kappaB signaling reduces virus load and gammaherpesvirus-induced pulmonary fibrosis | ||
177 | +Triptolide suppresses paraquat induced idiopathic pulmonary fibrosis by inhibiting TGFB1-dependent epithelial mesenchymal transition | ||
178 | +N-acetylcysteine downregulation of lysyl oxidase activity alleviating bleomycin-induced pulmonary fibrosis in rats | ||
179 | +Cytokine gene polymorphisms and BALF cytokine levels in interstitial lung diseases | ||
180 | +[The morphology and molecular bases of damage to the stem cell niche of respiratory acini in idiopathic interstitial pneumonias] | ||
181 | +Lactic acid is elevated in idiopathic pulmonary fibrosis and induces myofibroblast differentiation via pH-dependent activation of transforming growth factor-b | ||
182 | +Differential mRNA expression of insulin-like growth factor-1 splice variants in patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis | ||
183 | +The hedgehog system machinery controls transforming growth factor-b-dependent myofibroblastic differentiation in humans: involvement in idiopathic pulmonary fibrosis | ||
184 | +Effects and mechanisms of pirfenidone, prednisone and acetylcysteine on pulmonary fibrosis in rat idiopathic pulmonary fibrosis models | ||
185 | +PPAR-y ligands repress TGFb-induced myofibroblast differentiation by targeting the PI3K/Akt pathway: implications for therapy of fibrosis | ||
186 | +WISP1 mediates IL-6-dependent proliferation in primary human lung fibroblasts | ||
187 | +Melatonin attenuates TGFb1-induced epithelial-mesenchymal transition in lung alveolar epithelial cells | ||
188 | +JAK2 mediates lung fibrosis, pulmonary vascular remodelling and hypertension in idiopathic pulmonary fibrosis: an experimental study | ||
189 | +Ambroxol hydrochloride in the management of idiopathic pulmonary fibrosis: Clinical trials are the need of the hour | ||
190 | +Reactive oxygen species are required for maintenance and differentiation of primary lung fibroblasts in idiopathic pulmonary fibrosis | ||
191 | +MiR-5100 targets TOB2 to drive epithelial-mesenchymal transition associated with activating smad2/3 in lung epithelial cells | ||
192 | +IL-17A deficiency mitigates bleomycin-induced complement activation during lung fibrosis | ||
193 | +Inhibitory effect of receptor for advanced glycation end products (RAGE) on the TGF-b-induced alveolar epithelial to mesenchymal transition | ||
194 | +Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) promotes lung fibroblast proliferation, survival and differentiation to myofibroblasts | ||
195 | +TGF-beta-induced EMT: mechanisms and implications for fibrotic lung disease | ||
196 | +Pleural mesothelial cell differentiation and invasion in fibrogenic lung injury | ||
197 | +Absence of Thy-1 results in TGF-b induced MMP-9 expression and confers a profibrotic phenotype to human lung fibroblasts | ||
198 | +Signalling pathways from NADPH oxidase-4 to idiopathic pulmonary fibrosis | ||
199 | +Interplay between RAGE, CD44, and focal adhesion molecules in epithelial-mesenchymal transition of alveolar epithelial cells | ||
200 | +Are mast cells instrumental for fibrotic diseases? Idiopathic pulmonary fibrosis (IPF) is a fatal lung disorder of unknown etiology characterized by accumulation of lung fibroblasts and extracellular matrix deposition, ultimately leading to compromised tissue architecture and lung function capacity | ||
201 | +Association between cytokine removal by polymyxin B hemoperfusion and improved pulmonary oxygenation in patients with acute exacerbation of idiopathic pulmonary fibrosis | ||
202 | +Increased production and immunohistochemical localization of transforming growth factor-beta in idiopathic pulmonary fibrosis | ||
203 | +TNF-alpha, PDGF, and TGF-beta(1) expression by primary mouse bronchiolar-alveolar epithelial and mesenchymal cells: tnf-alpha induces TGF-beta(1) | ||
204 | +Anchorage-independent colony growth of pulmonary fibroblasts derived from fibrotic human lung tissue | ||
205 | +Overexpression of squamous cell carcinoma antigen in idiopathic pulmonary fibrosis: clinicopathological correlations | ||
206 | +Intrinsic defence capacity and therapeutic potential of natriuretic peptides in pulmonary hypertension associated with lung fibrosis | ||
207 | +Microsomal prostaglandin E synthase-1 deficiency exacerbates pulmonary fibrosis induced by bleomycin in mice | ||
208 | +Antifibrotic effects of cyclosporine A on TGF-b1-treated lung fibroblasts and lungs from bleomycin-treated mice: role of hypoxia-inducible factor-1a | ||
209 | +Preventive and therapeutic effects of thymosin b4 N-terminal fragment Ac-SDKP in the bleomycin model of pulmonary fibrosis | ||
210 | +The role of halofuginone in fibrosis: more to be explored? Fibrosis, which can be defined as an abnormal or excessive accumulation of extracellular matrix (ECM), particularly fibrillar collagens, is a key driver of progressive organ dysfunction in many inflammatory and metabolic diseases, including idiopathic pulmonary fibrosis (IPF), cirrhosis, nephropathy, and oral submucous fibrosis (OSF) | ||
211 | +Forkhead Box F1 (FOXF1) represses cell growth, COL1 and ARPC2 expression in lung fibroblasts in vitro | ||
212 | +Nitrated fatty acids reverse pulmonary fibrosis by dedifferentiating myofibroblasts and promoting collagen uptake by alveolar macrophages | ||
213 | +Serpin B4 isoform overexpression is associated with aberrant epithelial proliferation and lung cancer in idiopathic pulmonary fibrosis | ||
214 | +Modulation of specific beta cell gene (re)expression during in vitro expansion of human pancreatic islet cells | ||
215 | +Dehydroepiandrosterone has strong antifibrotic effects and is decreased in idiopathic pulmonary fibrosis | ||
216 | +Regulation of the effects of TGF-beta 1 by activation of latent TGF-beta 1 and differential expression of TGF-beta receptors (T beta R-I and T beta R-II) in idiopathic pulmonary fibrosis | ||
217 | +Establishment of the mouse model of acute exacerbation of idiopathic pulmonary fibrosis | ||
218 | +CCN5 overexpression inhibits profibrotic phenotypes via the PI3K/Akt signaling pathway in lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis and in an in vivo model of lung fibrosis | ||
219 | +Spiruchostatin A inhibits proliferation and differentiation of fibroblasts from patients with pulmonary fibrosis | ||
220 | +Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis | ||
221 | +Tumor necrosis factor superfamily 14 (LIGHT) controls thymic stromal lymphopoietin to drive pulmonary fibrosis | ||
222 | +High levels of IL-6 and IL-8 characterize early-on idiopathic pulmonary fibrosis acute exacerbations | ||
223 | +Mast cell chymase: an indispensable instrument in the pathological symphony of idiopathic pulmonary fibrosis? Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and fatal lung disease with no known etiology and treatment options | ||
224 | +Defect of pro-hepatocyte growth factor activation by fibroblasts in idiopathic pulmonary fibrosis | ||
225 | +Lung infection with gamma-herpesvirus induces progressive pulmonary fibrosis in Th2-biased mice | ||
226 | +Amplified canonical transforming growth factor-b signalling<i>via</i>heat shock protein 90 in pulmonary fibrosis | ||
227 | +Pirfenidone attenuates bleomycin-induced pulmonary fibrosis in mice by regulating Nrf2/Bach1 equilibrium | ||
228 | +Cytokine gene polymorphisms and serum cytokine levels in patients with idiopathic pulmonary fibrosis | ||
229 | +Thalidomide prevents bleomycin-induced pulmonary fibrosis in mice | ||
230 | +Reduced expression of BMP3 contributes to the development of pulmonary fibrosis and predicts the unfavorable prognosis in IIP patients | ||
231 | +The antifibrotic effects and mechanisms of microRNA-26a action in idiopathic pulmonary fibrosis | ||
232 | +The K+ channel KCa3.1 as a novel target for idiopathic pulmonary fibrosis | ||
233 | +The Epstein-Barr virus latent membrane protein 1 and transforming growth factor--b1 synergistically induce epithelial--mesenchymal transition in lung epithelial cells | ||
234 | +An inhibitor of NADPH oxidase-4 attenuates established pulmonary fibrosis in a rodent disease model | ||
235 | +Pleiotropic effect of the proton pump inhibitor esomeprazole leading to suppression of lung inflammation and fibrosis | ||
236 | +Activated human T lymphocytes inhibit TGFb-induced fibroblast to myofibroblast differentiation via prostaglandins D2 and E2 | ||
237 | +Peripheral depletion of NK cells and imbalance of the Treg/Th17 axis in idiopathic pulmonary fibrosis patients | ||
238 | +Bone morphogenetic protein-4 inhibitor gremlin is overexpressed in idiopathic pulmonary fibrosis | ||
239 | +Role of protease-activated receptor-2 in idiopathic pulmonary fibrosis | ||
240 | +Type V collagen induced tolerance suppresses collagen deposition, TGF-b and associated transcripts in pulmonary fibrosis | ||
241 | +Syndecan-2 is a novel target of insulin-like growth factor binding protein-3 and is over-expressed in fibrosis | ||
242 | +Extracellular superoxide dismutase has a highly specific localization in idiopathic pulmonary fibrosis/usual interstitial pneumonia | ||
243 | +Early growth response transcription factors: key mediators of fibrosis and novel targets for anti-fibrotic therapy | ||
244 | +Effects of the tumor suppressor PTEN on the pathogenesis of idiopathic pulmonary fibrosis in Chinese patients | ||
245 | +Different effects of growth factors on proliferation and matrix production of normal and fibrotic human lung fibroblasts | ||
246 | +The impact of TGF-b on lung fibrosis: from targeting to biomarkers | ||
247 | +Herpes virus infection is associated with vascular remodeling and pulmonary hypertension in idiopathic pulmonary fibrosis | ||
248 | +N-acetylcysteine inhibits TNF-alpha, sTNFR, and TGF-beta1 release by alveolar macrophages in idiopathic pulmonary fibrosis in vitro | ||
249 | +Recombinant human serum amyloid P in healthy volunteers and patients with pulmonary fibrosis | ||
250 | +Transforming growth factor beta1 induces epithelial-to-mesenchymal transition of A549 cells | ||
251 | +X-linked inhibitor of apoptosis regulates lung fibroblast resistance to Fas-mediated apoptosis | ||
252 | +Idiopathic pulmonary fibrosis: immunohistochemical analysis provides fresh insights into lung tissue remodelling with implications for novel prognostic markers | ||
253 | +PI3K p110y overexpression in idiopathic pulmonary fibrosis lung tissue and fibroblast cells: in vitro effects of its inhibition | ||
254 | +Alveolar epithelial cell injury with Epstein-Barr virus upregulates TGFbeta1 expression | ||
255 | +Expression of mucosa-related integrin alphaEbeta7 on alveolar T cells in interstitial lung diseases | ||
256 | +Effects of cigarette smoke extract on A549 cells and human lung fibroblasts treated with transforming growth factor-beta1 in a coculture system | ||
257 | +Nuclear factor erythroid 2-related factor 2 nuclear translocation induces myofibroblastic dedifferentiation in idiopathic pulmonary fibrosis | ||
258 | +Rapamycin regulates connective tissue growth factor expression of lung epithelial cells via phosphoinositide 3-kinase | ||
259 | +Peptide-mediated inhibition of mitogen-activated protein kinase-activated protein kinase-2 ameliorates bleomycin-induced pulmonary fibrosis | ||
260 | +Effect of glycosides based standardized fenugreek seed extract in bleomycin-induced pulmonary fibrosis in rats: Decisive role of Bax, Nrf2, NF-kB, Muc5ac, TNF-a and IL-1b | ||
261 | +Simvastatin inhibits growth factor expression and modulates profibrogenic markers in lung fibroblasts | ||
262 | +Activated MCTC mast cells infiltrate diseased lung areas in cystic fibrosis and idiopathic pulmonary fibrosis | ||
263 | +Type II alveolar epithelial cells and interstitial fibroblasts express connective tissue growth factor in IPF | ||
264 | +Crosstalk between TGF-b1 and complement activation augments epithelial injury in pulmonary fibrosis | ||
265 | +RhoA signaling modulates cyclin D1 expression in human lung fibroblasts; implications for idiopathic pulmonary fibrosis | ||
266 | +Titration of non-replicating adenovirus as a vector for transducing active TGF-beta1 gene expression causing inflammation and fibrogenesis in the lungs of C57BL/6 mice | ||
267 | +Age-driven developmental drift in the pathogenesis of idiopathic pulmonary fibrosis | ||
268 | +Current and novel drug therapies for idiopathic pulmonary fibrosis | ||
269 | +Proliferation of pulmonary interstitial fibroblasts is mediated by transforming growth factor-beta1-induced release of extracellular fibroblast growth factor-2 and phosphorylation of p38 MAPK and JNK | ||
270 | +Secreted protein acidic and rich in cysteine (SPARC) is upregulated by transforming growth factor (TGF)-b and is required for TGF-b-induced hydrogen peroxide production in fibroblasts | ||
271 | +Semaphorin 7a+ regulatory T cells are associated with progressive idiopathic pulmonary fibrosis and are implicated in transforming growth factor-b1-induced pulmonary fibrosis | ||
272 | +Regulation of transforming growth factor-b1-driven lung fibrosis by galectin-3 | ||
273 | +Reduced transcription of the Smad4 gene during pulmonary carcinogenesis in idiopathic pulmonary fibrosis | ||
274 | +Curcumin inhibits fibrosis-related effects in IPF fibroblasts and in mice following bleomycin-induced lung injury | ||
275 | +Targeting sphingosine kinase 1 attenuates bleomycin-induced pulmonary fibrosis | ||
276 | +Data on CUX1 isoforms in idiopathic pulmonary fibrosis lung and systemic sclerosis skin tissue sections | ||
277 | +Arsenic trioxide inhibits transforming growth factor-b1-induced fibroblast to myofibroblast differentiation in vitro and bleomycin induced lung fibrosis in vivo |
results/Partition_2/cluster1_tagged.txt
0 → 100644
1 | +Assessment of the effect of potential antifibrotic compounds on total and aVb6 integrin-mediated TGF-b <v>activation.</v> | ||
2 | +Resveratrol inhibits transforming growth factor-b-induced proliferation and differentiation of ex vivo human lung fibroblasts into myofibroblasts through <g>ERK</g>/<g>Akt</g> <u>inhibition </u>and <g>PTEN</g> restoration | ||
3 | +Immunoglobulin A in serum: an old acquaintance as a new prognostic biomarker in <d>idiopathic pulmonary fibrosis</d> | ||
4 | +[Pulmonary fibrosis--a therapeutic dilemma?] | ||
5 | +<g>Syndecan-2</g> exerts antifibrotic effects by promoting <g>caveolin-1</g>-mediated transforming growth factor-b receptor I internalization and inhibiting transforming growth factor-b1 signaling | ||
6 | +Modulation of specific beta cell gene (re)expression during in vitro expansion of human pancreatic islet cells | ||
7 | +Amplification of <g>TGFb</g> | ||
8 | +[<d>Idiopathic pulmonary fibrosis</d> and <d>lung cancer</d>] | ||
9 | +<g>Periostin</g> promotes <d>fibrosis</d> and predicts progression in patients with <d>idiopathic pulmonary fibrosis</d> | ||
10 | +<g>CCN5</g> <v>overexpression </v>inhibits profibrotic phenotypes via the <g>PI3K</g>/Akt signaling pathway in lung fibroblasts isolated from patients with <d>idiopathic pulmonary fibrosis</d> and in an in vivo model of <d>lung fibrosis</d> | ||
11 | +<g>Extracellular superoxide dismutase</g> has a highly specific <l>localization </l>in <d>idiopathic pulmonary fibrosis</d>/<d>usual interstitial pneumonia</d> | ||
12 | +Signaling pathways in the epithelial origins of <d>pulmonary fibrosis</d> | ||
13 | +Overexpression of <d>squamous cell carcinoma</d> antigen in <d>idiopathic pulmonary fibrosis</d>: clinicopathological correlations | ||
14 | +An ex vivo model to induce early <d>fibrosis</d>-like changes in human precision-cut lung slices | ||
15 | +The role of halofuginone in fibrosis: more to be explored? Fibrosis, which can be defined as an abnormal or excessive accumulation of extracellular matrix (ECM), particularly fibrillar collagens, is a key driver of progressive organ dysfunction in many inflammatory and metabolic diseases, including idiopathic pulmonary fibrosis (IPF), cirrhosis, nephropathy, and oral submucous fibrosis (OSF) | ||
16 | +Genomewide RNA expression profiling in lung identifies distinct signatures in <d>idiopathic pulmonary arterial hypertension</d> and <d>secondary pulmonary hypertension</d> | ||
17 | +Establishment of the mouse model of acute exacerbation of <d>idiopathic pulmonary fibrosis</d> | ||
18 | +Dehydroepiandrosterone has strong antifibrotic effects and is decreased in <d>idiopathic pulmonary fibrosis</d> | ||
19 | +Metformin <d>attenuates lung fibrosis</d> development via <g>NOX4</g> <u>suppression.</u> | ||
20 | +<g>Plasminogen activator inhibitor 1</g>, fibroblast apoptosis resistance, and aging-related susceptibility to lung <d>fibrosis</d> | ||
21 | +Cytokine gene polymorphisms and serum cytokine levels in patients with <d>idiopathic pulmonary fibrosis</d> | ||
22 | +Raised serum levels of <g>IGFBP-1</g> and <g>IGFBP-2</g> in <d>idiopathic pulmonary fibrosis</d> | ||
23 | +Determining the True Selectivity Profile of av Integrin Ligands Using Radioligand Binding: Applying an Old Solution to a New Problem | ||
24 | +Tumor <d>necrosis</d> factor superfamily 14 (<d>LIGHT</d>) controls <g>thymic stromal lymphopoietin</g> to drive <d>pulmonary fibrosis</d> | ||
25 | +<g>Pigment epithelium-derived factor</g> in <d>idiopathic pulmonary fibrosis</d>: a role in aberrant angiogenesis | ||
26 | +Methylation-mediated <g>BMPER</g> <e>expression </e>in fibroblast activation in vitro and lung <d>fibrosis</d> in mice in vivo | ||
27 | +<d>Fibrosis</d> of two: Epithelial cell-fibroblast interactions in <d>pulmonary fibrosis</d> | ||
28 | +Peptide-mediated inhibition of <g>mitogen-activated protein kinase-activated protein kinase-2</g> ameliorates bleomycin-induced <d>pulmonary fibrosis</d> | ||
29 | +Role of integrin-<v>mediated </v><g>TGFbeta</g> <v>activation </v>in the pathogenesis of <d>pulmonary fibrosis</d> | ||
30 | +Novel pharmacological approaches to manage <d>interstitial lung fibrosis</d> in the twenty-first century | ||
31 | +Lipoxin A4 Attenuates Constitutive and <g>TGF-b1</g>-Dependent Profibrotic Activity in Human Lung Myofibroblasts | ||
32 | +<g>Hsp90</g> <r>regulation </r>of fibroblast activation in <d>pulmonary fibrosis</d> | ||
33 | +<g>Glucagon like peptide-1</g> attenuates bleomycin-induced <d>pulmonary fibrosis</d>, involving the <u>inactivation </u>of NF-kB in mice | ||
34 | +<g>MiR-185</g>/<g>AKT</g> and <g>miR-29a</g>/collagen 1a pathways are <v>activated </v>in <d>IPF</d> | ||
35 | +Arsenic trioxide inhibits transforming growth factor-b1-induced <d>fibroblast to myofibroblast differentiation</d> in vitro and bleomycin induced lung <d>fibrosis</d> in vivo | ||
36 | +<g>Wilms' tumor 1</g> (<g>Wt1</g>) regulates pleural mesothelial cell plasticity and transition into myofibroblasts in <d>idiopathic pulmonary fibrosis</d> | ||
37 | +<g>miR-26a</g> suppresses EMT by disrupting the <g>Lin28B</g>/<g>let-7d</g> axis: potential cross-talks among miRNAs in <d>IPF</d> | ||
38 | +microRNA-1343 attenuates pathways of <d>fibrosis</d> by targeting the <g>TGF-b</g> receptors | ||
39 | +Kinase <u>inhibitors </u>fail to induce mesenchymal-epithelial transition in fibroblasts from fibrotic lung tissue | ||
40 | +<g>Transgelin</g> is a direct target of <g>TGF-beta</g>/<g>Smad3</g>-dependent epithelial cell <d>migration in lung fibrosis</d> | ||
41 | +The mannose-6-phosphate analogue, PXS64, inhibits <d>fibrosis</d> via <g>TGF-b1</g> pathway in human lung fibroblasts | ||
42 | +<u>Reduced </u><e>expression </e>of <g>BMP3</g> contributes to the development of <d>pulmonary fibrosis</d> and predicts the unfavorable prognosis in IIP patients | ||
43 | +Role of <g>CD248</g> as a potential severity marker in <d>idiopathic pulmonary fibrosis</d> | ||
44 | +Early growth response transcription factors: key mediators of <d>fibrosis</d> and novel targets for anti-fibrotic therapy | ||
45 | +<g>Toll-like receptor 4</g> activation attenuates profibrotic response in control lung fibroblasts but not in fibroblasts from patients with <d>IPF</d> | ||
46 | +<g>BAX inhibitor-1</g>-associated <g>V-ATPase</g> glycosylation <v>enhances </v>collagen degradation in <d>pulmonary fibrosis</d> | ||
47 | +Sphingosine-1-phosphate lyase is an endogenous suppressor of <d>pulmonary fibrosis</d>: role of <g>S1P</g> signalling and autophagy | ||
48 | +<g>Nuclear factor erythroid 2-related factor 2</g> nuclear translocation induces <d>myofibroblastic dedifferentiation</d> in <d>idiopathic pulmonary fibrosis</d> | ||
49 | +<g>Matrix metalloproteinase (MMP)-19</g> <u>deficient </u>fibroblasts display a profibrotic phenotype | ||
50 | +A translational preclinical model of <d>interstitial pulmonary fibrosis</d> and <d>pulmonary hypertension</d>: mechanistic pathways driving disease pathophysiology | ||
51 | +Comparative study of transforming growth factor-b signalling and regulatory molecules in human and canine <d>idiopathic pulmonary fibrosis</d> | ||
52 | +Cytokine gene polymorphisms and BALF cytokine levels in <d>interstitial lung diseases</d> | ||
53 | +<g>PI3K</g> p110y <v>overexpression </v>in <d>idiopathic pulmonary fibrosis lung</d> tissue and fibroblast cells: in vitro effects of its inhibition | ||
54 | +Low-dose paclitaxel ameliorates <d>pulmonary fibrosis</d> by suppressing <g>TGF-b1</g>/<g>Smad3</g> pathway via <g>miR-140</g> upregulation | ||
55 | +MicroRNAs in <d>idiopathic pulmonary fibrosis</d> | ||
56 | +Two-Way Conversion between Lipogenic and Myogenic Fibroblastic Phenotypes Marks the Progression and Resolution of Lung <d>Fibrosis</d> | ||
57 | +Membrane type-matrix metalloproteinases in <d>idiopathic pulmonary fibrosis</d> | ||
58 | +<g>BARD1</g> mediates <g>TGF-b</g> signaling in <d>pulmonary fibrosis</d> | ||
59 | +Increased <d>alveolar</d> soluble <g>annexin V</g> promotes <d>lung inflammation</d> and <d>fibrosis</d> | ||
60 | +Autophagy in <d>idiopathic pulmonary fibrosis</d> | ||
61 | +<g>TGF-b1</g> <v>induces </v><g>Fstl1</g> via the <g>Smad3</g>-<g>c-Jun</g> pathway in lung fibroblasts | ||
62 | +Genetic polymorphism in <g>matrix metalloproteinase-9</g> and <g>transforming growth factor-b1</g> and susceptibility to <d>combined pulmonary fibrosis</d> and <d>emphysema</d> in a Chinese population | ||
63 | +MS80, a novel sulfated oligosaccharide, inhibits <d>pulmonary fibrosis</d> by targeting <g>TGF-beta1</g> both in vitro and in vivo | ||
64 | +Protective role of gambogic acid in experimental <d>pulmonary fibrosis</d> in vitro and in vivo | ||
65 | +Sorafenib ameliorates bleomycin-induced <d>pulmonary fibrosis</d>: potential roles in the inhibition of epithelial-mesenchymal transition and fibroblast activation | ||
66 | +[Different cytokine profiles in <d>usual interstitial pneumonia</d> and <d>nonspecific interstitial pneumonia</d>] | ||
67 | +Simvastatin attenuates <g>TGF-b1</g>-induced epithelial-mesenchymal transition in human alveolar epithelial cells | ||
68 | +Expression of <g>suppressor of cytokine signaling 1</g> in the peripheral blood of patients with <d>idiopathic pulmonary fibrosis</d> | ||
69 | +Profibrotic role of <g>miR-154</g> in <d>pulmonary fibrosis</d> | ||
70 | +Anchorage-independent colony growth of pulmonary fibroblasts derived from fibrotic human lung tissue | ||
71 | +<g>Aortic carboxypeptidase-like protein</g> (<g>ACLP</g>) enhances lung myofibroblast differentiation through transforming growth factor b receptor-dependent and -independent pathways | ||
72 | +The latent form of <g>TGFbeta(1)</g> is induced by <g>TNFalpha</g> through an <g>ERK</g> specific pathway and is <v>activated </v>by asbestos-derived reactive oxygen species in vitro and in vivo | ||
73 | +Differential effects of human neutrophil peptide-1 on growth factor and <g>interleukin-8</g> production by human lung fibroblasts and epithelial cells | ||
74 | +Transforming growth factor-b1 downregulates <g>vascular endothelial growth factor</g>-D expression in human lung fibroblasts via the <g>Jun NH2-terminal kinase</g> signaling pathway | ||
75 | +<g>Ubiquitin carboxyl-terminal hydrolase-L5</g> promotes <g>TGFb-1</g> signaling by de-ubiquitinating and stabilizing <g>Smad2</g>/<g>Smad3</g> in <d>pulmonary fibrosis</d> | ||
76 | +Effects of particulate matter from straw burning on <d>lung fibrosis</d> in mice | ||
77 | +<g>miR -221</g> targets <g>HMGA2</g> to inhibit bleomycin -induced <d>pulmonary fibrosis</d> by regulating <g>TGF -b1</g>/<g>Smad3</g>-induced EMT | ||
78 | +<g>EZH2</g> enhances the differentiation of fibroblasts into myofibroblasts in <d>idiopathic pulmonary fibrosis</d> | ||
79 | +Effect of pirfenidone on proliferation, <g>TGF-b</g>-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts | ||
80 | +[Quantifying plasma levels of <g>transforming growth factor beta1</g> in <d>idiopathic pulmonary fibrosis</d>] | ||
81 | +The matricellular protein <g>CCN1</g> enhances <g>TGF-b1</g>/<g>SMAD3</g>-dependent profibrotic signaling in fibroblasts and contributes to fibrogenic responses to <d>lung injury</d> | ||
82 | +Tubastatin ameliorates <d>pulmonary fibrosis</d> by targeting the TGFb-PI3K-<g>Akt</g> pathway | ||
83 | +Lung fibrotic <g>tenascin-C</g> <v>upregulation </v>is associated with other extracellular matrix proteins and <v>induced </v>by TGFb1 | ||
84 | +Tannic acid attenuates TGF-b1-induced epithelial-to-mesenchymal transition by effectively intervening TGF-b signaling in lung epithelial cells | ||
85 | +Abrogation of <g>TGF-beta1</g>-induced fibroblast-myofibroblast differentiation by <g>histone deacetylase</g> <u>inhibition.</u> <d>Idiopathic pulmonary fibrosis</d> (<d>IPF</d>) is a devastating disease with no known effective pharmacological therapy | ||
86 | +<g>AKT2</g> | ||
87 | +Regulation of myofibroblast differentiation by <g>miR-424</g> during epithelial-to-mesenchymal transition | ||
88 | +Bleomycin in the setting of <d>lung fibrosis</d> induction: From biological mechanisms to counteractions | ||
89 | +MicroRNA-101 attenuates pulmonary fibrosis by inhibiting fibroblast proliferation and activation | ||
90 | +<g>Extracellular Matrix Metalloproteinase Inducer</g> (<g>EMMPRIN</g>) promotes lung fibroblast proliferation, survival and differentiation to myofibroblasts | ||
91 | +<g>TGF-b</g> activation and lung <d>fibrosis</d> | ||
92 | +<v>Increased </v>interleukin-1 receptor antagonist in <d>idiopathic pulmonary fibrosis</d> | ||
93 | +<g>TIAM1</g> inhibits lung fibroblast differentiation in <d>pulmonary fibrosis</d> | ||
94 | +Targeting <g>sphingosine kinase 1</g> attenuates bleomycin-induced <d>pulmonary fibrosis</d> | ||
95 | +Re-evaluation of fibrogenic cytokines in <d>lung fibrosis</d> | ||
96 | +Targeting genes for treatment in <d>idiopathic pulmonary fibrosis</d>: challenges and opportunities, promises and pitfalls | ||
97 | +Defect of pro-<g>hepatocyte growth factor</g> activation by fibroblasts in <d>idiopathic pulmonary fibrosis</d> | ||
98 | +Epithelial Cell Mitochondrial Dysfunction and <g>PINK1</g> | ||
99 | +<l>Release </l>of biologically active <g>TGF-beta1</g> by alveolar epithelial cells results in <d>pulmonary fibrosis</d> | ||
100 | +IPF lung fibroblasts have a senescent phenotype | ||
101 | +Autophagy and <d>inflammation</d> in chronic <d>respiratory disease</d> | ||
102 | +The profibrotic cytokine <g>transforming growth factor-b1</g> increases endothelial progenitor cell angiogenic properties | ||
103 | +Regulation of transforming growth factor-b1-driven lung <d>fibrosis</d> by <g>galectin-3</g> | ||
104 | +Epigenetic <r>Regulation </r>of <g>Caveolin-1</g> | ||
105 | +Expression of <g>150-kDa oxygen-regulated protein</g> (<g>ORP150</g>) stimulates bleomycin-induced <d>pulmonary fibrosis and dysfunction</d> in mice | ||
106 | +Role of endoplasmic reticulum stress in age-related susceptibility to lung <d>fibrosis</d> | ||
107 | +Alveolar epithelial cell injury with Epstein-Barr virus <v>upregulates </v><g>TGFbeta1</g> <e>expression.</e> <d>Idiopathic pulmonary fibrosis</d> (<d>IPF</d>) is a refractory and lethal <d>interstitial lung disease</d> characterized by alveolar epithelial cells apoptosis, fibroblast proliferation, and ECM protein deposition | ||
108 | +<d>Pulmonary fibrosis</d>: pathogenesis, etiology and regulation | ||
109 | +Activated MCTC mast cells infiltrate diseased lung areas in <d>cystic fibrosis</d> and <d>idiopathic pulmonary fibrosis</d> | ||
110 | +<g>PPAR</g>-y ligands repress <g>TGFb</g>-induced myofibroblast differentiation by targeting the <g>PI3K</g>/<g>Akt</g> pathway: implications for therapy of <d>fibrosis</d> | ||
111 | +De-ubiquitinating enzyme, <g>USP11</g>, promotes <g>transforming growth factor b-1</g> signaling through stabilization of transforming growth factor b receptor II | ||
112 | +Single-cell RNA sequencing identifies diverse roles of epithelial cells in <d>idiopathic pulmonary fibrosis</d> | ||
113 | +The antifibrotic effects and mechanisms of microRNA-26a action in <d>idiopathic pulmonary fibrosis</d> | ||
114 | +Phosphatase and tensin homolog deleted on chromosome 10 contributes to phenotype transformation of fibroblasts in <d>idiopathic pulmonary fibrosis</d> via multiple pathways | ||
115 | +Lower expression of platelet derived growth factor is associated with better overall survival rate of patients with idiopathic nonspecific interstitial pneumonia | ||
116 | +Investigation of bone marrow mesenchymal stem cells (BM MSCs) involvement in <d>Idiopathic Pulmonary Fibrosis</d> (<d>IPF</d>) | ||
117 | +<g>Neutrophil elastase</g> promotes myofibroblast <d>differentiation in lung fibrosis</d> | ||
118 | +<g>MAP3K19</g> | ||
119 | +Effect of Renshen Pingfei Decoction, a traditional Chinese prescription, on <d>IPF</d> <v>induced </v>by Bleomycin in rats and <r>regulation </r>of <g>TGF-b1</g>/<g>Smad3</g> | ||
120 | +Macrophage <g>Bone Morphogenic Protein Receptor 2</g> (<g>BMPR2</g>) <u>depletion </u>in <d>Idiopathic Pulmonary Fibrosis</d> (<d>IPF</d>) and Group III Pulmonary <d>Hypertension</d> | ||
121 | +<g>Cartilage oligomeric matrix protein</g> in <d>idiopathic pulmonary fibrosis</d> | ||
122 | +Negative regulation of myofibroblast differentiation by <g>PTEN</g> (Phosphatase and Tensin Homolog Deleted on chromosome 10) | ||
123 | +Data on <g>CUX1</g> isoforms in <d>idiopathic pulmonary fibrosis lung</d> and <d>systemic sclerosis</d> skin tissue sections | ||
124 | +Alveolar epithelial cells express mesenchymal proteins in patients with <d>idiopathic pulmonary fibrosis</d> | ||
125 | +<d>Idiopathic Pulmonary Fibrosis</d>: Aging, Mitochondrial Dysfunction, and Cellular Bioenergetics | ||
126 | +<g>SPARC</g> suppresses apoptosis of <d>idiopathic pulmonary fibrosis</d> fibroblasts through constitutive <v>activation </v>of <g>beta-catenin</g> | ||
127 | +Resveratrol-Mediated Repression and Reversion of Prostatic Myofibroblast Phenoconversion | ||
128 | +[The potential role of cytokines expression in <d>idiopathic pulmonary fibrosis</d>] | ||
129 | +Effect of an immunotoxin to <g>folate receptor beta</g> on bleomycin-induced <d>experimental pulmonary fibrosis</d> | ||
130 | +<v>Elevated </v><e>expression </e>of <g>NEU1</g> sialidase in <d>idiopathic pulmonary fibrosis</d> <v>provokes </v>pulmonary collagen deposition, <d>lymphocytosis</d>, and <d>fibrosis</d> | ||
131 | +Genetic partitioning of <g>interleukin-6</g> signalling in mice dissociates <g>Stat3</g> from <g>Smad3</g>-mediated <d>lung fibrosis</d> | ||
132 | +Reactive oxygen species are required for maintenance and differentiation of primary lung fibroblasts in <d>idiopathic pulmonary fibrosis</d> | ||
133 | +Oxidant-antioxidant imbalance as a potential contributor to the progression of human <d>pulmonary fibrosis</d> | ||
134 | +Increased production and immunohistochemical localization of <g>transforming growth factor-beta</g> in <d>idiopathic pulmonary fibrosis</d> | ||
135 | +N-acetylcysteine inhibits alveolar epithelial-mesenchymal transition | ||
136 | +Type V collagen induced tolerance suppresses collagen deposition, <g>TGF-b</g> and associated transcripts in <d>pulmonary fibrosis</d> | ||
137 | +<g>CUX1</g>/Wnt signaling regulates epithelial mesenchymal transition in EBV infected epithelial cells | ||
138 | +Lactic acid is elevated in <d>idiopathic pulmonary fibrosis</d> and induces myofibroblast differentiation via pH-dependent activation of transforming growth factor-b | ||
139 | +Preventive and therapeutic effects of thymosin b4 N-terminal fragment Ac-SDKP in the bleomycin model of pulmonary fibrosis | ||
140 | +Epithelial cell alpha3beta1 integrin links <g>beta-catenin</g> and Smad signaling to promote myofibroblast formation and <d>pulmonary fibrosis</d> | ||
141 | +EMT and <d>interstitial lung disease</d>: a mysterious relationship | ||
142 | +Pirfenidone exerts antifibrotic effects through <u>inhibition </u>of GLI transcription factors | ||
143 | +<g>STAT3</g>-mediated signaling dysregulates lung fibroblast-myofibroblast activation and differentiation in UIP/IPF | ||
144 | +Epithelial stem cell exhaustion in the pathogenesis of <d>idiopathic pulmonary fibrosis</d> | ||
145 | +FAK-related nonkinase is a multifunctional negative regulator of <d>pulmonary fibrosis</d> | ||
146 | +Nitrated fatty acids reverse <d>pulmonary fibrosis</d> by dedifferentiating myofibroblasts and promoting collagen uptake by alveolar macrophages | ||
147 | +Berberine attenuates bleomycin induced <d>pulmonary toxicity</d> and <d>fibrosis</d> via <u>suppressing </u><g>NF-kB</g> dependant <g>TGF-b</g> <v>activation:</v> a biphasic experimental study | ||
148 | +<g>N-acetyl-L-cysteine</g> inhibits <g>TGF-beta1</g>-induced profibrotic responses in fibroblasts | ||
149 | +Interleukin-17 induces human alveolar epithelial to mesenchymal cell transition via the <g>TGF-b1</g> <v>mediated </v><g>Smad2/3</g> and <g>ERK1/2</g> <v>activation.</v> <d>Idiopathic pulmonary fibrosis</d> (<d>IPF</d>) is a chronic and usually progressive <d>lung disease</d> and the epithelial-mesenchymal transition (EMT) may play an important role in the pathogenesis of <d>pulmonary fibrosis</d> | ||
150 | +<g>TGF-beta1</g> induces human alveolar epithelial to mesenchymal cell transition (EMT) | ||
151 | +Thalidomide prevents bleomycin-induced <d>pulmonary fibrosis</d> in mice | ||
152 | +Intratracheal bleomycin causes airway remodeling and airflow obstruction in mice | ||
153 | +Significance of <v>elevated </v>procollagen-III-peptide and <g>transforming growth factor-beta</g> levels of bronchoalveolar lavage fluids from <d>idiopathic pulmonary fibrosis</d> patients | ||
154 | +<g>MiR-338</g>* targeting <g>smoothened</g> to inhibit <d>pulmonary fibrosis</d> by epithelial-mesenchymal transition | ||
155 | +Proteasomal regulation of <d>pulmonary fibrosis</d> | ||
156 | +Epithelium-specific deletion of <g>TGF-b</g> receptor type II protects mice from bleomycin-induced <d>pulmonary fibrosis</d> | ||
157 | +<g>Renin</g> is an angiotensin-independent profibrotic mediator: role in <d>pulmonary fibrosis</d> | ||
158 | +Role for alpha3 integrin in EMT and <d>pulmonary fibrosis</d> | ||
159 | +Beyond <g>TGFb</g> - Novel ways to target airway and parenchymal <d>fibrosis</d> | ||
160 | +<g>Lysocardiolipin acyltransferase</g> regulates <g>TGF-b</g> mediated lung fibroblast differentiation | ||
161 | +Cytokine profiles in <d>idiopathic pulmonary fibrosis</d> suggest an important role for <g>TGF-beta</g> and <g>IL-10</g> | ||
162 | +<g>CXCL9</g> | ||
163 | +Differing Expression of Cytokines and <d>Tumor</d> | ||
164 | +Sphingosine-1-phosphate is increased in patients with <d>idiopathic pulmonary fibrosis</d> and mediates epithelial to mesenchymal transition | ||
165 | +<g>MiR-5100</g> targets <g>TOB2</g> to drive epithelial-mesenchymal transition associated with <v>activating </v><g>smad2/3</g> in lung epithelial cells | ||
166 | +The impact of <g>TGF-b</g> on lung <d>fibrosis</d>: from targeting to biomarkers | ||
167 | +Mast cell chymase: an indispensable instrument in the pathological symphony of <d>idiopathic pulmonary fibrosis</d>? <d>Idiopathic pulmonary fibrosis</d> (<d>IPF</d>) is a chronic, progressive and fatal <d>lung disease</d> with no known etiology and treatment options | ||
168 | +Leucine-rich a-2 glycoprotein promotes <d>lung fibrosis</d> by modulating <g>TGF-b</g> signaling in fibroblasts | ||
169 | +Normal Human Lung Epithelial Cells Inhibit Transforming Growth Factor-b Induced Myofibroblast Differentiation via Prostaglandin E2 | ||
170 | +Carbon monoxide-bound hemoglobin-vesicles for the treatment of bleomycin-induced <d>pulmonary fibrosis</d> | ||
171 | +Sustained <g>PI3K</g> | ||
172 | +miR-18a-5p <u>Inhibits </u>Sub-pleural Pulmonary Fibrosis by Targeting <g>TGF-b</g> | ||
173 | +Pirfenidone <u>inhibits </u>the <e>expression </e>of <g>HSP47</g> in <g>TGF-beta1</g>-stimulated human lung fibroblasts | ||
174 | +Tissue inhibitor of metalloproteinase-3 is up-regulated by <g>transforming growth factor-beta1</g> in vitro and expressed in fibroblastic foci in vivo in <d>idiopathic pulmonary fibrosis</d> | ||
175 | +Increased Galectin-9 Concentration and Number of CD4+Foxp3high+Cells in Bronchoalveolar Lavage Fluid of Patients with <d>Cryptogenic Organizing Pneumonia</d> | ||
176 | +Transforming growth factor-b <u>inhibits </u>IQ motif containing guanosine triphosphatase <v>activating </v>protein 1 <e>expression </e>in lung fibroblasts via the nuclear factor-kB signaling pathway | ||
177 | +<g>Yin yang 1</g> is a novel regulator of <d>pulmonary fibrosis</d> | ||
178 | +Role of <d>von Hippel-Lindau</d> protein in fibroblast proliferation and <d>fibrosis</d> | ||
179 | +<g>X-linked inhibitor of apoptosis</g> regulates lung fibroblast resistance to Fas-mediated apoptosis | ||
180 | +<d>Idiopathic pulmonary fibrosis</d>: pathobiology of novel approaches to treatment | ||
181 | +Age-driven developmental drift in the pathogenesis of <d>idiopathic pulmonary fibrosis</d> | ||
182 | +Endogenous <g>Semaphorin-7A</g> | ||
183 | +Progressive transforming growth factor beta1-induced <d>lung fibrosis</d> is blocked by an orally active <g>ALK5</g> kinase <u>inhibitor.</u> <d>Pulmonary fibrosis</d> is characterized by chronic scar formation and deposition of extracellular matrix, resulting in <d>impaired lung function</d> and <d>respiratory failure</d> | ||
184 | +Simvastatin inhibits growth factor expression and modulates profibrogenic markers in lung fibroblasts | ||
185 | +MicroRNA regulatory networks in <d>idiopathic pulmonary fibrosis</d> | ||
186 | +Fibroblastic foci, covered with <d>alveolar epithelia</d> exhibiting <d>epithelial-mesenchymal transition</d>, destroy <d>alveolar septa</d> by disrupting blood flow in <d>idiopathic pulmonary fibrosis</d> | ||
187 | +<e>Overproduction </e>of collagen and <u>diminished </u><g>SOCS1</g> <e>expression </e>are causally linked in fibroblasts from <d>idiopathic pulmonary fibrosis</d> | ||
188 | +<r>Regulation </r>of 26S Proteasome Activity in <d>Pulmonary Fibrosis</d> | ||
189 | +Therapeutic targets in fibrotic pathways | ||
190 | +Compromised peroxisomes in <d>idiopathic pulmonary fibrosis</d>, a vicious cycle inducing a higher fibrotic response via <g>TGF-b</g> signaling | ||
191 | +<d>Lung infection</d> with gamma-herpesvirus induces progressive <d>pulmonary fibrosis</d> in Th2-biased mice | ||
192 | +Mode of action of nintedanib in the treatment of <d>idiopathic pulmonary fibrosis</d> | ||
193 | +<g>Semaphorin 7a</g>+ regulatory T cells are associated with progressive <d>idiopathic pulmonary fibrosis</d> and are implicated in transforming growth factor-b1-induced <d>pulmonary fibrosis</d> | ||
194 | +Increased expression of 5-hydroxytryptamine2A/B receptors in <d>idiopathic pulmonary fibrosis</d>: a rationale for therapeutic intervention | ||
195 | +<v>Increased </v>deposition of chondroitin/dermatan sulfate glycosaminoglycan and <v>upregulation </v>of b1,3-glucuronosyltransferase I in <d>pulmonary fibrosis</d> | ||
196 | +Pathogenesis pathways of <d>idiopathic pulmonary fibrosis</d> in bleomycin-induced <d>lung injury</d> model in mice | ||
197 | +Latent cytomegalovirus infection exacerbates experimental <d>pulmonary fibrosis</d> by <v>activating </v><g>TGF-b1</g> | ||
198 | +<r>Effects </r>of antifibrotic agents on <g>TGF-beta1</g>, <g>CTGF</g> and <g>IFN-gamma</g> <e>expression </e>in patients with <d>idiopathic pulmonary fibrosis</d> | ||
199 | +<g>Microsomal prostaglandin E synthase-1</g> <u>deficiency </u>exacerbates <d>pulmonary fibrosis</d> induced by bleomycin in mice | ||
200 | +Inhibition of NF-kappaB signaling reduces virus load and gammaherpesvirus-induced <d>pulmonary fibrosis</d> | ||
201 | +Effects and mechanisms of pirfenidone, prednisone and acetylcysteine on <d>pulmonary fibrosis</d> in rat <d>idiopathic pulmonary fibrosis</d> models | ||
202 | +Accelerated epithelial cell senescence in <d>IPF</d> and the inhibitory role of <g>SIRT6</g> in <g>TGF-b</g>-induced senescence of human bronchial epithelial cells | ||
203 | +<g>Transforming growth factor-beta1</g> in <d>sarcoidosis</d> | ||
204 | +<g>TGF-b1</g> induces <g>tissue factor</g> expression in human lung fibroblasts in a <g>PI3K</g>/<g>JNK</g>/<g>Akt</g>-dependent and <g>AP-1</g>-dependent manner | ||
205 | +Epithelial-mesenchymal transition in chronic <d>hypersensitivity pneumonitis</d> | ||
206 | +Uncoupling of the profibrotic and hemostatic effects of <g>thrombin</g> in <d>lung fibrosis</d> | ||
207 | +Molecular targets in <d>pulmonary fibrosis</d>: the myofibroblast in focus | ||
208 | +Immunomodulation by mesenchymal stem cells in treating human <d>autoimmune disease-associated lung fibrosis</d> | ||
209 | +<u>Reduced </u>transcription of the <g>Smad4</g> gene during <d>pulmonary carcinogenesis</d> in <d>idiopathic pulmonary fibrosis</d> | ||
210 | +Intrinsic defence capacity and therapeutic potential of natriuretic peptides in <d>pulmonary hypertension</d> associated with <d>lung fibrosis</d> | ||
211 | +Curcumin inhibits <d>fibrosis</d>-related effects in <d>IPF</d> fibroblasts and in mice following bleomycin-induced <d>lung injury</d> | ||
212 | +<g>NADPH oxidase-4</g> mediates myofibroblast activation and fibrogenic responses to <d>lung injury</d> | ||
213 | +Anti-fibrotic Role of aB-crystallin Inhibition in Pleural and Subpleural <d>Fibrosis</d> | ||
214 | +Pleiotropic effect of the proton pump inhibitor esomeprazole leading to suppression of <d>lung inflammation</d> and <d>fibrosis</d> | ||
215 | +Reviews and prospectives of signaling pathway analysis in <d>idiopathic pulmonary fibrosis</d> | ||
216 | +Roles of p38 MAPK and <g>JNK</g> in <g>TGF-b1</g>-induced human alveolar epithelial to mesenchymal transition | ||
217 | +Predisposition for disrepair in the aged lung | ||
218 | +Possible involvement of pirfenidone metabolites in the antifibrotic action of a therapy for <d>idiopathic pulmonary fibrosis</d> | ||
219 | +N-acetylcysteine <u>downregulation </u>of <g>lysyl oxidase</g> activity alleviating bleomycin-induced <d>pulmonary fibrosis</d> in rats | ||
220 | +Evaluation of permeability alteration and epithelial-mesenchymal transition induced by <g>transforming growth factor-b1</g> in A549, NCI-H441, and Calu-3 cells: Development of an in vitro model of respiratory epithelial cells in <d>idiopathic pulmonary fibrosis</d> | ||
221 | +Epithelial contribution to the pro-fibrotic stiff microenvironment and myofibroblast population in lung <d>fibrosis</d> | ||
222 | +Interactions between <g>b-catenin</g> and <g>transforming growth factor-b</g> signaling pathways mediate epithelial-mesenchymal transition and are dependent on the transcriptional co-activator cAMP-response element-binding protein (<g>CREB)-binding protein</g> (<g>CBP</g>) | ||
223 | +BAL cytokine profile in different <d>interstitial lung diseases</d>: a focus on <d>systemic sclerosis</d> | ||
224 | +<g>Syndecan-2</g> is a novel target of <g>insulin-like growth factor binding protein-3</g> and is <v>over-expressed </v>in <d>fibrosis</d> | ||
225 | +Membrane-anchored <g>Serine Protease</g> <g>Matriptase</g> | ||
226 | +Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with <d>idiopathic pulmonary fibrosis</d> | ||
227 | +The small heat-shock protein aB-crystallin is essential for the nuclear <l>localization </l>of <g>Smad4</g>: impact on <d>pulmonary fibrosis</d> | ||
228 | +Medical treatment for <d>pulmonary fibrosis</d>: current trends, concepts, and prospects | ||
229 | +Ambroxol hydrochloride in the management of <d>idiopathic pulmonary fibrosis</d>: Clinical trials are the need of the hour | ||
230 | +Combined <u>inhibition </u>of <g>TGFb</g> and PDGF signaling attenuates radiation-induced <d>pulmonary fibrosis</d> | ||
231 | +Diagnostic Values For Club Cell Secretory Protein (<g>CC16</g>) in Serum of Patients of Combined Pulmonary Fibrosis and Emphysema | ||
232 | +<e>Effects </e>of <g>thymosin b4</g> and its N-terminal fragment Ac-SDKP on <g>TGF-b</g>-treated human lung fibroblasts and in the mouse model of bleomycin-induced <d>lung fibrosis</d> | ||
233 | +Matrix metalloproteinase 3 is a mediator of <d>pulmonary fibrosis</d> | ||
234 | +An <u>inhibitor </u>of NADPH oxidase-4 attenuates established <d>pulmonary fibrosis</d> in a <d>rodent disease</d> model | ||
235 | +<u>Inhibition </u>of <g>PI3K</g> prevents the proliferation and differentiation of human lung fibroblasts into myofibroblasts: the role of class I P110 isoforms | ||
236 | +<r>Effects </r>of doxycycline on <e>production </e>of growth factors and matrix metalloproteinases in <d>pulmonary fibrosis</d> | ||
237 | +Human placental mesenchymal stem cells of fetal origins-alleviated <d>inflammation</d> and <d>fibrosis</d> by attenuating <g>MyD88</g> signaling in bleomycin-induced <d>pulmonary fibrosis</d> mice | ||
238 | +Roles for <g>insulin-like growth factor I</g> and <g>transforming growth factor-beta</g> in <d>fibrotic lung disease</d> | ||
239 | +Role of <g>caveolin-1</g> in <d>fibrotic diseases</d> | ||
240 | +Olodaterol shows anti-fibrotic efficacy in in vitro and in vivo models of <d>pulmonary fibrosis</d> | ||
241 | +Novel Mechanisms for the Antifibrotic Action of Nintedanib | ||
242 | +[The morphology and molecular bases of damage to the stem cell niche of respiratory acini in <d>idiopathic interstitial pneumonias</d>] | ||
243 | +Pirfenidone inhibits myofibroblast differentiation and <d>lung fibrosis</d> development during insufficient mitophagy | ||
244 | +Insulin-like growth factor binding proteins 3 and 5 are <v>overexpressed </v>in <d>idiopathic pulmonary fibrosis</d> and contribute to extracellular matrix deposition | ||
245 | +<g>VEGF</g> ameliorates pulmonary <d>hypertension</d> through inhibition of endothelial apoptosis in experimental lung <d>fibrosis</d> in rats | ||
246 | +Rapamycin regulates connective tissue growth factor expression of lung epithelial cells via phosphoinositide 3-kinase | ||
247 | +Differential <e>expression </e>of alpha E beta 7 integrins on bronchoalveolar lavage T lymphocyte subsets: <r>regulation </r>by alpha 4 beta 1-integrin crosslinking and <g>TGF-beta</g> | ||
248 | +<v>Increased </v><g>TGF-beta1</g> in the lungs of asbestos-exposed rats and mice: <u>reduced </u><e>expression </e>in <g>TNF-alpha</g> receptor knockout mice | ||
249 | +Fibrotic myofibroblasts manifest genome-wide derangements of translational control | ||
250 | +<r>Regulation </r>of <g>TGF-b</g> storage and activation in the human <d>idiopathic pulmonary fibrosis lung</d> | ||
251 | +<d>Microsatellite instability</d> in transforming growth factor-beta 1 type II receptor gene in alveolar lining epithelial cells of <d>idiopathic pulmonary fibrosis</d> | ||
252 | +miR-92a <r>regulates </r><g>TGF-b1</g>-<v>induced </v><g>WISP1</g> <e>expression </e>in <d>pulmonary fibrosis</d> | ||
253 | +<u>Inhibition </u>of <g>PHGDH</g> | ||
254 | +The role of cytokines in human <d>lung fibrosis</d> | ||
255 | +Significant involvement of <g>CCL2</g> (<g>MCP-1</g>) in inflammatory disorders of the lung | ||
256 | +<g>TGF-beta</g>-induced EMT: mechanisms and implications for <d>fibrotic lung disease</d> | ||
257 | +Pirfenidone <u>inhibits </u><g>TGF-b1</g>-induced <e>over-expression </e>of collagen type I and <d>heat shock</d> protein 47 in A549 cells | ||
258 | +Bleomycin induces molecular changes directly relevant to <d>idiopathic pulmonary fibrosis</d>: a model for "active" disease | ||
259 | +The potential <r>role </r>of PDGF, <g>IGF-1</g>, <g>TGF-beta</g> <e>expression </e>in <d>idiopathic pulmonary fibrosis</d> | ||
260 | +<g>Connective tissue growth factor</g> <e>expression </e>and <v>induction </v>by <g>transforming growth factor-beta</g> is <u>abrogated </u>by simvastatin via a Rho signaling mechanism | ||
261 | +MOXIBUSTION HAS A POSITIVE EFFECT ON PULMONARY FIBROSIS: AN ALTERNATIVE APPROACH | ||
262 | +Sustained Activation of <g>Toll-Like Receptor 9</g> | ||
263 | +Molecular pathogenesis of <d>interstitial pneumonitis</d> with <g>TNF-alpha</g> transgenic mice | ||
264 | +MiR-541-5p <r>regulates </r><d>lung fibrosis</d> by <r>targeting </r>cyclic nucleotide phosphodiesterase 1A | ||
265 | +The pathogenesis of <d>idiopathic pulmonary fibrosis</d> | ||
266 | +Participation of miR-200 in <d>pulmonary fibrosis</d> | ||
267 | +<d>Autoimmunity</d> to Vimentin Is Associated with Outcomes of Patients with <d>Idiopathic Pulmonary Fibrosis</d> | ||
268 | +<g>TGF-beta 1</g>, but not <g>TGF-beta 2</g> or <g>TGF-beta 3</g>, is differentially present in epithelial cells of advanced <d>pulmonary fibrosis</d>: an immunohistochemical study | ||
269 | +Lysyl oxidases <r>regulate </r>fibrillar collagen remodelling in idiopathic pulmonary fibrosis | ||
270 | +Discovery and validation of extracellular/circulating microRNAs during <d>idiopathic pulmonary fibrosis disease</d> progression | ||
271 | +Recombinant human <g>serum amyloid P</g> in healthy volunteers and patients with <d>pulmonary fibrosis</d> | ||
272 | +<g>Gremlin</g>-mediated decrease in bone morphogenetic protein signaling promotes <d>pulmonary fibrosis</d> | ||
273 | +<v>Increased </v><e>expression </e>of <g>protease nexin-1</g> in fibroblasts during <d>idiopathic pulmonary fibrosis</d> <r>regulates </r><g>thrombin</g> activity and <g>fibronectin</g> <e>expression.</e> <d>Idiopathic pulmonary fibrosis</d> (<d>IPF</d>) is a chronic <d>diffuse lung disease</d> characterized by an accumulation of excess fibrous material in the lung | ||
274 | +Hyper-responsiveness of <d>IPF</d>/<d>UIP</d> fibroblasts: interplay between <g>TGFbeta1</g>, <g>IL-13</g> and <g>CCL2</g> | ||
275 | +<d>Idiopathic pulmonary fibrosis</d> in relation to gene polymorphisms of <g>transforming growth factor-b1</g> and <g>plasminogen activator inhibitor 1</g> | ||
276 | +<g>TNF-alpha</g>, PDGF, and <g>TGF-beta(1)</g> <e>expression </e>by primary mouse bronchiolar-alveolar epithelial and mesenchymal cells: <g>tnf-alpha</g> induces <g>TGF-beta(1)</g> | ||
277 | +<g>Transforming Growth Factor Beta 1</g> |
results/Partition_2/cluster2.txt
0 → 100644
1 | +FAK-related nonkinase is a multifunctional negative regulator of pulmonary fibrosis | ||
2 | +Bleomycin and IL-1beta-mediated pulmonary fibrosis is IL-17A dependent | ||
3 | +Diagnostic Values For Club Cell Secretory Protein (CC16) in Serum of Patients of Combined Pulmonary Fibrosis and Emphysema | ||
4 | +miR-26a suppresses EMT by disrupting the Lin28B/let-7d axis: potential cross-talks among miRNAs in IPF | ||
5 | +Hsp90 regulation of fibroblast activation in pulmonary fibrosis | ||
6 | +Epigenetic Regulation of Caveolin-1 Gene Expression in Lung Fibroblasts | ||
7 | +Targeting of Discoidin Domain Receptor 2 (DDR2) Prevents Myofibroblast Activation and Neovessel Formation During Pulmonary Fibrosis | ||
8 | +Epithelial Cell Mitochondrial Dysfunction and PINK1 Are Induced by Transforming Growth Factor- Beta1 in Pulmonary Fibrosis | ||
9 | +MiR-185/AKT and miR-29a/collagen 1a pathways are activated in IPF BAL cells | ||
10 | +Tubastatin ameliorates pulmonary fibrosis by targeting the TGFb-PI3K-Akt pathway | ||
11 | +The lncRNA H19 Mediates Pulmonary Fibrosis by Regulating the miR-196a/COL1A1 Axis | ||
12 | +Significant involvement of CCL2 (MCP-1) in inflammatory disorders of the lung | ||
13 | +Pirfenidone inhibits the expression of HSP47 in TGF-beta1-stimulated human lung fibroblasts | ||
14 | +Inhibition of PHGDH Attenuates Bleomycin-induced Pulmonary Fibrosis | ||
15 | +Effects of particulate matter from straw burning on lung fibrosis in mice | ||
16 | +BARD1 mediates TGF-b signaling in pulmonary fibrosis | ||
17 | +Renin is an angiotensin-independent profibrotic mediator: role in pulmonary fibrosis | ||
18 | +Regulation of myofibroblast differentiation by miR-424 during epithelial-to-mesenchymal transition | ||
19 | +Up-regulation of heparan sulfate 6-O-sulfation in idiopathic pulmonary fibrosis | ||
20 | +Mechanisms of fibrosis in coal workers' pneumoconiosis | ||
21 | +Transforming Growth Factor Beta 1 Activation, Storage, and Signaling Pathways in Idiopathic Pulmonary Fibrosis in Dogs | ||
22 | +Effect of substrate stiffness on pulmonary fibroblast activation by TGF-b | ||
23 | +Role for alpha3 integrin in EMT and pulmonary fibrosis | ||
24 | +Shikonin suppresses pulmonary fibroblasts proliferation and activation by regulating Akt and p38 MAPK signaling pathways | ||
25 | +Gremlin-mediated decrease in bone morphogenetic protein signaling promotes pulmonary fibrosis | ||
26 | +Molecular targets in pulmonary fibrosis: the myofibroblast in focus | ||
27 | +miR-92a regulates TGF-b1-induced WISP1 expression in pulmonary fibrosis | ||
28 | +Transgelin is a direct target of TGF-beta/Smad3-dependent epithelial cell migration in lung fibrosis | ||
29 | +Increased alveolar soluble annexin V promotes lung inflammation and fibrosis | ||
30 | +Developmental Reprogramming in Mesenchymal Stromal Cells of Human Subjects with Idiopathic Pulmonary Fibrosis | ||
31 | +Re-evaluation of fibrogenic cytokines in lung fibrosis | ||
32 | +Autoimmunity to Vimentin Is Associated with Outcomes of Patients with Idiopathic Pulmonary Fibrosis | ||
33 | +Lung myofibroblasts are characterized by down-regulated cyclooxygenase-2 and its main metabolite, prostaglandin E2 | ||
34 | +A critical role for the mTORC2 pathway in lung fibrosis | ||
35 | +Amplification of TGFb Induced ITGB6 Gene Transcription May Promote Pulmonary Fibrosis | ||
36 | +Fibrotic myofibroblasts manifest genome-wide derangements of translational control | ||
37 | +Inhibition and role of let-7d in idiopathic pulmonary fibrosis | ||
38 | +Rapamycin increases CCN2 expression of lung fibroblasts via phosphoinositide 3-kinase | ||
39 | +Predisposition for disrepair in the aged lung | ||
40 | +MicroRNA regulatory networks in idiopathic pulmonary fibrosis | ||
41 | +Macrophage Bone Morphogenic Protein Receptor 2 (BMPR2) depletion in Idiopathic Pulmonary Fibrosis (IPF) and Group III Pulmonary Hypertension | ||
42 | +Wnt coreceptor Lrp5 is a driver of idiopathic pulmonary fibrosis | ||
43 | +Pirfenidone inhibits myofibroblast differentiation and lung fibrosis development during insufficient mitophagy | ||
44 | +Resveratrol-Mediated Repression and Reversion of Prostatic Myofibroblast Phenoconversion | ||
45 | +Genetic partitioning of interleukin-6 signalling in mice dissociates Stat3 from Smad3-mediated lung fibrosis | ||
46 | +Transcription factor GATA-6 is expressed in quiescent myofibroblasts in idiopathic pulmonary fibrosis | ||
47 | +[Idiopathic pulmonary fibrosis and lung cancer] | ||
48 | +Role of caveolin-1 in fibrotic diseases | ||
49 | +Latent cytomegalovirus infection exacerbates experimental pulmonary fibrosis by activating TGF-b1 | ||
50 | +Sunitinib, a Small-Molecule Kinase Inhibitor, Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice | ||
51 | +Differing Expression of Cytokines and Tumor Markers in Combined Pulmonary Fibrosis and Emphysema Compared to Emphysema and Pulmonary Fibrosis | ||
52 | +miR-18a-5p Inhibits Sub-pleural Pulmonary Fibrosis by Targeting TGF-b Receptor II | ||
53 | +Caveolin-1: a critical regulator of lung fibrosis in idiopathic pulmonary fibrosis | ||
54 | +TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P | ||
55 | +Lysocardiolipin acyltransferase regulates TGF-b mediated lung fibroblast differentiation | ||
56 | +Azithromycin attenuates myofibroblast differentiation and lung fibrosis development through proteasomal degradation of NOX4 | ||
57 | +[Potential role of cytokines in idiopathic pulmonary fibrosis] | ||
58 | +The potential role of PDGF, IGF-1, TGF-beta expression in idiopathic pulmonary fibrosis | ||
59 | +Hyper-responsiveness of IPF/UIP fibroblasts: interplay between TGFbeta1, IL-13 and CCL2 | ||
60 | +Cytokine profiles in idiopathic pulmonary fibrosis suggest an important role for TGF-beta and IL-10 | ||
61 | +Therapeutic targets in fibrotic pathways | ||
62 | +Protective Effect of Ginsenoside Rg1 on Bleomycin-Induced Pulmonary Fibrosis in Rats: Involvement of Caveolin-1 and TGF-b1 Signal Pathway | ||
63 | +Suppression of plasminogen activator inhibitor-1 by RNA interference attenuates pulmonary fibrosis | ||
64 | +Pirfenidone exerts antifibrotic effects through inhibition of GLI transcription factors | ||
65 | +Profibrotic role of WNT10A via TGF-b signaling in idiopathic pulmonary fibrosis | ||
66 | +Mesenchymal Stem Cells Correct Inappropriate Epithelial-mesenchyme Relation in Pulmonary Fibrosis Using Stanniocalcin-1 | ||
67 | +microRNA-1343 attenuates pathways of fibrosis by targeting the TGF-b receptors | ||
68 | +Effect of Renshen Pingfei Decoction, a traditional Chinese prescription, on IPF induced by Bleomycin in rats and regulation of TGF-b1/Smad3 | ||
69 | +M2 macrophages induce EMT through the TGF-b/Smad2 signaling pathway | ||
70 | +Chop Deficiency Protects Mice Against Bleomycin-induced Pulmonary Fibrosis by Attenuating M2 Macrophage Production | ||
71 | +miR -221 targets HMGA2 to inhibit bleomycin -induced pulmonary fibrosis by regulating TGF -b1/Smad3-induced EMT | ||
72 | +Transforming Growth Factor (TGF)-b Promotes de Novo Serine Synthesis for Collagen Production | ||
73 | +Autophagy in idiopathic pulmonary fibrosis | ||
74 | +Overexpression of Sulf2 in idiopathic pulmonary fibrosis | ||
75 | +Two-Way Conversion between Lipogenic and Myogenic Fibroblastic Phenotypes Marks the Progression and Resolution of Lung Fibrosis | ||
76 | +Matrix metalloproteinase (MMP)-19 deficient fibroblasts display a profibrotic phenotype | ||
77 | +[Pulmonary fibrosis--a therapeutic dilemma?] | ||
78 | +Signaling pathways in the epithelial origins of pulmonary fibrosis | ||
79 | +FGF-1 reverts epithelial-mesenchymal transition induced by TGF-{beta}1 through MAPK/ERK kinase pathway | ||
80 | +Participation of miR-200 in pulmonary fibrosis | ||
81 | +Proteasomal regulation of pulmonary fibrosis | ||
82 | +Inhibition of HSP27 blocks fibrosis development and EMT features by promoting Snail degradation | ||
83 | +Normal Human Lung Epithelial Cells Inhibit Transforming Growth Factor-b Induced Myofibroblast Differentiation via Prostaglandin E2 | ||
84 | +The JAK2 pathway is activated in idiopathic pulmonary fibrosis | ||
85 | +Inhibition of the KCa3.1 Channel Alleviates Established Pulmonary Fibrosis in a Large Animal Model | ||
86 | +Human lung myofibroblast TGFb1-dependent Smad2/3 signalling is Ca(2+)-dependent and regulated by KCa3.1 K(+) channels | ||
87 | +AKT2 Regulates Pulmonary Inflammation and Fibrosis via Modulating Macrophage Activation | ||
88 | +Transforming growth factor-beta1 in sarcoidosis | ||
89 | +The anti-fibrotic effects of microRNA-153 by targeting TGFBR-2 in pulmonary fibrosis | ||
90 | +Cytokines in human lung fibrosis | ||
91 | +MicroRNA-101 attenuates pulmonary fibrosis by inhibiting fibroblast proliferation and activation | ||
92 | +Cartilage oligomeric matrix protein in idiopathic pulmonary fibrosis | ||
93 | +Novel Mechanisms for the Antifibrotic Action of Nintedanib | ||
94 | +Determining the True Selectivity Profile of av Integrin Ligands Using Radioligand Binding: Applying an Old Solution to a New Problem | ||
95 | +Increased Galectin-9 Concentration and Number of CD4+Foxp3high+Cells in Bronchoalveolar Lavage Fluid of Patients with Cryptogenic Organizing Pneumonia | ||
96 | +Cytokine gene polymorphisms in idiopathic pulmonary fibrosis | ||
97 | +Matrix metalloproteinase 3 is a mediator of pulmonary fibrosis | ||
98 | +Ubiquitin carboxyl-terminal hydrolase-L5 promotes TGFb-1 signaling by de-ubiquitinating and stabilizing Smad2/Smad3 in pulmonary fibrosis | ||
99 | +Cub domain containing protein 1 (CDCP1) negatively regulates TGFb signaling and myofibroblast differentiation | ||
100 | +The mannose-6-phosphate analogue, PXS64, inhibits fibrosis via TGF-b1 pathway in human lung fibroblasts | ||
101 | +Reduced Ets Domain-containing Protein Elk1 Promotes Pulmonary Fibrosis via Increased Integrin avb6 Expression | ||
102 | +N-acetylcysteine inhibits alveolar epithelial-mesenchymal transition | ||
103 | +Expression of RXFP1 Is Decreased in Idiopathic Pulmonary Fibrosis | ||
104 | +Pulmonary fibrosis: pathogenesis, etiology and regulation | ||
105 | +Smooth muscle alpha-actin expression and myofibroblast differentiation by TGFbeta are dependent upon MK2 | ||
106 | +Profibrotic role of miR-154 in pulmonary fibrosis | ||
107 | +miR-323a-3p regulates lung fibrosis by targeting multiple profibrotic pathways | ||
108 | +The Anti-fibrotic Effects and Mechanisms of MicroRNA-486-5p in Pulmonary Fibrosis | ||
109 | +Low-dose paclitaxel ameliorates pulmonary fibrosis by suppressing TGF-b1/Smad3 pathway via miR-140 upregulation | ||
110 | +IPF lung fibroblasts have a senescent phenotype | ||
111 | +MiR-338* targeting smoothened to inhibit pulmonary fibrosis by epithelial-mesenchymal transition | ||
112 | +MAP3K19 Is a Novel Regulator of TGF-b Signaling That Impacts Bleomycin-Induced Lung Injury and Pulmonary Fibrosis | ||
113 | +N-acetyl-L-cysteine inhibits TGF-beta1-induced profibrotic responses in fibroblasts | ||
114 | +Dysregulated Collagen Homeostasis by Matrix Stiffening and TGF-b1 in Fibroblasts from Idiopathic Pulmonary Fibrosis Patients: Role of FAK/Akt | ||
115 | +Sphingolipids in pulmonary fibrosis | ||
116 | +Sustained PI3K Activation exacerbates BLM-induced Lung Fibrosis via activation of pro-inflammatory and pro-fibrotic pathways | ||
117 | +Neutrophil elastase promotes myofibroblast differentiation in lung fibrosis | ||
118 | +Sustained Activation of Toll-Like Receptor 9 Induces an Invasive Phenotype in Lung Fibroblasts: Possible Implications in Idiopathic Pulmonary Fibrosis | ||
119 | +BALF N-acetylglucosaminidase and beta-galactosidase activities in idiopathic pulmonary fibrosis | ||
120 | +Transglutaminase 2 and its role in pulmonary fibrosis | ||
121 | +The role of cytokines in human lung fibrosis | ||
122 | +miR-9-5p suppresses pro-fibrogenic transformation of fibroblasts and prevents organ fibrosis by targeting NOX4 and TGFBR2 | ||
123 | +Regulation of 26S Proteasome Activity in Pulmonary Fibrosis | ||
124 | +Membrane-anchored Serine Protease Matriptase Is a Trigger of Pulmonary Fibrogenesis | ||
125 | +Pleural mesothelial cells in pleural and lung diseases | ||
126 | +[Different cytokine profiles in usual interstitial pneumonia and nonspecific interstitial pneumonia] | ||
127 | +Essential role for the ATG4B protease and autophagy in bleomycin-induced pulmonary fibrosis | ||
128 | +Deregulation of selective autophagy during aging and pulmonary fibrosis: the role of TGFb1 | ||
129 | +The Role of PPARs in Lung Fibrosis | ||
130 | +MiR-338* suppresses fibrotic pathogenesis in pulmonary fibrosis through targeting LPA1 | ||
131 | +Metformin attenuates lung fibrosis development via NOX4 suppression | ||
132 | +Investigation of bone marrow mesenchymal stem cells (BM MSCs) involvement in Idiopathic Pulmonary Fibrosis (IPF) | ||
133 | +The pathogenesis of idiopathic pulmonary fibrosis | ||
134 | +Interstitial fibrosis and growth factors | ||
135 | +TIAM1 inhibits lung fibroblast differentiation in pulmonary fibrosis | ||
136 | +Role of integrin-mediated TGFbeta activation in the pathogenesis of pulmonary fibrosis | ||
137 | +Leucine-rich a-2 glycoprotein promotes lung fibrosis by modulating TGF-b signaling in fibroblasts | ||
138 | +MiR-541-5p regulates lung fibrosis by targeting cyclic nucleotide phosphodiesterase 1A | ||
139 | +Lipoxin A4 Attenuates Constitutive and TGF-b1-Dependent Profibrotic Activity in Human Lung Myofibroblasts | ||
140 | +Role of von Hippel-Lindau protein in fibroblast proliferation and fibrosis | ||
141 | +miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis | ||
142 | +miR-31 is a negative regulator of fibrogenesis and pulmonary fibrosis | ||
143 | +TRPV4 mediates myofibroblast differentiation and pulmonary fibrosis in mice | ||
144 | +Cigarette Smoke Enhances the Expression of Profibrotic Molecules in Alveolar Epithelial Cells | ||
145 | +Sputum biomarkers in IPF: Evidence for raised gene expression and protein level of IGFBP-2, IL-8 and MMP-7 | ||
146 | +STAT3-mediated signaling dysregulates lung fibroblast-myofibroblast activation and differentiation in UIP/IPF | ||
147 | +TGF-b1 induces Fstl1 via the Smad3-c-Jun pathway in lung fibroblasts | ||
148 | +Matrix regulation of idiopathic pulmonary fibrosis: the role of enzymes | ||
149 | +Epithelial-mesenchymal transition in chronic hypersensitivity pneumonitis | ||
150 | +Idiopathic Pulmonary Fibrosis: Aging, Mitochondrial Dysfunction, and Cellular Bioenergetics | ||
151 | +HSP27 regulates TGF-b mediated lung fibroblast differentiation through the Smad3 and ERK pathways | ||
152 | +Inhibition of mechanosensitive signaling in myofibroblasts ameliorates experimental pulmonary fibrosis | ||
153 | +[A role for mesothelial cells in the genesis of idiopathic pulmonary fibrosis?] | ||
154 | +Pathogenesis of idiopathic pulmonary fibrosis | ||
155 | +SNAI transcription factors mediate epithelial-mesenchymal transition in lung fibrosis | ||
156 | +TGF-b activation and lung fibrosis | ||
157 | +Protective role of andrographolide in bleomycin-induced pulmonary fibrosis in mice | ||
158 | +[The potential role of cytokines expression in idiopathic pulmonary fibrosis] | ||
159 | +CXCL9 Regulates TGF-b1-Induced Epithelial to Mesenchymal Transition in Human Alveolar Epithelial Cells | ||
160 | +Autophagy and inflammation in chronic respiratory disease | ||
161 | +Bone morphogenetic protein-inducer tilorone identified by high-throughput screening is antifibrotic in vivo | ||
162 | +Reviews and prospectives of signaling pathway analysis in idiopathic pulmonary fibrosis | ||
163 | +Membrane type-matrix metalloproteinases in idiopathic pulmonary fibrosis | ||
164 | +Endothelin-1 induces alveolar epithelial-mesenchymal transition through endothelin type A receptor-mediated production of TGF-beta1 | ||
165 | +Lung fibrotic tenascin-C upregulation is associated with other extracellular matrix proteins and induced by TGFb1 | ||
166 | +EMT and interstitial lung disease: a mysterious relationship | ||
167 | +Anti-fibrotic Role of aB-crystallin Inhibition in Pleural and Subpleural Fibrosis | ||
168 | +Fibrosis of two: Epithelial cell-fibroblast interactions in pulmonary fibrosis | ||
169 | +Lysyl oxidases regulate fibrillar collagen remodelling in idiopathic pulmonary fibrosis | ||
170 | +MicroRNAs in idiopathic pulmonary fibrosis | ||
171 | +Yin yang 1 is a novel regulator of pulmonary fibrosis | ||
172 | +Abrogation of TGF-beta1-induced fibroblast-myofibroblast differentiation by histone deacetylase inhibition | ||
173 | +Expression of WNT5A in Idiopathic Pulmonary Fibrosis and Its Control by TGF-b and WNT7B in Human Lung Fibroblasts | ||
174 | +Negative regulation of myofibroblast differentiation by PTEN (Phosphatase and Tensin Homolog Deleted on chromosome 10) |
results/Partition_2/cluster2_tagged.txt
0 → 100644
1 | +M2 macrophages <v>induce </v><g>EMT</g> through the <g>TGF-b</g>/<g>Smad2</g> signaling pathway | ||
2 | +Up-regulation of heparan sulfate 6-O-sulfation in <d>idiopathic pulmonary fibrosis</d> | ||
3 | +<r>Regulation </r>of human lung fibroblast <g>C1q</g>-receptors by <g>transforming growth factor-beta</g> and <g>tumor necrosis factor-alpha</g> | ||
4 | +Comparison between conventional and "clinical" assessment of experimental lung <d>fibrosis</d> | ||
5 | +Pirfenidone attenuates bleomycin-induced pulmonary fibrosis in mice by <r>regulating </r><g>Nrf2</g>/<g>Bach1</g> equilibrium | ||
6 | +High levels of <g>IL-6</g> and <g>IL-8</g> characterize early-on <d>idiopathic pulmonary fibrosis</d> acute exacerbations | ||
7 | +Regulation of the effects of <g>TGF-beta 1</g> by activation of latent <g>TGF-beta 1</g> and differential <e>expression </e>of <g>TGF-beta receptors (T beta R-I and T beta R-II</g>) in <d>idiopathic pulmonary fibrosis</d> | ||
8 | +Peripheral depletion of NK cells and imbalance of the Treg/Th17 axis in <d>idiopathic pulmonary fibrosis</d> patients | ||
9 | +Developmental Reprogramming in Mesenchymal Stromal Cells of Human Subjects with <d>Idiopathic Pulmonary Fibrosis</d> | ||
10 | +<u>Inhibition </u>of <g>HSP27</g> blocks <d>fibrosis</d> development and EMT features by promoting <g>Snail</g> degradation | ||
11 | +<g>miR-9-5p</g> suppresses pro-fibrogenic transformation of fibroblasts and prevents organ <d>fibrosis</d> by targeting <g>NOX4</g> and <g>TGFBR2</g> | ||
12 | +Signalling pathways from NADPH oxidase-4 to <d>idiopathic pulmonary fibrosis</d> | ||
13 | +<r>Effects </r>of a leukotriene B4 receptor antagonist on bleomycin-induced <d>pulmonary fibrosis</d> | ||
14 | +Profibrotic role of <g>WNT10A</g> via <g>TGF-b</g> signaling in <d>idiopathic pulmonary fibrosis</d> | ||
15 | +Activated human T lymphocytes inhibit <g>TGFb</g>-induced fibroblast to myofibroblast differentiation via prostaglandins D2 and E2 | ||
16 | +The Role of PPARs in Lung <d>Fibrosis</d> | ||
17 | +Free radical generation induces epithelial-to-mesenchymal transition in lung epithelium via a <g>TGF-b1</g>-dependent mechanism | ||
18 | +The potential application of strategic released apigenin from polymeric carrier in pulmonary fibrosis | ||
19 | +<v>Overexpression </v>of <g>Sulf2</g> in <d>idiopathic pulmonary fibrosis</d> | ||
20 | +Essential role for the <g>ATG4B</g> protease and autophagy in bleomycin-induced <d>pulmonary fibrosis</d> | ||
21 | +Microarray profiling reveals <u>suppressed </u>interferon stimulated gene program in fibroblasts from scleroderma-associated <d>interstitial lung disease</d> | ||
22 | +<g>Bone morphogenetic protein-4</g> inhibitor <g>gremlin</g> is <v>overexpressed </v>in <d>idiopathic pulmonary fibrosis</d> | ||
23 | +Smooth muscle alpha-actin <e>expression </e>and myofibroblast differentiation by <g>TGFbeta</g> are <v>dependent </v>upon <g>MK2</g> | ||
24 | +The K+ channel <g>KCa3.1</g> as a novel target for <d>idiopathic pulmonary fibrosis</d> | ||
25 | +<g>Spiruchostatin A</g> inhibits proliferation and differentiation of fibroblasts from patients with <d>pulmonary fibrosis</d> | ||
26 | +<v>Elevated </v><g>sL1</g>-CAM levels in BALF and serum of <d>IPF</d> patients | ||
27 | +Lung myofibroblasts are characterized by <u>down-regulated </u><g>cyclooxygenase-2</g> and its main metabolite, prostaglandin E2 | ||
28 | +Cigarette Smoke Enhances the Expression of Profibrotic Molecules in Alveolar Epithelial Cells | ||
29 | +Microarray identifies ADAM family members as key responders to <g>TGF-beta1</g> in alveolar epithelial cells | ||
30 | +<g>IL-4</g> polymorphisms, HRCT score and lung tissue markers in <d>idiopathic pulmonary fibrosis</d> | ||
31 | +Titration of non-replicating adenovirus as a vector for <v>transducing </v>active <g>TGF-beta1</g> gene <e>expression </e>causing <d>inflammation</d> and fibrogenesis in the lungs of C57BL/6 mice | ||
32 | +Herpes <d>virus infection</d> is associated with vascular remodeling and <d>pulmonary hypertension</d> in <d>idiopathic pulmonary fibrosis</d> | ||
33 | +Effect of substrate stiffness on pulmonary fibroblast activation by <g>TGF-b</g> | ||
34 | +A critical role for the <g>mTORC2</g> pathway in <d>lung fibrosis</d> | ||
35 | +Microencapsulation of lefty-secreting engineered cells for <d>pulmonary fibrosis</d> therapy in mice | ||
36 | +Bile acids induce activation of alveolar epithelial cells and lung fibroblasts through farnesoid X receptor-dependent and independent pathways | ||
37 | +<g>TGF-beta</g> driven lung <d>fibrosis</d> is macrophage dependent and blocked by Serum amyloid P | ||
38 | +Exercise <u>Reduces </u>Lung <d>Fibrosis</d> | ||
39 | +Sputum biomarkers in <d>IPF</d>: Evidence for raised gene <e>expression </e>and protein level of <g>IGFBP-2</g>, <g>IL-8</g> and <g>MMP-7</g> | ||
40 | +<g>Forkhead Box F1</g> (<g>FOXF1</g>) <u>represses </u>cell growth, COL1 and <g>ARPC2</g> <e>expression </e>in lung fibroblasts in vitro | ||
41 | +Targeting of <g>Discoidin Domain Receptor 2</g> (<g>DDR2</g>) Prevents Myofibroblast Activation and Neovessel Formation During <d>Pulmonary Fibrosis</d> | ||
42 | +<g>MicroRNA-29c</g> regulates apoptosis sensitivity via modulation of the cell-surface death receptor, Fas, in lung fibroblasts | ||
43 | +<g>Prostaglandin F(2alpha) receptor</g> signaling facilitates bleomycin-induced <d>pulmonary fibrosis</d> independently of transforming growth factor-beta | ||
44 | +Role of <g>protease-activated receptor-2</g> in <d>idiopathic pulmonary fibrosis</d> | ||
45 | +<e>Expression </e>of mucosa-related integrin alphaEbeta7 on <d>alveolar T</d> cells in <d>interstitial lung diseases</d> | ||
46 | +Cytoskeletal protein modulation in <d>pulmonary alveolar myofibroblasts</d> during <d>idiopathic pulmonary fibrosis</d> | ||
47 | +<g>Transglutaminase 2</g> and its role in <d>pulmonary fibrosis</d> | ||
48 | +Sunitinib, a Small-Molecule Kinase <u>Inhibitor,</u> | ||
49 | +Fibroblasts from <d>idiopathic pulmonary fibrosis</d> and normal lungs differ in growth rate, apoptosis, and tissue <u>inhibitor </u>of metalloproteinases <e>expression.</e> <d>Idiopathic pulmonary fibrosis</d> (<d>IPF</d>) is a <d>chronic lung disorder</d> characterized by fibroblast proliferation and extracellular matrix accumulation | ||
50 | +<g>Chop</g> | ||
51 | +<g>VCAM-1</g> is a <g>TGF-b1</g> inducible gene <v>upregulated </v>in <d>idiopathic pulmonary fibrosis</d> | ||
52 | +<u>Suppression </u>of <g>plasminogen activator inhibitor-1</g> by RNA interference attenuates <d>pulmonary fibrosis</d> | ||
53 | +<g>WISP1</g> mediates <g>IL-6</g>-dependent proliferation in primary human lung fibroblasts | ||
54 | +<d>Idiopathic pulmonary fibrosis</d>: immunohistochemical analysis provides fresh insights into lung tissue remodelling with implications for novel prognostic markers | ||
55 | +Amplified canonical transforming growth factor-b signalling<i>via</i><d>heat shock</d> protein 90 in <d>pulmonary fibrosis</d> | ||
56 | +<v>Upregulation </v>of alveolar <e>levels </e>of activin B, but not activin A, in lungs of west highland white terriers with <d>idiopathic pulmonary fibrosis</d> and <d>diffuse alveolar damage</d> | ||
57 | +Absence of <g>Thy-1</g> results in <g>TGF-b</g> induced <g>MMP-9</g> expression and confers a profibrotic phenotype to human lung fibroblasts | ||
58 | +Shikonin suppresses pulmonary fibroblasts proliferation and activation by <r>regulating </r><g>Akt</g> and <g>p38</g> | ||
59 | +<g>JAK2</g> mediates <d>lung fibrosis</d>, <d>pulmonary vascular remodelling</d> and <d>hypertension</d> in <d>idiopathic pulmonary fibrosis</d>: an experimental study | ||
60 | +<g>TRPV4</g> mediates myofibroblast differentiation and <d>pulmonary fibrosis</d> in mice | ||
61 | +Modulation of <g>CD11c</g>+ lung dendritic cells in respect to <g>TGF-b</g> in experimental <d>pulmonary fibrosis</d> | ||
62 | +Melatonin attenuates <g>TGFb1</g>-induced epithelial-mesenchymal transition in lung alveolar epithelial cells | ||
63 | +Long-acting human serum albumin-thioredoxin fusion protein suppresses bleomycin-induced <d>pulmonary fibrosis progression</d> | ||
64 | +Fibrogenic Lung Injury Induces Non-Cell-Autonomous Fibroblast Invasion | ||
65 | +Induction of epithelial-mesenchymal transition in alveolar epithelial cells by <g>transforming growth factor-beta1</g>: potential role in <d>idiopathic pulmonary fibrosis</d> | ||
66 | +<r>Deregulation </r>of selective autophagy during aging and <d>pulmonary fibrosis</d>: the role of <g>TGFb1</g> | ||
67 | +Recent advances in molecular targets and treatment of <d>idiopathic pulmonary fibrosis</d>: focus on <g>TGFbeta</g> signaling and the myofibroblast | ||
68 | +<g>Bone morphogenetic protein</g>-inducer tilorone identified by high-throughput screening is antifibrotic in vivo | ||
69 | +Pleural mesothelial cell differentiation and invasion in <d>fibrogenic lung injury</d> | ||
70 | +<g>RhoA</g> signaling <r>modulates </r><g>cyclin D1</g> <e>expression </e>in human lung fibroblasts; implications for <d>idiopathic pulmonary fibrosis</d> | ||
71 | +Studies of <g>hepatocyte growth factor</g> in bronchoalveolar lavage fluid in chronic <d>interstitial lung diseases</d> | ||
72 | +Inhibitory effect of <g>receptor for advanced glycation end products</g> (<g>RAGE</g>) on the <g>TGF-b</g>-induced alveolar epithelial to mesenchymal transition | ||
73 | +Cytokine gene polymorphisms in <d>idiopathic pulmonary fibrosis</d> | ||
74 | +<g>Cub domain containing protein 1</g> (<g>CDCP1</g>) negatively regulates TGFb signaling and myofibroblast differentiation | ||
75 | +<e>Effects </e>of the <d>tumor</d> suppressor <g>PTEN</g> on the pathogenesis of <d>idiopathic pulmonary fibrosis</d> in Chinese patients | ||
76 | +Increased levels of prostaglandin E-major urinary metabolite (PGE-MUM) in chronic fibrosing <d>interstitial pneumonia</d> | ||
77 | +Mechanisms of <d>fibrosis</d> in <d>coal workers' pneumoconiosis</d> | ||
78 | +Different effects of growth factors on proliferation and matrix production of normal and fibrotic human lung fibroblasts | ||
79 | +Are mast cells instrumental for <d>fibrotic diseases</d>? <d>Idiopathic pulmonary fibrosis</d> (<d>IPF</d>) is a <d>fatal lung disorder</d> of unknown etiology characterized by accumulation of lung fibroblasts and extracellular matrix deposition, ultimately leading to compromised tissue architecture and lung function capacity | ||
80 | +<g>miR</g>-323a-3p regulates <d>lung fibrosis</d> by targeting multiple profibrotic pathways | ||
81 | +<g>TGF-b1</g> <v>stimulates </v><g>HDAC4</g> nucleus-to-cytoplasm <l>translocation </l>and <g>NADPH oxidase 4</g>-derived reactive oxygen species in normal human lung fibroblasts | ||
82 | +Effects of <d>cigarette smoke extract</d> on A549 cells and human lung fibroblasts treated with <g>transforming growth factor-beta1</g> in a coculture system | ||
83 | +Triptolide suppresses paraquat induced <d>idiopathic pulmonary fibrosis</d> by inhibiting <g>TGFB1</g>-dependent epithelial mesenchymal transition | ||
84 | +MicroRNA-326 regulates profibrotic functions of transforming growth factor-b in <d>pulmonary fibrosis</d> | ||
85 | +<g>Endothelin-1</g> <v>induces </v>alveolar epithelial-mesenchymal transition through endothelin type A receptor-<v>mediated </v><e>production </e>of <g>TGF-beta1</g> | ||
86 | +Differential mRNA expression of <g>insulin-like growth factor-1</g> splice variants in patients with <d>idiopathic pulmonary fibrosis</d> and <d>pulmonary sarcoidosis</d> | ||
87 | +<g>p63</g> - Key molecule in the early phase of <d>epithelial abnormality</d> in <d>idiopathic pulmonary fibrosis</d> | ||
88 | +Pathogenesis of <d>idiopathic pulmonary fibrosis</d> | ||
89 | +<u>Reduced </u><g>Ets Domain-containing Protein Elk1</g> | ||
90 | +Nitric oxide attenuates epithelial-mesenchymal transition in alveolar epithelial cells | ||
91 | +<g>HSP27</g> regulates <g>TGF-b</g> mediated lung fibroblast differentiation through the <g>Smad3</g> and <g>ERK</g> pathways | ||
92 | +<e>Expression </e>of <g>WNT5A</g> in <d>Idiopathic Pulmonary Fibrosis</d> and Its <r>Control </r>by <g>TGF-b</g> and <g>WNT7B</g> in Human Lung Fibroblasts | ||
93 | +The hedgehog system machinery controls transforming growth factor-b-dependent myofibroblastic differentiation in humans: involvement in <d>idiopathic pulmonary fibrosis</d> | ||
94 | +<v>Upregulation </v>of <g>activin</g>-B and <g>follistatin</g> in <d>pulmonary fibrosis</d> - a translational study using human biopsies and a specific inhibitor in mouse <d>fibrosis</d> models | ||
95 | +<u>Inhibition </u>of the <g>KCa3.1</g> | ||
96 | +<g>FGF-1</g> reverts epithelial-mesenchymal transition induced by <g>TGF-{beta}1</g> through MAPK/ERK kinase pathway | ||
97 | +Type II alveolar epithelial cells and interstitial fibroblasts express <g>connective tissue growth factor</g> in <d>IPF</d> | ||
98 | +<g>Transforming growth factor b1</g> (<g>TGFb1</g>)-induced CD44V6-<g>NOX4</g> signaling in pathogenesis of <d>idiopathic pulmonary fibrosis</d> | ||
99 | +Pleural mesothelial cells in <d>pleural and lung diseases</d> | ||
100 | +<d>Idiopathic pulmonary fibrosis</d>: an altered fibroblast proliferation linked to <d>cancer</d> biology | ||
101 | +Current and novel drug therapies for <d>idiopathic pulmonary fibrosis</d> | ||
102 | +<g>Caveolin-1</g>: a critical regulator of <d>lung fibrosis</d> in <d>idiopathic pulmonary fibrosis</d> | ||
103 | +<g>Protease activated receptor-1</g> regulates macrophage-mediated cellular senescence: a risk for <d>idiopathic pulmonary fibrosis</d> | ||
104 | +<g>Cthrc1</g> lowers pulmonary collagen associated with bleomycin-induced <d>fibrosis</d> and protects lung function | ||
105 | +Wnt coreceptor <g>Lrp5</g> is a driver of <d>idiopathic pulmonary fibrosis</d> | ||
106 | +Protective Effect of Ginsenoside Rg1 on Bleomycin-Induced Pulmonary Fibrosis in Rats: Involvement of <g>Caveolin-1</g> and <g>TGF-b1</g> | ||
107 | +The <g>JAK2</g> pathway is activated in <d>idiopathic pulmonary fibrosis</d> | ||
108 | +Sphingolipids in <d>pulmonary fibrosis</d> | ||
109 | +<g>miR-31</g> is a negative regulator of fibrogenesis and <d>pulmonary fibrosis</d> | ||
110 | +<u>Defect </u>of <g>hepatocyte growth factor</g> <l>secretion </l>by fibroblasts in <d>idiopathic pulmonary fibrosis</d> | ||
111 | +<g>NOX4</g>/NADPH oxidase <e>expression </e>is <v>increased </v>in pulmonary fibroblasts from patients with <d>idiopathic pulmonary fibrosis</d> and mediates <g>TGFbeta1</g>-induced fibroblast differentiation into myofibroblasts | ||
112 | +Sirtuin 7 is decreased in pulmonary fibrosis and regulates the fibrotic phenotype of lung fibroblasts | ||
113 | +Matrix regulation of <d>idiopathic pulmonary fibrosis</d>: the role of enzymes | ||
114 | +Pirfenidone for the treatment of <d>idiopathic pulmonary fibrosis</d> | ||
115 | +Rapamycin <v>increases </v><g>CCN2</g> <e>expression </e>of lung fibroblasts via <g>phosphoinositide 3-kinase</g> | ||
116 | +[The expressions and meanings of <g>BMP-7</g> and <g>TGF-b</g> in <d>idiopathic pulmonary fibrosis</d> and <d>idiopathic nonspecific interstitial pneumonia</d>] | ||
117 | +Human lung myofibroblast <g>TGFb1</g>-dependent <g>Smad2/3</g> signalling is Ca(2+)-dependent and <r>regulated </r>by <g>KCa3.1</g> | ||
118 | +The anti-fibrotic effect of <u>inhibition </u>of <g>TGFb</g>-<g>ALK5</g> signalling in experimental <d>pulmonary fibrosis</d> in mice is attenuated in the presence of concurrent y-herpesvirus infection | ||
119 | +[A role for mesothelial cells in the genesis of <d>idiopathic pulmonary fibrosis</d>?] | ||
120 | +Antifibrotic effects of <g>cyclosporine A</g> on <g>TGF-b1</g>-treated lung fibroblasts and lungs from bleomycin-treated mice: role of <g>hypoxia-inducible factor-1a</g> | ||
121 | +<g>TGF-beta 1</g> as an enhancer of Fas-mediated apoptosis of lung epithelial cells | ||
122 | +Mesenchymal Stem Cells Correct Inappropriate Epithelial-mesenchyme Relation in <d>Pulmonary Fibrosis</d> | ||
123 | +Angiotensin-<g>TGF-beta</g> 1 crosstalk in human <d>idiopathic pulmonary fibrosis</d>: autocrine mechanisms in myofibroblasts and macrophages | ||
124 | +SNAI transcription factors mediate epithelial-mesenchymal transition in <d>lung fibrosis</d> | ||
125 | +Proliferation of pulmonary interstitial fibroblasts is mediated by <g>transforming growth factor-beta1</g>-induced release of extracellular <g>fibroblast growth factor-2</g> and <p>phosphorylation </p>of <g>p38</g> | ||
126 | +Prognostic factors for <d>idiopathic pulmonary fibrosis</d>: clinical, physiologic, pathologic, and molecular aspects | ||
127 | +Hydrogen peroxide is a diffusible paracrine signal for the induction of epithelial cell death by activated myofibroblasts | ||
128 | +<g>Secreted protein acidic and rich in cysteine</g> (<g>SPARC</g>) is upregulated by transforming growth factor (TGF)-b and is required for <g>TGF-b</g>-induced hydrogen peroxide production in fibroblasts | ||
129 | +<g>MiR-338</g>* suppresses fibrotic pathogenesis in <d>pulmonary fibrosis</d> through targeting <g>LPA1</g> | ||
130 | +The lncRNA <g>H19</g> | ||
131 | +<e>Contribution </e>of the anaphylatoxin receptors, <g>C3aR</g> and <g>C5aR</g>, to the pathogenesis of <d>pulmonary fibrosis</d> | ||
132 | +Corilagin attenuates aerosol bleomycin-induced experimental <d>lung injury</d> | ||
133 | +[Potential role of cytokines in <d>idiopathic pulmonary fibrosis</d>] | ||
134 | +Protective role of andrographolide in bleomycin-induced <d>pulmonary fibrosis</d> in mice | ||
135 | +<g>Serpin B4</g> isoform overexpression is associated with aberrant epithelial proliferation and <d>lung cancer</d> in <d>idiopathic pulmonary fibrosis</d> | ||
136 | +Interstitial <d>fibrosis</d> and growth factors | ||
137 | +<u>Blockade </u>of the Wnt/b-catenin pathway attenuates bleomycin-induced <d>pulmonary fibrosis</d> | ||
138 | +Control of virus reactivation arrests pulmonary herpesvirus-induced <d>fibrosis</d> in IFN-gamma receptor-<u>deficient </u>mice | ||
139 | +BALF N-acetylglucosaminidase and <g>beta-galactosidase</g> activities in <d>idiopathic pulmonary fibrosis</d> | ||
140 | +Interplay between <g>RAGE</g>, <g>CD44</g>, and focal adhesion molecules in epithelial-mesenchymal transition of alveolar epithelial cells | ||
141 | +Antifibrotic properties of receptor for advanced glycation end products in <d>idiopathic pulmonary fibrosis</d> | ||
142 | +Dysregulated Collagen Homeostasis by Matrix Stiffening and <g>TGF-b1</g> in Fibroblasts from <d>Idiopathic Pulmonary Fibrosis</d> | ||
143 | +TGF-b1 T869C polymorphism may affect susceptibility to <d>idiopathic pulmonary fibrosis</d> and disease severity | ||
144 | +<g>Th1</g>/Th2 cytokine gene polymorphisms in patients with <d>idiopathic pulmonary fibrosis</d> | ||
145 | +Anti-pulmonary fibrotic activity of salvianolic acid B was screened by a novel method based on the cyto-biophysical properties | ||
146 | +Cytokines in human <d>lung fibrosis</d> | ||
147 | +<e>Expression </e>of <g>RXFP1</g> | ||
148 | +Plasma <g>CCN2</g> (connective tissue growth factor; <g>CTGF</g>) is a potential biomarker in <d>idiopathic pulmonary fibrosis</d> (<d>IPF</d>) | ||
149 | +Azithromycin attenuates myofibroblast differentiation and lung <d>fibrosis</d> development through <d>proteasomal degradation</d> of <g>NOX4</g> | ||
150 | +Transforming Growth Factor (TGF)-b Promotes de Novo Serine Synthesis for Collagen <e>Production.</e> <g>TGF-b</g> <v>promotes </v>excessive collagen deposition in <d>fibrotic diseases</d> such as <d>idiopathic pulmonary fibrosis</d> (<d>IPF</d>) | ||
151 | +Association between cytokine removal by polymyxin B hemoperfusion and improved pulmonary oxygenation in patients with acute exacerbation of <d>idiopathic pulmonary fibrosis</d> | ||
152 | +Crosstalk between <g>TGF-b1</g> and complement activation augments epithelial <d>injury in pulmonary fibrosis</d> | ||
153 | +Bleomycin and <g>IL-1beta</g>-mediated <d>pulmonary fibrosis</d> is <g>IL-17A</g> dependent | ||
154 | +miR-199a-5p Is <v>upregulated </v>during fibrogenic response to tissue injury and mediates TGFbeta-induced lung fibroblast activation by targeting <g>caveolin-1</g> | ||
155 | +Inhibition of mechanosensitive signaling in myofibroblasts ameliorates experimental <d>pulmonary fibrosis</d> | ||
156 | +Integrated analyses identify the involvement of microRNA-26a in epithelial-mesenchymal transition during <d>idiopathic pulmonary fibrosis</d> | ||
157 | +<g>Transforming growth factor beta1</g> induces epithelial-to-mesenchymal transition of A549 cells | ||
158 | +The anti-fibrotic effects of microRNA-153 by <r>targeting </r><g>TGFBR-2</g> in <d>pulmonary fibrosis</d> | ||
159 | +The Epstein-Barr virus latent membrane protein 1 and transforming growth factor--b1 synergistically induce epithelial--mesenchymal transition in lung epithelial cells | ||
160 | +<u>Defective </u>histone acetylation is <r>responsible </r>for the <u>diminished </u><e>expression </e>of <g>cyclooxygenase 2</g> in <d>idiopathic pulmonary fibrosis</d> | ||
161 | +y-Herpes virus-68, but not Pseudomonas aeruginosa or influenza A (H1N1), exacerbates <d>established murine lung fibrosis</d> | ||
162 | +Inhibition and role of <g>let-7d</g> in <d>idiopathic pulmonary fibrosis</d> | ||
163 | +Pleural mesothelial cell transformation into myofibroblasts and haptotactic migration in response to <g>TGF-beta1</g> in vitro | ||
164 | +Association of HLA and cytokine gene polymorphisms with <d>idiopathic pulmonary fibrosis</d> | ||
165 | +Signaling pathways and their miRNA regulators involved in the etiopathology of <d>idiopathic pulmonary fibrosis</d> (<d>IPF</d>) and <d>hypersensitivity pneumonitis</d> (<d>HP</d>) | ||
166 | +<g>miR-21</g> mediates fibrogenic activation of pulmonary fibroblasts and lung <d>fibrosis</d> | ||
167 | +<g>Transcription factor GATA-6</g> is <e>expressed </e>in quiescent myofibroblasts in <d>idiopathic pulmonary fibrosis</d> | ||
168 | +Inhibitory effects of amines from Citrus reticulata on bleomycin-induced <d>pulmonary fibrosis</d> in rats | ||
169 | +Thalidomide <u>reduces </u><g>IL-18</g>, <g>IL-8</g> and <g>TNF-alpha</g> <l>release </l>from alveolar macrophages in <d>interstitial lung disease</d> | ||
170 | +Effect of glycosides based standardized fenugreek seed extract in bleomycin-induced <d>pulmonary fibrosis</d> in rats: Decisive role of <g>Bax</g>, <g>Nrf2</g>, <g>NF-kB</g>, <g>Muc5ac</g>, <g>TNF-a</g> and <g>IL-1b</g> | ||
171 | +The Anti-fibrotic Effects and Mechanisms of MicroRNA-486-5p in <d>Pulmonary Fibrosis</d> | ||
172 | +The role of microRNA-155/liver X receptor pathway in experimental and <d>idiopathic pulmonary fibrosis</d> | ||
173 | +Epithelial-to-mesenchymal transition and its role in <g>EGFR</g>-mutant <d>lung adenocarcinoma</d> and <d>idiopathic pulmonary fibrosis</d> | ||
174 | +<g>Cysteine-rich protein 1</g> is regulated by <g>transforming growth factor-b1</g> and expressed in lung <d>fibrosis</d> |
1 | +#Cluster: 1 | ||
2 | +1_s 1 | ||
3 | +3_s 3 | ||
4 | +5_s 5 | ||
5 | +6_s 6 | ||
6 | +7_s 7 | ||
7 | +8_s 8 | ||
8 | +10_s 10 | ||
9 | +12_s 12 | ||
10 | +13_s 13 | ||
11 | +14_s 14 | ||
12 | +16_s 16 | ||
13 | +17_s 17 | ||
14 | +18_s 18 | ||
15 | +20_s 20 | ||
16 | +22_s 22 | ||
17 | +23_s 23 | ||
18 | +24_s 24 | ||
19 | +25_s 25 | ||
20 | +28_s 28 | ||
21 | +29_s 29 | ||
22 | +31_s 31 | ||
23 | +33_s 33 | ||
24 | +34_s 34 | ||
25 | +37_s 37 | ||
26 | +38_s 38 | ||
27 | +42_s 42 | ||
28 | +43_s 43 | ||
29 | +44_s 44 | ||
30 | +47_s 47 | ||
31 | +48_s 48 | ||
32 | +49_s 49 | ||
33 | +54_s 54 | ||
34 | +55_s 55 | ||
35 | +58_s 58 | ||
36 | +59_s 59 | ||
37 | +64_s 64 | ||
38 | +65_s 65 | ||
39 | +66_s 66 | ||
40 | +67_s 67 | ||
41 | +69_s 69 | ||
42 | +70_s 70 | ||
43 | +71_s 71 | ||
44 | +72_s 72 | ||
45 | +74_s 74 | ||
46 | +75_s 75 | ||
47 | +79_s 79 | ||
48 | +80_s 80 | ||
49 | +81_s 81 | ||
50 | +82_s 82 | ||
51 | +83_s 83 | ||
52 | +84_s 84 | ||
53 | +86_s 86 | ||
54 | +87_s 87 | ||
55 | +88_s 88 | ||
56 | +89_s 89 | ||
57 | +90_s 90 | ||
58 | +91_s 91 | ||
59 | +92_s 92 | ||
60 | +93_s 93 | ||
61 | +94_s 94 | ||
62 | +98_s 98 | ||
63 | +100_s 100 | ||
64 | +101_s 101 | ||
65 | +102_s 102 | ||
66 | +104_s 104 | ||
67 | +106_s 106 | ||
68 | +109_s 109 | ||
69 | +110_s 110 | ||
70 | +112_s 112 | ||
71 | +115_s 115 | ||
72 | +117_s 117 | ||
73 | +118_s 118 | ||
74 | +120_s 120 | ||
75 | +123_s 123 | ||
76 | +124_s 124 | ||
77 | +127_s 126 | ||
78 | +128_s 127 | ||
79 | +130_s 129 | ||
80 | +132_s 131 | ||
81 | +136_s 135 | ||
82 | +137_s 136 | ||
83 | +138_s 137 | ||
84 | +141_s 140 | ||
85 | +142_s 141 | ||
86 | +144_s 143 | ||
87 | +146_s 145 | ||
88 | +147_s 146 | ||
89 | +148_s 147 | ||
90 | +149_s 148 | ||
91 | +150_s 149 | ||
92 | +156_s 155 | ||
93 | +159_s 158 | ||
94 | +161_s 160 | ||
95 | +162_s 161 | ||
96 | +163_s 162 | ||
97 | +164_s 163 | ||
98 | +165_s 164 | ||
99 | +166_s 165 | ||
100 | +169_s 168 | ||
101 | +171_s 169 | ||
102 | +174_s 172 | ||
103 | +177_s 175 | ||
104 | +179_s 177 | ||
105 | +182_s 180 | ||
106 | +184_s 182 | ||
107 | +186_s 184 | ||
108 | +188_s 186 | ||
109 | +189_s 187 | ||
110 | +190_s 188 | ||
111 | +192_s 190 | ||
112 | +195_s 193 | ||
113 | +196_s 194 | ||
114 | +197_s 195 | ||
115 | +198_s 196 | ||
116 | +199_s 197 | ||
117 | +203_s 201 | ||
118 | +204_s 202 | ||
119 | +205_s 203 | ||
120 | +208_s 206 | ||
121 | +210_s 208 | ||
122 | +214_s 212 | ||
123 | +215_s 213 | ||
124 | +216_s 214 | ||
125 | +217_s 215 | ||
126 | +219_s 217 | ||
127 | +220_s 218 | ||
128 | +221_s 219 | ||
129 | +222_s 220 | ||
130 | +223_s 221 | ||
131 | +225_s 223 | ||
132 | +226_s 224 | ||
133 | +227_s 225 | ||
134 | +229_s 227 | ||
135 | +230_s 228 | ||
136 | +233_s 231 | ||
137 | +234_s 232 | ||
138 | +236_s 234 | ||
139 | +237_s 235 | ||
140 | +238_s 236 | ||
141 | +239_s 237 | ||
142 | +240_s 238 | ||
143 | +241_s 239 | ||
144 | +242_s 240 | ||
145 | +243_s 241 | ||
146 | +244_s 242 | ||
147 | +245_s 243 | ||
148 | +246_s 244 | ||
149 | +247_s 245 | ||
150 | +248_s 246 | ||
151 | +250_s 248 | ||
152 | +251_s 249 | ||
153 | +253_s 250 | ||
154 | +254_s 251 | ||
155 | +255_s 252 | ||
156 | +256_s 253 | ||
157 | +260_s 257 | ||
158 | +262_s 259 | ||
159 | +264_s 261 | ||
160 | +265_s 262 | ||
161 | +268_s 265 | ||
162 | +269_s 266 | ||
163 | +272_s 269 | ||
164 | +273_s 270 | ||
165 | +275_s 272 | ||
166 | +278_s 275 | ||
167 | +279_s 276 | ||
168 | +280_s 277 | ||
169 | +281_s 278 | ||
170 | +284_s 281 | ||
171 | +286_s 283 | ||
172 | +287_s 284 | ||
173 | +289_s 286 | ||
174 | +290_s 287 | ||
175 | +291_s 288 | ||
176 | +293_s 289 | ||
177 | +295_s 291 | ||
178 | +297_s 293 | ||
179 | +298_s 294 | ||
180 | +299_s 295 | ||
181 | +300_s 296 | ||
182 | +301_s 297 | ||
183 | +302_s 298 | ||
184 | +303_s 299 | ||
185 | +305_s 301 | ||
186 | +307_s 303 | ||
187 | +308_s 304 | ||
188 | +310_s 306 | ||
189 | +313_s 309 | ||
190 | +314_s 310 | ||
191 | +315_s 311 | ||
192 | +316_s 312 | ||
193 | +317_s 313 | ||
194 | +318_s 314 | ||
195 | +320_s 316 | ||
196 | +322_s 318 | ||
197 | +325_s 321 | ||
198 | +326_s 322 | ||
199 | +328_s 324 | ||
200 | +330_s 326 | ||
201 | +332_s 328 | ||
202 | +333_s 329 | ||
203 | +335_s 331 | ||
204 | +336_s 332 | ||
205 | +340_s 336 | ||
206 | +343_s 339 | ||
207 | +345_s 341 | ||
208 | +347_s 343 | ||
209 | +348_s 344 | ||
210 | +349_s 345 | ||
211 | +350_s 346 | ||
212 | +352_s 348 | ||
213 | +353_s 349 | ||
214 | +354_s 350 | ||
215 | +355_s 351 | ||
216 | +356_s 352 | ||
217 | +357_s 353 | ||
218 | +360_s 356 | ||
219 | +361_s 357 | ||
220 | +362_s 358 | ||
221 | +363_s 359 | ||
222 | +364_s 360 | ||
223 | +365_s 361 | ||
224 | +366_s 362 | ||
225 | +367_s 363 | ||
226 | +368_s 364 | ||
227 | +371_s 367 | ||
228 | +372_s 368 | ||
229 | +374_s 370 | ||
230 | +375_s 371 | ||
231 | +376_s 372 | ||
232 | +377_s 373 | ||
233 | +378_s 374 | ||
234 | +379_s 375 | ||
235 | +380_s 376 | ||
236 | +383_s 379 | ||
237 | +384_s 380 | ||
238 | +387_s 383 | ||
239 | +388_s 384 | ||
240 | +390_s 386 | ||
241 | +391_s 387 | ||
242 | +392_s 388 | ||
243 | +398_s 394 | ||
244 | +399_s 395 | ||
245 | +401_s 397 | ||
246 | +402_s 398 | ||
247 | +403_s 399 | ||
248 | +407_s 403 | ||
249 | +408_s 404 | ||
250 | +409_s 405 | ||
251 | +411_s 407 | ||
252 | +413_s 409 | ||
253 | +414_s 410 | ||
254 | +415_s 411 | ||
255 | +416_s 412 | ||
256 | +418_s 414 | ||
257 | +419_s 415 | ||
258 | +420_s 416 | ||
259 | +421_s 417 | ||
260 | +424_s 420 | ||
261 | +428_s 424 | ||
262 | +429_s 425 | ||
263 | +431_s 427 | ||
264 | +433_s 429 | ||
265 | +437_s 433 | ||
266 | +438_s 434 | ||
267 | +440_s 436 | ||
268 | +442_s 438 | ||
269 | +443_s 439 | ||
270 | +444_s 440 | ||
271 | +445_s 441 | ||
272 | +446_s 442 | ||
273 | +447_s 443 | ||
274 | +448_s 444 | ||
275 | +450_s 446 | ||
276 | +451_s 447 | ||
277 | +452_s 448 | ||
278 | +453_s 449 | ||
279 | +#Cluster: 2 | ||
280 | +9_s 9 | ||
281 | +19_s 19 | ||
282 | +21_s 21 | ||
283 | +26_s 26 | ||
284 | +32_s 32 | ||
285 | +39_s 39 | ||
286 | +52_s 52 | ||
287 | +73_s 73 | ||
288 | +77_s 77 | ||
289 | +95_s 95 | ||
290 | +107_s 107 | ||
291 | +113_s 113 | ||
292 | +125_s 125 | ||
293 | +129_s 128 | ||
294 | +131_s 130 | ||
295 | +145_s 144 | ||
296 | +153_s 152 | ||
297 | +158_s 157 | ||
298 | +172_s 170 | ||
299 | +175_s 173 | ||
300 | +180_s 178 | ||
301 | +200_s 198 | ||
302 | +202_s 200 | ||
303 | +207_s 205 | ||
304 | +224_s 222 | ||
305 | +228_s 226 | ||
306 | +231_s 229 | ||
307 | +259_s 256 | ||
308 | +263_s 260 | ||
309 | +274_s 271 | ||
310 | +283_s 280 | ||
311 | +288_s 285 | ||
312 | +306_s 302 | ||
313 | +321_s 317 | ||
314 | +323_s 319 | ||
315 | +334_s 330 | ||
316 | +359_s 355 | ||
317 | +382_s 378 | ||
318 | +395_s 391 | ||
319 | +417_s 413 | ||
320 | +434_s 430 | ||
321 | +454_s 450 | ||
322 | +#Cluster: 3 | ||
323 | +2_s 2 | ||
324 | +4_s 4 | ||
325 | +11_s 11 | ||
326 | +15_s 15 | ||
327 | +27_s 27 | ||
328 | +30_s 30 | ||
329 | +35_s 35 | ||
330 | +36_s 36 | ||
331 | +40_s 40 | ||
332 | +41_s 41 | ||
333 | +45_s 45 | ||
334 | +46_s 46 | ||
335 | +50_s 50 | ||
336 | +51_s 51 | ||
337 | +53_s 53 | ||
338 | +56_s 56 | ||
339 | +57_s 57 | ||
340 | +60_s 60 | ||
341 | +61_s 61 | ||
342 | +62_s 62 | ||
343 | +63_s 63 | ||
344 | +68_s 68 | ||
345 | +76_s 76 | ||
346 | +78_s 78 | ||
347 | +85_s 85 | ||
348 | +96_s 96 | ||
349 | +97_s 97 | ||
350 | +99_s 99 | ||
351 | +103_s 103 | ||
352 | +105_s 105 | ||
353 | +108_s 108 | ||
354 | +111_s 111 | ||
355 | +114_s 114 | ||
356 | +116_s 116 | ||
357 | +119_s 119 | ||
358 | +121_s 121 | ||
359 | +122_s 122 | ||
360 | +133_s 132 | ||
361 | +134_s 133 | ||
362 | +135_s 134 | ||
363 | +139_s 138 | ||
364 | +140_s 139 | ||
365 | +143_s 142 | ||
366 | +151_s 150 | ||
367 | +152_s 151 | ||
368 | +154_s 153 | ||
369 | +155_s 154 | ||
370 | +157_s 156 | ||
371 | +160_s 159 | ||
372 | +167_s 166 | ||
373 | +168_s 167 | ||
374 | +173_s 171 | ||
375 | +176_s 174 | ||
376 | +178_s 176 | ||
377 | +181_s 179 | ||
378 | +183_s 181 | ||
379 | +185_s 183 | ||
380 | +187_s 185 | ||
381 | +191_s 189 | ||
382 | +193_s 191 | ||
383 | +194_s 192 | ||
384 | +201_s 199 | ||
385 | +206_s 204 | ||
386 | +209_s 207 | ||
387 | +211_s 209 | ||
388 | +212_s 210 | ||
389 | +213_s 211 | ||
390 | +218_s 216 | ||
391 | +232_s 230 | ||
392 | +235_s 233 | ||
393 | +249_s 247 | ||
394 | +257_s 254 | ||
395 | +258_s 255 | ||
396 | +261_s 258 | ||
397 | +266_s 263 | ||
398 | +267_s 264 | ||
399 | +270_s 267 | ||
400 | +271_s 268 | ||
401 | +276_s 273 | ||
402 | +277_s 274 | ||
403 | +282_s 279 | ||
404 | +285_s 282 | ||
405 | +294_s 290 | ||
406 | +296_s 292 | ||
407 | +304_s 300 | ||
408 | +309_s 305 | ||
409 | +311_s 307 | ||
410 | +312_s 308 | ||
411 | +319_s 315 | ||
412 | +324_s 320 | ||
413 | +327_s 323 | ||
414 | +329_s 325 | ||
415 | +331_s 327 | ||
416 | +337_s 333 | ||
417 | +338_s 334 | ||
418 | +339_s 335 | ||
419 | +341_s 337 | ||
420 | +342_s 338 | ||
421 | +344_s 340 | ||
422 | +346_s 342 | ||
423 | +351_s 347 | ||
424 | +358_s 354 | ||
425 | +369_s 365 | ||
426 | +370_s 366 | ||
427 | +373_s 369 | ||
428 | +381_s 377 | ||
429 | +385_s 381 | ||
430 | +386_s 382 | ||
431 | +389_s 385 | ||
432 | +393_s 389 | ||
433 | +394_s 390 | ||
434 | +396_s 392 | ||
435 | +397_s 393 | ||
436 | +400_s 396 | ||
437 | +404_s 400 | ||
438 | +405_s 401 | ||
439 | +406_s 402 | ||
440 | +410_s 406 | ||
441 | +412_s 408 | ||
442 | +422_s 418 | ||
443 | +423_s 419 | ||
444 | +425_s 421 | ||
445 | +426_s 422 | ||
446 | +427_s 423 | ||
447 | +430_s 426 | ||
448 | +432_s 428 | ||
449 | +435_s 431 | ||
450 | +436_s 432 | ||
451 | +439_s 435 | ||
452 | +441_s 437 | ||
453 | +449_s 445 | ||
454 | +455_s 451 | ||
... | \ No newline at end of file | ... | \ No newline at end of file |
results/Partition_3/cluster1.txt
0 → 100644
1 | +Recent advances in molecular targets and treatment of idiopathic pulmonary fibrosis: focus on TGFbeta signaling and the myofibroblast | ||
2 | +Tissue inhibitor of metalloproteinase-3 is up-regulated by transforming growth factor-beta1 in vitro and expressed in fibroblastic foci in vivo in idiopathic pulmonary fibrosis | ||
3 | +Defective histone acetylation is responsible for the diminished expression of cyclooxygenase 2 in idiopathic pulmonary fibrosis | ||
4 | +EZH2 enhances the differentiation of fibroblasts into myofibroblasts in idiopathic pulmonary fibrosis | ||
5 | +y-Herpes virus-68, but not Pseudomonas aeruginosa or influenza A (H1N1), exacerbates established murine lung fibrosis | ||
6 | +Microarray identifies ADAM family members as key responders to TGF-beta1 in alveolar epithelial cells | ||
7 | +Anti-pulmonary fibrotic activity of salvianolic acid B was screened by a novel method based on the cyto-biophysical properties | ||
8 | +Targeting genes for treatment in idiopathic pulmonary fibrosis: challenges and opportunities, promises and pitfalls | ||
9 | +Th1/Th2 cytokine gene polymorphisms in patients with idiopathic pulmonary fibrosis | ||
10 | +VCAM-1 is a TGF-b1 inducible gene upregulated in idiopathic pulmonary fibrosis | ||
11 | +Integrated analyses identify the involvement of microRNA-26a in epithelial-mesenchymal transition during idiopathic pulmonary fibrosis | ||
12 | +Upregulation of alveolar levels of activin B, but not activin A, in lungs of west highland white terriers with idiopathic pulmonary fibrosis and diffuse alveolar damage | ||
13 | +Roles for insulin-like growth factor I and transforming growth factor-beta in fibrotic lung disease | ||
14 | +Combined inhibition of TGFb and PDGF signaling attenuates radiation-induced pulmonary fibrosis | ||
15 | +Glucagon like peptide-1 attenuates bleomycin-induced pulmonary fibrosis, involving the inactivation of NF-kB in mice | ||
16 | +Carbon monoxide-bound hemoglobin-vesicles for the treatment of bleomycin-induced pulmonary fibrosis | ||
17 | +Protease activated receptor-1 regulates macrophage-mediated cellular senescence: a risk for idiopathic pulmonary fibrosis | ||
18 | +Control of virus reactivation arrests pulmonary herpesvirus-induced fibrosis in IFN-gamma receptor-deficient mice | ||
19 | +Regulation of TGF-b storage and activation in the human idiopathic pulmonary fibrosis lung | ||
20 | +Interleukin-17 induces human alveolar epithelial to mesenchymal cell transition via the TGF-b1 mediated Smad2/3 and ERK1/2 activation | ||
21 | +Prognostic factors for idiopathic pulmonary fibrosis: clinical, physiologic, pathologic, and molecular aspects | ||
22 | +Progressive transforming growth factor beta1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor | ||
23 | +Toll-like receptor 4 activation attenuates profibrotic response in control lung fibroblasts but not in fibroblasts from patients with IPF | ||
24 | +Free radical generation induces epithelial-to-mesenchymal transition in lung epithelium via a TGF-b1-dependent mechanism | ||
25 | +Methylation-mediated BMPER expression in fibroblast activation in vitro and lung fibrosis in mice in vivo | ||
26 | +Upregulation of activin-B and follistatin in pulmonary fibrosis - a translational study using human biopsies and a specific inhibitor in mouse fibrosis models | ||
27 | +Resveratrol inhibits transforming growth factor-b-induced proliferation and differentiation of ex vivo human lung fibroblasts into myofibroblasts through ERK/Akt inhibition and PTEN restoration | ||
28 | +Effects of doxycycline on production of growth factors and matrix metalloproteinases in pulmonary fibrosis | ||
29 | +MS80, a novel sulfated oligosaccharide, inhibits pulmonary fibrosis by targeting TGF-beta1 both in vitro and in vivo | ||
30 | +Association of HLA and cytokine gene polymorphisms with idiopathic pulmonary fibrosis | ||
31 | +Oxidant-antioxidant imbalance as a potential contributor to the progression of human pulmonary fibrosis | ||
32 | +A translational preclinical model of interstitial pulmonary fibrosis and pulmonary hypertension: mechanistic pathways driving disease pathophysiology | ||
33 | +Epithelial cell alpha3beta1 integrin links beta-catenin and Smad signaling to promote myofibroblast formation and pulmonary fibrosis | ||
34 | +Pirfenidone for the treatment of idiopathic pulmonary fibrosis | ||
35 | +Interactions between b-catenin and transforming growth factor-b signaling pathways mediate epithelial-mesenchymal transition and are dependent on the transcriptional co-activator cAMP-response element-binding protein (CREB)-binding protein (CBP) | ||
36 | +Uncoupling of the profibrotic and hemostatic effects of thrombin in lung fibrosis | ||
37 | +Studies of hepatocyte growth factor in bronchoalveolar lavage fluid in chronic interstitial lung diseases | ||
38 | +Syndecan-2 exerts antifibrotic effects by promoting caveolin-1-mediated transforming growth factor-b receptor I internalization and inhibiting transforming growth factor-b1 signaling | ||
39 | +Compromised peroxisomes in idiopathic pulmonary fibrosis, a vicious cycle inducing a higher fibrotic response via TGF-b signaling | ||
40 | +Simvastatin attenuates TGF-b1-induced epithelial-mesenchymal transition in human alveolar epithelial cells | ||
41 | +Expression of 150-kDa oxygen-regulated protein (ORP150) stimulates bleomycin-induced pulmonary fibrosis and dysfunction in mice | ||
42 | +Kinase inhibitors fail to induce mesenchymal-epithelial transition in fibroblasts from fibrotic lung tissue | ||
43 | +The small heat-shock protein aB-crystallin is essential for the nuclear localization of Smad4: impact on pulmonary fibrosis | ||
44 | +Blockade of the Wnt/b-catenin pathway attenuates bleomycin-induced pulmonary fibrosis | ||
45 | +Epithelial stem cell exhaustion in the pathogenesis of idiopathic pulmonary fibrosis | ||
46 | +CUX1/Wnt signaling regulates epithelial mesenchymal transition in EBV infected epithelial cells | ||
47 | +Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis | ||
48 | +Idiopathic pulmonary fibrosis: an altered fibroblast proliferation linked to cancer biology | ||
49 | +Lower expression of platelet derived growth factor is associated with better overall survival rate of patients with idiopathic nonspecific interstitial pneumonia | ||
50 | +Elevated expression of NEU1 sialidase in idiopathic pulmonary fibrosis provokes pulmonary collagen deposition, lymphocytosis, and fibrosis | ||
51 | +TGF-beta 1, but not TGF-beta 2 or TGF-beta 3, is differentially present in epithelial cells of advanced pulmonary fibrosis: an immunohistochemical study | ||
52 | +Cthrc1 lowers pulmonary collagen associated with bleomycin-induced fibrosis and protects lung function | ||
53 | +Pigment epithelium-derived factor in idiopathic pulmonary fibrosis: a role in aberrant angiogenesis | ||
54 | +Cytoskeletal protein modulation in pulmonary alveolar myofibroblasts during idiopathic pulmonary fibrosis | ||
55 | +Increased expression of 5-hydroxytryptamine2A/B receptors in idiopathic pulmonary fibrosis: a rationale for therapeutic intervention | ||
56 | +Signaling pathways and their miRNA regulators involved in the etiopathology of idiopathic pulmonary fibrosis (IPF) and hypersensitivity pneumonitis (HP) | ||
57 | +Alveolar epithelial cells express mesenchymal proteins in patients with idiopathic pulmonary fibrosis | ||
58 | +TGF-b1 induces tissue factor expression in human lung fibroblasts in a PI3K/JNK/Akt-dependent and AP-1-dependent manner | ||
59 | +Inhibitory effects of amines from Citrus reticulata on bleomycin-induced pulmonary fibrosis in rats | ||
60 | +Focal adhesion kinase signaling determines the fate of lung epithelial cells in response to TGF-b | ||
61 | +Beyond TGFb - Novel ways to target airway and parenchymal fibrosis | ||
62 | +Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis | ||
63 | +The profibrotic cytokine transforming growth factor-b1 increases endothelial progenitor cell angiogenic properties | ||
64 | +Tannic acid attenuates TGF-b1-induced epithelial-to-mesenchymal transition by effectively intervening TGF-b signaling in lung epithelial cells | ||
65 | +Differential expression of alpha E beta 7 integrins on bronchoalveolar lavage T lymphocyte subsets: regulation by alpha 4 beta 1-integrin crosslinking and TGF-beta | ||
66 | +Elevated sL1-CAM levels in BALF and serum of IPF patients | ||
67 | +The potential application of strategic released apigenin from polymeric carrier in pulmonary fibrosis | ||
68 | +Immunomodulation by mesenchymal stem cells in treating human autoimmune disease-associated lung fibrosis | ||
69 | +Epithelial-to-mesenchymal transition and its role in EGFR-mutant lung adenocarcinoma and idiopathic pulmonary fibrosis | ||
70 | +Effects of thymosin b4 and its N-terminal fragment Ac-SDKP on TGF-b-treated human lung fibroblasts and in the mouse model of bleomycin-induced lung fibrosis | ||
71 | +Epithelial contribution to the pro-fibrotic stiff microenvironment and myofibroblast population in lung fibrosis | ||
72 | +The matricellular protein CCN1 enhances TGF-b1/SMAD3-dependent profibrotic signaling in fibroblasts and contributes to fibrogenic responses to lung injury | ||
73 | +MicroRNA-326 regulates profibrotic functions of transforming growth factor-b in pulmonary fibrosis | ||
74 | +Significance of elevated procollagen-III-peptide and transforming growth factor-beta levels of bronchoalveolar lavage fluids from idiopathic pulmonary fibrosis patients | ||
75 | +The latent form of TGFbeta(1) is induced by TNFalpha through an ERK specific pathway and is activated by asbestos-derived reactive oxygen species in vitro and in vivo | ||
76 | +Protective role of gambogic acid in experimental pulmonary fibrosis in vitro and in vivo | ||
77 | +An ex vivo model to induce early fibrosis-like changes in human precision-cut lung slices | ||
78 | +Differential effects of human neutrophil peptide-1 on growth factor and interleukin-8 production by human lung fibroblasts and epithelial cells | ||
79 | +Human placental mesenchymal stem cells of fetal origins-alleviated inflammation and fibrosis by attenuating MyD88 signaling in bleomycin-induced pulmonary fibrosis mice | ||
80 | +Fibroblasts from idiopathic pulmonary fibrosis and normal lungs differ in growth rate, apoptosis, and tissue inhibitor of metalloproteinases expression | ||
81 | +Phosphatase and tensin homolog deleted on chromosome 10 contributes to phenotype transformation of fibroblasts in idiopathic pulmonary fibrosis via multiple pathways | ||
82 | +Release of biologically active TGF-beta1 by alveolar epithelial cells results in pulmonary fibrosis | ||
83 | +Overproduction of collagen and diminished SOCS1 expression are causally linked in fibroblasts from idiopathic pulmonary fibrosis | ||
84 | +Thalidomide reduces IL-18, IL-8 and TNF-alpha release from alveolar macrophages in interstitial lung disease | ||
85 | +Pathogenesis pathways of idiopathic pulmonary fibrosis in bleomycin-induced lung injury model in mice | ||
86 | +VEGF ameliorates pulmonary hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in rats | ||
87 | +Genomewide RNA expression profiling in lung identifies distinct signatures in idiopathic pulmonary arterial hypertension and secondary pulmonary hypertension | ||
88 | +Transforming growth factor-b1 downregulates vascular endothelial growth factor-D expression in human lung fibroblasts via the Jun NH2-terminal kinase signaling pathway | ||
89 | +Corilagin attenuates aerosol bleomycin-induced experimental lung injury | ||
90 | +Bleomycin induces molecular changes directly relevant to idiopathic pulmonary fibrosis: a model for "active" disease | ||
91 | +Long-acting human serum albumin-thioredoxin fusion protein suppresses bleomycin-induced pulmonary fibrosis progression | ||
92 | +Angiotensin-TGF-beta 1 crosstalk in human idiopathic pulmonary fibrosis: autocrine mechanisms in myofibroblasts and macrophages | ||
93 | +miR-199a-5p Is upregulated during fibrogenic response to tissue injury and mediates TGFbeta-induced lung fibroblast activation by targeting caveolin-1 | ||
94 | +Increased expression of protease nexin-1 in fibroblasts during idiopathic pulmonary fibrosis regulates thrombin activity and fibronectin expression | ||
95 | +Plasma CCN2 (connective tissue growth factor; CTGF) is a potential biomarker in idiopathic pulmonary fibrosis (IPF) | ||
96 | +Cysteine-rich protein 1 is regulated by transforming growth factor-b1 and expressed in lung fibrosis | ||
97 | +Microencapsulation of lefty-secreting engineered cells for pulmonary fibrosis therapy in mice | ||
98 | +Accelerated epithelial cell senescence in IPF and the inhibitory role of SIRT6 in TGF-b-induced senescence of human bronchial epithelial cells | ||
99 | +Pleural mesothelial cell transformation into myofibroblasts and haptotactic migration in response to TGF-beta1 in vitro | ||
100 | +p63 - Key molecule in the early phase of epithelial abnormality in idiopathic pulmonary fibrosis | ||
101 | +Increased interleukin-1 receptor antagonist in idiopathic pulmonary fibrosis | ||
102 | +Molecular pathogenesis of interstitial pneumonitis with TNF-alpha transgenic mice | ||
103 | +Wilms' tumor 1 (Wt1) regulates pleural mesothelial cell plasticity and transition into myofibroblasts in idiopathic pulmonary fibrosis | ||
104 | +Epithelium-specific deletion of TGF-b receptor type II protects mice from bleomycin-induced pulmonary fibrosis | ||
105 | +Bleomycin in the setting of lung fibrosis induction: From biological mechanisms to counteractions | ||
106 | +Assessment of the effect of potential antifibrotic compounds on total and aVb6 integrin-mediated TGF-b activation | ||
107 | +The anti-fibrotic effect of inhibition of TGFb-ALK5 signalling in experimental pulmonary fibrosis in mice is attenuated in the presence of concurrent y-herpesvirus infection | ||
108 | +Plasminogen activator inhibitor 1, fibroblast apoptosis resistance, and aging-related susceptibility to lung fibrosis | ||
109 | +Antifibrotic properties of receptor for advanced glycation end products in idiopathic pulmonary fibrosis | ||
110 | +Genetic polymorphism in matrix metalloproteinase-9 and transforming growth factor-b1 and susceptibility to combined pulmonary fibrosis and emphysema in a Chinese population | ||
111 | +Berberine attenuates bleomycin induced pulmonary toxicity and fibrosis via suppressing NF-kB dependant TGF-b activation: a biphasic experimental study | ||
112 | +Transforming growth factor-b inhibits IQ motif containing guanosine triphosphatase activating protein 1 expression in lung fibroblasts via the nuclear factor-kB signaling pathway | ||
113 | +Role of CD248 as a potential severity marker in idiopathic pulmonary fibrosis | ||
114 | +Immunoglobulin A in serum: an old acquaintance as a new prognostic biomarker in idiopathic pulmonary fibrosis | ||
115 | +Defect of hepatocyte growth factor secretion by fibroblasts in idiopathic pulmonary fibrosis | ||
116 | +Possible involvement of pirfenidone metabolites in the antifibrotic action of a therapy for idiopathic pulmonary fibrosis | ||
117 | +Effect of pirfenidone on proliferation, TGF-b-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts | ||
118 | +Olodaterol shows anti-fibrotic efficacy in in vitro and in vivo models of pulmonary fibrosis | ||
119 | +[Quantifying plasma levels of transforming growth factor beta1 in idiopathic pulmonary fibrosis] | ||
120 | +BAX inhibitor-1-associated V-ATPase glycosylation enhances collagen degradation in pulmonary fibrosis | ||
121 | +Idiopathic pulmonary fibrosis: pathobiology of novel approaches to treatment | ||
122 | +Novel pharmacological approaches to manage interstitial lung fibrosis in the twenty-first century | ||
123 | +De-ubiquitinating enzyme, USP11, promotes transforming growth factor b-1 signaling through stabilization of transforming growth factor b receptor II | ||
124 | +SPARC suppresses apoptosis of idiopathic pulmonary fibrosis fibroblasts through constitutive activation of beta-catenin | ||
125 | +Aortic carboxypeptidase-like protein (ACLP) enhances lung myofibroblast differentiation through transforming growth factor b receptor-dependent and -independent pathways | ||
126 | +IL-4 polymorphisms, HRCT score and lung tissue markers in idiopathic pulmonary fibrosis | ||
127 | +TGF-beta1 induces human alveolar epithelial to mesenchymal cell transition (EMT) | ||
128 | +NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury | ||
129 | +TGF-beta 1 as an enhancer of Fas-mediated apoptosis of lung epithelial cells | ||
130 | +MicroRNA-29c regulates apoptosis sensitivity via modulation of the cell-surface death receptor, Fas, in lung fibroblasts | ||
131 | +Insulin-like growth factor binding proteins 3 and 5 are overexpressed in idiopathic pulmonary fibrosis and contribute to extracellular matrix deposition | ||
132 | +Bile acids induce activation of alveolar epithelial cells and lung fibroblasts through farnesoid X receptor-dependent and independent pathways | ||
133 | +Fibroblastic foci, covered with alveolar epithelia exhibiting epithelial-mesenchymal transition, destroy alveolar septa by disrupting blood flow in idiopathic pulmonary fibrosis | ||
134 | +Connective tissue growth factor expression and induction by transforming growth factor-beta is abrogated by simvastatin via a Rho signaling mechanism | ||
135 | +Regulation of human lung fibroblast C1q-receptors by transforming growth factor-beta and tumor necrosis factor-alpha | ||
136 | +Sorafenib ameliorates bleomycin-induced pulmonary fibrosis: potential roles in the inhibition of epithelial-mesenchymal transition and fibroblast activation | ||
137 | +Microarray profiling reveals suppressed interferon stimulated gene program in fibroblasts from scleroderma-associated interstitial lung disease | ||
138 | +Effects of antifibrotic agents on TGF-beta1, CTGF and IFN-gamma expression in patients with idiopathic pulmonary fibrosis | ||
139 | +NOX4/NADPH oxidase expression is increased in pulmonary fibroblasts from patients with idiopathic pulmonary fibrosis and mediates TGFbeta1-induced fibroblast differentiation into myofibroblasts | ||
140 | +[The expressions and meanings of BMP-7 and TGF-b in idiopathic pulmonary fibrosis and idiopathic nonspecific interstitial pneumonia] | ||
141 | +Increased deposition of chondroitin/dermatan sulfate glycosaminoglycan and upregulation of b1,3-glucuronosyltransferase I in pulmonary fibrosis | ||
142 | +Identification and validation of differentially expressed transcripts by RNA-sequencing of formalin-fixed, paraffin-embedded (FFPE) lung tissue from patients with Idiopathic Pulmonary Fibrosis | ||
143 | +Increased TGF-beta1 in the lungs of asbestos-exposed rats and mice: reduced expression in TNF-alpha receptor knockout mice | ||
144 | +Discovery and validation of extracellular/circulating microRNAs during idiopathic pulmonary fibrosis disease progression | ||
145 | +Idiopathic pulmonary fibrosis in relation to gene polymorphisms of transforming growth factor-b1 and plasminogen activator inhibitor 1 | ||
146 | +Comparative study of transforming growth factor-b signalling and regulatory molecules in human and canine idiopathic pulmonary fibrosis | ||
147 | +TGF-b1 T869C polymorphism may affect susceptibility to idiopathic pulmonary fibrosis and disease severity | ||
148 | +Inhibition of PI3K prevents the proliferation and differentiation of human lung fibroblasts into myofibroblasts: the role of class I P110 isoforms | ||
149 | +Medical treatment for pulmonary fibrosis: current trends, concepts, and prospects | ||
150 | +Contribution of the anaphylatoxin receptors, C3aR and C5aR, to the pathogenesis of pulmonary fibrosis | ||
151 | +Comparison between conventional and "clinical" assessment of experimental lung fibrosis | ||
152 | +Intratracheal bleomycin causes airway remodeling and airflow obstruction in mice | ||
153 | +Role of endoplasmic reticulum stress in age-related susceptibility to lung fibrosis | ||
154 | +Transforming growth factor b1 (TGFb1)-induced CD44V6-NOX4 signaling in pathogenesis of idiopathic pulmonary fibrosis | ||
155 | +Increased levels of prostaglandin E-major urinary metabolite (PGE-MUM) in chronic fibrosing interstitial pneumonia | ||
156 | +Pirfenidone inhibits TGF-b1-induced over-expression of collagen type I and heat shock protein 47 in A549 cells | ||
157 | +BAL cytokine profile in different interstitial lung diseases: a focus on systemic sclerosis | ||
158 | +Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis | ||
159 | +Effect of an immunotoxin to folate receptor beta on bleomycin-induced experimental pulmonary fibrosis | ||
160 | +Modulation of CD11c+ lung dendritic cells in respect to TGF-b in experimental pulmonary fibrosis | ||
161 | +Microsatellite instability in transforming growth factor-beta 1 type II receptor gene in alveolar lining epithelial cells of idiopathic pulmonary fibrosis | ||
162 | +Single-cell RNA sequencing identifies diverse roles of epithelial cells in idiopathic pulmonary fibrosis | ||
163 | +Expression of suppressor of cytokine signaling 1 in the peripheral blood of patients with idiopathic pulmonary fibrosis | ||
164 | +Prostaglandin F(2alpha) receptor signaling facilitates bleomycin-induced pulmonary fibrosis independently of transforming growth factor-beta | ||
165 | +Sphingosine-1-phosphate lyase is an endogenous suppressor of pulmonary fibrosis: role of S1P signalling and autophagy | ||
166 | +Roles of p38 MAPK and JNK in TGF-b1-induced human alveolar epithelial to mesenchymal transition | ||
167 | +The role of microRNA-155/liver X receptor pathway in experimental and idiopathic pulmonary fibrosis | ||
168 | +Sphingosine-1-phosphate is increased in patients with idiopathic pulmonary fibrosis and mediates epithelial to mesenchymal transition | ||
169 | +Nitric oxide attenuates epithelial-mesenchymal transition in alveolar epithelial cells | ||
170 | +Sirtuin 7 is decreased in pulmonary fibrosis and regulates the fibrotic phenotype of lung fibroblasts | ||
171 | +Evaluation of permeability alteration and epithelial-mesenchymal transition induced by transforming growth factor-b1 in A549, NCI-H441, and Calu-3 cells: Development of an in vitro model of respiratory epithelial cells in idiopathic pulmonary fibrosis | ||
172 | +Hydrogen peroxide is a diffusible paracrine signal for the induction of epithelial cell death by activated myofibroblasts | ||
173 | +TGF-b1 stimulates HDAC4 nucleus-to-cytoplasm translocation and NADPH oxidase 4-derived reactive oxygen species in normal human lung fibroblasts | ||
174 | +Effects of a leukotriene B4 receptor antagonist on bleomycin-induced pulmonary fibrosis | ||
175 | +Raised serum levels of IGFBP-1 and IGFBP-2 in idiopathic pulmonary fibrosis | ||
176 | +Inhibition of NF-kappaB signaling reduces virus load and gammaherpesvirus-induced pulmonary fibrosis | ||
177 | +Triptolide suppresses paraquat induced idiopathic pulmonary fibrosis by inhibiting TGFB1-dependent epithelial mesenchymal transition | ||
178 | +N-acetylcysteine downregulation of lysyl oxidase activity alleviating bleomycin-induced pulmonary fibrosis in rats | ||
179 | +Cytokine gene polymorphisms and BALF cytokine levels in interstitial lung diseases | ||
180 | +[The morphology and molecular bases of damage to the stem cell niche of respiratory acini in idiopathic interstitial pneumonias] | ||
181 | +Lactic acid is elevated in idiopathic pulmonary fibrosis and induces myofibroblast differentiation via pH-dependent activation of transforming growth factor-b | ||
182 | +Differential mRNA expression of insulin-like growth factor-1 splice variants in patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis | ||
183 | +The hedgehog system machinery controls transforming growth factor-b-dependent myofibroblastic differentiation in humans: involvement in idiopathic pulmonary fibrosis | ||
184 | +Effects and mechanisms of pirfenidone, prednisone and acetylcysteine on pulmonary fibrosis in rat idiopathic pulmonary fibrosis models | ||
185 | +PPAR-y ligands repress TGFb-induced myofibroblast differentiation by targeting the PI3K/Akt pathway: implications for therapy of fibrosis | ||
186 | +WISP1 mediates IL-6-dependent proliferation in primary human lung fibroblasts | ||
187 | +Melatonin attenuates TGFb1-induced epithelial-mesenchymal transition in lung alveolar epithelial cells | ||
188 | +JAK2 mediates lung fibrosis, pulmonary vascular remodelling and hypertension in idiopathic pulmonary fibrosis: an experimental study | ||
189 | +Ambroxol hydrochloride in the management of idiopathic pulmonary fibrosis: Clinical trials are the need of the hour | ||
190 | +Reactive oxygen species are required for maintenance and differentiation of primary lung fibroblasts in idiopathic pulmonary fibrosis | ||
191 | +MiR-5100 targets TOB2 to drive epithelial-mesenchymal transition associated with activating smad2/3 in lung epithelial cells | ||
192 | +IL-17A deficiency mitigates bleomycin-induced complement activation during lung fibrosis | ||
193 | +Inhibitory effect of receptor for advanced glycation end products (RAGE) on the TGF-b-induced alveolar epithelial to mesenchymal transition | ||
194 | +Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) promotes lung fibroblast proliferation, survival and differentiation to myofibroblasts | ||
195 | +TGF-beta-induced EMT: mechanisms and implications for fibrotic lung disease | ||
196 | +Pleural mesothelial cell differentiation and invasion in fibrogenic lung injury | ||
197 | +Absence of Thy-1 results in TGF-b induced MMP-9 expression and confers a profibrotic phenotype to human lung fibroblasts | ||
198 | +Signalling pathways from NADPH oxidase-4 to idiopathic pulmonary fibrosis | ||
199 | +Interplay between RAGE, CD44, and focal adhesion molecules in epithelial-mesenchymal transition of alveolar epithelial cells | ||
200 | +Are mast cells instrumental for fibrotic diseases? Idiopathic pulmonary fibrosis (IPF) is a fatal lung disorder of unknown etiology characterized by accumulation of lung fibroblasts and extracellular matrix deposition, ultimately leading to compromised tissue architecture and lung function capacity | ||
201 | +Association between cytokine removal by polymyxin B hemoperfusion and improved pulmonary oxygenation in patients with acute exacerbation of idiopathic pulmonary fibrosis | ||
202 | +Increased production and immunohistochemical localization of transforming growth factor-beta in idiopathic pulmonary fibrosis | ||
203 | +TNF-alpha, PDGF, and TGF-beta(1) expression by primary mouse bronchiolar-alveolar epithelial and mesenchymal cells: tnf-alpha induces TGF-beta(1) | ||
204 | +Anchorage-independent colony growth of pulmonary fibroblasts derived from fibrotic human lung tissue | ||
205 | +Overexpression of squamous cell carcinoma antigen in idiopathic pulmonary fibrosis: clinicopathological correlations | ||
206 | +Intrinsic defence capacity and therapeutic potential of natriuretic peptides in pulmonary hypertension associated with lung fibrosis | ||
207 | +Microsomal prostaglandin E synthase-1 deficiency exacerbates pulmonary fibrosis induced by bleomycin in mice | ||
208 | +Antifibrotic effects of cyclosporine A on TGF-b1-treated lung fibroblasts and lungs from bleomycin-treated mice: role of hypoxia-inducible factor-1a | ||
209 | +Preventive and therapeutic effects of thymosin b4 N-terminal fragment Ac-SDKP in the bleomycin model of pulmonary fibrosis | ||
210 | +The role of halofuginone in fibrosis: more to be explored? Fibrosis, which can be defined as an abnormal or excessive accumulation of extracellular matrix (ECM), particularly fibrillar collagens, is a key driver of progressive organ dysfunction in many inflammatory and metabolic diseases, including idiopathic pulmonary fibrosis (IPF), cirrhosis, nephropathy, and oral submucous fibrosis (OSF) | ||
211 | +Forkhead Box F1 (FOXF1) represses cell growth, COL1 and ARPC2 expression in lung fibroblasts in vitro | ||
212 | +Nitrated fatty acids reverse pulmonary fibrosis by dedifferentiating myofibroblasts and promoting collagen uptake by alveolar macrophages | ||
213 | +Serpin B4 isoform overexpression is associated with aberrant epithelial proliferation and lung cancer in idiopathic pulmonary fibrosis | ||
214 | +Modulation of specific beta cell gene (re)expression during in vitro expansion of human pancreatic islet cells | ||
215 | +Dehydroepiandrosterone has strong antifibrotic effects and is decreased in idiopathic pulmonary fibrosis | ||
216 | +Regulation of the effects of TGF-beta 1 by activation of latent TGF-beta 1 and differential expression of TGF-beta receptors (T beta R-I and T beta R-II) in idiopathic pulmonary fibrosis | ||
217 | +Establishment of the mouse model of acute exacerbation of idiopathic pulmonary fibrosis | ||
218 | +CCN5 overexpression inhibits profibrotic phenotypes via the PI3K/Akt signaling pathway in lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis and in an in vivo model of lung fibrosis | ||
219 | +Spiruchostatin A inhibits proliferation and differentiation of fibroblasts from patients with pulmonary fibrosis | ||
220 | +Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis | ||
221 | +Tumor necrosis factor superfamily 14 (LIGHT) controls thymic stromal lymphopoietin to drive pulmonary fibrosis | ||
222 | +High levels of IL-6 and IL-8 characterize early-on idiopathic pulmonary fibrosis acute exacerbations | ||
223 | +Mast cell chymase: an indispensable instrument in the pathological symphony of idiopathic pulmonary fibrosis? Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and fatal lung disease with no known etiology and treatment options | ||
224 | +Defect of pro-hepatocyte growth factor activation by fibroblasts in idiopathic pulmonary fibrosis | ||
225 | +Lung infection with gamma-herpesvirus induces progressive pulmonary fibrosis in Th2-biased mice | ||
226 | +Amplified canonical transforming growth factor-b signalling<i>via</i>heat shock protein 90 in pulmonary fibrosis | ||
227 | +Pirfenidone attenuates bleomycin-induced pulmonary fibrosis in mice by regulating Nrf2/Bach1 equilibrium | ||
228 | +Cytokine gene polymorphisms and serum cytokine levels in patients with idiopathic pulmonary fibrosis | ||
229 | +Thalidomide prevents bleomycin-induced pulmonary fibrosis in mice | ||
230 | +Reduced expression of BMP3 contributes to the development of pulmonary fibrosis and predicts the unfavorable prognosis in IIP patients | ||
231 | +The antifibrotic effects and mechanisms of microRNA-26a action in idiopathic pulmonary fibrosis | ||
232 | +The K+ channel KCa3.1 as a novel target for idiopathic pulmonary fibrosis | ||
233 | +The Epstein-Barr virus latent membrane protein 1 and transforming growth factor--b1 synergistically induce epithelial--mesenchymal transition in lung epithelial cells | ||
234 | +An inhibitor of NADPH oxidase-4 attenuates established pulmonary fibrosis in a rodent disease model | ||
235 | +Pleiotropic effect of the proton pump inhibitor esomeprazole leading to suppression of lung inflammation and fibrosis | ||
236 | +Activated human T lymphocytes inhibit TGFb-induced fibroblast to myofibroblast differentiation via prostaglandins D2 and E2 | ||
237 | +Peripheral depletion of NK cells and imbalance of the Treg/Th17 axis in idiopathic pulmonary fibrosis patients | ||
238 | +Bone morphogenetic protein-4 inhibitor gremlin is overexpressed in idiopathic pulmonary fibrosis | ||
239 | +Role of protease-activated receptor-2 in idiopathic pulmonary fibrosis | ||
240 | +Type V collagen induced tolerance suppresses collagen deposition, TGF-b and associated transcripts in pulmonary fibrosis | ||
241 | +Syndecan-2 is a novel target of insulin-like growth factor binding protein-3 and is over-expressed in fibrosis | ||
242 | +Extracellular superoxide dismutase has a highly specific localization in idiopathic pulmonary fibrosis/usual interstitial pneumonia | ||
243 | +Early growth response transcription factors: key mediators of fibrosis and novel targets for anti-fibrotic therapy | ||
244 | +Effects of the tumor suppressor PTEN on the pathogenesis of idiopathic pulmonary fibrosis in Chinese patients | ||
245 | +Different effects of growth factors on proliferation and matrix production of normal and fibrotic human lung fibroblasts | ||
246 | +The impact of TGF-b on lung fibrosis: from targeting to biomarkers | ||
247 | +Herpes virus infection is associated with vascular remodeling and pulmonary hypertension in idiopathic pulmonary fibrosis | ||
248 | +N-acetylcysteine inhibits TNF-alpha, sTNFR, and TGF-beta1 release by alveolar macrophages in idiopathic pulmonary fibrosis in vitro | ||
249 | +Recombinant human serum amyloid P in healthy volunteers and patients with pulmonary fibrosis | ||
250 | +Transforming growth factor beta1 induces epithelial-to-mesenchymal transition of A549 cells | ||
251 | +X-linked inhibitor of apoptosis regulates lung fibroblast resistance to Fas-mediated apoptosis | ||
252 | +Idiopathic pulmonary fibrosis: immunohistochemical analysis provides fresh insights into lung tissue remodelling with implications for novel prognostic markers | ||
253 | +PI3K p110y overexpression in idiopathic pulmonary fibrosis lung tissue and fibroblast cells: in vitro effects of its inhibition | ||
254 | +Alveolar epithelial cell injury with Epstein-Barr virus upregulates TGFbeta1 expression | ||
255 | +Expression of mucosa-related integrin alphaEbeta7 on alveolar T cells in interstitial lung diseases | ||
256 | +Effects of cigarette smoke extract on A549 cells and human lung fibroblasts treated with transforming growth factor-beta1 in a coculture system | ||
257 | +Nuclear factor erythroid 2-related factor 2 nuclear translocation induces myofibroblastic dedifferentiation in idiopathic pulmonary fibrosis | ||
258 | +Rapamycin regulates connective tissue growth factor expression of lung epithelial cells via phosphoinositide 3-kinase | ||
259 | +Peptide-mediated inhibition of mitogen-activated protein kinase-activated protein kinase-2 ameliorates bleomycin-induced pulmonary fibrosis | ||
260 | +Effect of glycosides based standardized fenugreek seed extract in bleomycin-induced pulmonary fibrosis in rats: Decisive role of Bax, Nrf2, NF-kB, Muc5ac, TNF-a and IL-1b | ||
261 | +Simvastatin inhibits growth factor expression and modulates profibrogenic markers in lung fibroblasts | ||
262 | +Activated MCTC mast cells infiltrate diseased lung areas in cystic fibrosis and idiopathic pulmonary fibrosis | ||
263 | +Type II alveolar epithelial cells and interstitial fibroblasts express connective tissue growth factor in IPF | ||
264 | +Crosstalk between TGF-b1 and complement activation augments epithelial injury in pulmonary fibrosis | ||
265 | +RhoA signaling modulates cyclin D1 expression in human lung fibroblasts; implications for idiopathic pulmonary fibrosis | ||
266 | +Titration of non-replicating adenovirus as a vector for transducing active TGF-beta1 gene expression causing inflammation and fibrogenesis in the lungs of C57BL/6 mice | ||
267 | +Age-driven developmental drift in the pathogenesis of idiopathic pulmonary fibrosis | ||
268 | +Current and novel drug therapies for idiopathic pulmonary fibrosis | ||
269 | +Proliferation of pulmonary interstitial fibroblasts is mediated by transforming growth factor-beta1-induced release of extracellular fibroblast growth factor-2 and phosphorylation of p38 MAPK and JNK | ||
270 | +Secreted protein acidic and rich in cysteine (SPARC) is upregulated by transforming growth factor (TGF)-b and is required for TGF-b-induced hydrogen peroxide production in fibroblasts | ||
271 | +Semaphorin 7a+ regulatory T cells are associated with progressive idiopathic pulmonary fibrosis and are implicated in transforming growth factor-b1-induced pulmonary fibrosis | ||
272 | +Regulation of transforming growth factor-b1-driven lung fibrosis by galectin-3 | ||
273 | +Reduced transcription of the Smad4 gene during pulmonary carcinogenesis in idiopathic pulmonary fibrosis | ||
274 | +Curcumin inhibits fibrosis-related effects in IPF fibroblasts and in mice following bleomycin-induced lung injury | ||
275 | +Targeting sphingosine kinase 1 attenuates bleomycin-induced pulmonary fibrosis | ||
276 | +Data on CUX1 isoforms in idiopathic pulmonary fibrosis lung and systemic sclerosis skin tissue sections | ||
277 | +Arsenic trioxide inhibits transforming growth factor-b1-induced fibroblast to myofibroblast differentiation in vitro and bleomycin induced lung fibrosis in vivo |
results/Partition_3/cluster1_tagged.txt
0 → 100644
1 | +Assessment of the effect of potential antifibrotic compounds on total and aVb6 integrin-mediated TGF-b <v>activation.</v> | ||
2 | +Resveratrol inhibits transforming growth factor-b-induced proliferation and differentiation of ex vivo human lung fibroblasts into myofibroblasts through <g>ERK</g>/<g>Akt</g> <u>inhibition </u>and <g>PTEN</g> restoration | ||
3 | +Immunoglobulin A in serum: an old acquaintance as a new prognostic biomarker in <d>idiopathic pulmonary fibrosis</d> | ||
4 | +[Pulmonary fibrosis--a therapeutic dilemma?] | ||
5 | +<g>Syndecan-2</g> exerts antifibrotic effects by promoting <g>caveolin-1</g>-mediated transforming growth factor-b receptor I internalization and inhibiting transforming growth factor-b1 signaling | ||
6 | +Modulation of specific beta cell gene (re)expression during in vitro expansion of human pancreatic islet cells | ||
7 | +Amplification of <g>TGFb</g> | ||
8 | +[<d>Idiopathic pulmonary fibrosis</d> and <d>lung cancer</d>] | ||
9 | +<g>Periostin</g> promotes <d>fibrosis</d> and predicts progression in patients with <d>idiopathic pulmonary fibrosis</d> | ||
10 | +<g>CCN5</g> <v>overexpression </v>inhibits profibrotic phenotypes via the <g>PI3K</g>/Akt signaling pathway in lung fibroblasts isolated from patients with <d>idiopathic pulmonary fibrosis</d> and in an in vivo model of <d>lung fibrosis</d> | ||
11 | +<g>Extracellular superoxide dismutase</g> has a highly specific <l>localization </l>in <d>idiopathic pulmonary fibrosis</d>/<d>usual interstitial pneumonia</d> | ||
12 | +Signaling pathways in the epithelial origins of <d>pulmonary fibrosis</d> | ||
13 | +Overexpression of <d>squamous cell carcinoma</d> antigen in <d>idiopathic pulmonary fibrosis</d>: clinicopathological correlations | ||
14 | +An ex vivo model to induce early <d>fibrosis</d>-like changes in human precision-cut lung slices | ||
15 | +The role of halofuginone in fibrosis: more to be explored? Fibrosis, which can be defined as an abnormal or excessive accumulation of extracellular matrix (ECM), particularly fibrillar collagens, is a key driver of progressive organ dysfunction in many inflammatory and metabolic diseases, including idiopathic pulmonary fibrosis (IPF), cirrhosis, nephropathy, and oral submucous fibrosis (OSF) | ||
16 | +Genomewide RNA expression profiling in lung identifies distinct signatures in <d>idiopathic pulmonary arterial hypertension</d> and <d>secondary pulmonary hypertension</d> | ||
17 | +Establishment of the mouse model of acute exacerbation of <d>idiopathic pulmonary fibrosis</d> | ||
18 | +Dehydroepiandrosterone has strong antifibrotic effects and is decreased in <d>idiopathic pulmonary fibrosis</d> | ||
19 | +Metformin <d>attenuates lung fibrosis</d> development via <g>NOX4</g> <u>suppression.</u> | ||
20 | +<g>Plasminogen activator inhibitor 1</g>, fibroblast apoptosis resistance, and aging-related susceptibility to lung <d>fibrosis</d> | ||
21 | +Cytokine gene polymorphisms and serum cytokine levels in patients with <d>idiopathic pulmonary fibrosis</d> | ||
22 | +Raised serum levels of <g>IGFBP-1</g> and <g>IGFBP-2</g> in <d>idiopathic pulmonary fibrosis</d> | ||
23 | +Determining the True Selectivity Profile of av Integrin Ligands Using Radioligand Binding: Applying an Old Solution to a New Problem | ||
24 | +Tumor <d>necrosis</d> factor superfamily 14 (<d>LIGHT</d>) controls <g>thymic stromal lymphopoietin</g> to drive <d>pulmonary fibrosis</d> | ||
25 | +<g>Pigment epithelium-derived factor</g> in <d>idiopathic pulmonary fibrosis</d>: a role in aberrant angiogenesis | ||
26 | +Methylation-mediated <g>BMPER</g> <e>expression </e>in fibroblast activation in vitro and lung <d>fibrosis</d> in mice in vivo | ||
27 | +<d>Fibrosis</d> of two: Epithelial cell-fibroblast interactions in <d>pulmonary fibrosis</d> | ||
28 | +Peptide-mediated inhibition of <g>mitogen-activated protein kinase-activated protein kinase-2</g> ameliorates bleomycin-induced <d>pulmonary fibrosis</d> | ||
29 | +Role of integrin-<v>mediated </v><g>TGFbeta</g> <v>activation </v>in the pathogenesis of <d>pulmonary fibrosis</d> | ||
30 | +Novel pharmacological approaches to manage <d>interstitial lung fibrosis</d> in the twenty-first century | ||
31 | +Lipoxin A4 Attenuates Constitutive and <g>TGF-b1</g>-Dependent Profibrotic Activity in Human Lung Myofibroblasts | ||
32 | +<g>Hsp90</g> <r>regulation </r>of fibroblast activation in <d>pulmonary fibrosis</d> | ||
33 | +<g>Glucagon like peptide-1</g> attenuates bleomycin-induced <d>pulmonary fibrosis</d>, involving the <u>inactivation </u>of NF-kB in mice | ||
34 | +<g>MiR-185</g>/<g>AKT</g> and <g>miR-29a</g>/collagen 1a pathways are <v>activated </v>in <d>IPF</d> | ||
35 | +Arsenic trioxide inhibits transforming growth factor-b1-induced <d>fibroblast to myofibroblast differentiation</d> in vitro and bleomycin induced lung <d>fibrosis</d> in vivo | ||
36 | +<g>Wilms' tumor 1</g> (<g>Wt1</g>) regulates pleural mesothelial cell plasticity and transition into myofibroblasts in <d>idiopathic pulmonary fibrosis</d> | ||
37 | +<g>miR-26a</g> suppresses EMT by disrupting the <g>Lin28B</g>/<g>let-7d</g> axis: potential cross-talks among miRNAs in <d>IPF</d> | ||
38 | +microRNA-1343 attenuates pathways of <d>fibrosis</d> by targeting the <g>TGF-b</g> receptors | ||
39 | +Kinase <u>inhibitors </u>fail to induce mesenchymal-epithelial transition in fibroblasts from fibrotic lung tissue | ||
40 | +<g>Transgelin</g> is a direct target of <g>TGF-beta</g>/<g>Smad3</g>-dependent epithelial cell <d>migration in lung fibrosis</d> | ||
41 | +The mannose-6-phosphate analogue, PXS64, inhibits <d>fibrosis</d> via <g>TGF-b1</g> pathway in human lung fibroblasts | ||
42 | +<u>Reduced </u><e>expression </e>of <g>BMP3</g> contributes to the development of <d>pulmonary fibrosis</d> and predicts the unfavorable prognosis in IIP patients | ||
43 | +Role of <g>CD248</g> as a potential severity marker in <d>idiopathic pulmonary fibrosis</d> | ||
44 | +Early growth response transcription factors: key mediators of <d>fibrosis</d> and novel targets for anti-fibrotic therapy | ||
45 | +<g>Toll-like receptor 4</g> activation attenuates profibrotic response in control lung fibroblasts but not in fibroblasts from patients with <d>IPF</d> | ||
46 | +<g>BAX inhibitor-1</g>-associated <g>V-ATPase</g> glycosylation <v>enhances </v>collagen degradation in <d>pulmonary fibrosis</d> | ||
47 | +Sphingosine-1-phosphate lyase is an endogenous suppressor of <d>pulmonary fibrosis</d>: role of <g>S1P</g> signalling and autophagy | ||
48 | +<g>Nuclear factor erythroid 2-related factor 2</g> nuclear translocation induces <d>myofibroblastic dedifferentiation</d> in <d>idiopathic pulmonary fibrosis</d> | ||
49 | +<g>Matrix metalloproteinase (MMP)-19</g> <u>deficient </u>fibroblasts display a profibrotic phenotype | ||
50 | +A translational preclinical model of <d>interstitial pulmonary fibrosis</d> and <d>pulmonary hypertension</d>: mechanistic pathways driving disease pathophysiology | ||
51 | +Comparative study of transforming growth factor-b signalling and regulatory molecules in human and canine <d>idiopathic pulmonary fibrosis</d> | ||
52 | +Cytokine gene polymorphisms and BALF cytokine levels in <d>interstitial lung diseases</d> | ||
53 | +<g>PI3K</g> p110y <v>overexpression </v>in <d>idiopathic pulmonary fibrosis lung</d> tissue and fibroblast cells: in vitro effects of its inhibition | ||
54 | +Low-dose paclitaxel ameliorates <d>pulmonary fibrosis</d> by suppressing <g>TGF-b1</g>/<g>Smad3</g> pathway via <g>miR-140</g> upregulation | ||
55 | +MicroRNAs in <d>idiopathic pulmonary fibrosis</d> | ||
56 | +Two-Way Conversion between Lipogenic and Myogenic Fibroblastic Phenotypes Marks the Progression and Resolution of Lung <d>Fibrosis</d> | ||
57 | +Membrane type-matrix metalloproteinases in <d>idiopathic pulmonary fibrosis</d> | ||
58 | +<g>BARD1</g> mediates <g>TGF-b</g> signaling in <d>pulmonary fibrosis</d> | ||
59 | +Increased <d>alveolar</d> soluble <g>annexin V</g> promotes <d>lung inflammation</d> and <d>fibrosis</d> | ||
60 | +Autophagy in <d>idiopathic pulmonary fibrosis</d> | ||
61 | +<g>TGF-b1</g> <v>induces </v><g>Fstl1</g> via the <g>Smad3</g>-<g>c-Jun</g> pathway in lung fibroblasts | ||
62 | +Genetic polymorphism in <g>matrix metalloproteinase-9</g> and <g>transforming growth factor-b1</g> and susceptibility to <d>combined pulmonary fibrosis</d> and <d>emphysema</d> in a Chinese population | ||
63 | +MS80, a novel sulfated oligosaccharide, inhibits <d>pulmonary fibrosis</d> by targeting <g>TGF-beta1</g> both in vitro and in vivo | ||
64 | +Protective role of gambogic acid in experimental <d>pulmonary fibrosis</d> in vitro and in vivo | ||
65 | +Sorafenib ameliorates bleomycin-induced <d>pulmonary fibrosis</d>: potential roles in the inhibition of epithelial-mesenchymal transition and fibroblast activation | ||
66 | +[Different cytokine profiles in <d>usual interstitial pneumonia</d> and <d>nonspecific interstitial pneumonia</d>] | ||
67 | +Simvastatin attenuates <g>TGF-b1</g>-induced epithelial-mesenchymal transition in human alveolar epithelial cells | ||
68 | +Expression of <g>suppressor of cytokine signaling 1</g> in the peripheral blood of patients with <d>idiopathic pulmonary fibrosis</d> | ||
69 | +Profibrotic role of <g>miR-154</g> in <d>pulmonary fibrosis</d> | ||
70 | +Anchorage-independent colony growth of pulmonary fibroblasts derived from fibrotic human lung tissue | ||
71 | +<g>Aortic carboxypeptidase-like protein</g> (<g>ACLP</g>) enhances lung myofibroblast differentiation through transforming growth factor b receptor-dependent and -independent pathways | ||
72 | +The latent form of <g>TGFbeta(1)</g> is induced by <g>TNFalpha</g> through an <g>ERK</g> specific pathway and is <v>activated </v>by asbestos-derived reactive oxygen species in vitro and in vivo | ||
73 | +Differential effects of human neutrophil peptide-1 on growth factor and <g>interleukin-8</g> production by human lung fibroblasts and epithelial cells | ||
74 | +Transforming growth factor-b1 downregulates <g>vascular endothelial growth factor</g>-D expression in human lung fibroblasts via the <g>Jun NH2-terminal kinase</g> signaling pathway | ||
75 | +<g>Ubiquitin carboxyl-terminal hydrolase-L5</g> promotes <g>TGFb-1</g> signaling by de-ubiquitinating and stabilizing <g>Smad2</g>/<g>Smad3</g> in <d>pulmonary fibrosis</d> | ||
76 | +Effects of particulate matter from straw burning on <d>lung fibrosis</d> in mice | ||
77 | +<g>miR -221</g> targets <g>HMGA2</g> to inhibit bleomycin -induced <d>pulmonary fibrosis</d> by regulating <g>TGF -b1</g>/<g>Smad3</g>-induced EMT | ||
78 | +<g>EZH2</g> enhances the differentiation of fibroblasts into myofibroblasts in <d>idiopathic pulmonary fibrosis</d> | ||
79 | +Effect of pirfenidone on proliferation, <g>TGF-b</g>-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts | ||
80 | +[Quantifying plasma levels of <g>transforming growth factor beta1</g> in <d>idiopathic pulmonary fibrosis</d>] | ||
81 | +The matricellular protein <g>CCN1</g> enhances <g>TGF-b1</g>/<g>SMAD3</g>-dependent profibrotic signaling in fibroblasts and contributes to fibrogenic responses to <d>lung injury</d> | ||
82 | +Tubastatin ameliorates <d>pulmonary fibrosis</d> by targeting the TGFb-PI3K-<g>Akt</g> pathway | ||
83 | +Lung fibrotic <g>tenascin-C</g> <v>upregulation </v>is associated with other extracellular matrix proteins and <v>induced </v>by TGFb1 | ||
84 | +Tannic acid attenuates TGF-b1-induced epithelial-to-mesenchymal transition by effectively intervening TGF-b signaling in lung epithelial cells | ||
85 | +Abrogation of <g>TGF-beta1</g>-induced fibroblast-myofibroblast differentiation by <g>histone deacetylase</g> <u>inhibition.</u> <d>Idiopathic pulmonary fibrosis</d> (<d>IPF</d>) is a devastating disease with no known effective pharmacological therapy | ||
86 | +<g>AKT2</g> | ||
87 | +Regulation of myofibroblast differentiation by <g>miR-424</g> during epithelial-to-mesenchymal transition | ||
88 | +Bleomycin in the setting of <d>lung fibrosis</d> induction: From biological mechanisms to counteractions | ||
89 | +MicroRNA-101 attenuates pulmonary fibrosis by inhibiting fibroblast proliferation and activation | ||
90 | +<g>Extracellular Matrix Metalloproteinase Inducer</g> (<g>EMMPRIN</g>) promotes lung fibroblast proliferation, survival and differentiation to myofibroblasts | ||
91 | +<g>TGF-b</g> activation and lung <d>fibrosis</d> | ||
92 | +<v>Increased </v>interleukin-1 receptor antagonist in <d>idiopathic pulmonary fibrosis</d> | ||
93 | +<g>TIAM1</g> inhibits lung fibroblast differentiation in <d>pulmonary fibrosis</d> | ||
94 | +Targeting <g>sphingosine kinase 1</g> attenuates bleomycin-induced <d>pulmonary fibrosis</d> | ||
95 | +Re-evaluation of fibrogenic cytokines in <d>lung fibrosis</d> | ||
96 | +Targeting genes for treatment in <d>idiopathic pulmonary fibrosis</d>: challenges and opportunities, promises and pitfalls | ||
97 | +Defect of pro-<g>hepatocyte growth factor</g> activation by fibroblasts in <d>idiopathic pulmonary fibrosis</d> | ||
98 | +Epithelial Cell Mitochondrial Dysfunction and <g>PINK1</g> | ||
99 | +<l>Release </l>of biologically active <g>TGF-beta1</g> by alveolar epithelial cells results in <d>pulmonary fibrosis</d> | ||
100 | +IPF lung fibroblasts have a senescent phenotype | ||
101 | +Autophagy and <d>inflammation</d> in chronic <d>respiratory disease</d> | ||
102 | +The profibrotic cytokine <g>transforming growth factor-b1</g> increases endothelial progenitor cell angiogenic properties | ||
103 | +Regulation of transforming growth factor-b1-driven lung <d>fibrosis</d> by <g>galectin-3</g> | ||
104 | +Epigenetic <r>Regulation </r>of <g>Caveolin-1</g> | ||
105 | +Expression of <g>150-kDa oxygen-regulated protein</g> (<g>ORP150</g>) stimulates bleomycin-induced <d>pulmonary fibrosis and dysfunction</d> in mice | ||
106 | +Role of endoplasmic reticulum stress in age-related susceptibility to lung <d>fibrosis</d> | ||
107 | +Alveolar epithelial cell injury with Epstein-Barr virus <v>upregulates </v><g>TGFbeta1</g> <e>expression.</e> <d>Idiopathic pulmonary fibrosis</d> (<d>IPF</d>) is a refractory and lethal <d>interstitial lung disease</d> characterized by alveolar epithelial cells apoptosis, fibroblast proliferation, and ECM protein deposition | ||
108 | +<d>Pulmonary fibrosis</d>: pathogenesis, etiology and regulation | ||
109 | +Activated MCTC mast cells infiltrate diseased lung areas in <d>cystic fibrosis</d> and <d>idiopathic pulmonary fibrosis</d> | ||
110 | +<g>PPAR</g>-y ligands repress <g>TGFb</g>-induced myofibroblast differentiation by targeting the <g>PI3K</g>/<g>Akt</g> pathway: implications for therapy of <d>fibrosis</d> | ||
111 | +De-ubiquitinating enzyme, <g>USP11</g>, promotes <g>transforming growth factor b-1</g> signaling through stabilization of transforming growth factor b receptor II | ||
112 | +Single-cell RNA sequencing identifies diverse roles of epithelial cells in <d>idiopathic pulmonary fibrosis</d> | ||
113 | +The antifibrotic effects and mechanisms of microRNA-26a action in <d>idiopathic pulmonary fibrosis</d> | ||
114 | +Phosphatase and tensin homolog deleted on chromosome 10 contributes to phenotype transformation of fibroblasts in <d>idiopathic pulmonary fibrosis</d> via multiple pathways | ||
115 | +Lower expression of platelet derived growth factor is associated with better overall survival rate of patients with idiopathic nonspecific interstitial pneumonia | ||
116 | +Investigation of bone marrow mesenchymal stem cells (BM MSCs) involvement in <d>Idiopathic Pulmonary Fibrosis</d> (<d>IPF</d>) | ||
117 | +<g>Neutrophil elastase</g> promotes myofibroblast <d>differentiation in lung fibrosis</d> | ||
118 | +<g>MAP3K19</g> | ||
119 | +Effect of Renshen Pingfei Decoction, a traditional Chinese prescription, on <d>IPF</d> <v>induced </v>by Bleomycin in rats and <r>regulation </r>of <g>TGF-b1</g>/<g>Smad3</g> | ||
120 | +Macrophage <g>Bone Morphogenic Protein Receptor 2</g> (<g>BMPR2</g>) <u>depletion </u>in <d>Idiopathic Pulmonary Fibrosis</d> (<d>IPF</d>) and Group III Pulmonary <d>Hypertension</d> | ||
121 | +<g>Cartilage oligomeric matrix protein</g> in <d>idiopathic pulmonary fibrosis</d> | ||
122 | +Negative regulation of myofibroblast differentiation by <g>PTEN</g> (Phosphatase and Tensin Homolog Deleted on chromosome 10) | ||
123 | +Data on <g>CUX1</g> isoforms in <d>idiopathic pulmonary fibrosis lung</d> and <d>systemic sclerosis</d> skin tissue sections | ||
124 | +Alveolar epithelial cells express mesenchymal proteins in patients with <d>idiopathic pulmonary fibrosis</d> | ||
125 | +<d>Idiopathic Pulmonary Fibrosis</d>: Aging, Mitochondrial Dysfunction, and Cellular Bioenergetics | ||
126 | +<g>SPARC</g> suppresses apoptosis of <d>idiopathic pulmonary fibrosis</d> fibroblasts through constitutive <v>activation </v>of <g>beta-catenin</g> | ||
127 | +Resveratrol-Mediated Repression and Reversion of Prostatic Myofibroblast Phenoconversion | ||
128 | +[The potential role of cytokines expression in <d>idiopathic pulmonary fibrosis</d>] | ||
129 | +Effect of an immunotoxin to <g>folate receptor beta</g> on bleomycin-induced <d>experimental pulmonary fibrosis</d> | ||
130 | +<v>Elevated </v><e>expression </e>of <g>NEU1</g> sialidase in <d>idiopathic pulmonary fibrosis</d> <v>provokes </v>pulmonary collagen deposition, <d>lymphocytosis</d>, and <d>fibrosis</d> | ||
131 | +Genetic partitioning of <g>interleukin-6</g> signalling in mice dissociates <g>Stat3</g> from <g>Smad3</g>-mediated <d>lung fibrosis</d> | ||
132 | +Reactive oxygen species are required for maintenance and differentiation of primary lung fibroblasts in <d>idiopathic pulmonary fibrosis</d> | ||
133 | +Oxidant-antioxidant imbalance as a potential contributor to the progression of human <d>pulmonary fibrosis</d> | ||
134 | +Increased production and immunohistochemical localization of <g>transforming growth factor-beta</g> in <d>idiopathic pulmonary fibrosis</d> | ||
135 | +N-acetylcysteine inhibits alveolar epithelial-mesenchymal transition | ||
136 | +Type V collagen induced tolerance suppresses collagen deposition, <g>TGF-b</g> and associated transcripts in <d>pulmonary fibrosis</d> | ||
137 | +<g>CUX1</g>/Wnt signaling regulates epithelial mesenchymal transition in EBV infected epithelial cells | ||
138 | +Lactic acid is elevated in <d>idiopathic pulmonary fibrosis</d> and induces myofibroblast differentiation via pH-dependent activation of transforming growth factor-b | ||
139 | +Preventive and therapeutic effects of thymosin b4 N-terminal fragment Ac-SDKP in the bleomycin model of pulmonary fibrosis | ||
140 | +Epithelial cell alpha3beta1 integrin links <g>beta-catenin</g> and Smad signaling to promote myofibroblast formation and <d>pulmonary fibrosis</d> | ||
141 | +EMT and <d>interstitial lung disease</d>: a mysterious relationship | ||
142 | +Pirfenidone exerts antifibrotic effects through <u>inhibition </u>of GLI transcription factors | ||
143 | +<g>STAT3</g>-mediated signaling dysregulates lung fibroblast-myofibroblast activation and differentiation in UIP/IPF | ||
144 | +Epithelial stem cell exhaustion in the pathogenesis of <d>idiopathic pulmonary fibrosis</d> | ||
145 | +FAK-related nonkinase is a multifunctional negative regulator of <d>pulmonary fibrosis</d> | ||
146 | +Nitrated fatty acids reverse <d>pulmonary fibrosis</d> by dedifferentiating myofibroblasts and promoting collagen uptake by alveolar macrophages | ||
147 | +Berberine attenuates bleomycin induced <d>pulmonary toxicity</d> and <d>fibrosis</d> via <u>suppressing </u><g>NF-kB</g> dependant <g>TGF-b</g> <v>activation:</v> a biphasic experimental study | ||
148 | +<g>N-acetyl-L-cysteine</g> inhibits <g>TGF-beta1</g>-induced profibrotic responses in fibroblasts | ||
149 | +Interleukin-17 induces human alveolar epithelial to mesenchymal cell transition via the <g>TGF-b1</g> <v>mediated </v><g>Smad2/3</g> and <g>ERK1/2</g> <v>activation.</v> <d>Idiopathic pulmonary fibrosis</d> (<d>IPF</d>) is a chronic and usually progressive <d>lung disease</d> and the epithelial-mesenchymal transition (EMT) may play an important role in the pathogenesis of <d>pulmonary fibrosis</d> | ||
150 | +<g>TGF-beta1</g> induces human alveolar epithelial to mesenchymal cell transition (EMT) | ||
151 | +Thalidomide prevents bleomycin-induced <d>pulmonary fibrosis</d> in mice | ||
152 | +Intratracheal bleomycin causes airway remodeling and airflow obstruction in mice | ||
153 | +Significance of <v>elevated </v>procollagen-III-peptide and <g>transforming growth factor-beta</g> levels of bronchoalveolar lavage fluids from <d>idiopathic pulmonary fibrosis</d> patients | ||
154 | +<g>MiR-338</g>* targeting <g>smoothened</g> to inhibit <d>pulmonary fibrosis</d> by epithelial-mesenchymal transition | ||
155 | +Proteasomal regulation of <d>pulmonary fibrosis</d> | ||
156 | +Epithelium-specific deletion of <g>TGF-b</g> receptor type II protects mice from bleomycin-induced <d>pulmonary fibrosis</d> | ||
157 | +<g>Renin</g> is an angiotensin-independent profibrotic mediator: role in <d>pulmonary fibrosis</d> | ||
158 | +Role for alpha3 integrin in EMT and <d>pulmonary fibrosis</d> | ||
159 | +Beyond <g>TGFb</g> - Novel ways to target airway and parenchymal <d>fibrosis</d> | ||
160 | +<g>Lysocardiolipin acyltransferase</g> regulates <g>TGF-b</g> mediated lung fibroblast differentiation | ||
161 | +Cytokine profiles in <d>idiopathic pulmonary fibrosis</d> suggest an important role for <g>TGF-beta</g> and <g>IL-10</g> | ||
162 | +<g>CXCL9</g> | ||
163 | +Differing Expression of Cytokines and <d>Tumor</d> | ||
164 | +Sphingosine-1-phosphate is increased in patients with <d>idiopathic pulmonary fibrosis</d> and mediates epithelial to mesenchymal transition | ||
165 | +<g>MiR-5100</g> targets <g>TOB2</g> to drive epithelial-mesenchymal transition associated with <v>activating </v><g>smad2/3</g> in lung epithelial cells | ||
166 | +The impact of <g>TGF-b</g> on lung <d>fibrosis</d>: from targeting to biomarkers | ||
167 | +Mast cell chymase: an indispensable instrument in the pathological symphony of <d>idiopathic pulmonary fibrosis</d>? <d>Idiopathic pulmonary fibrosis</d> (<d>IPF</d>) is a chronic, progressive and fatal <d>lung disease</d> with no known etiology and treatment options | ||
168 | +Leucine-rich a-2 glycoprotein promotes <d>lung fibrosis</d> by modulating <g>TGF-b</g> signaling in fibroblasts | ||
169 | +Normal Human Lung Epithelial Cells Inhibit Transforming Growth Factor-b Induced Myofibroblast Differentiation via Prostaglandin E2 | ||
170 | +Carbon monoxide-bound hemoglobin-vesicles for the treatment of bleomycin-induced <d>pulmonary fibrosis</d> | ||
171 | +Sustained <g>PI3K</g> | ||
172 | +miR-18a-5p <u>Inhibits </u>Sub-pleural Pulmonary Fibrosis by Targeting <g>TGF-b</g> | ||
173 | +Pirfenidone <u>inhibits </u>the <e>expression </e>of <g>HSP47</g> in <g>TGF-beta1</g>-stimulated human lung fibroblasts | ||
174 | +Tissue inhibitor of metalloproteinase-3 is up-regulated by <g>transforming growth factor-beta1</g> in vitro and expressed in fibroblastic foci in vivo in <d>idiopathic pulmonary fibrosis</d> | ||
175 | +Increased Galectin-9 Concentration and Number of CD4+Foxp3high+Cells in Bronchoalveolar Lavage Fluid of Patients with <d>Cryptogenic Organizing Pneumonia</d> | ||
176 | +Transforming growth factor-b <u>inhibits </u>IQ motif containing guanosine triphosphatase <v>activating </v>protein 1 <e>expression </e>in lung fibroblasts via the nuclear factor-kB signaling pathway | ||
177 | +<g>Yin yang 1</g> is a novel regulator of <d>pulmonary fibrosis</d> | ||
178 | +Role of <d>von Hippel-Lindau</d> protein in fibroblast proliferation and <d>fibrosis</d> | ||
179 | +<g>X-linked inhibitor of apoptosis</g> regulates lung fibroblast resistance to Fas-mediated apoptosis | ||
180 | +<d>Idiopathic pulmonary fibrosis</d>: pathobiology of novel approaches to treatment | ||
181 | +Age-driven developmental drift in the pathogenesis of <d>idiopathic pulmonary fibrosis</d> | ||
182 | +Endogenous <g>Semaphorin-7A</g> | ||
183 | +Progressive transforming growth factor beta1-induced <d>lung fibrosis</d> is blocked by an orally active <g>ALK5</g> kinase <u>inhibitor.</u> <d>Pulmonary fibrosis</d> is characterized by chronic scar formation and deposition of extracellular matrix, resulting in <d>impaired lung function</d> and <d>respiratory failure</d> | ||
184 | +Simvastatin inhibits growth factor expression and modulates profibrogenic markers in lung fibroblasts | ||
185 | +MicroRNA regulatory networks in <d>idiopathic pulmonary fibrosis</d> | ||
186 | +Fibroblastic foci, covered with <d>alveolar epithelia</d> exhibiting <d>epithelial-mesenchymal transition</d>, destroy <d>alveolar septa</d> by disrupting blood flow in <d>idiopathic pulmonary fibrosis</d> | ||
187 | +<e>Overproduction </e>of collagen and <u>diminished </u><g>SOCS1</g> <e>expression </e>are causally linked in fibroblasts from <d>idiopathic pulmonary fibrosis</d> | ||
188 | +<r>Regulation </r>of 26S Proteasome Activity in <d>Pulmonary Fibrosis</d> | ||
189 | +Therapeutic targets in fibrotic pathways | ||
190 | +Compromised peroxisomes in <d>idiopathic pulmonary fibrosis</d>, a vicious cycle inducing a higher fibrotic response via <g>TGF-b</g> signaling | ||
191 | +<d>Lung infection</d> with gamma-herpesvirus induces progressive <d>pulmonary fibrosis</d> in Th2-biased mice | ||
192 | +Mode of action of nintedanib in the treatment of <d>idiopathic pulmonary fibrosis</d> | ||
193 | +<g>Semaphorin 7a</g>+ regulatory T cells are associated with progressive <d>idiopathic pulmonary fibrosis</d> and are implicated in transforming growth factor-b1-induced <d>pulmonary fibrosis</d> | ||
194 | +Increased expression of 5-hydroxytryptamine2A/B receptors in <d>idiopathic pulmonary fibrosis</d>: a rationale for therapeutic intervention | ||
195 | +<v>Increased </v>deposition of chondroitin/dermatan sulfate glycosaminoglycan and <v>upregulation </v>of b1,3-glucuronosyltransferase I in <d>pulmonary fibrosis</d> | ||
196 | +Pathogenesis pathways of <d>idiopathic pulmonary fibrosis</d> in bleomycin-induced <d>lung injury</d> model in mice | ||
197 | +Latent cytomegalovirus infection exacerbates experimental <d>pulmonary fibrosis</d> by <v>activating </v><g>TGF-b1</g> | ||
198 | +<r>Effects </r>of antifibrotic agents on <g>TGF-beta1</g>, <g>CTGF</g> and <g>IFN-gamma</g> <e>expression </e>in patients with <d>idiopathic pulmonary fibrosis</d> | ||
199 | +<g>Microsomal prostaglandin E synthase-1</g> <u>deficiency </u>exacerbates <d>pulmonary fibrosis</d> induced by bleomycin in mice | ||
200 | +Inhibition of NF-kappaB signaling reduces virus load and gammaherpesvirus-induced <d>pulmonary fibrosis</d> | ||
201 | +Effects and mechanisms of pirfenidone, prednisone and acetylcysteine on <d>pulmonary fibrosis</d> in rat <d>idiopathic pulmonary fibrosis</d> models | ||
202 | +Accelerated epithelial cell senescence in <d>IPF</d> and the inhibitory role of <g>SIRT6</g> in <g>TGF-b</g>-induced senescence of human bronchial epithelial cells | ||
203 | +<g>Transforming growth factor-beta1</g> in <d>sarcoidosis</d> | ||
204 | +<g>TGF-b1</g> induces <g>tissue factor</g> expression in human lung fibroblasts in a <g>PI3K</g>/<g>JNK</g>/<g>Akt</g>-dependent and <g>AP-1</g>-dependent manner | ||
205 | +Epithelial-mesenchymal transition in chronic <d>hypersensitivity pneumonitis</d> | ||
206 | +Uncoupling of the profibrotic and hemostatic effects of <g>thrombin</g> in <d>lung fibrosis</d> | ||
207 | +Molecular targets in <d>pulmonary fibrosis</d>: the myofibroblast in focus | ||
208 | +Immunomodulation by mesenchymal stem cells in treating human <d>autoimmune disease-associated lung fibrosis</d> | ||
209 | +<u>Reduced </u>transcription of the <g>Smad4</g> gene during <d>pulmonary carcinogenesis</d> in <d>idiopathic pulmonary fibrosis</d> | ||
210 | +Intrinsic defence capacity and therapeutic potential of natriuretic peptides in <d>pulmonary hypertension</d> associated with <d>lung fibrosis</d> | ||
211 | +Curcumin inhibits <d>fibrosis</d>-related effects in <d>IPF</d> fibroblasts and in mice following bleomycin-induced <d>lung injury</d> | ||
212 | +<g>NADPH oxidase-4</g> mediates myofibroblast activation and fibrogenic responses to <d>lung injury</d> | ||
213 | +Anti-fibrotic Role of aB-crystallin Inhibition in Pleural and Subpleural <d>Fibrosis</d> | ||
214 | +Pleiotropic effect of the proton pump inhibitor esomeprazole leading to suppression of <d>lung inflammation</d> and <d>fibrosis</d> | ||
215 | +Reviews and prospectives of signaling pathway analysis in <d>idiopathic pulmonary fibrosis</d> | ||
216 | +Roles of p38 MAPK and <g>JNK</g> in <g>TGF-b1</g>-induced human alveolar epithelial to mesenchymal transition | ||
217 | +Predisposition for disrepair in the aged lung | ||
218 | +Possible involvement of pirfenidone metabolites in the antifibrotic action of a therapy for <d>idiopathic pulmonary fibrosis</d> | ||
219 | +N-acetylcysteine <u>downregulation </u>of <g>lysyl oxidase</g> activity alleviating bleomycin-induced <d>pulmonary fibrosis</d> in rats | ||
220 | +Evaluation of permeability alteration and epithelial-mesenchymal transition induced by <g>transforming growth factor-b1</g> in A549, NCI-H441, and Calu-3 cells: Development of an in vitro model of respiratory epithelial cells in <d>idiopathic pulmonary fibrosis</d> | ||
221 | +Epithelial contribution to the pro-fibrotic stiff microenvironment and myofibroblast population in lung <d>fibrosis</d> | ||
222 | +Interactions between <g>b-catenin</g> and <g>transforming growth factor-b</g> signaling pathways mediate epithelial-mesenchymal transition and are dependent on the transcriptional co-activator cAMP-response element-binding protein (<g>CREB)-binding protein</g> (<g>CBP</g>) | ||
223 | +BAL cytokine profile in different <d>interstitial lung diseases</d>: a focus on <d>systemic sclerosis</d> | ||
224 | +<g>Syndecan-2</g> is a novel target of <g>insulin-like growth factor binding protein-3</g> and is <v>over-expressed </v>in <d>fibrosis</d> | ||
225 | +Membrane-anchored <g>Serine Protease</g> <g>Matriptase</g> | ||
226 | +Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with <d>idiopathic pulmonary fibrosis</d> | ||
227 | +The small heat-shock protein aB-crystallin is essential for the nuclear <l>localization </l>of <g>Smad4</g>: impact on <d>pulmonary fibrosis</d> | ||
228 | +Medical treatment for <d>pulmonary fibrosis</d>: current trends, concepts, and prospects | ||
229 | +Ambroxol hydrochloride in the management of <d>idiopathic pulmonary fibrosis</d>: Clinical trials are the need of the hour | ||
230 | +Combined <u>inhibition </u>of <g>TGFb</g> and PDGF signaling attenuates radiation-induced <d>pulmonary fibrosis</d> | ||
231 | +Diagnostic Values For Club Cell Secretory Protein (<g>CC16</g>) in Serum of Patients of Combined Pulmonary Fibrosis and Emphysema | ||
232 | +<e>Effects </e>of <g>thymosin b4</g> and its N-terminal fragment Ac-SDKP on <g>TGF-b</g>-treated human lung fibroblasts and in the mouse model of bleomycin-induced <d>lung fibrosis</d> | ||
233 | +Matrix metalloproteinase 3 is a mediator of <d>pulmonary fibrosis</d> | ||
234 | +An <u>inhibitor </u>of NADPH oxidase-4 attenuates established <d>pulmonary fibrosis</d> in a <d>rodent disease</d> model | ||
235 | +<u>Inhibition </u>of <g>PI3K</g> prevents the proliferation and differentiation of human lung fibroblasts into myofibroblasts: the role of class I P110 isoforms | ||
236 | +<r>Effects </r>of doxycycline on <e>production </e>of growth factors and matrix metalloproteinases in <d>pulmonary fibrosis</d> | ||
237 | +Human placental mesenchymal stem cells of fetal origins-alleviated <d>inflammation</d> and <d>fibrosis</d> by attenuating <g>MyD88</g> signaling in bleomycin-induced <d>pulmonary fibrosis</d> mice | ||
238 | +Roles for <g>insulin-like growth factor I</g> and <g>transforming growth factor-beta</g> in <d>fibrotic lung disease</d> | ||
239 | +Role of <g>caveolin-1</g> in <d>fibrotic diseases</d> | ||
240 | +Olodaterol shows anti-fibrotic efficacy in in vitro and in vivo models of <d>pulmonary fibrosis</d> | ||
241 | +Novel Mechanisms for the Antifibrotic Action of Nintedanib | ||
242 | +[The morphology and molecular bases of damage to the stem cell niche of respiratory acini in <d>idiopathic interstitial pneumonias</d>] | ||
243 | +Pirfenidone inhibits myofibroblast differentiation and <d>lung fibrosis</d> development during insufficient mitophagy | ||
244 | +Insulin-like growth factor binding proteins 3 and 5 are <v>overexpressed </v>in <d>idiopathic pulmonary fibrosis</d> and contribute to extracellular matrix deposition | ||
245 | +<g>VEGF</g> ameliorates pulmonary <d>hypertension</d> through inhibition of endothelial apoptosis in experimental lung <d>fibrosis</d> in rats | ||
246 | +Rapamycin regulates connective tissue growth factor expression of lung epithelial cells via phosphoinositide 3-kinase | ||
247 | +Differential <e>expression </e>of alpha E beta 7 integrins on bronchoalveolar lavage T lymphocyte subsets: <r>regulation </r>by alpha 4 beta 1-integrin crosslinking and <g>TGF-beta</g> | ||
248 | +<v>Increased </v><g>TGF-beta1</g> in the lungs of asbestos-exposed rats and mice: <u>reduced </u><e>expression </e>in <g>TNF-alpha</g> receptor knockout mice | ||
249 | +Fibrotic myofibroblasts manifest genome-wide derangements of translational control | ||
250 | +<r>Regulation </r>of <g>TGF-b</g> storage and activation in the human <d>idiopathic pulmonary fibrosis lung</d> | ||
251 | +<d>Microsatellite instability</d> in transforming growth factor-beta 1 type II receptor gene in alveolar lining epithelial cells of <d>idiopathic pulmonary fibrosis</d> | ||
252 | +miR-92a <r>regulates </r><g>TGF-b1</g>-<v>induced </v><g>WISP1</g> <e>expression </e>in <d>pulmonary fibrosis</d> | ||
253 | +<u>Inhibition </u>of <g>PHGDH</g> | ||
254 | +The role of cytokines in human <d>lung fibrosis</d> | ||
255 | +Significant involvement of <g>CCL2</g> (<g>MCP-1</g>) in inflammatory disorders of the lung | ||
256 | +<g>TGF-beta</g>-induced EMT: mechanisms and implications for <d>fibrotic lung disease</d> | ||
257 | +Pirfenidone <u>inhibits </u><g>TGF-b1</g>-induced <e>over-expression </e>of collagen type I and <d>heat shock</d> protein 47 in A549 cells | ||
258 | +Bleomycin induces molecular changes directly relevant to <d>idiopathic pulmonary fibrosis</d>: a model for "active" disease | ||
259 | +The potential <r>role </r>of PDGF, <g>IGF-1</g>, <g>TGF-beta</g> <e>expression </e>in <d>idiopathic pulmonary fibrosis</d> | ||
260 | +<g>Connective tissue growth factor</g> <e>expression </e>and <v>induction </v>by <g>transforming growth factor-beta</g> is <u>abrogated </u>by simvastatin via a Rho signaling mechanism | ||
261 | +MOXIBUSTION HAS A POSITIVE EFFECT ON PULMONARY FIBROSIS: AN ALTERNATIVE APPROACH | ||
262 | +Sustained Activation of <g>Toll-Like Receptor 9</g> | ||
263 | +Molecular pathogenesis of <d>interstitial pneumonitis</d> with <g>TNF-alpha</g> transgenic mice | ||
264 | +MiR-541-5p <r>regulates </r><d>lung fibrosis</d> by <r>targeting </r>cyclic nucleotide phosphodiesterase 1A | ||
265 | +The pathogenesis of <d>idiopathic pulmonary fibrosis</d> | ||
266 | +Participation of miR-200 in <d>pulmonary fibrosis</d> | ||
267 | +<d>Autoimmunity</d> to Vimentin Is Associated with Outcomes of Patients with <d>Idiopathic Pulmonary Fibrosis</d> | ||
268 | +<g>TGF-beta 1</g>, but not <g>TGF-beta 2</g> or <g>TGF-beta 3</g>, is differentially present in epithelial cells of advanced <d>pulmonary fibrosis</d>: an immunohistochemical study | ||
269 | +Lysyl oxidases <r>regulate </r>fibrillar collagen remodelling in idiopathic pulmonary fibrosis | ||
270 | +Discovery and validation of extracellular/circulating microRNAs during <d>idiopathic pulmonary fibrosis disease</d> progression | ||
271 | +Recombinant human <g>serum amyloid P</g> in healthy volunteers and patients with <d>pulmonary fibrosis</d> | ||
272 | +<g>Gremlin</g>-mediated decrease in bone morphogenetic protein signaling promotes <d>pulmonary fibrosis</d> | ||
273 | +<v>Increased </v><e>expression </e>of <g>protease nexin-1</g> in fibroblasts during <d>idiopathic pulmonary fibrosis</d> <r>regulates </r><g>thrombin</g> activity and <g>fibronectin</g> <e>expression.</e> <d>Idiopathic pulmonary fibrosis</d> (<d>IPF</d>) is a chronic <d>diffuse lung disease</d> characterized by an accumulation of excess fibrous material in the lung | ||
274 | +Hyper-responsiveness of <d>IPF</d>/<d>UIP</d> fibroblasts: interplay between <g>TGFbeta1</g>, <g>IL-13</g> and <g>CCL2</g> | ||
275 | +<d>Idiopathic pulmonary fibrosis</d> in relation to gene polymorphisms of <g>transforming growth factor-b1</g> and <g>plasminogen activator inhibitor 1</g> | ||
276 | +<g>TNF-alpha</g>, PDGF, and <g>TGF-beta(1)</g> <e>expression </e>by primary mouse bronchiolar-alveolar epithelial and mesenchymal cells: <g>tnf-alpha</g> induces <g>TGF-beta(1)</g> | ||
277 | +<g>Transforming Growth Factor Beta 1</g> |
results/Partition_3/cluster2.txt
0 → 100644
1 | +Diagnostic Values For Club Cell Secretory Protein (CC16) in Serum of Patients of Combined Pulmonary Fibrosis and Emphysema | ||
2 | +Epigenetic Regulation of Caveolin-1 Gene Expression in Lung Fibroblasts | ||
3 | +Targeting of Discoidin Domain Receptor 2 (DDR2) Prevents Myofibroblast Activation and Neovessel Formation During Pulmonary Fibrosis | ||
4 | +Epithelial Cell Mitochondrial Dysfunction and PINK1 Are Induced by Transforming Growth Factor- Beta1 in Pulmonary Fibrosis | ||
5 | +The lncRNA H19 Mediates Pulmonary Fibrosis by Regulating the miR-196a/COL1A1 Axis | ||
6 | +Inhibition of PHGDH Attenuates Bleomycin-induced Pulmonary Fibrosis | ||
7 | +Transforming Growth Factor Beta 1 Activation, Storage, and Signaling Pathways in Idiopathic Pulmonary Fibrosis in Dogs | ||
8 | +Developmental Reprogramming in Mesenchymal Stromal Cells of Human Subjects with Idiopathic Pulmonary Fibrosis | ||
9 | +Autoimmunity to Vimentin Is Associated with Outcomes of Patients with Idiopathic Pulmonary Fibrosis | ||
10 | +Amplification of TGFb Induced ITGB6 Gene Transcription May Promote Pulmonary Fibrosis | ||
11 | +Macrophage Bone Morphogenic Protein Receptor 2 (BMPR2) depletion in Idiopathic Pulmonary Fibrosis (IPF) and Group III Pulmonary Hypertension | ||
12 | +Resveratrol-Mediated Repression and Reversion of Prostatic Myofibroblast Phenoconversion | ||
13 | +Sunitinib, a Small-Molecule Kinase Inhibitor, Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice | ||
14 | +Differing Expression of Cytokines and Tumor Markers in Combined Pulmonary Fibrosis and Emphysema Compared to Emphysema and Pulmonary Fibrosis | ||
15 | +miR-18a-5p Inhibits Sub-pleural Pulmonary Fibrosis by Targeting TGF-b Receptor II | ||
16 | +Hyper-responsiveness of IPF/UIP fibroblasts: interplay between TGFbeta1, IL-13 and CCL2 | ||
17 | +Protective Effect of Ginsenoside Rg1 on Bleomycin-Induced Pulmonary Fibrosis in Rats: Involvement of Caveolin-1 and TGF-b1 Signal Pathway | ||
18 | +Mesenchymal Stem Cells Correct Inappropriate Epithelial-mesenchyme Relation in Pulmonary Fibrosis Using Stanniocalcin-1 | ||
19 | +Chop Deficiency Protects Mice Against Bleomycin-induced Pulmonary Fibrosis by Attenuating M2 Macrophage Production | ||
20 | +Transforming Growth Factor (TGF)-b Promotes de Novo Serine Synthesis for Collagen Production | ||
21 | +Two-Way Conversion between Lipogenic and Myogenic Fibroblastic Phenotypes Marks the Progression and Resolution of Lung Fibrosis | ||
22 | +Normal Human Lung Epithelial Cells Inhibit Transforming Growth Factor-b Induced Myofibroblast Differentiation via Prostaglandin E2 | ||
23 | +Inhibition of the KCa3.1 Channel Alleviates Established Pulmonary Fibrosis in a Large Animal Model | ||
24 | +AKT2 Regulates Pulmonary Inflammation and Fibrosis via Modulating Macrophage Activation | ||
25 | +Novel Mechanisms for the Antifibrotic Action of Nintedanib | ||
26 | +Determining the True Selectivity Profile of av Integrin Ligands Using Radioligand Binding: Applying an Old Solution to a New Problem | ||
27 | +Increased Galectin-9 Concentration and Number of CD4+Foxp3high+Cells in Bronchoalveolar Lavage Fluid of Patients with Cryptogenic Organizing Pneumonia | ||
28 | +Reduced Ets Domain-containing Protein Elk1 Promotes Pulmonary Fibrosis via Increased Integrin avb6 Expression | ||
29 | +Expression of RXFP1 Is Decreased in Idiopathic Pulmonary Fibrosis | ||
30 | +The Anti-fibrotic Effects and Mechanisms of MicroRNA-486-5p in Pulmonary Fibrosis | ||
31 | +MAP3K19 Is a Novel Regulator of TGF-b Signaling That Impacts Bleomycin-Induced Lung Injury and Pulmonary Fibrosis | ||
32 | +Dysregulated Collagen Homeostasis by Matrix Stiffening and TGF-b1 in Fibroblasts from Idiopathic Pulmonary Fibrosis Patients: Role of FAK/Akt | ||
33 | +Sustained Activation of Toll-Like Receptor 9 Induces an Invasive Phenotype in Lung Fibroblasts: Possible Implications in Idiopathic Pulmonary Fibrosis | ||
34 | +Regulation of 26S Proteasome Activity in Pulmonary Fibrosis | ||
35 | +Membrane-anchored Serine Protease Matriptase Is a Trigger of Pulmonary Fibrogenesis | ||
36 | +The Role of PPARs in Lung Fibrosis | ||
37 | +Lipoxin A4 Attenuates Constitutive and TGF-b1-Dependent Profibrotic Activity in Human Lung Myofibroblasts | ||
38 | +Cigarette Smoke Enhances the Expression of Profibrotic Molecules in Alveolar Epithelial Cells | ||
39 | +Idiopathic Pulmonary Fibrosis: Aging, Mitochondrial Dysfunction, and Cellular Bioenergetics | ||
40 | +CXCL9 Regulates TGF-b1-Induced Epithelial to Mesenchymal Transition in Human Alveolar Epithelial Cells | ||
41 | +Anti-fibrotic Role of aB-crystallin Inhibition in Pleural and Subpleural Fibrosis | ||
42 | +Expression of WNT5A in Idiopathic Pulmonary Fibrosis and Its Control by TGF-b and WNT7B in Human Lung Fibroblasts |
results/Partition_3/cluster2_tagged.txt
0 → 100644
1 | +<r>Regulation </r>of human lung fibroblast <g>C1q</g>-receptors by <g>transforming growth factor-beta</g> and <g>tumor necrosis factor-alpha</g> | ||
2 | +High levels of <g>IL-6</g> and <g>IL-8</g> characterize early-on <d>idiopathic pulmonary fibrosis</d> acute exacerbations | ||
3 | +Regulation of the effects of <g>TGF-beta 1</g> by activation of latent <g>TGF-beta 1</g> and differential <e>expression </e>of <g>TGF-beta receptors (T beta R-I and T beta R-II</g>) in <d>idiopathic pulmonary fibrosis</d> | ||
4 | +Peripheral depletion of NK cells and imbalance of the Treg/Th17 axis in <d>idiopathic pulmonary fibrosis</d> patients | ||
5 | +<g>miR-9-5p</g> suppresses pro-fibrogenic transformation of fibroblasts and prevents organ <d>fibrosis</d> by targeting <g>NOX4</g> and <g>TGFBR2</g> | ||
6 | +Profibrotic role of <g>WNT10A</g> via <g>TGF-b</g> signaling in <d>idiopathic pulmonary fibrosis</d> | ||
7 | +Microarray profiling reveals <u>suppressed </u>interferon stimulated gene program in fibroblasts from scleroderma-associated <d>interstitial lung disease</d> | ||
8 | +<g>IL-4</g> polymorphisms, HRCT score and lung tissue markers in <d>idiopathic pulmonary fibrosis</d> | ||
9 | +Herpes <d>virus infection</d> is associated with vascular remodeling and <d>pulmonary hypertension</d> in <d>idiopathic pulmonary fibrosis</d> | ||
10 | +Microencapsulation of lefty-secreting engineered cells for <d>pulmonary fibrosis</d> therapy in mice | ||
11 | +Targeting of <g>Discoidin Domain Receptor 2</g> (<g>DDR2</g>) Prevents Myofibroblast Activation and Neovessel Formation During <d>Pulmonary Fibrosis</d> | ||
12 | +Role of <g>protease-activated receptor-2</g> in <d>idiopathic pulmonary fibrosis</d> | ||
13 | +<g>Chop</g> | ||
14 | +<g>VCAM-1</g> is a <g>TGF-b1</g> inducible gene <v>upregulated </v>in <d>idiopathic pulmonary fibrosis</d> | ||
15 | +<u>Suppression </u>of <g>plasminogen activator inhibitor-1</g> by RNA interference attenuates <d>pulmonary fibrosis</d> | ||
16 | +<g>JAK2</g> mediates <d>lung fibrosis</d>, <d>pulmonary vascular remodelling</d> and <d>hypertension</d> in <d>idiopathic pulmonary fibrosis</d>: an experimental study | ||
17 | +Melatonin attenuates <g>TGFb1</g>-induced epithelial-mesenchymal transition in lung alveolar epithelial cells | ||
18 | +<r>Deregulation </r>of selective autophagy during aging and <d>pulmonary fibrosis</d>: the role of <g>TGFb1</g> | ||
19 | +<g>RhoA</g> signaling <r>modulates </r><g>cyclin D1</g> <e>expression </e>in human lung fibroblasts; implications for <d>idiopathic pulmonary fibrosis</d> | ||
20 | +Inhibitory effect of <g>receptor for advanced glycation end products</g> (<g>RAGE</g>) on the <g>TGF-b</g>-induced alveolar epithelial to mesenchymal transition | ||
21 | +<e>Effects </e>of the <d>tumor</d> suppressor <g>PTEN</g> on the pathogenesis of <d>idiopathic pulmonary fibrosis</d> in Chinese patients | ||
22 | +Triptolide suppresses paraquat induced <d>idiopathic pulmonary fibrosis</d> by inhibiting <g>TGFB1</g>-dependent epithelial mesenchymal transition | ||
23 | +<g>Endothelin-1</g> <v>induces </v>alveolar epithelial-mesenchymal transition through endothelin type A receptor-<v>mediated </v><e>production </e>of <g>TGF-beta1</g> | ||
24 | +<g>p63</g> - Key molecule in the early phase of <d>epithelial abnormality</d> in <d>idiopathic pulmonary fibrosis</d> | ||
25 | +The hedgehog system machinery controls transforming growth factor-b-dependent myofibroblastic differentiation in humans: involvement in <d>idiopathic pulmonary fibrosis</d> | ||
26 | +<v>Upregulation </v>of <g>activin</g>-B and <g>follistatin</g> in <d>pulmonary fibrosis</d> - a translational study using human biopsies and a specific inhibitor in mouse <d>fibrosis</d> models | ||
27 | +<u>Inhibition </u>of the <g>KCa3.1</g> | ||
28 | +Current and novel drug therapies for <d>idiopathic pulmonary fibrosis</d> | ||
29 | +<g>Protease activated receptor-1</g> regulates macrophage-mediated cellular senescence: a risk for <d>idiopathic pulmonary fibrosis</d> | ||
30 | +Sphingolipids in <d>pulmonary fibrosis</d> | ||
31 | +Sirtuin 7 is decreased in pulmonary fibrosis and regulates the fibrotic phenotype of lung fibroblasts | ||
32 | +Pirfenidone for the treatment of <d>idiopathic pulmonary fibrosis</d> | ||
33 | +The anti-fibrotic effect of <u>inhibition </u>of <g>TGFb</g>-<g>ALK5</g> signalling in experimental <d>pulmonary fibrosis</d> in mice is attenuated in the presence of concurrent y-herpesvirus infection | ||
34 | +Angiotensin-<g>TGF-beta</g> 1 crosstalk in human <d>idiopathic pulmonary fibrosis</d>: autocrine mechanisms in myofibroblasts and macrophages | ||
35 | +SNAI transcription factors mediate epithelial-mesenchymal transition in <d>lung fibrosis</d> | ||
36 | +<g>MiR-338</g>* suppresses fibrotic pathogenesis in <d>pulmonary fibrosis</d> through targeting <g>LPA1</g> | ||
37 | +BALF N-acetylglucosaminidase and <g>beta-galactosidase</g> activities in <d>idiopathic pulmonary fibrosis</d> | ||
38 | +<g>Th1</g>/Th2 cytokine gene polymorphisms in patients with <d>idiopathic pulmonary fibrosis</d> | ||
39 | +Transforming Growth Factor (TGF)-b Promotes de Novo Serine Synthesis for Collagen <e>Production.</e> <g>TGF-b</g> <v>promotes </v>excessive collagen deposition in <d>fibrotic diseases</d> such as <d>idiopathic pulmonary fibrosis</d> (<d>IPF</d>) | ||
40 | +The Epstein-Barr virus latent membrane protein 1 and transforming growth factor--b1 synergistically induce epithelial--mesenchymal transition in lung epithelial cells | ||
41 | +<g>Transcription factor GATA-6</g> is <e>expressed </e>in quiescent myofibroblasts in <d>idiopathic pulmonary fibrosis</d> | ||
42 | +Epithelial-to-mesenchymal transition and its role in <g>EGFR</g>-mutant <d>lung adenocarcinoma</d> and <d>idiopathic pulmonary fibrosis</d> |
results/Partition_3/cluster3.txt
0 → 100644
1 | +FAK-related nonkinase is a multifunctional negative regulator of pulmonary fibrosis | ||
2 | +Bleomycin and IL-1beta-mediated pulmonary fibrosis is IL-17A dependent | ||
3 | +miR-26a suppresses EMT by disrupting the Lin28B/let-7d axis: potential cross-talks among miRNAs in IPF | ||
4 | +Hsp90 regulation of fibroblast activation in pulmonary fibrosis | ||
5 | +MiR-185/AKT and miR-29a/collagen 1a pathways are activated in IPF BAL cells | ||
6 | +Tubastatin ameliorates pulmonary fibrosis by targeting the TGFb-PI3K-Akt pathway | ||
7 | +Significant involvement of CCL2 (MCP-1) in inflammatory disorders of the lung | ||
8 | +Pirfenidone inhibits the expression of HSP47 in TGF-beta1-stimulated human lung fibroblasts | ||
9 | +Effects of particulate matter from straw burning on lung fibrosis in mice | ||
10 | +BARD1 mediates TGF-b signaling in pulmonary fibrosis | ||
11 | +Renin is an angiotensin-independent profibrotic mediator: role in pulmonary fibrosis | ||
12 | +Regulation of myofibroblast differentiation by miR-424 during epithelial-to-mesenchymal transition | ||
13 | +Up-regulation of heparan sulfate 6-O-sulfation in idiopathic pulmonary fibrosis | ||
14 | +Mechanisms of fibrosis in coal workers' pneumoconiosis | ||
15 | +Effect of substrate stiffness on pulmonary fibroblast activation by TGF-b | ||
16 | +Role for alpha3 integrin in EMT and pulmonary fibrosis | ||
17 | +Shikonin suppresses pulmonary fibroblasts proliferation and activation by regulating Akt and p38 MAPK signaling pathways | ||
18 | +Gremlin-mediated decrease in bone morphogenetic protein signaling promotes pulmonary fibrosis | ||
19 | +Molecular targets in pulmonary fibrosis: the myofibroblast in focus | ||
20 | +miR-92a regulates TGF-b1-induced WISP1 expression in pulmonary fibrosis | ||
21 | +Transgelin is a direct target of TGF-beta/Smad3-dependent epithelial cell migration in lung fibrosis | ||
22 | +Increased alveolar soluble annexin V promotes lung inflammation and fibrosis | ||
23 | +Re-evaluation of fibrogenic cytokines in lung fibrosis | ||
24 | +Lung myofibroblasts are characterized by down-regulated cyclooxygenase-2 and its main metabolite, prostaglandin E2 | ||
25 | +A critical role for the mTORC2 pathway in lung fibrosis | ||
26 | +Fibrotic myofibroblasts manifest genome-wide derangements of translational control | ||
27 | +Inhibition and role of let-7d in idiopathic pulmonary fibrosis | ||
28 | +Rapamycin increases CCN2 expression of lung fibroblasts via phosphoinositide 3-kinase | ||
29 | +Predisposition for disrepair in the aged lung | ||
30 | +MicroRNA regulatory networks in idiopathic pulmonary fibrosis | ||
31 | +Wnt coreceptor Lrp5 is a driver of idiopathic pulmonary fibrosis | ||
32 | +Pirfenidone inhibits myofibroblast differentiation and lung fibrosis development during insufficient mitophagy | ||
33 | +Genetic partitioning of interleukin-6 signalling in mice dissociates Stat3 from Smad3-mediated lung fibrosis | ||
34 | +Transcription factor GATA-6 is expressed in quiescent myofibroblasts in idiopathic pulmonary fibrosis | ||
35 | +[Idiopathic pulmonary fibrosis and lung cancer] | ||
36 | +Role of caveolin-1 in fibrotic diseases | ||
37 | +Latent cytomegalovirus infection exacerbates experimental pulmonary fibrosis by activating TGF-b1 | ||
38 | +Caveolin-1: a critical regulator of lung fibrosis in idiopathic pulmonary fibrosis | ||
39 | +TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P | ||
40 | +Lysocardiolipin acyltransferase regulates TGF-b mediated lung fibroblast differentiation | ||
41 | +Azithromycin attenuates myofibroblast differentiation and lung fibrosis development through proteasomal degradation of NOX4 | ||
42 | +[Potential role of cytokines in idiopathic pulmonary fibrosis] | ||
43 | +The potential role of PDGF, IGF-1, TGF-beta expression in idiopathic pulmonary fibrosis | ||
44 | +Cytokine profiles in idiopathic pulmonary fibrosis suggest an important role for TGF-beta and IL-10 | ||
45 | +Therapeutic targets in fibrotic pathways | ||
46 | +Suppression of plasminogen activator inhibitor-1 by RNA interference attenuates pulmonary fibrosis | ||
47 | +Pirfenidone exerts antifibrotic effects through inhibition of GLI transcription factors | ||
48 | +Profibrotic role of WNT10A via TGF-b signaling in idiopathic pulmonary fibrosis | ||
49 | +microRNA-1343 attenuates pathways of fibrosis by targeting the TGF-b receptors | ||
50 | +Effect of Renshen Pingfei Decoction, a traditional Chinese prescription, on IPF induced by Bleomycin in rats and regulation of TGF-b1/Smad3 | ||
51 | +M2 macrophages induce EMT through the TGF-b/Smad2 signaling pathway | ||
52 | +miR -221 targets HMGA2 to inhibit bleomycin -induced pulmonary fibrosis by regulating TGF -b1/Smad3-induced EMT | ||
53 | +Autophagy in idiopathic pulmonary fibrosis | ||
54 | +Overexpression of Sulf2 in idiopathic pulmonary fibrosis | ||
55 | +Matrix metalloproteinase (MMP)-19 deficient fibroblasts display a profibrotic phenotype | ||
56 | +[Pulmonary fibrosis--a therapeutic dilemma?] | ||
57 | +Signaling pathways in the epithelial origins of pulmonary fibrosis | ||
58 | +FGF-1 reverts epithelial-mesenchymal transition induced by TGF-{beta}1 through MAPK/ERK kinase pathway | ||
59 | +Participation of miR-200 in pulmonary fibrosis | ||
60 | +Proteasomal regulation of pulmonary fibrosis | ||
61 | +Inhibition of HSP27 blocks fibrosis development and EMT features by promoting Snail degradation | ||
62 | +The JAK2 pathway is activated in idiopathic pulmonary fibrosis | ||
63 | +Human lung myofibroblast TGFb1-dependent Smad2/3 signalling is Ca(2+)-dependent and regulated by KCa3.1 K(+) channels | ||
64 | +Transforming growth factor-beta1 in sarcoidosis | ||
65 | +The anti-fibrotic effects of microRNA-153 by targeting TGFBR-2 in pulmonary fibrosis | ||
66 | +Cytokines in human lung fibrosis | ||
67 | +MicroRNA-101 attenuates pulmonary fibrosis by inhibiting fibroblast proliferation and activation | ||
68 | +Cartilage oligomeric matrix protein in idiopathic pulmonary fibrosis | ||
69 | +Cytokine gene polymorphisms in idiopathic pulmonary fibrosis | ||
70 | +Matrix metalloproteinase 3 is a mediator of pulmonary fibrosis | ||
71 | +Ubiquitin carboxyl-terminal hydrolase-L5 promotes TGFb-1 signaling by de-ubiquitinating and stabilizing Smad2/Smad3 in pulmonary fibrosis | ||
72 | +Cub domain containing protein 1 (CDCP1) negatively regulates TGFb signaling and myofibroblast differentiation | ||
73 | +The mannose-6-phosphate analogue, PXS64, inhibits fibrosis via TGF-b1 pathway in human lung fibroblasts | ||
74 | +N-acetylcysteine inhibits alveolar epithelial-mesenchymal transition | ||
75 | +Pulmonary fibrosis: pathogenesis, etiology and regulation | ||
76 | +Smooth muscle alpha-actin expression and myofibroblast differentiation by TGFbeta are dependent upon MK2 | ||
77 | +Profibrotic role of miR-154 in pulmonary fibrosis | ||
78 | +miR-323a-3p regulates lung fibrosis by targeting multiple profibrotic pathways | ||
79 | +Low-dose paclitaxel ameliorates pulmonary fibrosis by suppressing TGF-b1/Smad3 pathway via miR-140 upregulation | ||
80 | +IPF lung fibroblasts have a senescent phenotype | ||
81 | +MiR-338* targeting smoothened to inhibit pulmonary fibrosis by epithelial-mesenchymal transition | ||
82 | +N-acetyl-L-cysteine inhibits TGF-beta1-induced profibrotic responses in fibroblasts | ||
83 | +Sphingolipids in pulmonary fibrosis | ||
84 | +Sustained PI3K Activation exacerbates BLM-induced Lung Fibrosis via activation of pro-inflammatory and pro-fibrotic pathways | ||
85 | +Neutrophil elastase promotes myofibroblast differentiation in lung fibrosis | ||
86 | +BALF N-acetylglucosaminidase and beta-galactosidase activities in idiopathic pulmonary fibrosis | ||
87 | +Transglutaminase 2 and its role in pulmonary fibrosis | ||
88 | +The role of cytokines in human lung fibrosis | ||
89 | +miR-9-5p suppresses pro-fibrogenic transformation of fibroblasts and prevents organ fibrosis by targeting NOX4 and TGFBR2 | ||
90 | +Pleural mesothelial cells in pleural and lung diseases | ||
91 | +[Different cytokine profiles in usual interstitial pneumonia and nonspecific interstitial pneumonia] | ||
92 | +Essential role for the ATG4B protease and autophagy in bleomycin-induced pulmonary fibrosis | ||
93 | +Deregulation of selective autophagy during aging and pulmonary fibrosis: the role of TGFb1 | ||
94 | +MiR-338* suppresses fibrotic pathogenesis in pulmonary fibrosis through targeting LPA1 | ||
95 | +Metformin attenuates lung fibrosis development via NOX4 suppression | ||
96 | +Investigation of bone marrow mesenchymal stem cells (BM MSCs) involvement in Idiopathic Pulmonary Fibrosis (IPF) | ||
97 | +The pathogenesis of idiopathic pulmonary fibrosis | ||
98 | +Interstitial fibrosis and growth factors | ||
99 | +TIAM1 inhibits lung fibroblast differentiation in pulmonary fibrosis | ||
100 | +Role of integrin-mediated TGFbeta activation in the pathogenesis of pulmonary fibrosis | ||
101 | +Leucine-rich a-2 glycoprotein promotes lung fibrosis by modulating TGF-b signaling in fibroblasts | ||
102 | +MiR-541-5p regulates lung fibrosis by targeting cyclic nucleotide phosphodiesterase 1A | ||
103 | +Role of von Hippel-Lindau protein in fibroblast proliferation and fibrosis | ||
104 | +miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis | ||
105 | +miR-31 is a negative regulator of fibrogenesis and pulmonary fibrosis | ||
106 | +TRPV4 mediates myofibroblast differentiation and pulmonary fibrosis in mice | ||
107 | +Sputum biomarkers in IPF: Evidence for raised gene expression and protein level of IGFBP-2, IL-8 and MMP-7 | ||
108 | +STAT3-mediated signaling dysregulates lung fibroblast-myofibroblast activation and differentiation in UIP/IPF | ||
109 | +TGF-b1 induces Fstl1 via the Smad3-c-Jun pathway in lung fibroblasts | ||
110 | +Matrix regulation of idiopathic pulmonary fibrosis: the role of enzymes | ||
111 | +Epithelial-mesenchymal transition in chronic hypersensitivity pneumonitis | ||
112 | +HSP27 regulates TGF-b mediated lung fibroblast differentiation through the Smad3 and ERK pathways | ||
113 | +Inhibition of mechanosensitive signaling in myofibroblasts ameliorates experimental pulmonary fibrosis | ||
114 | +[A role for mesothelial cells in the genesis of idiopathic pulmonary fibrosis?] | ||
115 | +Pathogenesis of idiopathic pulmonary fibrosis | ||
116 | +SNAI transcription factors mediate epithelial-mesenchymal transition in lung fibrosis | ||
117 | +TGF-b activation and lung fibrosis | ||
118 | +Protective role of andrographolide in bleomycin-induced pulmonary fibrosis in mice | ||
119 | +[The potential role of cytokines expression in idiopathic pulmonary fibrosis] | ||
120 | +Autophagy and inflammation in chronic respiratory disease | ||
121 | +Bone morphogenetic protein-inducer tilorone identified by high-throughput screening is antifibrotic in vivo | ||
122 | +Reviews and prospectives of signaling pathway analysis in idiopathic pulmonary fibrosis | ||
123 | +Membrane type-matrix metalloproteinases in idiopathic pulmonary fibrosis | ||
124 | +Endothelin-1 induces alveolar epithelial-mesenchymal transition through endothelin type A receptor-mediated production of TGF-beta1 | ||
125 | +Lung fibrotic tenascin-C upregulation is associated with other extracellular matrix proteins and induced by TGFb1 | ||
126 | +EMT and interstitial lung disease: a mysterious relationship | ||
127 | +Fibrosis of two: Epithelial cell-fibroblast interactions in pulmonary fibrosis | ||
128 | +Lysyl oxidases regulate fibrillar collagen remodelling in idiopathic pulmonary fibrosis | ||
129 | +MicroRNAs in idiopathic pulmonary fibrosis | ||
130 | +Yin yang 1 is a novel regulator of pulmonary fibrosis | ||
131 | +Abrogation of TGF-beta1-induced fibroblast-myofibroblast differentiation by histone deacetylase inhibition | ||
132 | +Negative regulation of myofibroblast differentiation by PTEN (Phosphatase and Tensin Homolog Deleted on chromosome 10) |
results/Partition_3/cluster3_tagged.txt
0 → 100644
1 | +M2 macrophages <v>induce </v><g>EMT</g> through the <g>TGF-b</g>/<g>Smad2</g> signaling pathway | ||
2 | +Up-regulation of heparan sulfate 6-O-sulfation in <d>idiopathic pulmonary fibrosis</d> | ||
3 | +Comparison between conventional and "clinical" assessment of experimental lung <d>fibrosis</d> | ||
4 | +Pirfenidone attenuates bleomycin-induced pulmonary fibrosis in mice by <r>regulating </r><g>Nrf2</g>/<g>Bach1</g> equilibrium | ||
5 | +Developmental Reprogramming in Mesenchymal Stromal Cells of Human Subjects with <d>Idiopathic Pulmonary Fibrosis</d> | ||
6 | +<u>Inhibition </u>of <g>HSP27</g> blocks <d>fibrosis</d> development and EMT features by promoting <g>Snail</g> degradation | ||
7 | +Signalling pathways from NADPH oxidase-4 to <d>idiopathic pulmonary fibrosis</d> | ||
8 | +<r>Effects </r>of a leukotriene B4 receptor antagonist on bleomycin-induced <d>pulmonary fibrosis</d> | ||
9 | +Activated human T lymphocytes inhibit <g>TGFb</g>-induced fibroblast to myofibroblast differentiation via prostaglandins D2 and E2 | ||
10 | +The Role of PPARs in Lung <d>Fibrosis</d> | ||
11 | +Free radical generation induces epithelial-to-mesenchymal transition in lung epithelium via a <g>TGF-b1</g>-dependent mechanism | ||
12 | +The potential application of strategic released apigenin from polymeric carrier in pulmonary fibrosis | ||
13 | +<v>Overexpression </v>of <g>Sulf2</g> in <d>idiopathic pulmonary fibrosis</d> | ||
14 | +Essential role for the <g>ATG4B</g> protease and autophagy in bleomycin-induced <d>pulmonary fibrosis</d> | ||
15 | +<g>Bone morphogenetic protein-4</g> inhibitor <g>gremlin</g> is <v>overexpressed </v>in <d>idiopathic pulmonary fibrosis</d> | ||
16 | +Smooth muscle alpha-actin <e>expression </e>and myofibroblast differentiation by <g>TGFbeta</g> are <v>dependent </v>upon <g>MK2</g> | ||
17 | +The K+ channel <g>KCa3.1</g> as a novel target for <d>idiopathic pulmonary fibrosis</d> | ||
18 | +<g>Spiruchostatin A</g> inhibits proliferation and differentiation of fibroblasts from patients with <d>pulmonary fibrosis</d> | ||
19 | +<v>Elevated </v><g>sL1</g>-CAM levels in BALF and serum of <d>IPF</d> patients | ||
20 | +Lung myofibroblasts are characterized by <u>down-regulated </u><g>cyclooxygenase-2</g> and its main metabolite, prostaglandin E2 | ||
21 | +Cigarette Smoke Enhances the Expression of Profibrotic Molecules in Alveolar Epithelial Cells | ||
22 | +Microarray identifies ADAM family members as key responders to <g>TGF-beta1</g> in alveolar epithelial cells | ||
23 | +Titration of non-replicating adenovirus as a vector for <v>transducing </v>active <g>TGF-beta1</g> gene <e>expression </e>causing <d>inflammation</d> and fibrogenesis in the lungs of C57BL/6 mice | ||
24 | +Effect of substrate stiffness on pulmonary fibroblast activation by <g>TGF-b</g> | ||
25 | +A critical role for the <g>mTORC2</g> pathway in <d>lung fibrosis</d> | ||
26 | +Bile acids induce activation of alveolar epithelial cells and lung fibroblasts through farnesoid X receptor-dependent and independent pathways | ||
27 | +<g>TGF-beta</g> driven lung <d>fibrosis</d> is macrophage dependent and blocked by Serum amyloid P | ||
28 | +Exercise <u>Reduces </u>Lung <d>Fibrosis</d> | ||
29 | +Sputum biomarkers in <d>IPF</d>: Evidence for raised gene <e>expression </e>and protein level of <g>IGFBP-2</g>, <g>IL-8</g> and <g>MMP-7</g> | ||
30 | +<g>Forkhead Box F1</g> (<g>FOXF1</g>) <u>represses </u>cell growth, COL1 and <g>ARPC2</g> <e>expression </e>in lung fibroblasts in vitro | ||
31 | +<g>MicroRNA-29c</g> regulates apoptosis sensitivity via modulation of the cell-surface death receptor, Fas, in lung fibroblasts | ||
32 | +<g>Prostaglandin F(2alpha) receptor</g> signaling facilitates bleomycin-induced <d>pulmonary fibrosis</d> independently of transforming growth factor-beta | ||
33 | +<e>Expression </e>of mucosa-related integrin alphaEbeta7 on <d>alveolar T</d> cells in <d>interstitial lung diseases</d> | ||
34 | +Cytoskeletal protein modulation in <d>pulmonary alveolar myofibroblasts</d> during <d>idiopathic pulmonary fibrosis</d> | ||
35 | +<g>Transglutaminase 2</g> and its role in <d>pulmonary fibrosis</d> | ||
36 | +Sunitinib, a Small-Molecule Kinase <u>Inhibitor,</u> | ||
37 | +Fibroblasts from <d>idiopathic pulmonary fibrosis</d> and normal lungs differ in growth rate, apoptosis, and tissue <u>inhibitor </u>of metalloproteinases <e>expression.</e> <d>Idiopathic pulmonary fibrosis</d> (<d>IPF</d>) is a <d>chronic lung disorder</d> characterized by fibroblast proliferation and extracellular matrix accumulation | ||
38 | +<g>WISP1</g> mediates <g>IL-6</g>-dependent proliferation in primary human lung fibroblasts | ||
39 | +<d>Idiopathic pulmonary fibrosis</d>: immunohistochemical analysis provides fresh insights into lung tissue remodelling with implications for novel prognostic markers | ||
40 | +Amplified canonical transforming growth factor-b signalling<i>via</i><d>heat shock</d> protein 90 in <d>pulmonary fibrosis</d> | ||
41 | +<v>Upregulation </v>of alveolar <e>levels </e>of activin B, but not activin A, in lungs of west highland white terriers with <d>idiopathic pulmonary fibrosis</d> and <d>diffuse alveolar damage</d> | ||
42 | +Absence of <g>Thy-1</g> results in <g>TGF-b</g> induced <g>MMP-9</g> expression and confers a profibrotic phenotype to human lung fibroblasts | ||
43 | +Shikonin suppresses pulmonary fibroblasts proliferation and activation by <r>regulating </r><g>Akt</g> and <g>p38</g> | ||
44 | +<g>TRPV4</g> mediates myofibroblast differentiation and <d>pulmonary fibrosis</d> in mice | ||
45 | +Modulation of <g>CD11c</g>+ lung dendritic cells in respect to <g>TGF-b</g> in experimental <d>pulmonary fibrosis</d> | ||
46 | +Long-acting human serum albumin-thioredoxin fusion protein suppresses bleomycin-induced <d>pulmonary fibrosis progression</d> | ||
47 | +Fibrogenic Lung Injury Induces Non-Cell-Autonomous Fibroblast Invasion | ||
48 | +Induction of epithelial-mesenchymal transition in alveolar epithelial cells by <g>transforming growth factor-beta1</g>: potential role in <d>idiopathic pulmonary fibrosis</d> | ||
49 | +Recent advances in molecular targets and treatment of <d>idiopathic pulmonary fibrosis</d>: focus on <g>TGFbeta</g> signaling and the myofibroblast | ||
50 | +<g>Bone morphogenetic protein</g>-inducer tilorone identified by high-throughput screening is antifibrotic in vivo | ||
51 | +Pleural mesothelial cell differentiation and invasion in <d>fibrogenic lung injury</d> | ||
52 | +Studies of <g>hepatocyte growth factor</g> in bronchoalveolar lavage fluid in chronic <d>interstitial lung diseases</d> | ||
53 | +Cytokine gene polymorphisms in <d>idiopathic pulmonary fibrosis</d> | ||
54 | +<g>Cub domain containing protein 1</g> (<g>CDCP1</g>) negatively regulates TGFb signaling and myofibroblast differentiation | ||
55 | +Increased levels of prostaglandin E-major urinary metabolite (PGE-MUM) in chronic fibrosing <d>interstitial pneumonia</d> | ||
56 | +Mechanisms of <d>fibrosis</d> in <d>coal workers' pneumoconiosis</d> | ||
57 | +Different effects of growth factors on proliferation and matrix production of normal and fibrotic human lung fibroblasts | ||
58 | +Are mast cells instrumental for <d>fibrotic diseases</d>? <d>Idiopathic pulmonary fibrosis</d> (<d>IPF</d>) is a <d>fatal lung disorder</d> of unknown etiology characterized by accumulation of lung fibroblasts and extracellular matrix deposition, ultimately leading to compromised tissue architecture and lung function capacity | ||
59 | +<g>miR</g>-323a-3p regulates <d>lung fibrosis</d> by targeting multiple profibrotic pathways | ||
60 | +<g>TGF-b1</g> <v>stimulates </v><g>HDAC4</g> nucleus-to-cytoplasm <l>translocation </l>and <g>NADPH oxidase 4</g>-derived reactive oxygen species in normal human lung fibroblasts | ||
61 | +Effects of <d>cigarette smoke extract</d> on A549 cells and human lung fibroblasts treated with <g>transforming growth factor-beta1</g> in a coculture system | ||
62 | +MicroRNA-326 regulates profibrotic functions of transforming growth factor-b in <d>pulmonary fibrosis</d> | ||
63 | +Differential mRNA expression of <g>insulin-like growth factor-1</g> splice variants in patients with <d>idiopathic pulmonary fibrosis</d> and <d>pulmonary sarcoidosis</d> | ||
64 | +Pathogenesis of <d>idiopathic pulmonary fibrosis</d> | ||
65 | +<u>Reduced </u><g>Ets Domain-containing Protein Elk1</g> | ||
66 | +Nitric oxide attenuates epithelial-mesenchymal transition in alveolar epithelial cells | ||
67 | +<g>HSP27</g> regulates <g>TGF-b</g> mediated lung fibroblast differentiation through the <g>Smad3</g> and <g>ERK</g> pathways | ||
68 | +<e>Expression </e>of <g>WNT5A</g> in <d>Idiopathic Pulmonary Fibrosis</d> and Its <r>Control </r>by <g>TGF-b</g> and <g>WNT7B</g> in Human Lung Fibroblasts | ||
69 | +<g>FGF-1</g> reverts epithelial-mesenchymal transition induced by <g>TGF-{beta}1</g> through MAPK/ERK kinase pathway | ||
70 | +Type II alveolar epithelial cells and interstitial fibroblasts express <g>connective tissue growth factor</g> in <d>IPF</d> | ||
71 | +<g>Transforming growth factor b1</g> (<g>TGFb1</g>)-induced CD44V6-<g>NOX4</g> signaling in pathogenesis of <d>idiopathic pulmonary fibrosis</d> | ||
72 | +Pleural mesothelial cells in <d>pleural and lung diseases</d> | ||
73 | +<d>Idiopathic pulmonary fibrosis</d>: an altered fibroblast proliferation linked to <d>cancer</d> biology | ||
74 | +<g>Caveolin-1</g>: a critical regulator of <d>lung fibrosis</d> in <d>idiopathic pulmonary fibrosis</d> | ||
75 | +<g>Cthrc1</g> lowers pulmonary collagen associated with bleomycin-induced <d>fibrosis</d> and protects lung function | ||
76 | +Wnt coreceptor <g>Lrp5</g> is a driver of <d>idiopathic pulmonary fibrosis</d> | ||
77 | +Protective Effect of Ginsenoside Rg1 on Bleomycin-Induced Pulmonary Fibrosis in Rats: Involvement of <g>Caveolin-1</g> and <g>TGF-b1</g> | ||
78 | +The <g>JAK2</g> pathway is activated in <d>idiopathic pulmonary fibrosis</d> | ||
79 | +<g>miR-31</g> is a negative regulator of fibrogenesis and <d>pulmonary fibrosis</d> | ||
80 | +<u>Defect </u>of <g>hepatocyte growth factor</g> <l>secretion </l>by fibroblasts in <d>idiopathic pulmonary fibrosis</d> | ||
81 | +<g>NOX4</g>/NADPH oxidase <e>expression </e>is <v>increased </v>in pulmonary fibroblasts from patients with <d>idiopathic pulmonary fibrosis</d> and mediates <g>TGFbeta1</g>-induced fibroblast differentiation into myofibroblasts | ||
82 | +Matrix regulation of <d>idiopathic pulmonary fibrosis</d>: the role of enzymes | ||
83 | +Rapamycin <v>increases </v><g>CCN2</g> <e>expression </e>of lung fibroblasts via <g>phosphoinositide 3-kinase</g> | ||
84 | +[The expressions and meanings of <g>BMP-7</g> and <g>TGF-b</g> in <d>idiopathic pulmonary fibrosis</d> and <d>idiopathic nonspecific interstitial pneumonia</d>] | ||
85 | +Human lung myofibroblast <g>TGFb1</g>-dependent <g>Smad2/3</g> signalling is Ca(2+)-dependent and <r>regulated </r>by <g>KCa3.1</g> | ||
86 | +[A role for mesothelial cells in the genesis of <d>idiopathic pulmonary fibrosis</d>?] | ||
87 | +Antifibrotic effects of <g>cyclosporine A</g> on <g>TGF-b1</g>-treated lung fibroblasts and lungs from bleomycin-treated mice: role of <g>hypoxia-inducible factor-1a</g> | ||
88 | +<g>TGF-beta 1</g> as an enhancer of Fas-mediated apoptosis of lung epithelial cells | ||
89 | +Mesenchymal Stem Cells Correct Inappropriate Epithelial-mesenchyme Relation in <d>Pulmonary Fibrosis</d> | ||
90 | +Proliferation of pulmonary interstitial fibroblasts is mediated by <g>transforming growth factor-beta1</g>-induced release of extracellular <g>fibroblast growth factor-2</g> and <p>phosphorylation </p>of <g>p38</g> | ||
91 | +Prognostic factors for <d>idiopathic pulmonary fibrosis</d>: clinical, physiologic, pathologic, and molecular aspects | ||
92 | +Hydrogen peroxide is a diffusible paracrine signal for the induction of epithelial cell death by activated myofibroblasts | ||
93 | +<g>Secreted protein acidic and rich in cysteine</g> (<g>SPARC</g>) is upregulated by transforming growth factor (TGF)-b and is required for <g>TGF-b</g>-induced hydrogen peroxide production in fibroblasts | ||
94 | +The lncRNA <g>H19</g> | ||
95 | +<e>Contribution </e>of the anaphylatoxin receptors, <g>C3aR</g> and <g>C5aR</g>, to the pathogenesis of <d>pulmonary fibrosis</d> | ||
96 | +Corilagin attenuates aerosol bleomycin-induced experimental <d>lung injury</d> | ||
97 | +[Potential role of cytokines in <d>idiopathic pulmonary fibrosis</d>] | ||
98 | +Protective role of andrographolide in bleomycin-induced <d>pulmonary fibrosis</d> in mice | ||
99 | +<g>Serpin B4</g> isoform overexpression is associated with aberrant epithelial proliferation and <d>lung cancer</d> in <d>idiopathic pulmonary fibrosis</d> | ||
100 | +Interstitial <d>fibrosis</d> and growth factors | ||
101 | +<u>Blockade </u>of the Wnt/b-catenin pathway attenuates bleomycin-induced <d>pulmonary fibrosis</d> | ||
102 | +Control of virus reactivation arrests pulmonary herpesvirus-induced <d>fibrosis</d> in IFN-gamma receptor-<u>deficient </u>mice | ||
103 | +Interplay between <g>RAGE</g>, <g>CD44</g>, and focal adhesion molecules in epithelial-mesenchymal transition of alveolar epithelial cells | ||
104 | +Antifibrotic properties of receptor for advanced glycation end products in <d>idiopathic pulmonary fibrosis</d> | ||
105 | +Dysregulated Collagen Homeostasis by Matrix Stiffening and <g>TGF-b1</g> in Fibroblasts from <d>Idiopathic Pulmonary Fibrosis</d> | ||
106 | +TGF-b1 T869C polymorphism may affect susceptibility to <d>idiopathic pulmonary fibrosis</d> and disease severity | ||
107 | +Anti-pulmonary fibrotic activity of salvianolic acid B was screened by a novel method based on the cyto-biophysical properties | ||
108 | +Cytokines in human <d>lung fibrosis</d> | ||
109 | +<e>Expression </e>of <g>RXFP1</g> | ||
110 | +Plasma <g>CCN2</g> (connective tissue growth factor; <g>CTGF</g>) is a potential biomarker in <d>idiopathic pulmonary fibrosis</d> (<d>IPF</d>) | ||
111 | +Azithromycin attenuates myofibroblast differentiation and lung <d>fibrosis</d> development through <d>proteasomal degradation</d> of <g>NOX4</g> | ||
112 | +Association between cytokine removal by polymyxin B hemoperfusion and improved pulmonary oxygenation in patients with acute exacerbation of <d>idiopathic pulmonary fibrosis</d> | ||
113 | +Crosstalk between <g>TGF-b1</g> and complement activation augments epithelial <d>injury in pulmonary fibrosis</d> | ||
114 | +Bleomycin and <g>IL-1beta</g>-mediated <d>pulmonary fibrosis</d> is <g>IL-17A</g> dependent | ||
115 | +miR-199a-5p Is <v>upregulated </v>during fibrogenic response to tissue injury and mediates TGFbeta-induced lung fibroblast activation by targeting <g>caveolin-1</g> | ||
116 | +Inhibition of mechanosensitive signaling in myofibroblasts ameliorates experimental <d>pulmonary fibrosis</d> | ||
117 | +Integrated analyses identify the involvement of microRNA-26a in epithelial-mesenchymal transition during <d>idiopathic pulmonary fibrosis</d> | ||
118 | +<g>Transforming growth factor beta1</g> induces epithelial-to-mesenchymal transition of A549 cells | ||
119 | +The anti-fibrotic effects of microRNA-153 by <r>targeting </r><g>TGFBR-2</g> in <d>pulmonary fibrosis</d> | ||
120 | +<u>Defective </u>histone acetylation is <r>responsible </r>for the <u>diminished </u><e>expression </e>of <g>cyclooxygenase 2</g> in <d>idiopathic pulmonary fibrosis</d> | ||
121 | +y-Herpes virus-68, but not Pseudomonas aeruginosa or influenza A (H1N1), exacerbates <d>established murine lung fibrosis</d> | ||
122 | +Inhibition and role of <g>let-7d</g> in <d>idiopathic pulmonary fibrosis</d> | ||
123 | +Pleural mesothelial cell transformation into myofibroblasts and haptotactic migration in response to <g>TGF-beta1</g> in vitro | ||
124 | +Association of HLA and cytokine gene polymorphisms with <d>idiopathic pulmonary fibrosis</d> | ||
125 | +Signaling pathways and their miRNA regulators involved in the etiopathology of <d>idiopathic pulmonary fibrosis</d> (<d>IPF</d>) and <d>hypersensitivity pneumonitis</d> (<d>HP</d>) | ||
126 | +<g>miR-21</g> mediates fibrogenic activation of pulmonary fibroblasts and lung <d>fibrosis</d> | ||
127 | +Inhibitory effects of amines from Citrus reticulata on bleomycin-induced <d>pulmonary fibrosis</d> in rats | ||
128 | +Thalidomide <u>reduces </u><g>IL-18</g>, <g>IL-8</g> and <g>TNF-alpha</g> <l>release </l>from alveolar macrophages in <d>interstitial lung disease</d> | ||
129 | +Effect of glycosides based standardized fenugreek seed extract in bleomycin-induced <d>pulmonary fibrosis</d> in rats: Decisive role of <g>Bax</g>, <g>Nrf2</g>, <g>NF-kB</g>, <g>Muc5ac</g>, <g>TNF-a</g> and <g>IL-1b</g> | ||
130 | +The Anti-fibrotic Effects and Mechanisms of MicroRNA-486-5p in <d>Pulmonary Fibrosis</d> | ||
131 | +The role of microRNA-155/liver X receptor pathway in experimental and <d>idiopathic pulmonary fibrosis</d> | ||
132 | +<g>Cysteine-rich protein 1</g> is regulated by <g>transforming growth factor-b1</g> and expressed in lung <d>fibrosis</d> |
1 | +#Cluster: 1 | ||
2 | +3_s 3 | ||
3 | +17_s 17 | ||
4 | +33_s 33 | ||
5 | +42_s 42 | ||
6 | +43_s 43 | ||
7 | +59_s 59 | ||
8 | +66_s 66 | ||
9 | +82_s 82 | ||
10 | +84_s 84 | ||
11 | +100_s 100 | ||
12 | +123_s 123 | ||
13 | +124_s 124 | ||
14 | +132_s 131 | ||
15 | +136_s 135 | ||
16 | +137_s 136 | ||
17 | +148_s 147 | ||
18 | +188_s 186 | ||
19 | +196_s 194 | ||
20 | +216_s 214 | ||
21 | +219_s 217 | ||
22 | +226_s 224 | ||
23 | +227_s 225 | ||
24 | +229_s 227 | ||
25 | +230_s 228 | ||
26 | +234_s 232 | ||
27 | +238_s 236 | ||
28 | +244_s 242 | ||
29 | +245_s 243 | ||
30 | +269_s 266 | ||
31 | +275_s 272 | ||
32 | +281_s 278 | ||
33 | +287_s 284 | ||
34 | +290_s 287 | ||
35 | +301_s 297 | ||
36 | +302_s 298 | ||
37 | +303_s 299 | ||
38 | +315_s 311 | ||
39 | +332_s 328 | ||
40 | +350_s 346 | ||
41 | +361_s 357 | ||
42 | +366_s 362 | ||
43 | +379_s 375 | ||
44 | +415_s 411 | ||
45 | +421_s 417 | ||
46 | +444_s 440 | ||
47 | +445_s 441 | ||
48 | +446_s 442 | ||
49 | +453_s 449 | ||
50 | +#Cluster: 2 | ||
51 | +1_s 1 | ||
52 | +5_s 5 | ||
53 | +6_s 6 | ||
54 | +7_s 7 | ||
55 | +8_s 8 | ||
56 | +10_s 10 | ||
57 | +12_s 12 | ||
58 | +13_s 13 | ||
59 | +14_s 14 | ||
60 | +16_s 16 | ||
61 | +18_s 18 | ||
62 | +20_s 20 | ||
63 | +22_s 22 | ||
64 | +23_s 23 | ||
65 | +24_s 24 | ||
66 | +25_s 25 | ||
67 | +28_s 28 | ||
68 | +29_s 29 | ||
69 | +31_s 31 | ||
70 | +34_s 34 | ||
71 | +37_s 37 | ||
72 | +38_s 38 | ||
73 | +44_s 44 | ||
74 | +47_s 47 | ||
75 | +48_s 48 | ||
76 | +49_s 49 | ||
77 | +54_s 54 | ||
78 | +55_s 55 | ||
79 | +58_s 58 | ||
80 | +64_s 64 | ||
81 | +65_s 65 | ||
82 | +67_s 67 | ||
83 | +69_s 69 | ||
84 | +70_s 70 | ||
85 | +71_s 71 | ||
86 | +72_s 72 | ||
87 | +74_s 74 | ||
88 | +75_s 75 | ||
89 | +79_s 79 | ||
90 | +80_s 80 | ||
91 | +81_s 81 | ||
92 | +83_s 83 | ||
93 | +86_s 86 | ||
94 | +87_s 87 | ||
95 | +88_s 88 | ||
96 | +89_s 89 | ||
97 | +90_s 90 | ||
98 | +91_s 91 | ||
99 | +92_s 92 | ||
100 | +93_s 93 | ||
101 | +94_s 94 | ||
102 | +98_s 98 | ||
103 | +101_s 101 | ||
104 | +102_s 102 | ||
105 | +104_s 104 | ||
106 | +106_s 106 | ||
107 | +109_s 109 | ||
108 | +110_s 110 | ||
109 | +112_s 112 | ||
110 | +115_s 115 | ||
111 | +117_s 117 | ||
112 | +118_s 118 | ||
113 | +120_s 120 | ||
114 | +127_s 126 | ||
115 | +128_s 127 | ||
116 | +130_s 129 | ||
117 | +138_s 137 | ||
118 | +141_s 140 | ||
119 | +142_s 141 | ||
120 | +144_s 143 | ||
121 | +146_s 145 | ||
122 | +147_s 146 | ||
123 | +149_s 148 | ||
124 | +150_s 149 | ||
125 | +156_s 155 | ||
126 | +159_s 158 | ||
127 | +161_s 160 | ||
128 | +162_s 161 | ||
129 | +163_s 162 | ||
130 | +164_s 163 | ||
131 | +165_s 164 | ||
132 | +166_s 165 | ||
133 | +169_s 168 | ||
134 | +171_s 169 | ||
135 | +174_s 172 | ||
136 | +177_s 175 | ||
137 | +179_s 177 | ||
138 | +182_s 180 | ||
139 | +184_s 182 | ||
140 | +186_s 184 | ||
141 | +189_s 187 | ||
142 | +190_s 188 | ||
143 | +192_s 190 | ||
144 | +195_s 193 | ||
145 | +197_s 195 | ||
146 | +198_s 196 | ||
147 | +199_s 197 | ||
148 | +203_s 201 | ||
149 | +204_s 202 | ||
150 | +205_s 203 | ||
151 | +208_s 206 | ||
152 | +210_s 208 | ||
153 | +214_s 212 | ||
154 | +215_s 213 | ||
155 | +217_s 215 | ||
156 | +220_s 218 | ||
157 | +221_s 219 | ||
158 | +222_s 220 | ||
159 | +223_s 221 | ||
160 | +225_s 223 | ||
161 | +233_s 231 | ||
162 | +236_s 234 | ||
163 | +237_s 235 | ||
164 | +239_s 237 | ||
165 | +240_s 238 | ||
166 | +241_s 239 | ||
167 | +242_s 240 | ||
168 | +243_s 241 | ||
169 | +246_s 244 | ||
170 | +247_s 245 | ||
171 | +248_s 246 | ||
172 | +250_s 248 | ||
173 | +251_s 249 | ||
174 | +253_s 250 | ||
175 | +254_s 251 | ||
176 | +255_s 252 | ||
177 | +256_s 253 | ||
178 | +260_s 257 | ||
179 | +262_s 259 | ||
180 | +264_s 261 | ||
181 | +265_s 262 | ||
182 | +268_s 265 | ||
183 | +272_s 269 | ||
184 | +273_s 270 | ||
185 | +278_s 275 | ||
186 | +279_s 276 | ||
187 | +280_s 277 | ||
188 | +284_s 281 | ||
189 | +286_s 283 | ||
190 | +289_s 286 | ||
191 | +291_s 288 | ||
192 | +293_s 289 | ||
193 | +295_s 291 | ||
194 | +297_s 293 | ||
195 | +298_s 294 | ||
196 | +299_s 295 | ||
197 | +300_s 296 | ||
198 | +305_s 301 | ||
199 | +307_s 303 | ||
200 | +308_s 304 | ||
201 | +310_s 306 | ||
202 | +313_s 309 | ||
203 | +314_s 310 | ||
204 | +316_s 312 | ||
205 | +317_s 313 | ||
206 | +318_s 314 | ||
207 | +320_s 316 | ||
208 | +322_s 318 | ||
209 | +325_s 321 | ||
210 | +326_s 322 | ||
211 | +328_s 324 | ||
212 | +330_s 326 | ||
213 | +333_s 329 | ||
214 | +335_s 331 | ||
215 | +336_s 332 | ||
216 | +340_s 336 | ||
217 | +343_s 339 | ||
218 | +345_s 341 | ||
219 | +347_s 343 | ||
220 | +348_s 344 | ||
221 | +349_s 345 | ||
222 | +352_s 348 | ||
223 | +353_s 349 | ||
224 | +354_s 350 | ||
225 | +355_s 351 | ||
226 | +356_s 352 | ||
227 | +357_s 353 | ||
228 | +360_s 356 | ||
229 | +362_s 358 | ||
230 | +363_s 359 | ||
231 | +364_s 360 | ||
232 | +365_s 361 | ||
233 | +367_s 363 | ||
234 | +368_s 364 | ||
235 | +371_s 367 | ||
236 | +372_s 368 | ||
237 | +374_s 370 | ||
238 | +375_s 371 | ||
239 | +376_s 372 | ||
240 | +377_s 373 | ||
241 | +378_s 374 | ||
242 | +380_s 376 | ||
243 | +383_s 379 | ||
244 | +384_s 380 | ||
245 | +387_s 383 | ||
246 | +388_s 384 | ||
247 | +390_s 386 | ||
248 | +391_s 387 | ||
249 | +392_s 388 | ||
250 | +398_s 394 | ||
251 | +399_s 395 | ||
252 | +401_s 397 | ||
253 | +402_s 398 | ||
254 | +403_s 399 | ||
255 | +407_s 403 | ||
256 | +408_s 404 | ||
257 | +409_s 405 | ||
258 | +411_s 407 | ||
259 | +413_s 409 | ||
260 | +414_s 410 | ||
261 | +416_s 412 | ||
262 | +418_s 414 | ||
263 | +419_s 415 | ||
264 | +420_s 416 | ||
265 | +424_s 420 | ||
266 | +428_s 424 | ||
267 | +429_s 425 | ||
268 | +431_s 427 | ||
269 | +433_s 429 | ||
270 | +437_s 433 | ||
271 | +438_s 434 | ||
272 | +440_s 436 | ||
273 | +442_s 438 | ||
274 | +443_s 439 | ||
275 | +447_s 443 | ||
276 | +448_s 444 | ||
277 | +450_s 446 | ||
278 | +451_s 447 | ||
279 | +452_s 448 | ||
280 | +#Cluster: 3 | ||
281 | +9_s 9 | ||
282 | +19_s 19 | ||
283 | +21_s 21 | ||
284 | +26_s 26 | ||
285 | +32_s 32 | ||
286 | +39_s 39 | ||
287 | +52_s 52 | ||
288 | +73_s 73 | ||
289 | +77_s 77 | ||
290 | +95_s 95 | ||
291 | +107_s 107 | ||
292 | +113_s 113 | ||
293 | +125_s 125 | ||
294 | +129_s 128 | ||
295 | +131_s 130 | ||
296 | +145_s 144 | ||
297 | +153_s 152 | ||
298 | +158_s 157 | ||
299 | +172_s 170 | ||
300 | +175_s 173 | ||
301 | +180_s 178 | ||
302 | +200_s 198 | ||
303 | +202_s 200 | ||
304 | +207_s 205 | ||
305 | +224_s 222 | ||
306 | +228_s 226 | ||
307 | +231_s 229 | ||
308 | +259_s 256 | ||
309 | +263_s 260 | ||
310 | +274_s 271 | ||
311 | +283_s 280 | ||
312 | +288_s 285 | ||
313 | +306_s 302 | ||
314 | +321_s 317 | ||
315 | +323_s 319 | ||
316 | +334_s 330 | ||
317 | +359_s 355 | ||
318 | +382_s 378 | ||
319 | +395_s 391 | ||
320 | +417_s 413 | ||
321 | +434_s 430 | ||
322 | +454_s 450 | ||
323 | +#Cluster: 4 | ||
324 | +2_s 2 | ||
325 | +4_s 4 | ||
326 | +11_s 11 | ||
327 | +15_s 15 | ||
328 | +27_s 27 | ||
329 | +30_s 30 | ||
330 | +35_s 35 | ||
331 | +36_s 36 | ||
332 | +40_s 40 | ||
333 | +41_s 41 | ||
334 | +45_s 45 | ||
335 | +46_s 46 | ||
336 | +50_s 50 | ||
337 | +51_s 51 | ||
338 | +53_s 53 | ||
339 | +56_s 56 | ||
340 | +57_s 57 | ||
341 | +60_s 60 | ||
342 | +61_s 61 | ||
343 | +62_s 62 | ||
344 | +63_s 63 | ||
345 | +68_s 68 | ||
346 | +76_s 76 | ||
347 | +78_s 78 | ||
348 | +85_s 85 | ||
349 | +96_s 96 | ||
350 | +97_s 97 | ||
351 | +99_s 99 | ||
352 | +103_s 103 | ||
353 | +105_s 105 | ||
354 | +108_s 108 | ||
355 | +111_s 111 | ||
356 | +114_s 114 | ||
357 | +116_s 116 | ||
358 | +119_s 119 | ||
359 | +121_s 121 | ||
360 | +122_s 122 | ||
361 | +133_s 132 | ||
362 | +134_s 133 | ||
363 | +135_s 134 | ||
364 | +139_s 138 | ||
365 | +140_s 139 | ||
366 | +143_s 142 | ||
367 | +151_s 150 | ||
368 | +152_s 151 | ||
369 | +154_s 153 | ||
370 | +155_s 154 | ||
371 | +157_s 156 | ||
372 | +160_s 159 | ||
373 | +167_s 166 | ||
374 | +168_s 167 | ||
375 | +173_s 171 | ||
376 | +176_s 174 | ||
377 | +178_s 176 | ||
378 | +181_s 179 | ||
379 | +183_s 181 | ||
380 | +185_s 183 | ||
381 | +187_s 185 | ||
382 | +191_s 189 | ||
383 | +193_s 191 | ||
384 | +194_s 192 | ||
385 | +201_s 199 | ||
386 | +206_s 204 | ||
387 | +209_s 207 | ||
388 | +211_s 209 | ||
389 | +212_s 210 | ||
390 | +213_s 211 | ||
391 | +218_s 216 | ||
392 | +232_s 230 | ||
393 | +235_s 233 | ||
394 | +249_s 247 | ||
395 | +257_s 254 | ||
396 | +258_s 255 | ||
397 | +261_s 258 | ||
398 | +266_s 263 | ||
399 | +267_s 264 | ||
400 | +270_s 267 | ||
401 | +271_s 268 | ||
402 | +276_s 273 | ||
403 | +277_s 274 | ||
404 | +282_s 279 | ||
405 | +285_s 282 | ||
406 | +294_s 290 | ||
407 | +296_s 292 | ||
408 | +304_s 300 | ||
409 | +309_s 305 | ||
410 | +311_s 307 | ||
411 | +312_s 308 | ||
412 | +319_s 315 | ||
413 | +324_s 320 | ||
414 | +327_s 323 | ||
415 | +329_s 325 | ||
416 | +331_s 327 | ||
417 | +337_s 333 | ||
418 | +338_s 334 | ||
419 | +339_s 335 | ||
420 | +341_s 337 | ||
421 | +342_s 338 | ||
422 | +344_s 340 | ||
423 | +346_s 342 | ||
424 | +351_s 347 | ||
425 | +358_s 354 | ||
426 | +369_s 365 | ||
427 | +370_s 366 | ||
428 | +373_s 369 | ||
429 | +381_s 377 | ||
430 | +385_s 381 | ||
431 | +386_s 382 | ||
432 | +389_s 385 | ||
433 | +393_s 389 | ||
434 | +394_s 390 | ||
435 | +396_s 392 | ||
436 | +397_s 393 | ||
437 | +400_s 396 | ||
438 | +404_s 400 | ||
439 | +405_s 401 | ||
440 | +406_s 402 | ||
441 | +410_s 406 | ||
442 | +412_s 408 | ||
443 | +422_s 418 | ||
444 | +423_s 419 | ||
445 | +425_s 421 | ||
446 | +426_s 422 | ||
447 | +427_s 423 | ||
448 | +430_s 426 | ||
449 | +432_s 428 | ||
450 | +435_s 431 | ||
451 | +436_s 432 | ||
452 | +439_s 435 | ||
453 | +441_s 437 | ||
454 | +449_s 445 | ||
455 | +455_s 451 | ||
... | \ No newline at end of file | ... | \ No newline at end of file |
results/Partition_4/cluster1.txt
0 → 100644
1 | +Tissue inhibitor of metalloproteinase-3 is up-regulated by transforming growth factor-beta1 in vitro and expressed in fibroblastic foci in vivo in idiopathic pulmonary fibrosis | ||
2 | +Upregulation of alveolar levels of activin B, but not activin A, in lungs of west highland white terriers with idiopathic pulmonary fibrosis and diffuse alveolar damage | ||
3 | +Progressive transforming growth factor beta1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor | ||
4 | +Upregulation of activin-B and follistatin in pulmonary fibrosis - a translational study using human biopsies and a specific inhibitor in mouse fibrosis models | ||
5 | +Resveratrol inhibits transforming growth factor-b-induced proliferation and differentiation of ex vivo human lung fibroblasts into myofibroblasts through ERK/Akt inhibition and PTEN restoration | ||
6 | +Interactions between b-catenin and transforming growth factor-b signaling pathways mediate epithelial-mesenchymal transition and are dependent on the transcriptional co-activator cAMP-response element-binding protein (CREB)-binding protein (CBP) | ||
7 | +Syndecan-2 exerts antifibrotic effects by promoting caveolin-1-mediated transforming growth factor-b receptor I internalization and inhibiting transforming growth factor-b1 signaling | ||
8 | +Lower expression of platelet derived growth factor is associated with better overall survival rate of patients with idiopathic nonspecific interstitial pneumonia | ||
9 | +TGF-beta 1, but not TGF-beta 2 or TGF-beta 3, is differentially present in epithelial cells of advanced pulmonary fibrosis: an immunohistochemical study | ||
10 | +Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis | ||
11 | +Significance of elevated procollagen-III-peptide and transforming growth factor-beta levels of bronchoalveolar lavage fluids from idiopathic pulmonary fibrosis patients | ||
12 | +The latent form of TGFbeta(1) is induced by TNFalpha through an ERK specific pathway and is activated by asbestos-derived reactive oxygen species in vitro and in vivo | ||
13 | +Human placental mesenchymal stem cells of fetal origins-alleviated inflammation and fibrosis by attenuating MyD88 signaling in bleomycin-induced pulmonary fibrosis mice | ||
14 | +Fibroblasts from idiopathic pulmonary fibrosis and normal lungs differ in growth rate, apoptosis, and tissue inhibitor of metalloproteinases expression | ||
15 | +Phosphatase and tensin homolog deleted on chromosome 10 contributes to phenotype transformation of fibroblasts in idiopathic pulmonary fibrosis via multiple pathways | ||
16 | +Transforming growth factor-b1 downregulates vascular endothelial growth factor-D expression in human lung fibroblasts via the Jun NH2-terminal kinase signaling pathway | ||
17 | +The anti-fibrotic effect of inhibition of TGFb-ALK5 signalling in experimental pulmonary fibrosis in mice is attenuated in the presence of concurrent y-herpesvirus infection | ||
18 | +Transforming growth factor-b inhibits IQ motif containing guanosine triphosphatase activating protein 1 expression in lung fibroblasts via the nuclear factor-kB signaling pathway | ||
19 | +De-ubiquitinating enzyme, USP11, promotes transforming growth factor b-1 signaling through stabilization of transforming growth factor b receptor II | ||
20 | +Aortic carboxypeptidase-like protein (ACLP) enhances lung myofibroblast differentiation through transforming growth factor b receptor-dependent and -independent pathways | ||
21 | +Insulin-like growth factor binding proteins 3 and 5 are overexpressed in idiopathic pulmonary fibrosis and contribute to extracellular matrix deposition | ||
22 | +Bile acids induce activation of alveolar epithelial cells and lung fibroblasts through farnesoid X receptor-dependent and independent pathways | ||
23 | +Fibroblastic foci, covered with alveolar epithelia exhibiting epithelial-mesenchymal transition, destroy alveolar septa by disrupting blood flow in idiopathic pulmonary fibrosis | ||
24 | +Connective tissue growth factor expression and induction by transforming growth factor-beta is abrogated by simvastatin via a Rho signaling mechanism | ||
25 | +Sorafenib ameliorates bleomycin-induced pulmonary fibrosis: potential roles in the inhibition of epithelial-mesenchymal transition and fibroblast activation | ||
26 | +NOX4/NADPH oxidase expression is increased in pulmonary fibroblasts from patients with idiopathic pulmonary fibrosis and mediates TGFbeta1-induced fibroblast differentiation into myofibroblasts | ||
27 | +Idiopathic pulmonary fibrosis in relation to gene polymorphisms of transforming growth factor-b1 and plasminogen activator inhibitor 1 | ||
28 | +Comparative study of transforming growth factor-b signalling and regulatory molecules in human and canine idiopathic pulmonary fibrosis | ||
29 | +Microsatellite instability in transforming growth factor-beta 1 type II receptor gene in alveolar lining epithelial cells of idiopathic pulmonary fibrosis | ||
30 | +Prostaglandin F(2alpha) receptor signaling facilitates bleomycin-induced pulmonary fibrosis independently of transforming growth factor-beta | ||
31 | +Sphingosine-1-phosphate is increased in patients with idiopathic pulmonary fibrosis and mediates epithelial to mesenchymal transition | ||
32 | +Evaluation of permeability alteration and epithelial-mesenchymal transition induced by transforming growth factor-b1 in A549, NCI-H441, and Calu-3 cells: Development of an in vitro model of respiratory epithelial cells in idiopathic pulmonary fibrosis | ||
33 | +TGF-b1 stimulates HDAC4 nucleus-to-cytoplasm translocation and NADPH oxidase 4-derived reactive oxygen species in normal human lung fibroblasts | ||
34 | +Lactic acid is elevated in idiopathic pulmonary fibrosis and induces myofibroblast differentiation via pH-dependent activation of transforming growth factor-b | ||
35 | +Differential mRNA expression of insulin-like growth factor-1 splice variants in patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis | ||
36 | +The hedgehog system machinery controls transforming growth factor-b-dependent myofibroblastic differentiation in humans: involvement in idiopathic pulmonary fibrosis | ||
37 | +Reactive oxygen species are required for maintenance and differentiation of primary lung fibroblasts in idiopathic pulmonary fibrosis | ||
38 | +Are mast cells instrumental for fibrotic diseases? Idiopathic pulmonary fibrosis (IPF) is a fatal lung disorder of unknown etiology characterized by accumulation of lung fibroblasts and extracellular matrix deposition, ultimately leading to compromised tissue architecture and lung function capacity | ||
39 | +The role of halofuginone in fibrosis: more to be explored? Fibrosis, which can be defined as an abnormal or excessive accumulation of extracellular matrix (ECM), particularly fibrillar collagens, is a key driver of progressive organ dysfunction in many inflammatory and metabolic diseases, including idiopathic pulmonary fibrosis (IPF), cirrhosis, nephropathy, and oral submucous fibrosis (OSF) | ||
40 | +CCN5 overexpression inhibits profibrotic phenotypes via the PI3K/Akt signaling pathway in lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis and in an in vivo model of lung fibrosis | ||
41 | +Mast cell chymase: an indispensable instrument in the pathological symphony of idiopathic pulmonary fibrosis? Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and fatal lung disease with no known etiology and treatment options | ||
42 | +The Epstein-Barr virus latent membrane protein 1 and transforming growth factor--b1 synergistically induce epithelial--mesenchymal transition in lung epithelial cells | ||
43 | +PI3K p110y overexpression in idiopathic pulmonary fibrosis lung tissue and fibroblast cells: in vitro effects of its inhibition | ||
44 | +Rapamycin regulates connective tissue growth factor expression of lung epithelial cells via phosphoinositide 3-kinase | ||
45 | +Proliferation of pulmonary interstitial fibroblasts is mediated by transforming growth factor-beta1-induced release of extracellular fibroblast growth factor-2 and phosphorylation of p38 MAPK and JNK | ||
46 | +Secreted protein acidic and rich in cysteine (SPARC) is upregulated by transforming growth factor (TGF)-b and is required for TGF-b-induced hydrogen peroxide production in fibroblasts | ||
47 | +Semaphorin 7a+ regulatory T cells are associated with progressive idiopathic pulmonary fibrosis and are implicated in transforming growth factor-b1-induced pulmonary fibrosis | ||
48 | +Arsenic trioxide inhibits transforming growth factor-b1-induced fibroblast to myofibroblast differentiation in vitro and bleomycin induced lung fibrosis in vivo |
results/Partition_4/cluster1_tagged.txt
0 → 100644
1 | +Resveratrol inhibits transforming growth factor-b-induced proliferation and differentiation of ex vivo human lung fibroblasts into myofibroblasts through <g>ERK</g>/<g>Akt</g> <u>inhibition </u>and <g>PTEN</g> restoration | ||
2 | +Signaling pathways in the epithelial origins of <d>pulmonary fibrosis</d> | ||
3 | +Raised serum levels of <g>IGFBP-1</g> and <g>IGFBP-2</g> in <d>idiopathic pulmonary fibrosis</d> | ||
4 | +Methylation-mediated <g>BMPER</g> <e>expression </e>in fibroblast activation in vitro and lung <d>fibrosis</d> in mice in vivo | ||
5 | +<d>Fibrosis</d> of two: Epithelial cell-fibroblast interactions in <d>pulmonary fibrosis</d> | ||
6 | +Arsenic trioxide inhibits transforming growth factor-b1-induced <d>fibroblast to myofibroblast differentiation</d> in vitro and bleomycin induced lung <d>fibrosis</d> in vivo | ||
7 | +microRNA-1343 attenuates pathways of <d>fibrosis</d> by targeting the <g>TGF-b</g> receptors | ||
8 | +<g>Matrix metalloproteinase (MMP)-19</g> <u>deficient </u>fibroblasts display a profibrotic phenotype | ||
9 | +Comparative study of transforming growth factor-b signalling and regulatory molecules in human and canine <d>idiopathic pulmonary fibrosis</d> | ||
10 | +Genetic polymorphism in <g>matrix metalloproteinase-9</g> and <g>transforming growth factor-b1</g> and susceptibility to <d>combined pulmonary fibrosis</d> and <d>emphysema</d> in a Chinese population | ||
11 | +Transforming growth factor-b1 downregulates <g>vascular endothelial growth factor</g>-D expression in human lung fibroblasts via the <g>Jun NH2-terminal kinase</g> signaling pathway | ||
12 | +<g>Ubiquitin carboxyl-terminal hydrolase-L5</g> promotes <g>TGFb-1</g> signaling by de-ubiquitinating and stabilizing <g>Smad2</g>/<g>Smad3</g> in <d>pulmonary fibrosis</d> | ||
13 | +Effect of pirfenidone on proliferation, <g>TGF-b</g>-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts | ||
14 | +[Quantifying plasma levels of <g>transforming growth factor beta1</g> in <d>idiopathic pulmonary fibrosis</d>] | ||
15 | +The matricellular protein <g>CCN1</g> enhances <g>TGF-b1</g>/<g>SMAD3</g>-dependent profibrotic signaling in fibroblasts and contributes to fibrogenic responses to <d>lung injury</d> | ||
16 | +Bleomycin in the setting of <d>lung fibrosis</d> induction: From biological mechanisms to counteractions | ||
17 | +Alveolar epithelial cell injury with Epstein-Barr virus <v>upregulates </v><g>TGFbeta1</g> <e>expression.</e> <d>Idiopathic pulmonary fibrosis</d> (<d>IPF</d>) is a refractory and lethal <d>interstitial lung disease</d> characterized by alveolar epithelial cells apoptosis, fibroblast proliferation, and ECM protein deposition | ||
18 | +Single-cell RNA sequencing identifies diverse roles of epithelial cells in <d>idiopathic pulmonary fibrosis</d> | ||
19 | +Data on <g>CUX1</g> isoforms in <d>idiopathic pulmonary fibrosis lung</d> and <d>systemic sclerosis</d> skin tissue sections | ||
20 | +<d>Idiopathic Pulmonary Fibrosis</d>: Aging, Mitochondrial Dysfunction, and Cellular Bioenergetics | ||
21 | +Genetic partitioning of <g>interleukin-6</g> signalling in mice dissociates <g>Stat3</g> from <g>Smad3</g>-mediated <d>lung fibrosis</d> | ||
22 | +Reactive oxygen species are required for maintenance and differentiation of primary lung fibroblasts in <d>idiopathic pulmonary fibrosis</d> | ||
23 | +Oxidant-antioxidant imbalance as a potential contributor to the progression of human <d>pulmonary fibrosis</d> | ||
24 | +Increased production and immunohistochemical localization of <g>transforming growth factor-beta</g> in <d>idiopathic pulmonary fibrosis</d> | ||
25 | +Type V collagen induced tolerance suppresses collagen deposition, <g>TGF-b</g> and associated transcripts in <d>pulmonary fibrosis</d> | ||
26 | +Preventive and therapeutic effects of thymosin b4 N-terminal fragment Ac-SDKP in the bleomycin model of pulmonary fibrosis | ||
27 | +FAK-related nonkinase is a multifunctional negative regulator of <d>pulmonary fibrosis</d> | ||
28 | +Nitrated fatty acids reverse <d>pulmonary fibrosis</d> by dedifferentiating myofibroblasts and promoting collagen uptake by alveolar macrophages | ||
29 | +Cytokine profiles in <d>idiopathic pulmonary fibrosis</d> suggest an important role for <g>TGF-beta</g> and <g>IL-10</g> | ||
30 | +Sphingosine-1-phosphate is increased in patients with <d>idiopathic pulmonary fibrosis</d> and mediates epithelial to mesenchymal transition | ||
31 | +Leucine-rich a-2 glycoprotein promotes <d>lung fibrosis</d> by modulating <g>TGF-b</g> signaling in fibroblasts | ||
32 | +Sustained <g>PI3K</g> | ||
33 | +Pirfenidone <u>inhibits </u>the <e>expression </e>of <g>HSP47</g> in <g>TGF-beta1</g>-stimulated human lung fibroblasts | ||
34 | +Age-driven developmental drift in the pathogenesis of <d>idiopathic pulmonary fibrosis</d> | ||
35 | +Endogenous <g>Semaphorin-7A</g> | ||
36 | +Progressive transforming growth factor beta1-induced <d>lung fibrosis</d> is blocked by an orally active <g>ALK5</g> kinase <u>inhibitor.</u> <d>Pulmonary fibrosis</d> is characterized by chronic scar formation and deposition of extracellular matrix, resulting in <d>impaired lung function</d> and <d>respiratory failure</d> | ||
37 | +Compromised peroxisomes in <d>idiopathic pulmonary fibrosis</d>, a vicious cycle inducing a higher fibrotic response via <g>TGF-b</g> signaling | ||
38 | +Inhibition of NF-kappaB signaling reduces virus load and gammaherpesvirus-induced <d>pulmonary fibrosis</d> | ||
39 | +Intrinsic defence capacity and therapeutic potential of natriuretic peptides in <d>pulmonary hypertension</d> associated with <d>lung fibrosis</d> | ||
40 | +Possible involvement of pirfenidone metabolites in the antifibrotic action of a therapy for <d>idiopathic pulmonary fibrosis</d> | ||
41 | +BAL cytokine profile in different <d>interstitial lung diseases</d>: a focus on <d>systemic sclerosis</d> | ||
42 | +Matrix metalloproteinase 3 is a mediator of <d>pulmonary fibrosis</d> | ||
43 | +<u>Inhibition </u>of <g>PHGDH</g> | ||
44 | +Bleomycin induces molecular changes directly relevant to <d>idiopathic pulmonary fibrosis</d>: a model for "active" disease | ||
45 | +Lysyl oxidases <r>regulate </r>fibrillar collagen remodelling in idiopathic pulmonary fibrosis | ||
46 | +Discovery and validation of extracellular/circulating microRNAs during <d>idiopathic pulmonary fibrosis disease</d> progression | ||
47 | +Recombinant human <g>serum amyloid P</g> in healthy volunteers and patients with <d>pulmonary fibrosis</d> | ||
48 | +<g>Transforming Growth Factor Beta 1</g> |
results/Partition_4/cluster2.txt
0 → 100644
1 | +Recent advances in molecular targets and treatment of idiopathic pulmonary fibrosis: focus on TGFbeta signaling and the myofibroblast | ||
2 | +Defective histone acetylation is responsible for the diminished expression of cyclooxygenase 2 in idiopathic pulmonary fibrosis | ||
3 | +EZH2 enhances the differentiation of fibroblasts into myofibroblasts in idiopathic pulmonary fibrosis | ||
4 | +y-Herpes virus-68, but not Pseudomonas aeruginosa or influenza A (H1N1), exacerbates established murine lung fibrosis | ||
5 | +Microarray identifies ADAM family members as key responders to TGF-beta1 in alveolar epithelial cells | ||
6 | +Anti-pulmonary fibrotic activity of salvianolic acid B was screened by a novel method based on the cyto-biophysical properties | ||
7 | +Targeting genes for treatment in idiopathic pulmonary fibrosis: challenges and opportunities, promises and pitfalls | ||
8 | +Th1/Th2 cytokine gene polymorphisms in patients with idiopathic pulmonary fibrosis | ||
9 | +VCAM-1 is a TGF-b1 inducible gene upregulated in idiopathic pulmonary fibrosis | ||
10 | +Integrated analyses identify the involvement of microRNA-26a in epithelial-mesenchymal transition during idiopathic pulmonary fibrosis | ||
11 | +Roles for insulin-like growth factor I and transforming growth factor-beta in fibrotic lung disease | ||
12 | +Combined inhibition of TGFb and PDGF signaling attenuates radiation-induced pulmonary fibrosis | ||
13 | +Glucagon like peptide-1 attenuates bleomycin-induced pulmonary fibrosis, involving the inactivation of NF-kB in mice | ||
14 | +Carbon monoxide-bound hemoglobin-vesicles for the treatment of bleomycin-induced pulmonary fibrosis | ||
15 | +Protease activated receptor-1 regulates macrophage-mediated cellular senescence: a risk for idiopathic pulmonary fibrosis | ||
16 | +Control of virus reactivation arrests pulmonary herpesvirus-induced fibrosis in IFN-gamma receptor-deficient mice | ||
17 | +Regulation of TGF-b storage and activation in the human idiopathic pulmonary fibrosis lung | ||
18 | +Interleukin-17 induces human alveolar epithelial to mesenchymal cell transition via the TGF-b1 mediated Smad2/3 and ERK1/2 activation | ||
19 | +Prognostic factors for idiopathic pulmonary fibrosis: clinical, physiologic, pathologic, and molecular aspects | ||
20 | +Toll-like receptor 4 activation attenuates profibrotic response in control lung fibroblasts but not in fibroblasts from patients with IPF | ||
21 | +Free radical generation induces epithelial-to-mesenchymal transition in lung epithelium via a TGF-b1-dependent mechanism | ||
22 | +Methylation-mediated BMPER expression in fibroblast activation in vitro and lung fibrosis in mice in vivo | ||
23 | +Effects of doxycycline on production of growth factors and matrix metalloproteinases in pulmonary fibrosis | ||
24 | +MS80, a novel sulfated oligosaccharide, inhibits pulmonary fibrosis by targeting TGF-beta1 both in vitro and in vivo | ||
25 | +Association of HLA and cytokine gene polymorphisms with idiopathic pulmonary fibrosis | ||
26 | +Oxidant-antioxidant imbalance as a potential contributor to the progression of human pulmonary fibrosis | ||
27 | +A translational preclinical model of interstitial pulmonary fibrosis and pulmonary hypertension: mechanistic pathways driving disease pathophysiology | ||
28 | +Epithelial cell alpha3beta1 integrin links beta-catenin and Smad signaling to promote myofibroblast formation and pulmonary fibrosis | ||
29 | +Pirfenidone for the treatment of idiopathic pulmonary fibrosis | ||
30 | +Uncoupling of the profibrotic and hemostatic effects of thrombin in lung fibrosis | ||
31 | +Studies of hepatocyte growth factor in bronchoalveolar lavage fluid in chronic interstitial lung diseases | ||
32 | +Compromised peroxisomes in idiopathic pulmonary fibrosis, a vicious cycle inducing a higher fibrotic response via TGF-b signaling | ||
33 | +Simvastatin attenuates TGF-b1-induced epithelial-mesenchymal transition in human alveolar epithelial cells | ||
34 | +Expression of 150-kDa oxygen-regulated protein (ORP150) stimulates bleomycin-induced pulmonary fibrosis and dysfunction in mice | ||
35 | +Kinase inhibitors fail to induce mesenchymal-epithelial transition in fibroblasts from fibrotic lung tissue | ||
36 | +The small heat-shock protein aB-crystallin is essential for the nuclear localization of Smad4: impact on pulmonary fibrosis | ||
37 | +Blockade of the Wnt/b-catenin pathway attenuates bleomycin-induced pulmonary fibrosis | ||
38 | +Epithelial stem cell exhaustion in the pathogenesis of idiopathic pulmonary fibrosis | ||
39 | +CUX1/Wnt signaling regulates epithelial mesenchymal transition in EBV infected epithelial cells | ||
40 | +Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis | ||
41 | +Idiopathic pulmonary fibrosis: an altered fibroblast proliferation linked to cancer biology | ||
42 | +Elevated expression of NEU1 sialidase in idiopathic pulmonary fibrosis provokes pulmonary collagen deposition, lymphocytosis, and fibrosis | ||
43 | +Cthrc1 lowers pulmonary collagen associated with bleomycin-induced fibrosis and protects lung function | ||
44 | +Pigment epithelium-derived factor in idiopathic pulmonary fibrosis: a role in aberrant angiogenesis | ||
45 | +Cytoskeletal protein modulation in pulmonary alveolar myofibroblasts during idiopathic pulmonary fibrosis | ||
46 | +Increased expression of 5-hydroxytryptamine2A/B receptors in idiopathic pulmonary fibrosis: a rationale for therapeutic intervention | ||
47 | +Signaling pathways and their miRNA regulators involved in the etiopathology of idiopathic pulmonary fibrosis (IPF) and hypersensitivity pneumonitis (HP) | ||
48 | +Alveolar epithelial cells express mesenchymal proteins in patients with idiopathic pulmonary fibrosis | ||
49 | +TGF-b1 induces tissue factor expression in human lung fibroblasts in a PI3K/JNK/Akt-dependent and AP-1-dependent manner | ||
50 | +Inhibitory effects of amines from Citrus reticulata on bleomycin-induced pulmonary fibrosis in rats | ||
51 | +Focal adhesion kinase signaling determines the fate of lung epithelial cells in response to TGF-b | ||
52 | +Beyond TGFb - Novel ways to target airway and parenchymal fibrosis | ||
53 | +The profibrotic cytokine transforming growth factor-b1 increases endothelial progenitor cell angiogenic properties | ||
54 | +Tannic acid attenuates TGF-b1-induced epithelial-to-mesenchymal transition by effectively intervening TGF-b signaling in lung epithelial cells | ||
55 | +Differential expression of alpha E beta 7 integrins on bronchoalveolar lavage T lymphocyte subsets: regulation by alpha 4 beta 1-integrin crosslinking and TGF-beta | ||
56 | +Elevated sL1-CAM levels in BALF and serum of IPF patients | ||
57 | +The potential application of strategic released apigenin from polymeric carrier in pulmonary fibrosis | ||
58 | +Immunomodulation by mesenchymal stem cells in treating human autoimmune disease-associated lung fibrosis | ||
59 | +Epithelial-to-mesenchymal transition and its role in EGFR-mutant lung adenocarcinoma and idiopathic pulmonary fibrosis | ||
60 | +Effects of thymosin b4 and its N-terminal fragment Ac-SDKP on TGF-b-treated human lung fibroblasts and in the mouse model of bleomycin-induced lung fibrosis | ||
61 | +Epithelial contribution to the pro-fibrotic stiff microenvironment and myofibroblast population in lung fibrosis | ||
62 | +The matricellular protein CCN1 enhances TGF-b1/SMAD3-dependent profibrotic signaling in fibroblasts and contributes to fibrogenic responses to lung injury | ||
63 | +MicroRNA-326 regulates profibrotic functions of transforming growth factor-b in pulmonary fibrosis | ||
64 | +Protective role of gambogic acid in experimental pulmonary fibrosis in vitro and in vivo | ||
65 | +An ex vivo model to induce early fibrosis-like changes in human precision-cut lung slices | ||
66 | +Differential effects of human neutrophil peptide-1 on growth factor and interleukin-8 production by human lung fibroblasts and epithelial cells | ||
67 | +Release of biologically active TGF-beta1 by alveolar epithelial cells results in pulmonary fibrosis | ||
68 | +Overproduction of collagen and diminished SOCS1 expression are causally linked in fibroblasts from idiopathic pulmonary fibrosis | ||
69 | +Thalidomide reduces IL-18, IL-8 and TNF-alpha release from alveolar macrophages in interstitial lung disease | ||
70 | +Pathogenesis pathways of idiopathic pulmonary fibrosis in bleomycin-induced lung injury model in mice | ||
71 | +VEGF ameliorates pulmonary hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in rats | ||
72 | +Genomewide RNA expression profiling in lung identifies distinct signatures in idiopathic pulmonary arterial hypertension and secondary pulmonary hypertension | ||
73 | +Corilagin attenuates aerosol bleomycin-induced experimental lung injury | ||
74 | +Bleomycin induces molecular changes directly relevant to idiopathic pulmonary fibrosis: a model for "active" disease | ||
75 | +Long-acting human serum albumin-thioredoxin fusion protein suppresses bleomycin-induced pulmonary fibrosis progression | ||
76 | +Angiotensin-TGF-beta 1 crosstalk in human idiopathic pulmonary fibrosis: autocrine mechanisms in myofibroblasts and macrophages | ||
77 | +miR-199a-5p Is upregulated during fibrogenic response to tissue injury and mediates TGFbeta-induced lung fibroblast activation by targeting caveolin-1 | ||
78 | +Increased expression of protease nexin-1 in fibroblasts during idiopathic pulmonary fibrosis regulates thrombin activity and fibronectin expression | ||
79 | +Plasma CCN2 (connective tissue growth factor; CTGF) is a potential biomarker in idiopathic pulmonary fibrosis (IPF) | ||
80 | +Cysteine-rich protein 1 is regulated by transforming growth factor-b1 and expressed in lung fibrosis | ||
81 | +Microencapsulation of lefty-secreting engineered cells for pulmonary fibrosis therapy in mice | ||
82 | +Accelerated epithelial cell senescence in IPF and the inhibitory role of SIRT6 in TGF-b-induced senescence of human bronchial epithelial cells | ||
83 | +Pleural mesothelial cell transformation into myofibroblasts and haptotactic migration in response to TGF-beta1 in vitro | ||
84 | +p63 - Key molecule in the early phase of epithelial abnormality in idiopathic pulmonary fibrosis | ||
85 | +Increased interleukin-1 receptor antagonist in idiopathic pulmonary fibrosis | ||
86 | +Molecular pathogenesis of interstitial pneumonitis with TNF-alpha transgenic mice | ||
87 | +Wilms' tumor 1 (Wt1) regulates pleural mesothelial cell plasticity and transition into myofibroblasts in idiopathic pulmonary fibrosis | ||
88 | +Epithelium-specific deletion of TGF-b receptor type II protects mice from bleomycin-induced pulmonary fibrosis | ||
89 | +Bleomycin in the setting of lung fibrosis induction: From biological mechanisms to counteractions | ||
90 | +Assessment of the effect of potential antifibrotic compounds on total and aVb6 integrin-mediated TGF-b activation | ||
91 | +Plasminogen activator inhibitor 1, fibroblast apoptosis resistance, and aging-related susceptibility to lung fibrosis | ||
92 | +Antifibrotic properties of receptor for advanced glycation end products in idiopathic pulmonary fibrosis | ||
93 | +Genetic polymorphism in matrix metalloproteinase-9 and transforming growth factor-b1 and susceptibility to combined pulmonary fibrosis and emphysema in a Chinese population | ||
94 | +Berberine attenuates bleomycin induced pulmonary toxicity and fibrosis via suppressing NF-kB dependant TGF-b activation: a biphasic experimental study | ||
95 | +Role of CD248 as a potential severity marker in idiopathic pulmonary fibrosis | ||
96 | +Immunoglobulin A in serum: an old acquaintance as a new prognostic biomarker in idiopathic pulmonary fibrosis | ||
97 | +Defect of hepatocyte growth factor secretion by fibroblasts in idiopathic pulmonary fibrosis | ||
98 | +Possible involvement of pirfenidone metabolites in the antifibrotic action of a therapy for idiopathic pulmonary fibrosis | ||
99 | +Effect of pirfenidone on proliferation, TGF-b-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts | ||
100 | +Olodaterol shows anti-fibrotic efficacy in in vitro and in vivo models of pulmonary fibrosis | ||
101 | +[Quantifying plasma levels of transforming growth factor beta1 in idiopathic pulmonary fibrosis] | ||
102 | +BAX inhibitor-1-associated V-ATPase glycosylation enhances collagen degradation in pulmonary fibrosis | ||
103 | +Idiopathic pulmonary fibrosis: pathobiology of novel approaches to treatment | ||
104 | +Novel pharmacological approaches to manage interstitial lung fibrosis in the twenty-first century | ||
105 | +SPARC suppresses apoptosis of idiopathic pulmonary fibrosis fibroblasts through constitutive activation of beta-catenin | ||
106 | +IL-4 polymorphisms, HRCT score and lung tissue markers in idiopathic pulmonary fibrosis | ||
107 | +TGF-beta1 induces human alveolar epithelial to mesenchymal cell transition (EMT) | ||
108 | +NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury | ||
109 | +TGF-beta 1 as an enhancer of Fas-mediated apoptosis of lung epithelial cells | ||
110 | +MicroRNA-29c regulates apoptosis sensitivity via modulation of the cell-surface death receptor, Fas, in lung fibroblasts | ||
111 | +Regulation of human lung fibroblast C1q-receptors by transforming growth factor-beta and tumor necrosis factor-alpha | ||
112 | +Microarray profiling reveals suppressed interferon stimulated gene program in fibroblasts from scleroderma-associated interstitial lung disease | ||
113 | +Effects of antifibrotic agents on TGF-beta1, CTGF and IFN-gamma expression in patients with idiopathic pulmonary fibrosis | ||
114 | +[The expressions and meanings of BMP-7 and TGF-b in idiopathic pulmonary fibrosis and idiopathic nonspecific interstitial pneumonia] | ||
115 | +Increased deposition of chondroitin/dermatan sulfate glycosaminoglycan and upregulation of b1,3-glucuronosyltransferase I in pulmonary fibrosis | ||
116 | +Identification and validation of differentially expressed transcripts by RNA-sequencing of formalin-fixed, paraffin-embedded (FFPE) lung tissue from patients with Idiopathic Pulmonary Fibrosis | ||
117 | +Increased TGF-beta1 in the lungs of asbestos-exposed rats and mice: reduced expression in TNF-alpha receptor knockout mice | ||
118 | +Discovery and validation of extracellular/circulating microRNAs during idiopathic pulmonary fibrosis disease progression | ||
119 | +TGF-b1 T869C polymorphism may affect susceptibility to idiopathic pulmonary fibrosis and disease severity | ||
120 | +Inhibition of PI3K prevents the proliferation and differentiation of human lung fibroblasts into myofibroblasts: the role of class I P110 isoforms | ||
121 | +Medical treatment for pulmonary fibrosis: current trends, concepts, and prospects | ||
122 | +Contribution of the anaphylatoxin receptors, C3aR and C5aR, to the pathogenesis of pulmonary fibrosis | ||
123 | +Comparison between conventional and "clinical" assessment of experimental lung fibrosis | ||
124 | +Intratracheal bleomycin causes airway remodeling and airflow obstruction in mice | ||
125 | +Role of endoplasmic reticulum stress in age-related susceptibility to lung fibrosis | ||
126 | +Transforming growth factor b1 (TGFb1)-induced CD44V6-NOX4 signaling in pathogenesis of idiopathic pulmonary fibrosis | ||
127 | +Increased levels of prostaglandin E-major urinary metabolite (PGE-MUM) in chronic fibrosing interstitial pneumonia | ||
128 | +Pirfenidone inhibits TGF-b1-induced over-expression of collagen type I and heat shock protein 47 in A549 cells | ||
129 | +BAL cytokine profile in different interstitial lung diseases: a focus on systemic sclerosis | ||
130 | +Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis | ||
131 | +Effect of an immunotoxin to folate receptor beta on bleomycin-induced experimental pulmonary fibrosis | ||
132 | +Modulation of CD11c+ lung dendritic cells in respect to TGF-b in experimental pulmonary fibrosis | ||
133 | +Single-cell RNA sequencing identifies diverse roles of epithelial cells in idiopathic pulmonary fibrosis | ||
134 | +Expression of suppressor of cytokine signaling 1 in the peripheral blood of patients with idiopathic pulmonary fibrosis | ||
135 | +Sphingosine-1-phosphate lyase is an endogenous suppressor of pulmonary fibrosis: role of S1P signalling and autophagy | ||
136 | +Roles of p38 MAPK and JNK in TGF-b1-induced human alveolar epithelial to mesenchymal transition | ||
137 | +The role of microRNA-155/liver X receptor pathway in experimental and idiopathic pulmonary fibrosis | ||
138 | +Nitric oxide attenuates epithelial-mesenchymal transition in alveolar epithelial cells | ||
139 | +Sirtuin 7 is decreased in pulmonary fibrosis and regulates the fibrotic phenotype of lung fibroblasts | ||
140 | +Hydrogen peroxide is a diffusible paracrine signal for the induction of epithelial cell death by activated myofibroblasts | ||
141 | +Effects of a leukotriene B4 receptor antagonist on bleomycin-induced pulmonary fibrosis | ||
142 | +Raised serum levels of IGFBP-1 and IGFBP-2 in idiopathic pulmonary fibrosis | ||
143 | +Inhibition of NF-kappaB signaling reduces virus load and gammaherpesvirus-induced pulmonary fibrosis | ||
144 | +Triptolide suppresses paraquat induced idiopathic pulmonary fibrosis by inhibiting TGFB1-dependent epithelial mesenchymal transition | ||
145 | +N-acetylcysteine downregulation of lysyl oxidase activity alleviating bleomycin-induced pulmonary fibrosis in rats | ||
146 | +Cytokine gene polymorphisms and BALF cytokine levels in interstitial lung diseases | ||
147 | +[The morphology and molecular bases of damage to the stem cell niche of respiratory acini in idiopathic interstitial pneumonias] | ||
148 | +Effects and mechanisms of pirfenidone, prednisone and acetylcysteine on pulmonary fibrosis in rat idiopathic pulmonary fibrosis models | ||
149 | +PPAR-y ligands repress TGFb-induced myofibroblast differentiation by targeting the PI3K/Akt pathway: implications for therapy of fibrosis | ||
150 | +WISP1 mediates IL-6-dependent proliferation in primary human lung fibroblasts | ||
151 | +Melatonin attenuates TGFb1-induced epithelial-mesenchymal transition in lung alveolar epithelial cells | ||
152 | +JAK2 mediates lung fibrosis, pulmonary vascular remodelling and hypertension in idiopathic pulmonary fibrosis: an experimental study | ||
153 | +Ambroxol hydrochloride in the management of idiopathic pulmonary fibrosis: Clinical trials are the need of the hour | ||
154 | +MiR-5100 targets TOB2 to drive epithelial-mesenchymal transition associated with activating smad2/3 in lung epithelial cells | ||
155 | +IL-17A deficiency mitigates bleomycin-induced complement activation during lung fibrosis | ||
156 | +Inhibitory effect of receptor for advanced glycation end products (RAGE) on the TGF-b-induced alveolar epithelial to mesenchymal transition | ||
157 | +Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) promotes lung fibroblast proliferation, survival and differentiation to myofibroblasts | ||
158 | +TGF-beta-induced EMT: mechanisms and implications for fibrotic lung disease | ||
159 | +Pleural mesothelial cell differentiation and invasion in fibrogenic lung injury | ||
160 | +Absence of Thy-1 results in TGF-b induced MMP-9 expression and confers a profibrotic phenotype to human lung fibroblasts | ||
161 | +Signalling pathways from NADPH oxidase-4 to idiopathic pulmonary fibrosis | ||
162 | +Interplay between RAGE, CD44, and focal adhesion molecules in epithelial-mesenchymal transition of alveolar epithelial cells | ||
163 | +Association between cytokine removal by polymyxin B hemoperfusion and improved pulmonary oxygenation in patients with acute exacerbation of idiopathic pulmonary fibrosis | ||
164 | +Increased production and immunohistochemical localization of transforming growth factor-beta in idiopathic pulmonary fibrosis | ||
165 | +TNF-alpha, PDGF, and TGF-beta(1) expression by primary mouse bronchiolar-alveolar epithelial and mesenchymal cells: tnf-alpha induces TGF-beta(1) | ||
166 | +Anchorage-independent colony growth of pulmonary fibroblasts derived from fibrotic human lung tissue | ||
167 | +Overexpression of squamous cell carcinoma antigen in idiopathic pulmonary fibrosis: clinicopathological correlations | ||
168 | +Intrinsic defence capacity and therapeutic potential of natriuretic peptides in pulmonary hypertension associated with lung fibrosis | ||
169 | +Microsomal prostaglandin E synthase-1 deficiency exacerbates pulmonary fibrosis induced by bleomycin in mice | ||
170 | +Antifibrotic effects of cyclosporine A on TGF-b1-treated lung fibroblasts and lungs from bleomycin-treated mice: role of hypoxia-inducible factor-1a | ||
171 | +Preventive and therapeutic effects of thymosin b4 N-terminal fragment Ac-SDKP in the bleomycin model of pulmonary fibrosis | ||
172 | +Forkhead Box F1 (FOXF1) represses cell growth, COL1 and ARPC2 expression in lung fibroblasts in vitro | ||
173 | +Nitrated fatty acids reverse pulmonary fibrosis by dedifferentiating myofibroblasts and promoting collagen uptake by alveolar macrophages | ||
174 | +Serpin B4 isoform overexpression is associated with aberrant epithelial proliferation and lung cancer in idiopathic pulmonary fibrosis | ||
175 | +Modulation of specific beta cell gene (re)expression during in vitro expansion of human pancreatic islet cells | ||
176 | +Dehydroepiandrosterone has strong antifibrotic effects and is decreased in idiopathic pulmonary fibrosis | ||
177 | +Regulation of the effects of TGF-beta 1 by activation of latent TGF-beta 1 and differential expression of TGF-beta receptors (T beta R-I and T beta R-II) in idiopathic pulmonary fibrosis | ||
178 | +Establishment of the mouse model of acute exacerbation of idiopathic pulmonary fibrosis | ||
179 | +Spiruchostatin A inhibits proliferation and differentiation of fibroblasts from patients with pulmonary fibrosis | ||
180 | +Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis | ||
181 | +Tumor necrosis factor superfamily 14 (LIGHT) controls thymic stromal lymphopoietin to drive pulmonary fibrosis | ||
182 | +High levels of IL-6 and IL-8 characterize early-on idiopathic pulmonary fibrosis acute exacerbations | ||
183 | +Defect of pro-hepatocyte growth factor activation by fibroblasts in idiopathic pulmonary fibrosis | ||
184 | +Lung infection with gamma-herpesvirus induces progressive pulmonary fibrosis in Th2-biased mice | ||
185 | +Amplified canonical transforming growth factor-b signalling<i>via</i>heat shock protein 90 in pulmonary fibrosis | ||
186 | +Pirfenidone attenuates bleomycin-induced pulmonary fibrosis in mice by regulating Nrf2/Bach1 equilibrium | ||
187 | +Cytokine gene polymorphisms and serum cytokine levels in patients with idiopathic pulmonary fibrosis | ||
188 | +Thalidomide prevents bleomycin-induced pulmonary fibrosis in mice | ||
189 | +Reduced expression of BMP3 contributes to the development of pulmonary fibrosis and predicts the unfavorable prognosis in IIP patients | ||
190 | +The antifibrotic effects and mechanisms of microRNA-26a action in idiopathic pulmonary fibrosis | ||
191 | +The K+ channel KCa3.1 as a novel target for idiopathic pulmonary fibrosis | ||
192 | +An inhibitor of NADPH oxidase-4 attenuates established pulmonary fibrosis in a rodent disease model | ||
193 | +Pleiotropic effect of the proton pump inhibitor esomeprazole leading to suppression of lung inflammation and fibrosis | ||
194 | +Activated human T lymphocytes inhibit TGFb-induced fibroblast to myofibroblast differentiation via prostaglandins D2 and E2 | ||
195 | +Peripheral depletion of NK cells and imbalance of the Treg/Th17 axis in idiopathic pulmonary fibrosis patients | ||
196 | +Bone morphogenetic protein-4 inhibitor gremlin is overexpressed in idiopathic pulmonary fibrosis | ||
197 | +Role of protease-activated receptor-2 in idiopathic pulmonary fibrosis | ||
198 | +Type V collagen induced tolerance suppresses collagen deposition, TGF-b and associated transcripts in pulmonary fibrosis | ||
199 | +Syndecan-2 is a novel target of insulin-like growth factor binding protein-3 and is over-expressed in fibrosis | ||
200 | +Extracellular superoxide dismutase has a highly specific localization in idiopathic pulmonary fibrosis/usual interstitial pneumonia | ||
201 | +Early growth response transcription factors: key mediators of fibrosis and novel targets for anti-fibrotic therapy | ||
202 | +Effects of the tumor suppressor PTEN on the pathogenesis of idiopathic pulmonary fibrosis in Chinese patients | ||
203 | +Different effects of growth factors on proliferation and matrix production of normal and fibrotic human lung fibroblasts | ||
204 | +The impact of TGF-b on lung fibrosis: from targeting to biomarkers | ||
205 | +Herpes virus infection is associated with vascular remodeling and pulmonary hypertension in idiopathic pulmonary fibrosis | ||
206 | +N-acetylcysteine inhibits TNF-alpha, sTNFR, and TGF-beta1 release by alveolar macrophages in idiopathic pulmonary fibrosis in vitro | ||
207 | +Recombinant human serum amyloid P in healthy volunteers and patients with pulmonary fibrosis | ||
208 | +Transforming growth factor beta1 induces epithelial-to-mesenchymal transition of A549 cells | ||
209 | +X-linked inhibitor of apoptosis regulates lung fibroblast resistance to Fas-mediated apoptosis | ||
210 | +Idiopathic pulmonary fibrosis: immunohistochemical analysis provides fresh insights into lung tissue remodelling with implications for novel prognostic markers | ||
211 | +Alveolar epithelial cell injury with Epstein-Barr virus upregulates TGFbeta1 expression | ||
212 | +Expression of mucosa-related integrin alphaEbeta7 on alveolar T cells in interstitial lung diseases | ||
213 | +Effects of cigarette smoke extract on A549 cells and human lung fibroblasts treated with transforming growth factor-beta1 in a coculture system | ||
214 | +Nuclear factor erythroid 2-related factor 2 nuclear translocation induces myofibroblastic dedifferentiation in idiopathic pulmonary fibrosis | ||
215 | +Peptide-mediated inhibition of mitogen-activated protein kinase-activated protein kinase-2 ameliorates bleomycin-induced pulmonary fibrosis | ||
216 | +Effect of glycosides based standardized fenugreek seed extract in bleomycin-induced pulmonary fibrosis in rats: Decisive role of Bax, Nrf2, NF-kB, Muc5ac, TNF-a and IL-1b | ||
217 | +Simvastatin inhibits growth factor expression and modulates profibrogenic markers in lung fibroblasts | ||
218 | +Activated MCTC mast cells infiltrate diseased lung areas in cystic fibrosis and idiopathic pulmonary fibrosis | ||
219 | +Type II alveolar epithelial cells and interstitial fibroblasts express connective tissue growth factor in IPF | ||
220 | +Crosstalk between TGF-b1 and complement activation augments epithelial injury in pulmonary fibrosis | ||
221 | +RhoA signaling modulates cyclin D1 expression in human lung fibroblasts; implications for idiopathic pulmonary fibrosis | ||
222 | +Titration of non-replicating adenovirus as a vector for transducing active TGF-beta1 gene expression causing inflammation and fibrogenesis in the lungs of C57BL/6 mice | ||
223 | +Age-driven developmental drift in the pathogenesis of idiopathic pulmonary fibrosis | ||
224 | +Current and novel drug therapies for idiopathic pulmonary fibrosis | ||
225 | +Regulation of transforming growth factor-b1-driven lung fibrosis by galectin-3 | ||
226 | +Reduced transcription of the Smad4 gene during pulmonary carcinogenesis in idiopathic pulmonary fibrosis | ||
227 | +Curcumin inhibits fibrosis-related effects in IPF fibroblasts and in mice following bleomycin-induced lung injury | ||
228 | +Targeting sphingosine kinase 1 attenuates bleomycin-induced pulmonary fibrosis | ||
229 | +Data on CUX1 isoforms in idiopathic pulmonary fibrosis lung and systemic sclerosis skin tissue sections |
results/Partition_4/cluster2_tagged.txt
0 → 100644
1 | +Assessment of the effect of potential antifibrotic compounds on total and aVb6 integrin-mediated TGF-b <v>activation.</v> | ||
2 | +Immunoglobulin A in serum: an old acquaintance as a new prognostic biomarker in <d>idiopathic pulmonary fibrosis</d> | ||
3 | +[Pulmonary fibrosis--a therapeutic dilemma?] | ||
4 | +<g>Syndecan-2</g> exerts antifibrotic effects by promoting <g>caveolin-1</g>-mediated transforming growth factor-b receptor I internalization and inhibiting transforming growth factor-b1 signaling | ||
5 | +Modulation of specific beta cell gene (re)expression during in vitro expansion of human pancreatic islet cells | ||
6 | +Amplification of <g>TGFb</g> | ||
7 | +[<d>Idiopathic pulmonary fibrosis</d> and <d>lung cancer</d>] | ||
8 | +<g>Periostin</g> promotes <d>fibrosis</d> and predicts progression in patients with <d>idiopathic pulmonary fibrosis</d> | ||
9 | +<g>CCN5</g> <v>overexpression </v>inhibits profibrotic phenotypes via the <g>PI3K</g>/Akt signaling pathway in lung fibroblasts isolated from patients with <d>idiopathic pulmonary fibrosis</d> and in an in vivo model of <d>lung fibrosis</d> | ||
10 | +<g>Extracellular superoxide dismutase</g> has a highly specific <l>localization </l>in <d>idiopathic pulmonary fibrosis</d>/<d>usual interstitial pneumonia</d> | ||
11 | +Overexpression of <d>squamous cell carcinoma</d> antigen in <d>idiopathic pulmonary fibrosis</d>: clinicopathological correlations | ||
12 | +An ex vivo model to induce early <d>fibrosis</d>-like changes in human precision-cut lung slices | ||
13 | +The role of halofuginone in fibrosis: more to be explored? Fibrosis, which can be defined as an abnormal or excessive accumulation of extracellular matrix (ECM), particularly fibrillar collagens, is a key driver of progressive organ dysfunction in many inflammatory and metabolic diseases, including idiopathic pulmonary fibrosis (IPF), cirrhosis, nephropathy, and oral submucous fibrosis (OSF) | ||
14 | +Genomewide RNA expression profiling in lung identifies distinct signatures in <d>idiopathic pulmonary arterial hypertension</d> and <d>secondary pulmonary hypertension</d> | ||
15 | +Establishment of the mouse model of acute exacerbation of <d>idiopathic pulmonary fibrosis</d> | ||
16 | +Dehydroepiandrosterone has strong antifibrotic effects and is decreased in <d>idiopathic pulmonary fibrosis</d> | ||
17 | +Metformin <d>attenuates lung fibrosis</d> development via <g>NOX4</g> <u>suppression.</u> | ||
18 | +<g>Plasminogen activator inhibitor 1</g>, fibroblast apoptosis resistance, and aging-related susceptibility to lung <d>fibrosis</d> | ||
19 | +Cytokine gene polymorphisms and serum cytokine levels in patients with <d>idiopathic pulmonary fibrosis</d> | ||
20 | +Determining the True Selectivity Profile of av Integrin Ligands Using Radioligand Binding: Applying an Old Solution to a New Problem | ||
21 | +Tumor <d>necrosis</d> factor superfamily 14 (<d>LIGHT</d>) controls <g>thymic stromal lymphopoietin</g> to drive <d>pulmonary fibrosis</d> | ||
22 | +<g>Pigment epithelium-derived factor</g> in <d>idiopathic pulmonary fibrosis</d>: a role in aberrant angiogenesis | ||
23 | +Peptide-mediated inhibition of <g>mitogen-activated protein kinase-activated protein kinase-2</g> ameliorates bleomycin-induced <d>pulmonary fibrosis</d> | ||
24 | +Role of integrin-<v>mediated </v><g>TGFbeta</g> <v>activation </v>in the pathogenesis of <d>pulmonary fibrosis</d> | ||
25 | +Novel pharmacological approaches to manage <d>interstitial lung fibrosis</d> in the twenty-first century | ||
26 | +Lipoxin A4 Attenuates Constitutive and <g>TGF-b1</g>-Dependent Profibrotic Activity in Human Lung Myofibroblasts | ||
27 | +<g>Hsp90</g> <r>regulation </r>of fibroblast activation in <d>pulmonary fibrosis</d> | ||
28 | +<g>Glucagon like peptide-1</g> attenuates bleomycin-induced <d>pulmonary fibrosis</d>, involving the <u>inactivation </u>of NF-kB in mice | ||
29 | +<g>MiR-185</g>/<g>AKT</g> and <g>miR-29a</g>/collagen 1a pathways are <v>activated </v>in <d>IPF</d> | ||
30 | +<g>Wilms' tumor 1</g> (<g>Wt1</g>) regulates pleural mesothelial cell plasticity and transition into myofibroblasts in <d>idiopathic pulmonary fibrosis</d> | ||
31 | +<g>miR-26a</g> suppresses EMT by disrupting the <g>Lin28B</g>/<g>let-7d</g> axis: potential cross-talks among miRNAs in <d>IPF</d> | ||
32 | +Kinase <u>inhibitors </u>fail to induce mesenchymal-epithelial transition in fibroblasts from fibrotic lung tissue | ||
33 | +<g>Transgelin</g> is a direct target of <g>TGF-beta</g>/<g>Smad3</g>-dependent epithelial cell <d>migration in lung fibrosis</d> | ||
34 | +The mannose-6-phosphate analogue, PXS64, inhibits <d>fibrosis</d> via <g>TGF-b1</g> pathway in human lung fibroblasts | ||
35 | +<u>Reduced </u><e>expression </e>of <g>BMP3</g> contributes to the development of <d>pulmonary fibrosis</d> and predicts the unfavorable prognosis in IIP patients | ||
36 | +Role of <g>CD248</g> as a potential severity marker in <d>idiopathic pulmonary fibrosis</d> | ||
37 | +Early growth response transcription factors: key mediators of <d>fibrosis</d> and novel targets for anti-fibrotic therapy | ||
38 | +<g>Toll-like receptor 4</g> activation attenuates profibrotic response in control lung fibroblasts but not in fibroblasts from patients with <d>IPF</d> | ||
39 | +<g>BAX inhibitor-1</g>-associated <g>V-ATPase</g> glycosylation <v>enhances </v>collagen degradation in <d>pulmonary fibrosis</d> | ||
40 | +Sphingosine-1-phosphate lyase is an endogenous suppressor of <d>pulmonary fibrosis</d>: role of <g>S1P</g> signalling and autophagy | ||
41 | +<g>Nuclear factor erythroid 2-related factor 2</g> nuclear translocation induces <d>myofibroblastic dedifferentiation</d> in <d>idiopathic pulmonary fibrosis</d> | ||
42 | +A translational preclinical model of <d>interstitial pulmonary fibrosis</d> and <d>pulmonary hypertension</d>: mechanistic pathways driving disease pathophysiology | ||
43 | +Cytokine gene polymorphisms and BALF cytokine levels in <d>interstitial lung diseases</d> | ||
44 | +<g>PI3K</g> p110y <v>overexpression </v>in <d>idiopathic pulmonary fibrosis lung</d> tissue and fibroblast cells: in vitro effects of its inhibition | ||
45 | +Low-dose paclitaxel ameliorates <d>pulmonary fibrosis</d> by suppressing <g>TGF-b1</g>/<g>Smad3</g> pathway via <g>miR-140</g> upregulation | ||
46 | +MicroRNAs in <d>idiopathic pulmonary fibrosis</d> | ||
47 | +Two-Way Conversion between Lipogenic and Myogenic Fibroblastic Phenotypes Marks the Progression and Resolution of Lung <d>Fibrosis</d> | ||
48 | +Membrane type-matrix metalloproteinases in <d>idiopathic pulmonary fibrosis</d> | ||
49 | +<g>BARD1</g> mediates <g>TGF-b</g> signaling in <d>pulmonary fibrosis</d> | ||
50 | +Increased <d>alveolar</d> soluble <g>annexin V</g> promotes <d>lung inflammation</d> and <d>fibrosis</d> | ||
51 | +Autophagy in <d>idiopathic pulmonary fibrosis</d> | ||
52 | +<g>TGF-b1</g> <v>induces </v><g>Fstl1</g> via the <g>Smad3</g>-<g>c-Jun</g> pathway in lung fibroblasts | ||
53 | +MS80, a novel sulfated oligosaccharide, inhibits <d>pulmonary fibrosis</d> by targeting <g>TGF-beta1</g> both in vitro and in vivo | ||
54 | +Protective role of gambogic acid in experimental <d>pulmonary fibrosis</d> in vitro and in vivo | ||
55 | +Sorafenib ameliorates bleomycin-induced <d>pulmonary fibrosis</d>: potential roles in the inhibition of epithelial-mesenchymal transition and fibroblast activation | ||
56 | +[Different cytokine profiles in <d>usual interstitial pneumonia</d> and <d>nonspecific interstitial pneumonia</d>] | ||
57 | +Simvastatin attenuates <g>TGF-b1</g>-induced epithelial-mesenchymal transition in human alveolar epithelial cells | ||
58 | +Expression of <g>suppressor of cytokine signaling 1</g> in the peripheral blood of patients with <d>idiopathic pulmonary fibrosis</d> | ||
59 | +Profibrotic role of <g>miR-154</g> in <d>pulmonary fibrosis</d> | ||
60 | +Anchorage-independent colony growth of pulmonary fibroblasts derived from fibrotic human lung tissue | ||
61 | +<g>Aortic carboxypeptidase-like protein</g> (<g>ACLP</g>) enhances lung myofibroblast differentiation through transforming growth factor b receptor-dependent and -independent pathways | ||
62 | +The latent form of <g>TGFbeta(1)</g> is induced by <g>TNFalpha</g> through an <g>ERK</g> specific pathway and is <v>activated </v>by asbestos-derived reactive oxygen species in vitro and in vivo | ||
63 | +Differential effects of human neutrophil peptide-1 on growth factor and <g>interleukin-8</g> production by human lung fibroblasts and epithelial cells | ||
64 | +Effects of particulate matter from straw burning on <d>lung fibrosis</d> in mice | ||
65 | +<g>miR -221</g> targets <g>HMGA2</g> to inhibit bleomycin -induced <d>pulmonary fibrosis</d> by regulating <g>TGF -b1</g>/<g>Smad3</g>-induced EMT | ||
66 | +<g>EZH2</g> enhances the differentiation of fibroblasts into myofibroblasts in <d>idiopathic pulmonary fibrosis</d> | ||
67 | +Tubastatin ameliorates <d>pulmonary fibrosis</d> by targeting the TGFb-PI3K-<g>Akt</g> pathway | ||
68 | +Lung fibrotic <g>tenascin-C</g> <v>upregulation </v>is associated with other extracellular matrix proteins and <v>induced </v>by TGFb1 | ||
69 | +Tannic acid attenuates TGF-b1-induced epithelial-to-mesenchymal transition by effectively intervening TGF-b signaling in lung epithelial cells | ||
70 | +Abrogation of <g>TGF-beta1</g>-induced fibroblast-myofibroblast differentiation by <g>histone deacetylase</g> <u>inhibition.</u> <d>Idiopathic pulmonary fibrosis</d> (<d>IPF</d>) is a devastating disease with no known effective pharmacological therapy | ||
71 | +<g>AKT2</g> | ||
72 | +Regulation of myofibroblast differentiation by <g>miR-424</g> during epithelial-to-mesenchymal transition | ||
73 | +MicroRNA-101 attenuates pulmonary fibrosis by inhibiting fibroblast proliferation and activation | ||
74 | +<g>Extracellular Matrix Metalloproteinase Inducer</g> (<g>EMMPRIN</g>) promotes lung fibroblast proliferation, survival and differentiation to myofibroblasts | ||
75 | +<g>TGF-b</g> activation and lung <d>fibrosis</d> | ||
76 | +<v>Increased </v>interleukin-1 receptor antagonist in <d>idiopathic pulmonary fibrosis</d> | ||
77 | +<g>TIAM1</g> inhibits lung fibroblast differentiation in <d>pulmonary fibrosis</d> | ||
78 | +Targeting <g>sphingosine kinase 1</g> attenuates bleomycin-induced <d>pulmonary fibrosis</d> | ||
79 | +Re-evaluation of fibrogenic cytokines in <d>lung fibrosis</d> | ||
80 | +Targeting genes for treatment in <d>idiopathic pulmonary fibrosis</d>: challenges and opportunities, promises and pitfalls | ||
81 | +Defect of pro-<g>hepatocyte growth factor</g> activation by fibroblasts in <d>idiopathic pulmonary fibrosis</d> | ||
82 | +Epithelial Cell Mitochondrial Dysfunction and <g>PINK1</g> | ||
83 | +<l>Release </l>of biologically active <g>TGF-beta1</g> by alveolar epithelial cells results in <d>pulmonary fibrosis</d> | ||
84 | +IPF lung fibroblasts have a senescent phenotype | ||
85 | +Autophagy and <d>inflammation</d> in chronic <d>respiratory disease</d> | ||
86 | +The profibrotic cytokine <g>transforming growth factor-b1</g> increases endothelial progenitor cell angiogenic properties | ||
87 | +Regulation of transforming growth factor-b1-driven lung <d>fibrosis</d> by <g>galectin-3</g> | ||
88 | +Epigenetic <r>Regulation </r>of <g>Caveolin-1</g> | ||
89 | +Expression of <g>150-kDa oxygen-regulated protein</g> (<g>ORP150</g>) stimulates bleomycin-induced <d>pulmonary fibrosis and dysfunction</d> in mice | ||
90 | +Role of endoplasmic reticulum stress in age-related susceptibility to lung <d>fibrosis</d> | ||
91 | +<d>Pulmonary fibrosis</d>: pathogenesis, etiology and regulation | ||
92 | +Activated MCTC mast cells infiltrate diseased lung areas in <d>cystic fibrosis</d> and <d>idiopathic pulmonary fibrosis</d> | ||
93 | +<g>PPAR</g>-y ligands repress <g>TGFb</g>-induced myofibroblast differentiation by targeting the <g>PI3K</g>/<g>Akt</g> pathway: implications for therapy of <d>fibrosis</d> | ||
94 | +De-ubiquitinating enzyme, <g>USP11</g>, promotes <g>transforming growth factor b-1</g> signaling through stabilization of transforming growth factor b receptor II | ||
95 | +The antifibrotic effects and mechanisms of microRNA-26a action in <d>idiopathic pulmonary fibrosis</d> | ||
96 | +Phosphatase and tensin homolog deleted on chromosome 10 contributes to phenotype transformation of fibroblasts in <d>idiopathic pulmonary fibrosis</d> via multiple pathways | ||
97 | +Lower expression of platelet derived growth factor is associated with better overall survival rate of patients with idiopathic nonspecific interstitial pneumonia | ||
98 | +Investigation of bone marrow mesenchymal stem cells (BM MSCs) involvement in <d>Idiopathic Pulmonary Fibrosis</d> (<d>IPF</d>) | ||
99 | +<g>Neutrophil elastase</g> promotes myofibroblast <d>differentiation in lung fibrosis</d> | ||
100 | +<g>MAP3K19</g> | ||
101 | +Effect of Renshen Pingfei Decoction, a traditional Chinese prescription, on <d>IPF</d> <v>induced </v>by Bleomycin in rats and <r>regulation </r>of <g>TGF-b1</g>/<g>Smad3</g> | ||
102 | +Macrophage <g>Bone Morphogenic Protein Receptor 2</g> (<g>BMPR2</g>) <u>depletion </u>in <d>Idiopathic Pulmonary Fibrosis</d> (<d>IPF</d>) and Group III Pulmonary <d>Hypertension</d> | ||
103 | +<g>Cartilage oligomeric matrix protein</g> in <d>idiopathic pulmonary fibrosis</d> | ||
104 | +Negative regulation of myofibroblast differentiation by <g>PTEN</g> (Phosphatase and Tensin Homolog Deleted on chromosome 10) | ||
105 | +Alveolar epithelial cells express mesenchymal proteins in patients with <d>idiopathic pulmonary fibrosis</d> | ||
106 | +<g>SPARC</g> suppresses apoptosis of <d>idiopathic pulmonary fibrosis</d> fibroblasts through constitutive <v>activation </v>of <g>beta-catenin</g> | ||
107 | +Resveratrol-Mediated Repression and Reversion of Prostatic Myofibroblast Phenoconversion | ||
108 | +[The potential role of cytokines expression in <d>idiopathic pulmonary fibrosis</d>] | ||
109 | +Effect of an immunotoxin to <g>folate receptor beta</g> on bleomycin-induced <d>experimental pulmonary fibrosis</d> | ||
110 | +<v>Elevated </v><e>expression </e>of <g>NEU1</g> sialidase in <d>idiopathic pulmonary fibrosis</d> <v>provokes </v>pulmonary collagen deposition, <d>lymphocytosis</d>, and <d>fibrosis</d> | ||
111 | +N-acetylcysteine inhibits alveolar epithelial-mesenchymal transition | ||
112 | +<g>CUX1</g>/Wnt signaling regulates epithelial mesenchymal transition in EBV infected epithelial cells | ||
113 | +Lactic acid is elevated in <d>idiopathic pulmonary fibrosis</d> and induces myofibroblast differentiation via pH-dependent activation of transforming growth factor-b | ||
114 | +Epithelial cell alpha3beta1 integrin links <g>beta-catenin</g> and Smad signaling to promote myofibroblast formation and <d>pulmonary fibrosis</d> | ||
115 | +EMT and <d>interstitial lung disease</d>: a mysterious relationship | ||
116 | +Pirfenidone exerts antifibrotic effects through <u>inhibition </u>of GLI transcription factors | ||
117 | +<g>STAT3</g>-mediated signaling dysregulates lung fibroblast-myofibroblast activation and differentiation in UIP/IPF | ||
118 | +Epithelial stem cell exhaustion in the pathogenesis of <d>idiopathic pulmonary fibrosis</d> | ||
119 | +Berberine attenuates bleomycin induced <d>pulmonary toxicity</d> and <d>fibrosis</d> via <u>suppressing </u><g>NF-kB</g> dependant <g>TGF-b</g> <v>activation:</v> a biphasic experimental study | ||
120 | +<g>N-acetyl-L-cysteine</g> inhibits <g>TGF-beta1</g>-induced profibrotic responses in fibroblasts | ||
121 | +Interleukin-17 induces human alveolar epithelial to mesenchymal cell transition via the <g>TGF-b1</g> <v>mediated </v><g>Smad2/3</g> and <g>ERK1/2</g> <v>activation.</v> <d>Idiopathic pulmonary fibrosis</d> (<d>IPF</d>) is a chronic and usually progressive <d>lung disease</d> and the epithelial-mesenchymal transition (EMT) may play an important role in the pathogenesis of <d>pulmonary fibrosis</d> | ||
122 | +<g>TGF-beta1</g> induces human alveolar epithelial to mesenchymal cell transition (EMT) | ||
123 | +Thalidomide prevents bleomycin-induced <d>pulmonary fibrosis</d> in mice | ||
124 | +Intratracheal bleomycin causes airway remodeling and airflow obstruction in mice | ||
125 | +Significance of <v>elevated </v>procollagen-III-peptide and <g>transforming growth factor-beta</g> levels of bronchoalveolar lavage fluids from <d>idiopathic pulmonary fibrosis</d> patients | ||
126 | +<g>MiR-338</g>* targeting <g>smoothened</g> to inhibit <d>pulmonary fibrosis</d> by epithelial-mesenchymal transition | ||
127 | +Proteasomal regulation of <d>pulmonary fibrosis</d> | ||
128 | +Epithelium-specific deletion of <g>TGF-b</g> receptor type II protects mice from bleomycin-induced <d>pulmonary fibrosis</d> | ||
129 | +<g>Renin</g> is an angiotensin-independent profibrotic mediator: role in <d>pulmonary fibrosis</d> | ||
130 | +Role for alpha3 integrin in EMT and <d>pulmonary fibrosis</d> | ||
131 | +Beyond <g>TGFb</g> - Novel ways to target airway and parenchymal <d>fibrosis</d> | ||
132 | +<g>Lysocardiolipin acyltransferase</g> regulates <g>TGF-b</g> mediated lung fibroblast differentiation | ||
133 | +<g>CXCL9</g> | ||
134 | +Differing Expression of Cytokines and <d>Tumor</d> | ||
135 | +<g>MiR-5100</g> targets <g>TOB2</g> to drive epithelial-mesenchymal transition associated with <v>activating </v><g>smad2/3</g> in lung epithelial cells | ||
136 | +The impact of <g>TGF-b</g> on lung <d>fibrosis</d>: from targeting to biomarkers | ||
137 | +Mast cell chymase: an indispensable instrument in the pathological symphony of <d>idiopathic pulmonary fibrosis</d>? <d>Idiopathic pulmonary fibrosis</d> (<d>IPF</d>) is a chronic, progressive and fatal <d>lung disease</d> with no known etiology and treatment options | ||
138 | +Normal Human Lung Epithelial Cells Inhibit Transforming Growth Factor-b Induced Myofibroblast Differentiation via Prostaglandin E2 | ||
139 | +Carbon monoxide-bound hemoglobin-vesicles for the treatment of bleomycin-induced <d>pulmonary fibrosis</d> | ||
140 | +miR-18a-5p <u>Inhibits </u>Sub-pleural Pulmonary Fibrosis by Targeting <g>TGF-b</g> | ||
141 | +Tissue inhibitor of metalloproteinase-3 is up-regulated by <g>transforming growth factor-beta1</g> in vitro and expressed in fibroblastic foci in vivo in <d>idiopathic pulmonary fibrosis</d> | ||
142 | +Increased Galectin-9 Concentration and Number of CD4+Foxp3high+Cells in Bronchoalveolar Lavage Fluid of Patients with <d>Cryptogenic Organizing Pneumonia</d> | ||
143 | +Transforming growth factor-b <u>inhibits </u>IQ motif containing guanosine triphosphatase <v>activating </v>protein 1 <e>expression </e>in lung fibroblasts via the nuclear factor-kB signaling pathway | ||
144 | +<g>Yin yang 1</g> is a novel regulator of <d>pulmonary fibrosis</d> | ||
145 | +Role of <d>von Hippel-Lindau</d> protein in fibroblast proliferation and <d>fibrosis</d> | ||
146 | +<g>X-linked inhibitor of apoptosis</g> regulates lung fibroblast resistance to Fas-mediated apoptosis | ||
147 | +<d>Idiopathic pulmonary fibrosis</d>: pathobiology of novel approaches to treatment | ||
148 | +Simvastatin inhibits growth factor expression and modulates profibrogenic markers in lung fibroblasts | ||
149 | +MicroRNA regulatory networks in <d>idiopathic pulmonary fibrosis</d> | ||
150 | +Fibroblastic foci, covered with <d>alveolar epithelia</d> exhibiting <d>epithelial-mesenchymal transition</d>, destroy <d>alveolar septa</d> by disrupting blood flow in <d>idiopathic pulmonary fibrosis</d> | ||
151 | +<e>Overproduction </e>of collagen and <u>diminished </u><g>SOCS1</g> <e>expression </e>are causally linked in fibroblasts from <d>idiopathic pulmonary fibrosis</d> | ||
152 | +<r>Regulation </r>of 26S Proteasome Activity in <d>Pulmonary Fibrosis</d> | ||
153 | +Therapeutic targets in fibrotic pathways | ||
154 | +<d>Lung infection</d> with gamma-herpesvirus induces progressive <d>pulmonary fibrosis</d> in Th2-biased mice | ||
155 | +Mode of action of nintedanib in the treatment of <d>idiopathic pulmonary fibrosis</d> | ||
156 | +<g>Semaphorin 7a</g>+ regulatory T cells are associated with progressive <d>idiopathic pulmonary fibrosis</d> and are implicated in transforming growth factor-b1-induced <d>pulmonary fibrosis</d> | ||
157 | +Increased expression of 5-hydroxytryptamine2A/B receptors in <d>idiopathic pulmonary fibrosis</d>: a rationale for therapeutic intervention | ||
158 | +<v>Increased </v>deposition of chondroitin/dermatan sulfate glycosaminoglycan and <v>upregulation </v>of b1,3-glucuronosyltransferase I in <d>pulmonary fibrosis</d> | ||
159 | +Pathogenesis pathways of <d>idiopathic pulmonary fibrosis</d> in bleomycin-induced <d>lung injury</d> model in mice | ||
160 | +Latent cytomegalovirus infection exacerbates experimental <d>pulmonary fibrosis</d> by <v>activating </v><g>TGF-b1</g> | ||
161 | +<r>Effects </r>of antifibrotic agents on <g>TGF-beta1</g>, <g>CTGF</g> and <g>IFN-gamma</g> <e>expression </e>in patients with <d>idiopathic pulmonary fibrosis</d> | ||
162 | +<g>Microsomal prostaglandin E synthase-1</g> <u>deficiency </u>exacerbates <d>pulmonary fibrosis</d> induced by bleomycin in mice | ||
163 | +Effects and mechanisms of pirfenidone, prednisone and acetylcysteine on <d>pulmonary fibrosis</d> in rat <d>idiopathic pulmonary fibrosis</d> models | ||
164 | +Accelerated epithelial cell senescence in <d>IPF</d> and the inhibitory role of <g>SIRT6</g> in <g>TGF-b</g>-induced senescence of human bronchial epithelial cells | ||
165 | +<g>Transforming growth factor-beta1</g> in <d>sarcoidosis</d> | ||
166 | +<g>TGF-b1</g> induces <g>tissue factor</g> expression in human lung fibroblasts in a <g>PI3K</g>/<g>JNK</g>/<g>Akt</g>-dependent and <g>AP-1</g>-dependent manner | ||
167 | +Epithelial-mesenchymal transition in chronic <d>hypersensitivity pneumonitis</d> | ||
168 | +Uncoupling of the profibrotic and hemostatic effects of <g>thrombin</g> in <d>lung fibrosis</d> | ||
169 | +Molecular targets in <d>pulmonary fibrosis</d>: the myofibroblast in focus | ||
170 | +Immunomodulation by mesenchymal stem cells in treating human <d>autoimmune disease-associated lung fibrosis</d> | ||
171 | +<u>Reduced </u>transcription of the <g>Smad4</g> gene during <d>pulmonary carcinogenesis</d> in <d>idiopathic pulmonary fibrosis</d> | ||
172 | +Curcumin inhibits <d>fibrosis</d>-related effects in <d>IPF</d> fibroblasts and in mice following bleomycin-induced <d>lung injury</d> | ||
173 | +<g>NADPH oxidase-4</g> mediates myofibroblast activation and fibrogenic responses to <d>lung injury</d> | ||
174 | +Anti-fibrotic Role of aB-crystallin Inhibition in Pleural and Subpleural <d>Fibrosis</d> | ||
175 | +Pleiotropic effect of the proton pump inhibitor esomeprazole leading to suppression of <d>lung inflammation</d> and <d>fibrosis</d> | ||
176 | +Reviews and prospectives of signaling pathway analysis in <d>idiopathic pulmonary fibrosis</d> | ||
177 | +Roles of p38 MAPK and <g>JNK</g> in <g>TGF-b1</g>-induced human alveolar epithelial to mesenchymal transition | ||
178 | +Predisposition for disrepair in the aged lung | ||
179 | +N-acetylcysteine <u>downregulation </u>of <g>lysyl oxidase</g> activity alleviating bleomycin-induced <d>pulmonary fibrosis</d> in rats | ||
180 | +Evaluation of permeability alteration and epithelial-mesenchymal transition induced by <g>transforming growth factor-b1</g> in A549, NCI-H441, and Calu-3 cells: Development of an in vitro model of respiratory epithelial cells in <d>idiopathic pulmonary fibrosis</d> | ||
181 | +Epithelial contribution to the pro-fibrotic stiff microenvironment and myofibroblast population in lung <d>fibrosis</d> | ||
182 | +Interactions between <g>b-catenin</g> and <g>transforming growth factor-b</g> signaling pathways mediate epithelial-mesenchymal transition and are dependent on the transcriptional co-activator cAMP-response element-binding protein (<g>CREB)-binding protein</g> (<g>CBP</g>) | ||
183 | +<g>Syndecan-2</g> is a novel target of <g>insulin-like growth factor binding protein-3</g> and is <v>over-expressed </v>in <d>fibrosis</d> | ||
184 | +Membrane-anchored <g>Serine Protease</g> <g>Matriptase</g> | ||
185 | +Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with <d>idiopathic pulmonary fibrosis</d> | ||
186 | +The small heat-shock protein aB-crystallin is essential for the nuclear <l>localization </l>of <g>Smad4</g>: impact on <d>pulmonary fibrosis</d> | ||
187 | +Medical treatment for <d>pulmonary fibrosis</d>: current trends, concepts, and prospects | ||
188 | +Ambroxol hydrochloride in the management of <d>idiopathic pulmonary fibrosis</d>: Clinical trials are the need of the hour | ||
189 | +Combined <u>inhibition </u>of <g>TGFb</g> and PDGF signaling attenuates radiation-induced <d>pulmonary fibrosis</d> | ||
190 | +Diagnostic Values For Club Cell Secretory Protein (<g>CC16</g>) in Serum of Patients of Combined Pulmonary Fibrosis and Emphysema | ||
191 | +<e>Effects </e>of <g>thymosin b4</g> and its N-terminal fragment Ac-SDKP on <g>TGF-b</g>-treated human lung fibroblasts and in the mouse model of bleomycin-induced <d>lung fibrosis</d> | ||
192 | +An <u>inhibitor </u>of NADPH oxidase-4 attenuates established <d>pulmonary fibrosis</d> in a <d>rodent disease</d> model | ||
193 | +<u>Inhibition </u>of <g>PI3K</g> prevents the proliferation and differentiation of human lung fibroblasts into myofibroblasts: the role of class I P110 isoforms | ||
194 | +<r>Effects </r>of doxycycline on <e>production </e>of growth factors and matrix metalloproteinases in <d>pulmonary fibrosis</d> | ||
195 | +Human placental mesenchymal stem cells of fetal origins-alleviated <d>inflammation</d> and <d>fibrosis</d> by attenuating <g>MyD88</g> signaling in bleomycin-induced <d>pulmonary fibrosis</d> mice | ||
196 | +Roles for <g>insulin-like growth factor I</g> and <g>transforming growth factor-beta</g> in <d>fibrotic lung disease</d> | ||
197 | +Role of <g>caveolin-1</g> in <d>fibrotic diseases</d> | ||
198 | +Olodaterol shows anti-fibrotic efficacy in in vitro and in vivo models of <d>pulmonary fibrosis</d> | ||
199 | +Novel Mechanisms for the Antifibrotic Action of Nintedanib | ||
200 | +[The morphology and molecular bases of damage to the stem cell niche of respiratory acini in <d>idiopathic interstitial pneumonias</d>] | ||
201 | +Pirfenidone inhibits myofibroblast differentiation and <d>lung fibrosis</d> development during insufficient mitophagy | ||
202 | +Insulin-like growth factor binding proteins 3 and 5 are <v>overexpressed </v>in <d>idiopathic pulmonary fibrosis</d> and contribute to extracellular matrix deposition | ||
203 | +<g>VEGF</g> ameliorates pulmonary <d>hypertension</d> through inhibition of endothelial apoptosis in experimental lung <d>fibrosis</d> in rats | ||
204 | +Rapamycin regulates connective tissue growth factor expression of lung epithelial cells via phosphoinositide 3-kinase | ||
205 | +Differential <e>expression </e>of alpha E beta 7 integrins on bronchoalveolar lavage T lymphocyte subsets: <r>regulation </r>by alpha 4 beta 1-integrin crosslinking and <g>TGF-beta</g> | ||
206 | +<v>Increased </v><g>TGF-beta1</g> in the lungs of asbestos-exposed rats and mice: <u>reduced </u><e>expression </e>in <g>TNF-alpha</g> receptor knockout mice | ||
207 | +Fibrotic myofibroblasts manifest genome-wide derangements of translational control | ||
208 | +<r>Regulation </r>of <g>TGF-b</g> storage and activation in the human <d>idiopathic pulmonary fibrosis lung</d> | ||
209 | +<d>Microsatellite instability</d> in transforming growth factor-beta 1 type II receptor gene in alveolar lining epithelial cells of <d>idiopathic pulmonary fibrosis</d> | ||
210 | +miR-92a <r>regulates </r><g>TGF-b1</g>-<v>induced </v><g>WISP1</g> <e>expression </e>in <d>pulmonary fibrosis</d> | ||
211 | +The role of cytokines in human <d>lung fibrosis</d> | ||
212 | +Significant involvement of <g>CCL2</g> (<g>MCP-1</g>) in inflammatory disorders of the lung | ||
213 | +<g>TGF-beta</g>-induced EMT: mechanisms and implications for <d>fibrotic lung disease</d> | ||
214 | +Pirfenidone <u>inhibits </u><g>TGF-b1</g>-induced <e>over-expression </e>of collagen type I and <d>heat shock</d> protein 47 in A549 cells | ||
215 | +The potential <r>role </r>of PDGF, <g>IGF-1</g>, <g>TGF-beta</g> <e>expression </e>in <d>idiopathic pulmonary fibrosis</d> | ||
216 | +<g>Connective tissue growth factor</g> <e>expression </e>and <v>induction </v>by <g>transforming growth factor-beta</g> is <u>abrogated </u>by simvastatin via a Rho signaling mechanism | ||
217 | +MOXIBUSTION HAS A POSITIVE EFFECT ON PULMONARY FIBROSIS: AN ALTERNATIVE APPROACH | ||
218 | +Sustained Activation of <g>Toll-Like Receptor 9</g> | ||
219 | +Molecular pathogenesis of <d>interstitial pneumonitis</d> with <g>TNF-alpha</g> transgenic mice | ||
220 | +MiR-541-5p <r>regulates </r><d>lung fibrosis</d> by <r>targeting </r>cyclic nucleotide phosphodiesterase 1A | ||
221 | +The pathogenesis of <d>idiopathic pulmonary fibrosis</d> | ||
222 | +Participation of miR-200 in <d>pulmonary fibrosis</d> | ||
223 | +<d>Autoimmunity</d> to Vimentin Is Associated with Outcomes of Patients with <d>Idiopathic Pulmonary Fibrosis</d> | ||
224 | +<g>TGF-beta 1</g>, but not <g>TGF-beta 2</g> or <g>TGF-beta 3</g>, is differentially present in epithelial cells of advanced <d>pulmonary fibrosis</d>: an immunohistochemical study | ||
225 | +<g>Gremlin</g>-mediated decrease in bone morphogenetic protein signaling promotes <d>pulmonary fibrosis</d> | ||
226 | +<v>Increased </v><e>expression </e>of <g>protease nexin-1</g> in fibroblasts during <d>idiopathic pulmonary fibrosis</d> <r>regulates </r><g>thrombin</g> activity and <g>fibronectin</g> <e>expression.</e> <d>Idiopathic pulmonary fibrosis</d> (<d>IPF</d>) is a chronic <d>diffuse lung disease</d> characterized by an accumulation of excess fibrous material in the lung | ||
227 | +Hyper-responsiveness of <d>IPF</d>/<d>UIP</d> fibroblasts: interplay between <g>TGFbeta1</g>, <g>IL-13</g> and <g>CCL2</g> | ||
228 | +<d>Idiopathic pulmonary fibrosis</d> in relation to gene polymorphisms of <g>transforming growth factor-b1</g> and <g>plasminogen activator inhibitor 1</g> | ||
229 | +<g>TNF-alpha</g>, PDGF, and <g>TGF-beta(1)</g> <e>expression </e>by primary mouse bronchiolar-alveolar epithelial and mesenchymal cells: <g>tnf-alpha</g> induces <g>TGF-beta(1)</g> |
results/Partition_4/cluster3.txt
0 → 100644
1 | +Diagnostic Values For Club Cell Secretory Protein (CC16) in Serum of Patients of Combined Pulmonary Fibrosis and Emphysema | ||
2 | +Epigenetic Regulation of Caveolin-1 Gene Expression in Lung Fibroblasts | ||
3 | +Targeting of Discoidin Domain Receptor 2 (DDR2) Prevents Myofibroblast Activation and Neovessel Formation During Pulmonary Fibrosis | ||
4 | +Epithelial Cell Mitochondrial Dysfunction and PINK1 Are Induced by Transforming Growth Factor- Beta1 in Pulmonary Fibrosis | ||
5 | +The lncRNA H19 Mediates Pulmonary Fibrosis by Regulating the miR-196a/COL1A1 Axis | ||
6 | +Inhibition of PHGDH Attenuates Bleomycin-induced Pulmonary Fibrosis | ||
7 | +Transforming Growth Factor Beta 1 Activation, Storage, and Signaling Pathways in Idiopathic Pulmonary Fibrosis in Dogs | ||
8 | +Developmental Reprogramming in Mesenchymal Stromal Cells of Human Subjects with Idiopathic Pulmonary Fibrosis | ||
9 | +Autoimmunity to Vimentin Is Associated with Outcomes of Patients with Idiopathic Pulmonary Fibrosis | ||
10 | +Amplification of TGFb Induced ITGB6 Gene Transcription May Promote Pulmonary Fibrosis | ||
11 | +Macrophage Bone Morphogenic Protein Receptor 2 (BMPR2) depletion in Idiopathic Pulmonary Fibrosis (IPF) and Group III Pulmonary Hypertension | ||
12 | +Resveratrol-Mediated Repression and Reversion of Prostatic Myofibroblast Phenoconversion | ||
13 | +Sunitinib, a Small-Molecule Kinase Inhibitor, Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice | ||
14 | +Differing Expression of Cytokines and Tumor Markers in Combined Pulmonary Fibrosis and Emphysema Compared to Emphysema and Pulmonary Fibrosis | ||
15 | +miR-18a-5p Inhibits Sub-pleural Pulmonary Fibrosis by Targeting TGF-b Receptor II | ||
16 | +Hyper-responsiveness of IPF/UIP fibroblasts: interplay between TGFbeta1, IL-13 and CCL2 | ||
17 | +Protective Effect of Ginsenoside Rg1 on Bleomycin-Induced Pulmonary Fibrosis in Rats: Involvement of Caveolin-1 and TGF-b1 Signal Pathway | ||
18 | +Mesenchymal Stem Cells Correct Inappropriate Epithelial-mesenchyme Relation in Pulmonary Fibrosis Using Stanniocalcin-1 | ||
19 | +Chop Deficiency Protects Mice Against Bleomycin-induced Pulmonary Fibrosis by Attenuating M2 Macrophage Production | ||
20 | +Transforming Growth Factor (TGF)-b Promotes de Novo Serine Synthesis for Collagen Production | ||
21 | +Two-Way Conversion between Lipogenic and Myogenic Fibroblastic Phenotypes Marks the Progression and Resolution of Lung Fibrosis | ||
22 | +Normal Human Lung Epithelial Cells Inhibit Transforming Growth Factor-b Induced Myofibroblast Differentiation via Prostaglandin E2 | ||
23 | +Inhibition of the KCa3.1 Channel Alleviates Established Pulmonary Fibrosis in a Large Animal Model | ||
24 | +AKT2 Regulates Pulmonary Inflammation and Fibrosis via Modulating Macrophage Activation | ||
25 | +Novel Mechanisms for the Antifibrotic Action of Nintedanib | ||
26 | +Determining the True Selectivity Profile of av Integrin Ligands Using Radioligand Binding: Applying an Old Solution to a New Problem | ||
27 | +Increased Galectin-9 Concentration and Number of CD4+Foxp3high+Cells in Bronchoalveolar Lavage Fluid of Patients with Cryptogenic Organizing Pneumonia | ||
28 | +Reduced Ets Domain-containing Protein Elk1 Promotes Pulmonary Fibrosis via Increased Integrin avb6 Expression | ||
29 | +Expression of RXFP1 Is Decreased in Idiopathic Pulmonary Fibrosis | ||
30 | +The Anti-fibrotic Effects and Mechanisms of MicroRNA-486-5p in Pulmonary Fibrosis | ||
31 | +MAP3K19 Is a Novel Regulator of TGF-b Signaling That Impacts Bleomycin-Induced Lung Injury and Pulmonary Fibrosis | ||
32 | +Dysregulated Collagen Homeostasis by Matrix Stiffening and TGF-b1 in Fibroblasts from Idiopathic Pulmonary Fibrosis Patients: Role of FAK/Akt | ||
33 | +Sustained Activation of Toll-Like Receptor 9 Induces an Invasive Phenotype in Lung Fibroblasts: Possible Implications in Idiopathic Pulmonary Fibrosis | ||
34 | +Regulation of 26S Proteasome Activity in Pulmonary Fibrosis | ||
35 | +Membrane-anchored Serine Protease Matriptase Is a Trigger of Pulmonary Fibrogenesis | ||
36 | +The Role of PPARs in Lung Fibrosis | ||
37 | +Lipoxin A4 Attenuates Constitutive and TGF-b1-Dependent Profibrotic Activity in Human Lung Myofibroblasts | ||
38 | +Cigarette Smoke Enhances the Expression of Profibrotic Molecules in Alveolar Epithelial Cells | ||
39 | +Idiopathic Pulmonary Fibrosis: Aging, Mitochondrial Dysfunction, and Cellular Bioenergetics | ||
40 | +CXCL9 Regulates TGF-b1-Induced Epithelial to Mesenchymal Transition in Human Alveolar Epithelial Cells | ||
41 | +Anti-fibrotic Role of aB-crystallin Inhibition in Pleural and Subpleural Fibrosis | ||
42 | +Expression of WNT5A in Idiopathic Pulmonary Fibrosis and Its Control by TGF-b and WNT7B in Human Lung Fibroblasts |
results/Partition_4/cluster3_tagged.txt
0 → 100644
1 | +<r>Regulation </r>of human lung fibroblast <g>C1q</g>-receptors by <g>transforming growth factor-beta</g> and <g>tumor necrosis factor-alpha</g> | ||
2 | +High levels of <g>IL-6</g> and <g>IL-8</g> characterize early-on <d>idiopathic pulmonary fibrosis</d> acute exacerbations | ||
3 | +Regulation of the effects of <g>TGF-beta 1</g> by activation of latent <g>TGF-beta 1</g> and differential <e>expression </e>of <g>TGF-beta receptors (T beta R-I and T beta R-II</g>) in <d>idiopathic pulmonary fibrosis</d> | ||
4 | +Peripheral depletion of NK cells and imbalance of the Treg/Th17 axis in <d>idiopathic pulmonary fibrosis</d> patients | ||
5 | +<g>miR-9-5p</g> suppresses pro-fibrogenic transformation of fibroblasts and prevents organ <d>fibrosis</d> by targeting <g>NOX4</g> and <g>TGFBR2</g> | ||
6 | +Profibrotic role of <g>WNT10A</g> via <g>TGF-b</g> signaling in <d>idiopathic pulmonary fibrosis</d> | ||
7 | +Microarray profiling reveals <u>suppressed </u>interferon stimulated gene program in fibroblasts from scleroderma-associated <d>interstitial lung disease</d> | ||
8 | +<g>IL-4</g> polymorphisms, HRCT score and lung tissue markers in <d>idiopathic pulmonary fibrosis</d> | ||
9 | +Herpes <d>virus infection</d> is associated with vascular remodeling and <d>pulmonary hypertension</d> in <d>idiopathic pulmonary fibrosis</d> | ||
10 | +Microencapsulation of lefty-secreting engineered cells for <d>pulmonary fibrosis</d> therapy in mice | ||
11 | +Targeting of <g>Discoidin Domain Receptor 2</g> (<g>DDR2</g>) Prevents Myofibroblast Activation and Neovessel Formation During <d>Pulmonary Fibrosis</d> | ||
12 | +Role of <g>protease-activated receptor-2</g> in <d>idiopathic pulmonary fibrosis</d> | ||
13 | +<g>Chop</g> | ||
14 | +<g>VCAM-1</g> is a <g>TGF-b1</g> inducible gene <v>upregulated </v>in <d>idiopathic pulmonary fibrosis</d> | ||
15 | +<u>Suppression </u>of <g>plasminogen activator inhibitor-1</g> by RNA interference attenuates <d>pulmonary fibrosis</d> | ||
16 | +<g>JAK2</g> mediates <d>lung fibrosis</d>, <d>pulmonary vascular remodelling</d> and <d>hypertension</d> in <d>idiopathic pulmonary fibrosis</d>: an experimental study | ||
17 | +Melatonin attenuates <g>TGFb1</g>-induced epithelial-mesenchymal transition in lung alveolar epithelial cells | ||
18 | +<r>Deregulation </r>of selective autophagy during aging and <d>pulmonary fibrosis</d>: the role of <g>TGFb1</g> | ||
19 | +<g>RhoA</g> signaling <r>modulates </r><g>cyclin D1</g> <e>expression </e>in human lung fibroblasts; implications for <d>idiopathic pulmonary fibrosis</d> | ||
20 | +Inhibitory effect of <g>receptor for advanced glycation end products</g> (<g>RAGE</g>) on the <g>TGF-b</g>-induced alveolar epithelial to mesenchymal transition | ||
21 | +<e>Effects </e>of the <d>tumor</d> suppressor <g>PTEN</g> on the pathogenesis of <d>idiopathic pulmonary fibrosis</d> in Chinese patients | ||
22 | +Triptolide suppresses paraquat induced <d>idiopathic pulmonary fibrosis</d> by inhibiting <g>TGFB1</g>-dependent epithelial mesenchymal transition | ||
23 | +<g>Endothelin-1</g> <v>induces </v>alveolar epithelial-mesenchymal transition through endothelin type A receptor-<v>mediated </v><e>production </e>of <g>TGF-beta1</g> | ||
24 | +<g>p63</g> - Key molecule in the early phase of <d>epithelial abnormality</d> in <d>idiopathic pulmonary fibrosis</d> | ||
25 | +The hedgehog system machinery controls transforming growth factor-b-dependent myofibroblastic differentiation in humans: involvement in <d>idiopathic pulmonary fibrosis</d> | ||
26 | +<v>Upregulation </v>of <g>activin</g>-B and <g>follistatin</g> in <d>pulmonary fibrosis</d> - a translational study using human biopsies and a specific inhibitor in mouse <d>fibrosis</d> models | ||
27 | +<u>Inhibition </u>of the <g>KCa3.1</g> | ||
28 | +Current and novel drug therapies for <d>idiopathic pulmonary fibrosis</d> | ||
29 | +<g>Protease activated receptor-1</g> regulates macrophage-mediated cellular senescence: a risk for <d>idiopathic pulmonary fibrosis</d> | ||
30 | +Sphingolipids in <d>pulmonary fibrosis</d> | ||
31 | +Sirtuin 7 is decreased in pulmonary fibrosis and regulates the fibrotic phenotype of lung fibroblasts | ||
32 | +Pirfenidone for the treatment of <d>idiopathic pulmonary fibrosis</d> | ||
33 | +The anti-fibrotic effect of <u>inhibition </u>of <g>TGFb</g>-<g>ALK5</g> signalling in experimental <d>pulmonary fibrosis</d> in mice is attenuated in the presence of concurrent y-herpesvirus infection | ||
34 | +Angiotensin-<g>TGF-beta</g> 1 crosstalk in human <d>idiopathic pulmonary fibrosis</d>: autocrine mechanisms in myofibroblasts and macrophages | ||
35 | +SNAI transcription factors mediate epithelial-mesenchymal transition in <d>lung fibrosis</d> | ||
36 | +<g>MiR-338</g>* suppresses fibrotic pathogenesis in <d>pulmonary fibrosis</d> through targeting <g>LPA1</g> | ||
37 | +BALF N-acetylglucosaminidase and <g>beta-galactosidase</g> activities in <d>idiopathic pulmonary fibrosis</d> | ||
38 | +<g>Th1</g>/Th2 cytokine gene polymorphisms in patients with <d>idiopathic pulmonary fibrosis</d> | ||
39 | +Transforming Growth Factor (TGF)-b Promotes de Novo Serine Synthesis for Collagen <e>Production.</e> <g>TGF-b</g> <v>promotes </v>excessive collagen deposition in <d>fibrotic diseases</d> such as <d>idiopathic pulmonary fibrosis</d> (<d>IPF</d>) | ||
40 | +The Epstein-Barr virus latent membrane protein 1 and transforming growth factor--b1 synergistically induce epithelial--mesenchymal transition in lung epithelial cells | ||
41 | +<g>Transcription factor GATA-6</g> is <e>expressed </e>in quiescent myofibroblasts in <d>idiopathic pulmonary fibrosis</d> | ||
42 | +Epithelial-to-mesenchymal transition and its role in <g>EGFR</g>-mutant <d>lung adenocarcinoma</d> and <d>idiopathic pulmonary fibrosis</d> |
results/Partition_4/cluster4.txt
0 → 100644
1 | +FAK-related nonkinase is a multifunctional negative regulator of pulmonary fibrosis | ||
2 | +Bleomycin and IL-1beta-mediated pulmonary fibrosis is IL-17A dependent | ||
3 | +miR-26a suppresses EMT by disrupting the Lin28B/let-7d axis: potential cross-talks among miRNAs in IPF | ||
4 | +Hsp90 regulation of fibroblast activation in pulmonary fibrosis | ||
5 | +MiR-185/AKT and miR-29a/collagen 1a pathways are activated in IPF BAL cells | ||
6 | +Tubastatin ameliorates pulmonary fibrosis by targeting the TGFb-PI3K-Akt pathway | ||
7 | +Significant involvement of CCL2 (MCP-1) in inflammatory disorders of the lung | ||
8 | +Pirfenidone inhibits the expression of HSP47 in TGF-beta1-stimulated human lung fibroblasts | ||
9 | +Effects of particulate matter from straw burning on lung fibrosis in mice | ||
10 | +BARD1 mediates TGF-b signaling in pulmonary fibrosis | ||
11 | +Renin is an angiotensin-independent profibrotic mediator: role in pulmonary fibrosis | ||
12 | +Regulation of myofibroblast differentiation by miR-424 during epithelial-to-mesenchymal transition | ||
13 | +Up-regulation of heparan sulfate 6-O-sulfation in idiopathic pulmonary fibrosis | ||
14 | +Mechanisms of fibrosis in coal workers' pneumoconiosis | ||
15 | +Effect of substrate stiffness on pulmonary fibroblast activation by TGF-b | ||
16 | +Role for alpha3 integrin in EMT and pulmonary fibrosis | ||
17 | +Shikonin suppresses pulmonary fibroblasts proliferation and activation by regulating Akt and p38 MAPK signaling pathways | ||
18 | +Gremlin-mediated decrease in bone morphogenetic protein signaling promotes pulmonary fibrosis | ||
19 | +Molecular targets in pulmonary fibrosis: the myofibroblast in focus | ||
20 | +miR-92a regulates TGF-b1-induced WISP1 expression in pulmonary fibrosis | ||
21 | +Transgelin is a direct target of TGF-beta/Smad3-dependent epithelial cell migration in lung fibrosis | ||
22 | +Increased alveolar soluble annexin V promotes lung inflammation and fibrosis | ||
23 | +Re-evaluation of fibrogenic cytokines in lung fibrosis | ||
24 | +Lung myofibroblasts are characterized by down-regulated cyclooxygenase-2 and its main metabolite, prostaglandin E2 | ||
25 | +A critical role for the mTORC2 pathway in lung fibrosis | ||
26 | +Fibrotic myofibroblasts manifest genome-wide derangements of translational control | ||
27 | +Inhibition and role of let-7d in idiopathic pulmonary fibrosis | ||
28 | +Rapamycin increases CCN2 expression of lung fibroblasts via phosphoinositide 3-kinase | ||
29 | +Predisposition for disrepair in the aged lung | ||
30 | +MicroRNA regulatory networks in idiopathic pulmonary fibrosis | ||
31 | +Wnt coreceptor Lrp5 is a driver of idiopathic pulmonary fibrosis | ||
32 | +Pirfenidone inhibits myofibroblast differentiation and lung fibrosis development during insufficient mitophagy | ||
33 | +Genetic partitioning of interleukin-6 signalling in mice dissociates Stat3 from Smad3-mediated lung fibrosis | ||
34 | +Transcription factor GATA-6 is expressed in quiescent myofibroblasts in idiopathic pulmonary fibrosis | ||
35 | +[Idiopathic pulmonary fibrosis and lung cancer] | ||
36 | +Role of caveolin-1 in fibrotic diseases | ||
37 | +Latent cytomegalovirus infection exacerbates experimental pulmonary fibrosis by activating TGF-b1 | ||
38 | +Caveolin-1: a critical regulator of lung fibrosis in idiopathic pulmonary fibrosis | ||
39 | +TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P | ||
40 | +Lysocardiolipin acyltransferase regulates TGF-b mediated lung fibroblast differentiation | ||
41 | +Azithromycin attenuates myofibroblast differentiation and lung fibrosis development through proteasomal degradation of NOX4 | ||
42 | +[Potential role of cytokines in idiopathic pulmonary fibrosis] | ||
43 | +The potential role of PDGF, IGF-1, TGF-beta expression in idiopathic pulmonary fibrosis | ||
44 | +Cytokine profiles in idiopathic pulmonary fibrosis suggest an important role for TGF-beta and IL-10 | ||
45 | +Therapeutic targets in fibrotic pathways | ||
46 | +Suppression of plasminogen activator inhibitor-1 by RNA interference attenuates pulmonary fibrosis | ||
47 | +Pirfenidone exerts antifibrotic effects through inhibition of GLI transcription factors | ||
48 | +Profibrotic role of WNT10A via TGF-b signaling in idiopathic pulmonary fibrosis | ||
49 | +microRNA-1343 attenuates pathways of fibrosis by targeting the TGF-b receptors | ||
50 | +Effect of Renshen Pingfei Decoction, a traditional Chinese prescription, on IPF induced by Bleomycin in rats and regulation of TGF-b1/Smad3 | ||
51 | +M2 macrophages induce EMT through the TGF-b/Smad2 signaling pathway | ||
52 | +miR -221 targets HMGA2 to inhibit bleomycin -induced pulmonary fibrosis by regulating TGF -b1/Smad3-induced EMT | ||
53 | +Autophagy in idiopathic pulmonary fibrosis | ||
54 | +Overexpression of Sulf2 in idiopathic pulmonary fibrosis | ||
55 | +Matrix metalloproteinase (MMP)-19 deficient fibroblasts display a profibrotic phenotype | ||
56 | +[Pulmonary fibrosis--a therapeutic dilemma?] | ||
57 | +Signaling pathways in the epithelial origins of pulmonary fibrosis | ||
58 | +FGF-1 reverts epithelial-mesenchymal transition induced by TGF-{beta}1 through MAPK/ERK kinase pathway | ||
59 | +Participation of miR-200 in pulmonary fibrosis | ||
60 | +Proteasomal regulation of pulmonary fibrosis | ||
61 | +Inhibition of HSP27 blocks fibrosis development and EMT features by promoting Snail degradation | ||
62 | +The JAK2 pathway is activated in idiopathic pulmonary fibrosis | ||
63 | +Human lung myofibroblast TGFb1-dependent Smad2/3 signalling is Ca(2+)-dependent and regulated by KCa3.1 K(+) channels | ||
64 | +Transforming growth factor-beta1 in sarcoidosis | ||
65 | +The anti-fibrotic effects of microRNA-153 by targeting TGFBR-2 in pulmonary fibrosis | ||
66 | +Cytokines in human lung fibrosis | ||
67 | +MicroRNA-101 attenuates pulmonary fibrosis by inhibiting fibroblast proliferation and activation | ||
68 | +Cartilage oligomeric matrix protein in idiopathic pulmonary fibrosis | ||
69 | +Cytokine gene polymorphisms in idiopathic pulmonary fibrosis | ||
70 | +Matrix metalloproteinase 3 is a mediator of pulmonary fibrosis | ||
71 | +Ubiquitin carboxyl-terminal hydrolase-L5 promotes TGFb-1 signaling by de-ubiquitinating and stabilizing Smad2/Smad3 in pulmonary fibrosis | ||
72 | +Cub domain containing protein 1 (CDCP1) negatively regulates TGFb signaling and myofibroblast differentiation | ||
73 | +The mannose-6-phosphate analogue, PXS64, inhibits fibrosis via TGF-b1 pathway in human lung fibroblasts | ||
74 | +N-acetylcysteine inhibits alveolar epithelial-mesenchymal transition | ||
75 | +Pulmonary fibrosis: pathogenesis, etiology and regulation | ||
76 | +Smooth muscle alpha-actin expression and myofibroblast differentiation by TGFbeta are dependent upon MK2 | ||
77 | +Profibrotic role of miR-154 in pulmonary fibrosis | ||
78 | +miR-323a-3p regulates lung fibrosis by targeting multiple profibrotic pathways | ||
79 | +Low-dose paclitaxel ameliorates pulmonary fibrosis by suppressing TGF-b1/Smad3 pathway via miR-140 upregulation | ||
80 | +IPF lung fibroblasts have a senescent phenotype | ||
81 | +MiR-338* targeting smoothened to inhibit pulmonary fibrosis by epithelial-mesenchymal transition | ||
82 | +N-acetyl-L-cysteine inhibits TGF-beta1-induced profibrotic responses in fibroblasts | ||
83 | +Sphingolipids in pulmonary fibrosis | ||
84 | +Sustained PI3K Activation exacerbates BLM-induced Lung Fibrosis via activation of pro-inflammatory and pro-fibrotic pathways | ||
85 | +Neutrophil elastase promotes myofibroblast differentiation in lung fibrosis | ||
86 | +BALF N-acetylglucosaminidase and beta-galactosidase activities in idiopathic pulmonary fibrosis | ||
87 | +Transglutaminase 2 and its role in pulmonary fibrosis | ||
88 | +The role of cytokines in human lung fibrosis | ||
89 | +miR-9-5p suppresses pro-fibrogenic transformation of fibroblasts and prevents organ fibrosis by targeting NOX4 and TGFBR2 | ||
90 | +Pleural mesothelial cells in pleural and lung diseases | ||
91 | +[Different cytokine profiles in usual interstitial pneumonia and nonspecific interstitial pneumonia] | ||
92 | +Essential role for the ATG4B protease and autophagy in bleomycin-induced pulmonary fibrosis | ||
93 | +Deregulation of selective autophagy during aging and pulmonary fibrosis: the role of TGFb1 | ||
94 | +MiR-338* suppresses fibrotic pathogenesis in pulmonary fibrosis through targeting LPA1 | ||
95 | +Metformin attenuates lung fibrosis development via NOX4 suppression | ||
96 | +Investigation of bone marrow mesenchymal stem cells (BM MSCs) involvement in Idiopathic Pulmonary Fibrosis (IPF) | ||
97 | +The pathogenesis of idiopathic pulmonary fibrosis | ||
98 | +Interstitial fibrosis and growth factors | ||
99 | +TIAM1 inhibits lung fibroblast differentiation in pulmonary fibrosis | ||
100 | +Role of integrin-mediated TGFbeta activation in the pathogenesis of pulmonary fibrosis | ||
101 | +Leucine-rich a-2 glycoprotein promotes lung fibrosis by modulating TGF-b signaling in fibroblasts | ||
102 | +MiR-541-5p regulates lung fibrosis by targeting cyclic nucleotide phosphodiesterase 1A | ||
103 | +Role of von Hippel-Lindau protein in fibroblast proliferation and fibrosis | ||
104 | +miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis | ||
105 | +miR-31 is a negative regulator of fibrogenesis and pulmonary fibrosis | ||
106 | +TRPV4 mediates myofibroblast differentiation and pulmonary fibrosis in mice | ||
107 | +Sputum biomarkers in IPF: Evidence for raised gene expression and protein level of IGFBP-2, IL-8 and MMP-7 | ||
108 | +STAT3-mediated signaling dysregulates lung fibroblast-myofibroblast activation and differentiation in UIP/IPF | ||
109 | +TGF-b1 induces Fstl1 via the Smad3-c-Jun pathway in lung fibroblasts | ||
110 | +Matrix regulation of idiopathic pulmonary fibrosis: the role of enzymes | ||
111 | +Epithelial-mesenchymal transition in chronic hypersensitivity pneumonitis | ||
112 | +HSP27 regulates TGF-b mediated lung fibroblast differentiation through the Smad3 and ERK pathways | ||
113 | +Inhibition of mechanosensitive signaling in myofibroblasts ameliorates experimental pulmonary fibrosis | ||
114 | +[A role for mesothelial cells in the genesis of idiopathic pulmonary fibrosis?] | ||
115 | +Pathogenesis of idiopathic pulmonary fibrosis | ||
116 | +SNAI transcription factors mediate epithelial-mesenchymal transition in lung fibrosis | ||
117 | +TGF-b activation and lung fibrosis | ||
118 | +Protective role of andrographolide in bleomycin-induced pulmonary fibrosis in mice | ||
119 | +[The potential role of cytokines expression in idiopathic pulmonary fibrosis] | ||
120 | +Autophagy and inflammation in chronic respiratory disease | ||
121 | +Bone morphogenetic protein-inducer tilorone identified by high-throughput screening is antifibrotic in vivo | ||
122 | +Reviews and prospectives of signaling pathway analysis in idiopathic pulmonary fibrosis | ||
123 | +Membrane type-matrix metalloproteinases in idiopathic pulmonary fibrosis | ||
124 | +Endothelin-1 induces alveolar epithelial-mesenchymal transition through endothelin type A receptor-mediated production of TGF-beta1 | ||
125 | +Lung fibrotic tenascin-C upregulation is associated with other extracellular matrix proteins and induced by TGFb1 | ||
126 | +EMT and interstitial lung disease: a mysterious relationship | ||
127 | +Fibrosis of two: Epithelial cell-fibroblast interactions in pulmonary fibrosis | ||
128 | +Lysyl oxidases regulate fibrillar collagen remodelling in idiopathic pulmonary fibrosis | ||
129 | +MicroRNAs in idiopathic pulmonary fibrosis | ||
130 | +Yin yang 1 is a novel regulator of pulmonary fibrosis | ||
131 | +Abrogation of TGF-beta1-induced fibroblast-myofibroblast differentiation by histone deacetylase inhibition | ||
132 | +Negative regulation of myofibroblast differentiation by PTEN (Phosphatase and Tensin Homolog Deleted on chromosome 10) |
results/Partition_4/cluster4_tagged.txt
0 → 100644
1 | +M2 macrophages <v>induce </v><g>EMT</g> through the <g>TGF-b</g>/<g>Smad2</g> signaling pathway | ||
2 | +Up-regulation of heparan sulfate 6-O-sulfation in <d>idiopathic pulmonary fibrosis</d> | ||
3 | +Comparison between conventional and "clinical" assessment of experimental lung <d>fibrosis</d> | ||
4 | +Pirfenidone attenuates bleomycin-induced pulmonary fibrosis in mice by <r>regulating </r><g>Nrf2</g>/<g>Bach1</g> equilibrium | ||
5 | +Developmental Reprogramming in Mesenchymal Stromal Cells of Human Subjects with <d>Idiopathic Pulmonary Fibrosis</d> | ||
6 | +<u>Inhibition </u>of <g>HSP27</g> blocks <d>fibrosis</d> development and EMT features by promoting <g>Snail</g> degradation | ||
7 | +Signalling pathways from NADPH oxidase-4 to <d>idiopathic pulmonary fibrosis</d> | ||
8 | +<r>Effects </r>of a leukotriene B4 receptor antagonist on bleomycin-induced <d>pulmonary fibrosis</d> | ||
9 | +Activated human T lymphocytes inhibit <g>TGFb</g>-induced fibroblast to myofibroblast differentiation via prostaglandins D2 and E2 | ||
10 | +The Role of PPARs in Lung <d>Fibrosis</d> | ||
11 | +Free radical generation induces epithelial-to-mesenchymal transition in lung epithelium via a <g>TGF-b1</g>-dependent mechanism | ||
12 | +The potential application of strategic released apigenin from polymeric carrier in pulmonary fibrosis | ||
13 | +<v>Overexpression </v>of <g>Sulf2</g> in <d>idiopathic pulmonary fibrosis</d> | ||
14 | +Essential role for the <g>ATG4B</g> protease and autophagy in bleomycin-induced <d>pulmonary fibrosis</d> | ||
15 | +<g>Bone morphogenetic protein-4</g> inhibitor <g>gremlin</g> is <v>overexpressed </v>in <d>idiopathic pulmonary fibrosis</d> | ||
16 | +Smooth muscle alpha-actin <e>expression </e>and myofibroblast differentiation by <g>TGFbeta</g> are <v>dependent </v>upon <g>MK2</g> | ||
17 | +The K+ channel <g>KCa3.1</g> as a novel target for <d>idiopathic pulmonary fibrosis</d> | ||
18 | +<g>Spiruchostatin A</g> inhibits proliferation and differentiation of fibroblasts from patients with <d>pulmonary fibrosis</d> | ||
19 | +<v>Elevated </v><g>sL1</g>-CAM levels in BALF and serum of <d>IPF</d> patients | ||
20 | +Lung myofibroblasts are characterized by <u>down-regulated </u><g>cyclooxygenase-2</g> and its main metabolite, prostaglandin E2 | ||
21 | +Cigarette Smoke Enhances the Expression of Profibrotic Molecules in Alveolar Epithelial Cells | ||
22 | +Microarray identifies ADAM family members as key responders to <g>TGF-beta1</g> in alveolar epithelial cells | ||
23 | +Titration of non-replicating adenovirus as a vector for <v>transducing </v>active <g>TGF-beta1</g> gene <e>expression </e>causing <d>inflammation</d> and fibrogenesis in the lungs of C57BL/6 mice | ||
24 | +Effect of substrate stiffness on pulmonary fibroblast activation by <g>TGF-b</g> | ||
25 | +A critical role for the <g>mTORC2</g> pathway in <d>lung fibrosis</d> | ||
26 | +Bile acids induce activation of alveolar epithelial cells and lung fibroblasts through farnesoid X receptor-dependent and independent pathways | ||
27 | +<g>TGF-beta</g> driven lung <d>fibrosis</d> is macrophage dependent and blocked by Serum amyloid P | ||
28 | +Exercise <u>Reduces </u>Lung <d>Fibrosis</d> | ||
29 | +Sputum biomarkers in <d>IPF</d>: Evidence for raised gene <e>expression </e>and protein level of <g>IGFBP-2</g>, <g>IL-8</g> and <g>MMP-7</g> | ||
30 | +<g>Forkhead Box F1</g> (<g>FOXF1</g>) <u>represses </u>cell growth, COL1 and <g>ARPC2</g> <e>expression </e>in lung fibroblasts in vitro | ||
31 | +<g>MicroRNA-29c</g> regulates apoptosis sensitivity via modulation of the cell-surface death receptor, Fas, in lung fibroblasts | ||
32 | +<g>Prostaglandin F(2alpha) receptor</g> signaling facilitates bleomycin-induced <d>pulmonary fibrosis</d> independently of transforming growth factor-beta | ||
33 | +<e>Expression </e>of mucosa-related integrin alphaEbeta7 on <d>alveolar T</d> cells in <d>interstitial lung diseases</d> | ||
34 | +Cytoskeletal protein modulation in <d>pulmonary alveolar myofibroblasts</d> during <d>idiopathic pulmonary fibrosis</d> | ||
35 | +<g>Transglutaminase 2</g> and its role in <d>pulmonary fibrosis</d> | ||
36 | +Sunitinib, a Small-Molecule Kinase <u>Inhibitor,</u> | ||
37 | +Fibroblasts from <d>idiopathic pulmonary fibrosis</d> and normal lungs differ in growth rate, apoptosis, and tissue <u>inhibitor </u>of metalloproteinases <e>expression.</e> <d>Idiopathic pulmonary fibrosis</d> (<d>IPF</d>) is a <d>chronic lung disorder</d> characterized by fibroblast proliferation and extracellular matrix accumulation | ||
38 | +<g>WISP1</g> mediates <g>IL-6</g>-dependent proliferation in primary human lung fibroblasts | ||
39 | +<d>Idiopathic pulmonary fibrosis</d>: immunohistochemical analysis provides fresh insights into lung tissue remodelling with implications for novel prognostic markers | ||
40 | +Amplified canonical transforming growth factor-b signalling<i>via</i><d>heat shock</d> protein 90 in <d>pulmonary fibrosis</d> | ||
41 | +<v>Upregulation </v>of alveolar <e>levels </e>of activin B, but not activin A, in lungs of west highland white terriers with <d>idiopathic pulmonary fibrosis</d> and <d>diffuse alveolar damage</d> | ||
42 | +Absence of <g>Thy-1</g> results in <g>TGF-b</g> induced <g>MMP-9</g> expression and confers a profibrotic phenotype to human lung fibroblasts | ||
43 | +Shikonin suppresses pulmonary fibroblasts proliferation and activation by <r>regulating </r><g>Akt</g> and <g>p38</g> | ||
44 | +<g>TRPV4</g> mediates myofibroblast differentiation and <d>pulmonary fibrosis</d> in mice | ||
45 | +Modulation of <g>CD11c</g>+ lung dendritic cells in respect to <g>TGF-b</g> in experimental <d>pulmonary fibrosis</d> | ||
46 | +Long-acting human serum albumin-thioredoxin fusion protein suppresses bleomycin-induced <d>pulmonary fibrosis progression</d> | ||
47 | +Fibrogenic Lung Injury Induces Non-Cell-Autonomous Fibroblast Invasion | ||
48 | +Induction of epithelial-mesenchymal transition in alveolar epithelial cells by <g>transforming growth factor-beta1</g>: potential role in <d>idiopathic pulmonary fibrosis</d> | ||
49 | +Recent advances in molecular targets and treatment of <d>idiopathic pulmonary fibrosis</d>: focus on <g>TGFbeta</g> signaling and the myofibroblast | ||
50 | +<g>Bone morphogenetic protein</g>-inducer tilorone identified by high-throughput screening is antifibrotic in vivo | ||
51 | +Pleural mesothelial cell differentiation and invasion in <d>fibrogenic lung injury</d> | ||
52 | +Studies of <g>hepatocyte growth factor</g> in bronchoalveolar lavage fluid in chronic <d>interstitial lung diseases</d> | ||
53 | +Cytokine gene polymorphisms in <d>idiopathic pulmonary fibrosis</d> | ||
54 | +<g>Cub domain containing protein 1</g> (<g>CDCP1</g>) negatively regulates TGFb signaling and myofibroblast differentiation | ||
55 | +Increased levels of prostaglandin E-major urinary metabolite (PGE-MUM) in chronic fibrosing <d>interstitial pneumonia</d> | ||
56 | +Mechanisms of <d>fibrosis</d> in <d>coal workers' pneumoconiosis</d> | ||
57 | +Different effects of growth factors on proliferation and matrix production of normal and fibrotic human lung fibroblasts | ||
58 | +Are mast cells instrumental for <d>fibrotic diseases</d>? <d>Idiopathic pulmonary fibrosis</d> (<d>IPF</d>) is a <d>fatal lung disorder</d> of unknown etiology characterized by accumulation of lung fibroblasts and extracellular matrix deposition, ultimately leading to compromised tissue architecture and lung function capacity | ||
59 | +<g>miR</g>-323a-3p regulates <d>lung fibrosis</d> by targeting multiple profibrotic pathways | ||
60 | +<g>TGF-b1</g> <v>stimulates </v><g>HDAC4</g> nucleus-to-cytoplasm <l>translocation </l>and <g>NADPH oxidase 4</g>-derived reactive oxygen species in normal human lung fibroblasts | ||
61 | +Effects of <d>cigarette smoke extract</d> on A549 cells and human lung fibroblasts treated with <g>transforming growth factor-beta1</g> in a coculture system | ||
62 | +MicroRNA-326 regulates profibrotic functions of transforming growth factor-b in <d>pulmonary fibrosis</d> | ||
63 | +Differential mRNA expression of <g>insulin-like growth factor-1</g> splice variants in patients with <d>idiopathic pulmonary fibrosis</d> and <d>pulmonary sarcoidosis</d> | ||
64 | +Pathogenesis of <d>idiopathic pulmonary fibrosis</d> | ||
65 | +<u>Reduced </u><g>Ets Domain-containing Protein Elk1</g> | ||
66 | +Nitric oxide attenuates epithelial-mesenchymal transition in alveolar epithelial cells | ||
67 | +<g>HSP27</g> regulates <g>TGF-b</g> mediated lung fibroblast differentiation through the <g>Smad3</g> and <g>ERK</g> pathways | ||
68 | +<e>Expression </e>of <g>WNT5A</g> in <d>Idiopathic Pulmonary Fibrosis</d> and Its <r>Control </r>by <g>TGF-b</g> and <g>WNT7B</g> in Human Lung Fibroblasts | ||
69 | +<g>FGF-1</g> reverts epithelial-mesenchymal transition induced by <g>TGF-{beta}1</g> through MAPK/ERK kinase pathway | ||
70 | +Type II alveolar epithelial cells and interstitial fibroblasts express <g>connective tissue growth factor</g> in <d>IPF</d> | ||
71 | +<g>Transforming growth factor b1</g> (<g>TGFb1</g>)-induced CD44V6-<g>NOX4</g> signaling in pathogenesis of <d>idiopathic pulmonary fibrosis</d> | ||
72 | +Pleural mesothelial cells in <d>pleural and lung diseases</d> | ||
73 | +<d>Idiopathic pulmonary fibrosis</d>: an altered fibroblast proliferation linked to <d>cancer</d> biology | ||
74 | +<g>Caveolin-1</g>: a critical regulator of <d>lung fibrosis</d> in <d>idiopathic pulmonary fibrosis</d> | ||
75 | +<g>Cthrc1</g> lowers pulmonary collagen associated with bleomycin-induced <d>fibrosis</d> and protects lung function | ||
76 | +Wnt coreceptor <g>Lrp5</g> is a driver of <d>idiopathic pulmonary fibrosis</d> | ||
77 | +Protective Effect of Ginsenoside Rg1 on Bleomycin-Induced Pulmonary Fibrosis in Rats: Involvement of <g>Caveolin-1</g> and <g>TGF-b1</g> | ||
78 | +The <g>JAK2</g> pathway is activated in <d>idiopathic pulmonary fibrosis</d> | ||
79 | +<g>miR-31</g> is a negative regulator of fibrogenesis and <d>pulmonary fibrosis</d> | ||
80 | +<u>Defect </u>of <g>hepatocyte growth factor</g> <l>secretion </l>by fibroblasts in <d>idiopathic pulmonary fibrosis</d> | ||
81 | +<g>NOX4</g>/NADPH oxidase <e>expression </e>is <v>increased </v>in pulmonary fibroblasts from patients with <d>idiopathic pulmonary fibrosis</d> and mediates <g>TGFbeta1</g>-induced fibroblast differentiation into myofibroblasts | ||
82 | +Matrix regulation of <d>idiopathic pulmonary fibrosis</d>: the role of enzymes | ||
83 | +Rapamycin <v>increases </v><g>CCN2</g> <e>expression </e>of lung fibroblasts via <g>phosphoinositide 3-kinase</g> | ||
84 | +[The expressions and meanings of <g>BMP-7</g> and <g>TGF-b</g> in <d>idiopathic pulmonary fibrosis</d> and <d>idiopathic nonspecific interstitial pneumonia</d>] | ||
85 | +Human lung myofibroblast <g>TGFb1</g>-dependent <g>Smad2/3</g> signalling is Ca(2+)-dependent and <r>regulated </r>by <g>KCa3.1</g> | ||
86 | +[A role for mesothelial cells in the genesis of <d>idiopathic pulmonary fibrosis</d>?] | ||
87 | +Antifibrotic effects of <g>cyclosporine A</g> on <g>TGF-b1</g>-treated lung fibroblasts and lungs from bleomycin-treated mice: role of <g>hypoxia-inducible factor-1a</g> | ||
88 | +<g>TGF-beta 1</g> as an enhancer of Fas-mediated apoptosis of lung epithelial cells | ||
89 | +Mesenchymal Stem Cells Correct Inappropriate Epithelial-mesenchyme Relation in <d>Pulmonary Fibrosis</d> | ||
90 | +Proliferation of pulmonary interstitial fibroblasts is mediated by <g>transforming growth factor-beta1</g>-induced release of extracellular <g>fibroblast growth factor-2</g> and <p>phosphorylation </p>of <g>p38</g> | ||
91 | +Prognostic factors for <d>idiopathic pulmonary fibrosis</d>: clinical, physiologic, pathologic, and molecular aspects | ||
92 | +Hydrogen peroxide is a diffusible paracrine signal for the induction of epithelial cell death by activated myofibroblasts | ||
93 | +<g>Secreted protein acidic and rich in cysteine</g> (<g>SPARC</g>) is upregulated by transforming growth factor (TGF)-b and is required for <g>TGF-b</g>-induced hydrogen peroxide production in fibroblasts | ||
94 | +The lncRNA <g>H19</g> | ||
95 | +<e>Contribution </e>of the anaphylatoxin receptors, <g>C3aR</g> and <g>C5aR</g>, to the pathogenesis of <d>pulmonary fibrosis</d> | ||
96 | +Corilagin attenuates aerosol bleomycin-induced experimental <d>lung injury</d> | ||
97 | +[Potential role of cytokines in <d>idiopathic pulmonary fibrosis</d>] | ||
98 | +Protective role of andrographolide in bleomycin-induced <d>pulmonary fibrosis</d> in mice | ||
99 | +<g>Serpin B4</g> isoform overexpression is associated with aberrant epithelial proliferation and <d>lung cancer</d> in <d>idiopathic pulmonary fibrosis</d> | ||
100 | +Interstitial <d>fibrosis</d> and growth factors | ||
101 | +<u>Blockade </u>of the Wnt/b-catenin pathway attenuates bleomycin-induced <d>pulmonary fibrosis</d> | ||
102 | +Control of virus reactivation arrests pulmonary herpesvirus-induced <d>fibrosis</d> in IFN-gamma receptor-<u>deficient </u>mice | ||
103 | +Interplay between <g>RAGE</g>, <g>CD44</g>, and focal adhesion molecules in epithelial-mesenchymal transition of alveolar epithelial cells | ||
104 | +Antifibrotic properties of receptor for advanced glycation end products in <d>idiopathic pulmonary fibrosis</d> | ||
105 | +Dysregulated Collagen Homeostasis by Matrix Stiffening and <g>TGF-b1</g> in Fibroblasts from <d>Idiopathic Pulmonary Fibrosis</d> | ||
106 | +TGF-b1 T869C polymorphism may affect susceptibility to <d>idiopathic pulmonary fibrosis</d> and disease severity | ||
107 | +Anti-pulmonary fibrotic activity of salvianolic acid B was screened by a novel method based on the cyto-biophysical properties | ||
108 | +Cytokines in human <d>lung fibrosis</d> | ||
109 | +<e>Expression </e>of <g>RXFP1</g> | ||
110 | +Plasma <g>CCN2</g> (connective tissue growth factor; <g>CTGF</g>) is a potential biomarker in <d>idiopathic pulmonary fibrosis</d> (<d>IPF</d>) | ||
111 | +Azithromycin attenuates myofibroblast differentiation and lung <d>fibrosis</d> development through <d>proteasomal degradation</d> of <g>NOX4</g> | ||
112 | +Association between cytokine removal by polymyxin B hemoperfusion and improved pulmonary oxygenation in patients with acute exacerbation of <d>idiopathic pulmonary fibrosis</d> | ||
113 | +Crosstalk between <g>TGF-b1</g> and complement activation augments epithelial <d>injury in pulmonary fibrosis</d> | ||
114 | +Bleomycin and <g>IL-1beta</g>-mediated <d>pulmonary fibrosis</d> is <g>IL-17A</g> dependent | ||
115 | +miR-199a-5p Is <v>upregulated </v>during fibrogenic response to tissue injury and mediates TGFbeta-induced lung fibroblast activation by targeting <g>caveolin-1</g> | ||
116 | +Inhibition of mechanosensitive signaling in myofibroblasts ameliorates experimental <d>pulmonary fibrosis</d> | ||
117 | +Integrated analyses identify the involvement of microRNA-26a in epithelial-mesenchymal transition during <d>idiopathic pulmonary fibrosis</d> | ||
118 | +<g>Transforming growth factor beta1</g> induces epithelial-to-mesenchymal transition of A549 cells | ||
119 | +The anti-fibrotic effects of microRNA-153 by <r>targeting </r><g>TGFBR-2</g> in <d>pulmonary fibrosis</d> | ||
120 | +<u>Defective </u>histone acetylation is <r>responsible </r>for the <u>diminished </u><e>expression </e>of <g>cyclooxygenase 2</g> in <d>idiopathic pulmonary fibrosis</d> | ||
121 | +y-Herpes virus-68, but not Pseudomonas aeruginosa or influenza A (H1N1), exacerbates <d>established murine lung fibrosis</d> | ||
122 | +Inhibition and role of <g>let-7d</g> in <d>idiopathic pulmonary fibrosis</d> | ||
123 | +Pleural mesothelial cell transformation into myofibroblasts and haptotactic migration in response to <g>TGF-beta1</g> in vitro | ||
124 | +Association of HLA and cytokine gene polymorphisms with <d>idiopathic pulmonary fibrosis</d> | ||
125 | +Signaling pathways and their miRNA regulators involved in the etiopathology of <d>idiopathic pulmonary fibrosis</d> (<d>IPF</d>) and <d>hypersensitivity pneumonitis</d> (<d>HP</d>) | ||
126 | +<g>miR-21</g> mediates fibrogenic activation of pulmonary fibroblasts and lung <d>fibrosis</d> | ||
127 | +Inhibitory effects of amines from Citrus reticulata on bleomycin-induced <d>pulmonary fibrosis</d> in rats | ||
128 | +Thalidomide <u>reduces </u><g>IL-18</g>, <g>IL-8</g> and <g>TNF-alpha</g> <l>release </l>from alveolar macrophages in <d>interstitial lung disease</d> | ||
129 | +Effect of glycosides based standardized fenugreek seed extract in bleomycin-induced <d>pulmonary fibrosis</d> in rats: Decisive role of <g>Bax</g>, <g>Nrf2</g>, <g>NF-kB</g>, <g>Muc5ac</g>, <g>TNF-a</g> and <g>IL-1b</g> | ||
130 | +The Anti-fibrotic Effects and Mechanisms of MicroRNA-486-5p in <d>Pulmonary Fibrosis</d> | ||
131 | +The role of microRNA-155/liver X receptor pathway in experimental and <d>idiopathic pulmonary fibrosis</d> | ||
132 | +<g>Cysteine-rich protein 1</g> is regulated by <g>transforming growth factor-b1</g> and expressed in lung <d>fibrosis</d> |
-
Please register or login to post a comment